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Background: Scaphoid fractures account for 90% of carpal fractures and occur predominantly in young
men. Immediate surgical fixation of this fracture has increased.
Objective: To compare the clinical effectiveness and cost-effectiveness of surgical fixation with cast
treatment and early fixation in adults with scaphoid waist fractures that fail to unite.
Design: Multicentre, pragmatic, open-label, parallel two-arm randomised controlled trial with an economic
evaluation and a nested qualitative study.
Setting: Orthopaedic departments of 31 hospitals in England and Wales recruited from July 2013, with
final follow-up in September 2017.
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Participants: Adults (aged ≥ 16 years) presenting within 2 weeks of injury with a clear, bicortical fracture
of the scaphoid waist on plain radiographs.
Interventions: Early surgical fixation using Conformité Européenne-marked headless compression screws.
Below-elbow cast immobilisation for 6–10 weeks and urgent fixation of confirmed non-union.
Main outcome measures: The primary outcome and end point was the Patient-Rated Wrist Evaluation
total score at 52 weeks, with a clinically relevant difference of 6 points. Secondary outcomes included
Patient-Rated Wrist Evaluation pain and function subscales, Short Form questionnaire 12-items, bone
union, range of movement, grip strength, complications and return to work.
Results: The mean age of 439 participants was 33 years; 363 participants were male (83%) and 269
participants had an undisplaced fracture (61%). The primary analysis was on 408 participants with valid
Patient-Rated Wrist Evaluation outcome data for at least one post-randomisation time point (surgery,
n = 203 of 219; cast, n = 205 of 220). There was no clinically relevant difference in the Patient-Rated Wrist
Evaluation total score at 52 weeks: the mean score in the cast group was 14.0 (95% confidence interval
11.3 to 16.6) and in the surgery group was 11.9 (95% confidence interval 9.2 to 14.5), with an adjusted
mean difference of –2.1 in favour of surgery (95% confidence interval –5.8 to 1.6; p = 0.27). The non-union
rate was low (surgery group, n = 1; cast group, n = 4). Eight participants in the surgery group had a total of
11 reoperations and one participant in the cast group required a reoperation for non-union. The base-case
economic analysis at 52 weeks found that surgery cost £1295 per patient more (95% confidence interval
£1084 to £1504) than cast treatment. The base-case analysis of a lifetime-extrapolated model confirmed
that the cast treatment pathway was more cost-effective. The nested qualitative study identified patients’
desire to have a ‘sense of recovering’, which surgeons should address at the outset.
Limitation: There were 17 participants who had initial cast treatment and surgery for confirmed non-union,
which in 14 cases was within 6 months from randomisation and in three cases was after 6 months. Three of
the four participants in the cast group who had a non-union at 52 weeks were not offered surgery.
Conclusions: Adult patients with an undisplaced or minimally displaced scaphoid waist fracture should
have cast immobilisation and suspected non-unions immediately confirmed and urgently fixed. Patients
should be followed up at 5 years to investigate the effect of partial union, degenerative arthritis, malunion
and screw problems on their quality of life.
Trial registration: Current Controlled Trials ISRCTN67901257.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 52.
See the NIHR Journals Library website for further project information.
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Plain English summary
F racture of the scaphoid bone (one of eight small bones in the wrist) is common in young active people.It is caused by a fall on the hand or the hand being suddenly forced backwards. The usual treatment is
to rest the wrist in a plaster cast for 6–10 weeks and allow the broken bone to heal. In 1 in 10 cases in
which the fracture is treated in a plaster cast, the bone does not heal and an operation is needed. In the
operation, the broken bone is held still with a screw. In the last few years, it has become more common to
fix the broken bone with a screw in the first few days after injury, instead of resting the wrist in a plaster
cast. It is not clear if fixing the bone early with a screw, compared with resting the wrist in a cast, gives
better outcomes for patients and if one treatment is better value for money for the NHS.
In this study, 439 adult patients agreed either to have surgery to hold the broken scaphoid with a special
screw or to have the wrist held still in a plaster cast (with surgery offered after 6 weeks to those who were
still not healed). The decision about which treatment to use was made using randomisation, which is
similar to tossing a coin. Patients reported their own wrist pain and function at 6, 12, 26 and 52 weeks.
Information was also collected on general health, bone healing, grip strength and range of movement,
complications from treatment and costs.
No important differences were found in patients’ wrist pain and function at 52 weeks. The bone did not heal
properly in four patients in the surgery group or in nine patients in the plaster cast group at 52 weeks. For
one of these patients in the surgery group and four of these patients in the plaster cast group, the bone did
not join at all. Eight patients in the surgery group had further surgery following their initial operation to fix
their wrist, and one patient in the cast group required repeated surgery because the bone did not join at all.
The overall cost of treating with a plaster cast was lower than that of early surgery. Therefore, the findings
of the study suggest that a plaster cast should be used initially and that the bone should be immediately
fixed with a screw if it does not heal.
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Scientific summary
Background
Scaphoid fractures account for 90% of all carpal fractures and occur predominantly in young active men.
Typically, the scaphoid fractures when the wrist is suddenly extended, either when putting the hand out to
break a fall or when the palm is struck forcibly by an object. Most fractures (64%) affect the waist of the
scaphoid. Despite insufficient evidence, there is an increasing trend to immediately surgically fix this fracture
rather than immobilising the wrist in a cast and then fixing only those that fail to unite.
Objectives
The objective was to evaluate the clinical effectiveness and cost-effectiveness of surgical fixation compared with
cast treatment (with early fixation of those that fail to unite) of scaphoid waist fractures in adults. A qualitative
study was also conducted to explore patient experience of fracture and its treatment, and to investigate
attitudes towards, and experiences of, participating in a surgical clinical trial.
Design
The Scaphoid Waist Internal Fixation for Fractures Trial (SWIFFT) was a multicentre, pragmatic, open-label,
parallel two-arm randomised controlled trial with an economic evaluation (within-trial and extrapolated
analyses) and nested qualitative study. Patients were randomised on an equal basis to receive either of the
two treatment options via a remote randomisation service. Randomisation was stratified by the presence or
lack of displacement of the fracture. This was defined as a step or gap of 1–2 mm inclusive, as seen on any
radiographic view. Random block sizes of 6 and 12 were used. Follow-up was at 6, 12, 26 and 52 weeks.
Data collection included imaging (radiographs and computed tomography scans) at baseline and at 6, 12
and 52 weeks. Hospital forms and participant questionnaires were also used to collect data. There was no
blinding of outcome assessment.
The economic evaluation assessed the relative cost-effectiveness of surgical fixation compared with cast
treatment using costs and outcomes collected over 52 weeks. The costs and outcomes were extrapolated
and modelled over the lifetimes of a patient cohort owing to the potential long-term future burden of
osteoarthritis and other adverse events. This model permitted the inclusion of additional treatment pathways
and analyses of a number of relevant scenarios to explore the key drivers of cost-effectiveness that warrant
extra focus and future research.
The nested qualitative study used purposive sampling of those SWIFFT participants who indicated a
willingness to be interviewed within 6 weeks of randomisation and at 52 weeks (n = 30). Both men and
women, experiencing different treatments, of different ages and occupations, were purposively selected.
Patients who declined to participate in the trial were also purposively selected to be interviewed (n = 10).
All interviews were semistructured and, where possible, were undertaken face to face at a time and
location convenient to the participant.
Setting
Trial recruitment was undertaken from the orthopaedic departments of 30 NHS hospitals in England and
one hospital in Wales. Patients were recruited from fracture clinics from 23 July 2013 to 26 July 2016.
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Participants
Adults (aged ≥ 16 years) presenting at a participating site within 2 weeks of their injury and in whom
surgery could be undertaken within 2 weeks of presentation to the NHS, and with a clear, unequivocal
bicortical fracture of the scaphoid waist seen on a scaphoid series of plain radiographs, were considered
for inclusion. Patients were excluded from the trial if their fracture had > 2-mm displacement, as these
are likely to be unstable and require surgical intervention; if they had a concurrent wrist fracture in the
opposite limb; if they had a trans-scaphoid perilunate dislocation; if they had multiple injuries in the same
limb; if they lacked the mental capacity to comply with treatment or data collection; if they were pregnant,
as radiation exposure would be contraindicated; or if they were not a resident in the trauma catchment
area of the participating site to allow follow-up.
Interventions
The intervention involved early percutaneous or open surgical fixation using standard Conformité
Européenne-marked headless compression screws. The choice of implant was the surgeon’s decision.
To avoid learning-curve problems, surgeons used techniques with which they were fully familiar. The
comparator was below-elbow cast immobilisation for 6–10 weeks, with or without inclusion of the thumb,
and urgent fixation performed when non-union was confirmed. All participants randomised into the two
groups received standardised written physiotherapy advice, detailing the exercises they needed to perform
for rehabilitation following their injury.
Main outcome measures
The primary outcome and end point was the Patient-Rated Wrist Evaluation total score (scale 0–100,
with lower scores indicating better outcomes) at 52 weeks. It was also completed at 6, 12 and 26 weeks.
The trial was powered to detect a clinically relevant difference in the Patient-Rated Wrist Evaluation of
6 points, assuming a standard deviation of 20 (equivalent to an effect size of 0.3) at 52 weeks.
Secondary outcomes were the subscale scores of pain and function of the Patient-Rated Wrist Evaluation;
the physical component summary and mental component summary scores of the Short Form questionnaire
12-items; bone union; range of movement and grip strength; complications; and return to work and
unpaid recreational activities. In addition, resource use and the EuroQol-5 Dimensions, three-level version,
were collected and a literature review was performed to inform the health economic evaluation.
All patient-reported outcomes (i.e. Patient-Rated Wrist Evaluation; Short Form questionnaire 12-items;
EuroQol-5 Dimensions, three-level version; return to work; and unpaid recreational activities) were
collected by post, in hospital clinics or occasionally over the telephone, at 6, 12, 26 and 52 weeks. Bone
union was assessed on radiographs at 6, 12 and 52 weeks and computed tomography scans at 52 weeks.
The other outcomes (i.e. range of movement and grip strength, as well as complications) were collected in
routine hospital clinics at 6 and 12 weeks, and additionally at 52 weeks.
Statistical analysis
Analyses were conducted using the principles of intention to treat, analysing participants in the groups to
which they were originally randomised, using two-sided statistical tests assessed at the 5% significance level.
The primary outcome (total Patient-Rated Wrist Evaluation scores) was compared between the two
randomised groups using a covariance pattern, mixed-effect linear regression model incorporating all
post-randomisation time points. Treatment group, time point, a treatment-by-time interaction, participant
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age at randomisation, baseline fracture displacement and dominance of injured hand were included as
fixed effects, and participant was included as a random effect (to account for the repeated observations
per participant). This analysis included any participant with valid Patient-Rated Wrist Evaluation outcome
data for at least one post-randomisation time point. It therefore does not include the small number of
participants who provided no post-randomisation Patient-Rated Wrist Evaluation data. An estimate of the
difference between treatment groups in total Patient-Rated Wrist Evaluation score was extracted for each
time point and overall, with a 95% confidence interval and p-value. The treatment effect estimate for the
52-week time point served as the primary outcome. The treatment effects for the 6-, 12- and 26-week
time points, and the overall effect, served as secondary outcomes.
Sensitivity analyses were specified a priori to explore the effect of the following: missing data (using multiple
imputation by chained equations); handling multisite data [including site as a random effect (within which
participants were nested) in the model as described for the analyses of the primary outcome]; the timing
of the data collection by repeating the analysis of the primary outcome including only data collected within
agreed time frames around each time point; separately excluding participants who three raters agreed based
on the baseline images that (1) there was no fracture or (2) the displacement of the fracture was > 2 mm;
and non-compliance using a complier-average causal effect analysis. Current smoking status (yes/no) was
included as a covariate in the primary analysis model in a post hoc sensitivity check to adjust for a chance
imbalance at baseline. In total, three subgroup analyses were undertaken: one exploring patient treatment
preferences as expressed at baseline and two exploring baseline fracture displacement.
The secondary outcomes of the pain and function subscales of the Patient-Rated Wrist Evaluation, the
physical component summary and mental component summary of the Short Form questionnaire 12-items,
and grip strength were summarised descriptively for each time point by treatment group and overall,
and were analysed using the same method as the primary outcome adjusting for the same covariates.
The extent of union was presented at 6, 12 and 52 weeks by randomised group. Regression methods were
used to analyse the union data only at 52 weeks, dichotomising participants as ‘probably need surgery’ and
‘probably do not need surgery’ and also using the repeated measures of dichotomised union at 6, 12 and
52 weeks. Rates of malunion (based on the ratio of the scaphoid height to length at thresholds of 0.6 and 0.7)
were presented overall and for each treatment group at 6, 12 and 52 weeks. Complications that were defined
as medical, surgical or plaster cast were presented for each treatment group at 6, 12 and 52 weeks using only
data collected at the hospital and not the data on complications identified elsewhere. Logistic regression that
adjusted for age, hand dominance and fracture displacement was used to analyse the data for participants
who had at least one of these complications over 52 weeks. This analysis did not address the severity of the
complication or any of the complications identified elsewhere. All serious and non-serious adverse events and
complications noted on review of the imaging were summarised by treatment group.
Economic analysis
The perspective of the economic analysis was that of the UK NHS and Personal Social Services. For the
within-trial analysis, the EuroQol-5 Dimensions, three-level version, was collected from patient questionnaires
to permit the estimation of quality-adjusted life-years for each patient for the 52 weeks of the trial. The
resource use data, collected from patient questionnaires and hospital forms, were used to estimate costs
that were expressed in Great British pounds at 2017 prices. Differences in mean costs and quality-adjusted
life-years at 52 weeks were used to estimate the incremental cost-effectiveness ratio of surgery compared
with cast for a ‘within-trial’ analysis. Multiple imputation of missing data was used with an intention-to-treat
analysis to estimate a base-case incremental cost-effectiveness ratio, adjusting for the baseline quality of
life. The extrapolated analysis used data from a literature review and from the trial to estimate the health
and resource use implications beyond the time frame of the trial for four treatment options: no treatment,
cast immobilisation only, cast immobilisation followed by immediate surgery for confirmed non-union, and
surgical fixation. This included estimating the incremental cost-effectiveness ratio and net health benefit
for the four treatment options, estimating the probability of each strategy as being cost-effective at a given
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willingness-to-pay threshold using a cost-effectiveness acceptability curve, as well as a series of scenario
analyses to explore the impact of structural uncertainty on the results.
Qualitative analysis
The discursive, exploratory and semistructured nature of the data led to an inductive, thematic approach
to the data analysis. A systematic and structured approach was used, including data familiarisation, theme
identification and thematic model generation to explore the data on their own terms and to prioritise the
insight generated therein.
Clinical effectiveness results
Of the 1047 patients who met the inclusion criteria, 775 were eligible, of whom 439 were randomised.
The mean age of the trial participants was 33 years; 363 were male (83%) and 269 had an undisplaced
fracture (61%). The independent review by three raters of baseline imaging confirmed that only one
participant had no fracture.
Of the 219 participants allocated to surgery, 188 (86%) received the treatment as allocated. The main
operating surgeon was most commonly a consultant (66%) and the consultant was also the most common
assisting surgeon when a specialist trainee was the operating surgeon. Of the 220 participants allocated to
plaster cast, only six (3%) immediately switched to surgery following randomisation. Of the 17 participants in
the plaster cast group who had surgery for early identified non-union, 14 had this surgery within 6 months
from randomisation and three were treated after 6 months. Three of the four participants in the plaster cast
group who had non-union identified at 52 weeks had not been offered surgery during the 52-week follow-up.
The primary analysis was on the 408 participants providing valid Patient-Rated Wrist Evaluation outcome
data for at least one post-randomisation time point [surgery, n = 203 of 219 (93%); cast, n = 205 of 220
(93%)] using the principles of intention to treat (participants were analysed in the group to which
they were originally randomised regardless of non-adherence to their allocated treatment). There was
no clinically relevant difference in the total Patient-Rated Wrist Evaluation score at 52 weeks: the cast
group mean score was 14.0 (95% confidence interval 11.3 to 16.6) and the surgery group mean score
was 11.9 (95% confidence interval 9.2 to 14.5), with an adjusted mean difference of –2.1 in favour of
surgery (95% confidence interval –5.8 to 1.6; p = 0.27). A complier-average causal effect analysis to take
non-compliance into account found, at 52 weeks, an increased difference in favour of surgery in the total
Patient-Rated Wrist Evaluation score of –3.1 (95% confidence interval –7.3 to 1.1; p = 0.15). The adjusted
mean difference in total Patient-Rated Wrist Evaluation score in favour of surgery at 6 weeks was –4.2
(95% confidence interval –8.5 to 0.1; p = 0.06), at 12 weeks was –5.6 (95% confidence interval –9.8 to
–1.4; p = 0.01), at 26 weeks was –0.3 (95% confidence interval –4.1 to 3.6; p = 0.89) and overall was
–3.0 (95% confidence interval –6.3 to 0.3; p = 0.07). The sensitivity analyses that have been described
produced similar results on the total Patient-Rated Wrist Evaluation score to the primary analysis. This
included the post hoc sensitivity analysis that adjusted for smoking status. No significant interaction was
observed between randomised allocation and treatment preference or fracture displacement on the total
Patient-Rated Wrist Evaluation score.
For secondary outcomes, the adjusted mean difference at 52 weeks in favour of surgery in the Patient-Rated
Wrist Evaluation pain subscale was –1.1 (95% confidence interval –3.3 to 1.0; p = 0.31) and for the function
subscale was –1.0 (95% confidence interval –2.6 to 0.7; p = 0.25). For the Short Form questionnaire 12-items
mental component summary at 52 weeks, the adjusted mean difference was –1.2 points (95% confidence
interval –3.3 to 0.8 points; p = 0.24) favouring the plaster cast group. In the Short Form questionnaire
12-items physical component summary, the adjusted mean difference was 1.6 points (95% confidence
interval 0.2 to 3.1 points; p = 0.03) favouring the surgery group, although there was no statistically significant
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difference at 6 or 26 weeks. There was little difference in range of movement at 52 weeks between the two
groups or in adjusted mean grip strength. The rate of non-union in both groups was low. Participants in
the surgery group (4 of 219, 1.8%) were less likely than those in the plaster cast group (9 of 220, 4.1%) to
have non- or only slight union of their fracture at 52 weeks (i.e. probably needing surgery versus probably
not needing surgery), but this difference was not statistically significant. Based on these figures, 44 patients
would need to be offered surgery instead of a cast to prevent one extra non-union or slight union at 52 weeks.
At 52 weeks, using the 0.7 threshold of the ratio of scaphoid height to length, malunion increased between
baseline and 52 weeks on computed tomography scans and was similar (3.2%) in the two groups. The rate
of screws penetrating the neighbouring joint of 1 mm or more was unexpectedly high (36.2%, 68/188
who had initial surgery). There were eight participants in the surgery group who had 11 reoperations and
one participant in the cast group required a reoperation for non-union. There were no intraoperative
complications. Surgical complications occurred in 14.2% of participants in the surgery group and 1.4% of
participants in the plaster cast group. Cast issues, which were usually minor, occurred in 2.7% and 20.5%
of the surgery and plaster cast group, respectively. There were inconsistencies in reporting complications
between the complications form and adverse event form. Plaster cast softening or breaking and symptoms
of non-union were described as ‘adverse events’. At least one non-serious ‘adverse event’ was reported
for 24 (11.0%) participants in the surgery group and 29 (13.2%) participants in the plaster cast group.
All three serious adverse events were in the surgery group. Furthermore, complications were also identified
on review of the imaging. One patient in the surgery group required partial wrist fusion for surgery-related
complications.
Cost-effectiveness results
The base-case economic analysis showed that, at 52 weeks, the cost of initial surgical intervention was,
on average, £1295 more per patient (95% confidence interval £1084 to £1504) than the cost of cast
immobilisation with surgery for non-union. Surgery was slightly more beneficial in terms of utilities, but
this difference was not significant. The incremental cost per quality-adjusted life-year at 52 weeks for
surgery compared with cast immobilisation with early fixation of confirmed non-union was £81,962 per
quality-adjusted life-year.
The economic evaluation base-case analysis of the extrapolated long-term model established that the initial
use of a cast with immediate fixation of confirmed non-union was the most cost-effective option over the
discounted lifetime of the patient, with a 61% probability of being cost-effective at the willingness-to-pay
threshold of £20,000 per quality-adjusted life-year. The net health benefit at this threshold was also the
highest, at 19.02. This was followed by primary surgical fixation, the use of a cast without a surgical option
and, finally, no treatment.
Qualitative study findings
The nested qualitative study identified that how a patient understands their scaphoid fracture and perceives
their own ‘sense of recovering’ was important in their assessment of treatment success. Notably, the act
of plaster cast removal was an important threshold in a patient’s sense of returning to normal. A broadly
positive attitude towards surgery among those interviewed reflected the finding at baseline that, when
consenting participants did have a preference for treatment, it was predominantly in favour of surgery.
This may have been a consequence of participants’ concerns about the duration of immobilisation in a
plaster cast and the uncertainty (however small) of the need for further treatment.
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Conclusions
Among adults with a waist scaphoid fracture that is undisplaced or minimally displaced, the evidence
suggests that patients should be immobilised in a cast and that all suspected non-unions be immediately
investigated and those that are confirmed urgently fixed. Surgeons should address, at the outset, patients’
desire to have a ‘sense of recovering’.
Recommendation for future research
The planned 5-year follow-up of trial participants will help explore the outcomes of participants with a
partial union of the scaphoid fracture, and the impact of the progression of degenerative arthritis, malunion
and screw problems (malposition and penetration within joints) on quality of life. This will further inform the
areas of uncertainty in the extrapolated model.
Trial registration
This trial is registered as ISRCTN67901257.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment
programme and will be published in full in Health Technology Assessment; Vol. 24, No. 52. See the NIHR
Journals Library website for further project information.
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Chapter 1 Introduction
Scaphoid fracture accounts for 90% of all carpal fractures1 and 2–7% of all fractures.2 It is an importantpublic health problem, as it predominantly affects young active individuals (mean age 29 years)3 in their
most productive working years.
The scaphoid typically fractures when the wrist is suddenly extended either when putting the hand out to
break a fall or when the palm is struck forcibly by an object.
Most fractures (64%) affect the waist of the scaphoid, but 5% affect the proximal pole (the proximal 20%
of the scaphoid) and around 13.3% involve the distal part of the scaphoid. The tuberosity fractures in
18.1% of cases. Figure 1 illustrates this.
The scaphoid, lunate and triquetrum form the proximal carpal row, attached to each other by ligaments.
These bones are subject to loads when the muscles whose tendons cross the wrist bones contract. This
row acts together like a helix. When the scaphoid flexes under load, the triquetrum extends so that the
middle section, the lunate, remains in a neutral and stable position.5,6
A fracture of the scaphoid breaks this helix so that the two parts then rotate; the distal scaphoid fragment
flexes under load while the remainder of the proximal carpal helix extends. After a fracture, the proximal
carpal row can no longer stabilise the distal carpal row and hence the wrist. The resulting abnormal loading
between the distal part of the broken scaphoid and the distal radius leads to cartilage degeneration and
arthritis, while the proximal part extends, causing carpal collapse. This pattern after failure of union is called
a scaphoid non-union advanced collapse (SNAC) wrist.7
Scaphoid fractures disrupt the proximal carpal row and alter the complex mechanics of this row, thereby
altering how the wrist is stabilised to permit the hand and digits to function efficiently.
13%
18%
38%
26%
5%
TuberosityDistal
Distal intra-ar
ticular
Waist distal
Waist proximalProxim
al pole
FIGURE 1 Locations of scaphoid fractures and the proportions reported (information sourced from Garala et al.4)
Non-tuberosity fractures account for 81.9% of all scaphoid fractures and 78.2% of these involve the waist.
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1
About 88–90% of these fractures unite when treated initially in a plaster cast. However, 10–12% of scaphoid
fractures treated with plaster cast do not unite, with a higher incidence (14–50%) in displaced fractures.8–10
Retrograde intraosseous circulation11 jeopardises the blood circulation, particularly in the proximal scaphoid,
and may explain the higher failure of union in proximal fractures. Non-union, if untreated, almost inevitably
leads to arthritis, especially in the radioscaphoid joint, usually within 5 years.12,13 This disables patients at a
very young age.
Diagnosis of the fracture is usually confirmed in emergency departments on radiographs of the scaphoid
taken in different projections and it is usual to obtain a ‘scaphoid series of radiographs’, which include
posterior–anterior, lateral and 45° supination and pronation views, as shown in Figure 2. In addition, an
elongated view of the scaphoid is obtained to avoid missing any fractures that may be obscured because
of the palmar and radial inclination of the scaphoid. It is possible to have an incomplete fracture of the
scaphoid and these usually heal uneventfully.14 However, clear and bicortical fractures cause clinical
concern, as these are more likely to be unstable.
Treatments
Getting a fracture to heal restores the integrity of the proximal carpal row and thereby the stability of the
wrist. This stability restores hand function, reduces the feeling of weakness and significantly reduces the
risk of carpal collapse and the resulting arthritis15 (SNAC).
The aim of treatment is to immobilise the fracture while the physiological processes of healing occur.
Immobilising the fracture fragments relative to one another can be done in various ways. Movement
between fracture fragments can be constrained by immobilising the injured wrist in a cast or by surgically
introducing a screw across the fracture.
(a)
(d) (e)
(b)
(c)
FIGURE 2 Five radiographic views of the scaphoid. (a) Posterior–anterior view, in which the fracture is just visible;
(b) elongated scaphoid view, in which the fracture is ‘clear’ and ‘bicortical’; the gap could be > 1mm and the radial
margin shows a small step; (c) semisupine oblique view; (d) lateral view, through which alignment can be assessed;
and (e) semiprone view, which also shows the fracture and suggests displacement.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Fixation
Immediate surgical fixation may avoid the need to immobilise the wrist in a cast and could accelerate
return to function, work and sport;16 however, this method requires the person to have an operation and
be exposed to surgical risks. The fracture is fixed with a standard Conformité Européenne (CE)-marked
headless screw generating compression at the fracture site but avoiding the pressure effects of the screw
head on articular cartilage. This can be done either percutaneously or in open surgery.17–19 The surgical
techniques for this method are well described and are now standard.20–22 These screws did not change
during the recruitment period for this study. Some surgeons use splintage for the first few weeks after surgery.
Cast treatment
The usual treatment is immobilisation in a below-elbow cast for 6–10 weeks, followed by mobilisation.
The type of below elbow cast used does not affect union rate.8 The 10–12% of patients who develop
non-union [as seen on radiographs and/or computed tomography (CT) scans] usually have urgent surgical
fixation. This is the current standard non-operative pathway.3
Current evidence
Eight randomised controlled trials (RCTs)3,18,23–28 have reported on 463 participants with undisplaced or
minimally displaced fractures of the scaphoid waist who had either of these two treatments. These RCTs
had small sample sizes (ranging from 25 to 88 participants) and have been systematically reviewed nine
times;29–37 these reviews all commented on the low quality of the evidence.
Some studies reported that fracture fixation facilitated earlier restoration of function and return to previous
activity levels, especially if a cast or splint was not used after fixation, but patients had a higher rate of
complications, of between 9% and 22%, although these were usually minor.3,18,25
It is unclear if patients who had surgical fixation of undisplaced or minimally displaced scaphoid fractures
had better longer-term benefits than those treated in a cast.
The rate of union was similar between the surgical and cast treatments, with early fixation of those
fractures that failed to unite.3 Another study28 reported similar outcomes at 10 years.
Displaced fractures
A scaphoid fracture is considered displaced if there is a step or gap of ≥1 mm.38 Angulation and rotation
between fragments are more difficult to assess. A systematic review reported that non-union occurs in
around 18% of displaced fractures39 and that, when treated in a cast, the relative risk of non-union
between undisplaced and displaced fractures is 4.4 [95% confidence interval (CI) 2.3 to 8.7].39 At present,
the evidence of the treatment of displaced fractures is weak and recommendations are based on case
series.40 When the displacement is > 2 mm, clinicians consider the fracture so unstable that they usually
recommend early reduction and fixation.
Increase in surgical activity
Despite insufficient evidence, there is an increasing trend41 to immediately fix scaphoid fracture rather than
to immobilise in a cast for 6 weeks and fix only the 10–12% that fail to unite.3 This current trend to fix
fractures may be attributed to short-term benefits, but concerns remain about the lack of evidence on the
long-term benefits and additional risks of surgery, such as malunion, infection, implant-related problems
and avascular necrosis.
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Hospital Episode Statistics for NHS hospitals in England recorded a two-third increase in acute scaphoid
fracture fixations between 2007/8 and 2009/10 (1534, 1720 and 2582 in 2007/8, 2008/9 and 2009/10,
respectively), before this study was commissioned. The rate of surgical fixation42 rose very slightly from
37% to 41% from 2007/8 to 2008/9 but then increased sharply to 62% in 2009/10. This trend of an
increasing intervention rate emphasised the need for this study.
Economic aspects
There is also a lack of information on the economic aspects43 of this injury and its treatment. One study
used a decision-analytic model43 and utility scores were obtained from 50 medical students. This study
concluded that early fixation provided more quality-adjusted life-years (QALYs) and consumed fewer
economic resources than cast treatment. However, a different view has also been suggested,44,45 namely
that cast treatment is economically less costly. This conclusion came from studies of both non-randomised
(95 patients) and randomised evidence (52 patients), based on a comparison of direct and indirect costs in
patients who had their fracture treated in a cast or had it fixed.
What do patients feel and experience?
There is little published evidence on patients’ experiences and preferences after a scaphoid fracture.
Understanding our patients’ priorities helps efficient patient-centred clinical decision-making. We know
little about patients’ experience of their recovery and the impact that the injury and treatment have on
them. We also have a poor understanding of the issues pertinent to recruiting participants in surgical
clinical trials.46,47
Five-year review
The long-term consequences of cast immobilisation and internal fixation have not been adequately
determined in RCTs. The consolidation of partial union of the fracture has not been investigated, nor has
the progression of carpal malalignment or the development of arthritis. Although this report focuses on
outcomes at 52 weeks, the study will investigate function, impairment and arthritis at 5 years.48
Null hypothesis
There is no difference in the Patient-Rated Wrist Evaluation (PRWE)49 score at the 52-week follow-up
between adults with a scaphoid waist fracture treated with screw fixation versus those treated with plaster
cast immobilisation and with fixation of only those fractures that fail to unite.
Research question
Our aim was to determine the clinical effectiveness and cost-effectiveness of surgical fixation versus plaster
cast treatment (with early fixation of 10–12% of fractures that fail to unite) of scaphoid waist fractures in
adults in an adequately powered multicentre pragmatic RCT [the Scaphoid Waist Internal Fixation for
Fractures Trial (SWIFFT)]48 and to qualitatively investigate patients’ experiences of their treatment and
participation in the trial.
Research objectives
Our primary objective was to determine the effectiveness of surgical fixation versus non-operative plaster
cast treatment (with fixation of those that fail to unite, estimated to be 10–12% of the total) of scaphoid
waist fractures in adults. The outcome was assessed using the PRWE50 (a patient self-reported assessment
of wrist pain and function) at 52 weeks, which was the primary end point. The PRWE was also completed
at 6, 12 and 26 weeks and will be completed at 5 years. The power of the study permitted identification
of a clinically meaningful difference of 6 points in the PRWE.
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Our secondary objectives were to:
l assess radiological union of the fracture at 52 weeks using radiographs and CT scans; recovery of wrist
range and strength; return to work and unpaid recreational activities; and complications
l conduct an economic analysis to investigate the cost-effectiveness of surgical fixation versus initial
immobilisation in a plaster cast
l qualitatively explore patients’ experiences of fracture and its treatment and to investigate attitudes
towards, and experiences of, participating in a surgical clinical research trial
l undertake a 5-year clinical review of all trial participants to determine the long-term consequences of
cast immobilisation and internal fixation.
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Chapter 2 Trial design and methods
This chapter describes the trial design and methods used to address the objectives regarding the clinicaleffectiveness of the health-care interventions being compared. The methods of the health economic
evaluation and the nested qualitative study are described in their dedicated chapters.
Trial design
This was a multicentre, stratified [displacement present or not, with equal allocation (1 : 1)], parallel-group
design conducted in England and Wales among patients aged ≥ 16 years with a clear bicortical fracture of
the scaphoid waist as seen on plain radiographs. Patients were randomly assigned to either immediate
surgical fixation or initial non-operative wrist immobilisation in a below-elbow cast with later surgical
fixation of only those fractures that failed to unite.
Participants
The diagnosis of fracture was on standard radiographic views available at each hospital (i.e. posterior–anterior,
lateral, 45° semiprone, 45° semisupine) and an elongated scaphoid view (e.g. Ziter51). If these radiographic
views were not taken routinely at a participating site, we sought to obtain them after the patient had
consented in the trial to confirm eligibility before randomisation.
A CT scan was also taken at baseline to compare with the CT scan at 52 weeks for the bone union assessment.
The baseline CT scan was taken within 2 weeks of the patient’s injury (i.e. before randomisation) or, if that
was not feasible, before surgery if the patient was allocated to surgery. It was decided that, although
eligibility assessments should be based on the radiographic views, because a baseline CT scan was available,
it was necessary for a member of the radiology team to confirm whether a fracture was visible or not. If the
baseline CT scan was viewed before randomisation, and a member of the radiology team could not confirm
to the participating site staff that there was a clear bicortical fracture of the scaphoid waist, the surgeon
would decide whether or not to continue to recruit the patient. This was to prevent the potential for an
immediate crossover to plaster cast if the surgeon thought there was a not a sufficiently visible fracture to
operate on. If this happened after randomisation, the patient remained in the trial because there was a
fracture on the series of radiographic views. This could, however, influence the surgeon’s decision to
continue to operate on the patient when allocated to surgery (i.e. could lead to a crossover).
Inclusion criteria
Patients were eligible for the trial if they:
l were skeletally mature and aged ≥ 16 years
l presented at a participating site within 2 weeks of their injury and within which time it was feasible to
have surgery
l had a clear, unequivocal bicortical fracture of the scaphoid waist seen on a series of plain radiographs
of the scaphoid that:
– did not involve the proximal pole (the proximal 20% of the scaphoid) and
– included minimally displaced fractures with a step or gap of ≤ 2 mm on any radiographic view.
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Exclusion criteria
Patients were excluded from the trial if:
l their fracture had > 2-mm displacement, as these fractures are likely to be unstable and require
surgical intervention
l they had a concurrent wrist fracture in the opposite limb
l they had a trans-scaphoid perilunate dislocation
l they had multiple injuries in the same limb
l they lacked the mental capacity to comply with treatment or data collection
l they were pregnant, because radiation exposure would be contraindicated
l they were not resident in the trauma catchment area of a participating site to allow follow-up.
Setting
The trial recruited from the orthopaedic departments of 30 NHS hospitals in England and one hospital in
Wales. There were three additional hospitals in England that screened for patients but did not recruit to
the trial. Recruitment started in July 2013 and the final follow-up was in September 2017. All 34 participating
trusts are listed in Appendix 1.
Interventions
Cast treatment followed by surgical fixation if there is confirmed non-union
The control treatment was non-operative, with wrist immobilisation in a below-elbow cast for 6–10 weeks,
followed by mobilisation. The below-elbow cast could include the thumb or not, as this does not affect
union rate.8 Early CT was obtained if plain radiographs at 6–12 weeks raised any suspicion of non-union.
If non-union was confirmed on radiographs and/or CT scans, urgent surgical fixation was expected to
be performed and was encouraged by the trial team, which monitored this with the completion of the
6- and 12-week treatment confirmation forms (see Report Supplementary Materials 1 and 2). The surgical
procedure to treat a non-union and postoperative care were similar to the surgical arm of this trial. Cast
immobilisation, identification and confirmation of non-union at 6–12 weeks, and immediate surgical fixation
of confirmed non-union is the current standard non-operative pathway.3 We anticipated that most, if not all,
fixation of confirmed non-union would occur by around 12 weeks.
Surgical fixation
Surgical treatment was by percutaneous or open surgical fixation depending on the surgeon’s preferred
technique. Standard CE-marked headless compression screws18,52 were used to avoid the pressure effects
of the screw head on articular cartilage. These are standard surgical techniques.20–22 The type of implant
used was not restricted, but the screw used was recorded (see Report Supplementary Material 3). The
surgical approach or the postoperative care was not specified and was instead left to clinical discretion,
as it was expected that most surgeons would use some splintage for the first few weeks after surgery.
The application of a plaster cast or splint following surgery, and its duration, was recorded. At each
recruiting site, it was agreed which surgeons would fix the scaphoid fractures and that surgeons would
use techniques with which they were familiar to avoid learning-curve problems.
Rehabilitation
All participants randomised into the two groups received standardised, written physiotherapy advice
detailing the exercises they needed to perform for rehabilitation following their injury (see Report
Supplementary Material 4). All participants were advised to move their shoulder, elbow and finger joints
fully within the limits of their comfort. Those participants treated in a cast performed range-of-movement
exercises at the wrist as soon as their plaster cast was removed at the 6-week follow-up appointment as
long as there were no concerns regarding bone union. Those participants who had the fracture fixed
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began their wrist exercises as soon as comfort permitted, if they did not have a plaster cast, or as soon as
the cast was removed. Any other rehabilitation input beyond the written information sheet (including a
formal referral to physiotherapy) was the decision of the treating clinicians. A record of any additional
rehabilitation input (including the reason for referral and number of appointments) was recorded at the
52-week hospital visit.
Outcomes
The outcomes and the time points when various outcomes were assessed are described below.
Primary outcome
The primary outcome and end point for the trial was the PRWE total score at 52 weeks from randomisation.
The PRWE was completed at baseline for the time before and after injury, and at 6, 12, 26 and 52 weeks,
and will be completed 5 years after randomisation. The PRWE is a 15-item questionnaire that is completed
by the participant. It is a brief, reliable and valid instrument for assessing wrist pain and disability.50,53 Scoring
for all the questions is on a 10-point ordered scale, ranging from ‘no pain’ or ‘no difficultly’ (0) to ‘worst ever
pain’ or ‘unable to do’ (10). A total score can be computed on a scale of 0–100 (0 = no disability), as well as
two non-overlapping subscales (pain and function), which are weighted equally. The PRWE score was chosen
as the primary outcome because patient-reported functional outcomes are favoured for decision-making and
it allows the assessment of both wrist pain and function.
Two small RCTs3,18 of patients with scaphoid fractures have demonstrated that there is little change in
objective and subjective outcomes between 26 and 52 weeks. In the case of the 10–12% of patients who
are treated initially in cast but do not heal, surgery should be performed between 6 and 12 weeks after
randomisation. Therefore, if assessed at 26 weeks, this would leave only 14–20 weeks for healing and
recovery to take place. To allow all patients the time to heal from surgery and to stabilise after any
complications, 52 weeks was chosen as the primary end point.
Secondary outcomes
The secondary outcomes were health-related quality of life (HRQoL), bone union, range of movement and
grip strength, return to work and unpaid recreational activities, and complications.
Health-related quality of life
Patient-Rated Wrist Evaluation
The total PRWE scores at the other time points (6, 12, and 26 weeks) and the PRWE subscale scores of pain
and function were secondary outcomes.
Short Form questionnaire 12-items
The Short Form questionnaire 12-items (SF-12) is a generic patient-reported outcome measure of physical
and mental health, the population norms of which have a mean of 50 points and a standard deviation
of 10 points; higher scores indicate better health.54 The SF-12 was completed at 6, 12, 26 and 52 weeks
to measure the potential broader consequences of a scaphoid fracture on participants’ physical and
mental health.
EuroQol
The EuroQol-5 Dimensions, three-level version (EQ-5D-3L), is a validated, generic patient-reported outcome
measure covering five health domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression)
with three response options to each domain.55,56 The use of this non-fracture-specific instrument allows
the assessment of HRQoL outcomes in the health economic analysis. The EQ-5D-3L has high validity and
reliability in proximal humerus fractures57 and hip fractures.58 It was completed at baseline and at 6, 12,
26 and 52 weeks.
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Bone union
The secondary outcome of bone union59 was determined at 52 weeks (in line with the primary end point).
A CT scan and a series of plain radiographs were obtained comprising posterior–anterior, lateral, 45°
semiprone and 45° semisupine views and an elongated scaphoid view (e.g. Ziter-type view). Routine
radiographs were also collected for bone union assessment at 6- and 12-week hospital clinics.
Union was defined as complete disappearance of the fracture line8 on radiographs and complete bridging
on CT scans60,61 in comparison with those taken at baseline. Partial union was based on the proportion of
the fracture plane traversed by bridging trabeculae on true sagittal and coronal multiplanar reconstructions
(MPRs) of the scaphoid on CT. CT was used to determine non-union, as there is only poor to moderate
inter-observer agreement (range of kappa from 0.11 to 0.53) when determining the union of a scaphoid
fracture on plain radiographs.62
Scaphoid fracture displacement was assessed on radiographs and on a CT scan.63
Malunion was assessed on the 52-week CT scan.64 Malunion was defined as a ratio of scaphoid height to
length ≥ 0.6 in the true sagittal axis of the scaphoid, to assess any humpback deformity.65
A limitation of this assessment of bone union, however, was that the presence of the screw to fix the fracture
would unblind the observer regarding whether the participant had had an operation or not. To minimise
the potential for this to introduce bias, two consultant radiologists with a special interest in musculoskeletal
radiology and a consultant orthopaedic surgeon (chief investigator) interpreted the plain radiographs and
CT scans independently of each other. All three met to discuss cases in which there was discordance in line
with the rules defined in the standard operating procedure (see Report Supplementary Material 5). The two
radiologists were both employed at participating hospital sites (Leicester and Birmingham). During the trial,
they did not report on plain radiographs or CT scans of the scaphoid during clinical practice, in an attempt to
maintain independence when reporting on the imaging of trial participants.
Range of movement and grip strength
The range of movement of both wrists was measured using a goniometer66 and the grip strength of both
hands was measured using a calibrated Jamar dynamometer.67–70 Both were recorded at baseline and at 6,
12 and 52 weeks (see Report Supplementary Material 6). The measurements were performed with the
subject seated and their arm by their side, their elbow bent at 90° and their wrist in a neutral position
for rotation.71 Staff were advised to use the second setting on the Jamar dynamometer, except for when
testing participants with large hands, when the third setting was used.72 The Beighton joint laxity score
(excluding the thumb count for the injured wrist) was recorded at baseline to measure the hypermobility
of joints.73 These assessments were standardised across participating sites using an instruction sheet
(see Report Supplementary Material 7).
Return to work and unpaid recreational activities
This was established through participant self-reporting on the number of days off work and their ability to
perform usual activities when at work and when performing unpaid recreational activities. This was
recorded at the 6-, 12-, 26- and 52-week follow-ups.
Complications
Expected and unexpected complications were recorded at the 6-, 12- and 52-week hospital visits (see Report
Supplementary Material 8). The expected complications included:
l infection, defined as ‘surgical site infection’74
l delayed wound healing, defined as any wound that had not healed by 2 weeks
l complex regional pain syndrome (CRPS), defined as a puffy, painful swelling of the whole hand
restricting full tuck of the fingers at 2 weeks
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l nerve events (hypoaesthesia or numbness in the territory of the palmar cutaneous branch of the median
nerve, superficial division of the radial nerve or the median nerve)
l vessel events [large (> 2 cm) haematoma in the line of the radial artery]
l screw-related complications (protrusion of either end into the adjacent joint, fracture or bending of the
screw, a radiolucent halo around any part of the screw > 1 mm, screw backing out or moving)
l degenerative changes in the adjacent joints75
l avascular necrosis76 of the proximal pole of the scaphoid.
In addition, the three raters reviewed the imaging at each time point for complications. This included
assessing the presence (or not) of OA, the presence (or not) of screw penetration, screw lucency (none,
< 1 mm or 1–2 mm) and avascular necrosis (no radiodensity, just radiodense, marked radiodensity on one
view or one MPR, or marked radiodensity on more than one view or MPR).
Sample size
For surgery to justify its increased costs and the exposure to risk, it must result in greater or quicker
improvement in patients’ wrist symptoms and function than non-operative management. A 6-point
improvement in the PRWE score in the surgery group (compared with the controls) was chosen to be the
minimally clinical important difference. The standard deviation of the PRWE score at 52 weeks was taken
to be 20 points based on the PRWE user manual.49 This figure was reported for distal radius fracture rather
than scaphoid fracture at 6 months. The only published evidence for scaphoid fracture implies a standard
deviation in the range of 8–10 points;28 however, this estimate was at a median of 10 years after the
patient’s injury. To be conservative, a standard deviation of 20 was chosen. This gives a standard effect
size of 0.3 for the 6-point PRWE difference. A superiority design was used to observe an effect size of 0.3
at 80% power using a two-sided 5% significance level requiring 350 participants in total. After allowing
for 20% attrition, the recruitment target was 438 participants (219 surgery and 219 plaster cast). The
estimate of attrition was expected to be realistic, given that four previous RCTs (three studies had a single
centre and one study had two centres) of the treatment of scaphoid fractures had reported response rates
for completion of patient-reported functional outcomes to be between 77% and 100%.31
There were no planned interim analyses for the trial or stopping guidelines. There was, however, an
internal pilot study from which the data contributed to the final analyses. The primary reason for the pilot
study was to check the assumptions about the site set-up, patient recruitment and the feasibility of the
trial. The independent oversight committees reviewed the progress that was made during the internal pilot
and recommended that the trial continue with the planned increase in the number of sites. In the absence
of a standard deviation for the primary outcome at 52 weeks, this was estimated from the participants
who were recruited into the internal pilot study. This estimate corroborated the standard deviation chosen
for the sample size calculation.
Recruitment
A research nurse identified patients who were potentially eligible for fracture clinics, referred from accident
and emergency (A&E) departments or other sources (e.g. walk-in centres, cottage hospitals). The orthopaedic
surgeon confirmed eligibility (see Report Supplementary Material 9) and invited the patient to consider
joining the study. The research nurse or clinician provided the patient with an information sheet (see Report
Supplementary Material 10) and answered any questions. The patient was asked to consent at that time or
was offered up to 48 hours to discuss the study with family or friends before deciding whether to take part
or not. When patients gave consent (see Report Supplementary Material 11), they were asked to complete
a baseline form (see Report Supplementary Material 12). The site staff then contacted York Trials Unit (YTU),
either by telephone or via the internet, to access the secure randomisation service. For patients who did
not consent, a form was completed to record the following aspects: reasons for non-consent, patient and
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surgeon treatment preferences, and the agreed treatment plan (see Report Supplementary Material 13).
Both patients who consented to take part in the trial [using the main trial information sheet (see Report
Supplementary Material 10)] and those who did not consent to take part in the trial [using a separate
information sheet (see Report Supplementary Material 14)] were invited to take part in an interview.
This is explained further in Chapter 5.
Strategies for achieving adequate participant enrolment to reach the target sample size included seeking
advice from a patient focus group, sharing best practice with the research nurses at participating sites,
and biannual discussions with our principal investigators (PIs) at the scientific meetings of the British
Society for Surgery of the Hand (BSSH). Hospital staff were provided with training about study procedures
at the site initiation visits and with a trial site manual. During the trial, training sessions and reminders
were communicated using e-mail bulletins, face-to-face meetings with the PIs at BSSH conferences and
a training day with research nurses. In addition, the trial co-ordinators provided support and guidance
to staff at participating sites (e.g. when new staff joined or replaced existing site staff) and also sought
guidance from the chief investigator.
Randomisation
The randomisation sequence was based on a computer-generated randomisation algorithm provided by
a remote randomisation service (telephone or online access) at YTU. The unit of randomisation was the
individual patient on a 1 : 1 basis. As the non-union rate for displaced scaphoid fractures is 14%, compared
with 10% for transverse undisplaced fractures,8,10,39 randomisation was stratified by the presence or not of
displacement as assessed by the staff at the recruiting site. Random block sizes of 6 and 12 were used.
Displacement was defined as a step or gap of 1–2 mm inclusive as seen on any radiographic view. The
research nurse used the remote randomisation service to register eligible and consenting participants before
computer generation of the allocation. The research nurse then informed the treating surgeon of the
allocation. This ensured treatment concealment and immediate unbiased allocation.
Blinding
As the trial was pragmatic and compared surgery with initial cast treatment, blinding of participants and
clinicians to treatment allocation was not possible. When possible, the treating surgeon took no part in
the postoperative assessment of participants. The statistician was blind to group allocation until after data
were hard locked and no further changes could be made. To minimise bias in the assessment of bone
union, all radiographs and CT scans were assessed independently by two consultant musculoskeletal
radiologists and a consultant orthopaedic surgeon (chief investigator). Any disagreement was resolved
through discussion.
Statistical methods
Analyses were conducted using the principles of intention to treat (ITT), including all randomised participants
in the groups to which they were allocated, where data were available. Analyses were conducted in
Stata® v15 (StataCorp LP, College Station, TX, USA) using two-sided statistical tests assessed at the 5%
significance level.
Recruitment
Site and patient recruitment was presented. The characteristics of the population of patients who were
screened, ineligible and eligible, stratified by consent, were summarised. The flow of participants through
the trial was presented in a Consolidated Standards of Reporting Trials (CONSORT) diagram.
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Baseline characteristics of randomised participants
Baseline participant characteristics and fracture details were summarised descriptively overall and by
randomised group, both ‘as randomised’ and ‘as analysed’, comparing the groups as included in the primary
outcome analysis model (i.e. with full data for the baseline covariates and valid PRWE data for at least one
post-randomisation time point). No formal statistical comparisons were undertaken on baseline data.
Follow-up
For each time point, the number of participant questionnaires sent and returned, with median
[interquartile range (IQR)] days to completion and return, was presented by treatment group and overall.
The number of questionnaires completed at home, over the telephone or in the hospital was reported.
Return rates for hospital forms were tabulated by randomised group and time point.
Hospital visits
Participants were asked to attend a hospital follow-up visit at 6, 12 and 52 weeks post randomisation.
Baseline participant characteristics and fracture details were summarised descriptively overall and by
randomised group according to whether or not participants attended the hospital visit at each time point.
Compliance with random allocation and treatment received
The treatment received by participants in the two groups was summarised, with reasons given for any
treatment crossover.
Primary outcome (Patient-Rated Wrist Evaluation) analysis
The PRWE was assessed at baseline (pre and post injury, prior to randomisation) and at 6, 12, 26 and
52 weeks post randomisation. The PRWE total score is a value between 0 and 100, where a higher score
indicates worse pain and functioning. The score is computed by scoring the two subscales out of 50
(pain = sum of items 1–5; function = sum of items 6–15 divided by two) and summing them, so that
pain and function problems are weighted equally. If there was up to one missing item in each subscale,
then the missing item was replaced by the mean of the completed items within that subscale.49 If two
consecutive responses (between 0 and 10) to a particular item were selected, then the higher of the two
(the worse response) was taken for analysis. Other ambiguous responses were treated as missing. If more than
one item was missing in either subscale, then a score for that subscale, or for the total, could not be calculated.
The number and percentage of participants with valid and partial PRWE data were reported by randomised
group and time point. Baseline participant characteristics and fracture details were summarised descriptively
overall and by randomised group according to whether or not participants had valid PRWE outcome data
at each post-randomisation time point. Total PRWE scores were summarised by time point according to
whether or not participants had valid data for (1) all post-randomisation time points, (2) at least one, but not all,
post-randomisation time points or (3) no post-randomisation time points. PRWE scores (subscales and total)
were summarised descriptively by treatment group and overall.
Total PRWE scores were compared between the two groups using a covariance pattern, mixed-effect
linear regression model incorporating all post-randomisation time points. Treatment group, time point,
a treatment-by-time interaction, participant age at randomisation, baseline fracture displacement and
dominance of injured hand were included as fixed effects, and participant was included as a random effect
(repeated observations per participant). Fracture displacement was used as a stratification factor in the
randomisation; however, there were several instances in which the wrong displacement category was used
in the randomisation. Such stratification errors were identified when there was a discrepancy between the
data provided at randomisation and the data recorded on the study eligibility form. If the randomisation
data were incorrect, a file note was raised and the trial statistician was notified; if the data on the study
eligibility form were incorrect, the form was amended. The displacement used in the randomisation was
the variable included in the primary analysis, but the errors were discussed. The primary model was not
adjusted for baseline total PRWE, as, in this young population, we expected pre-injury PRWE score to be
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low and have little variability and post-injury PRWE score to be confounded, as patients would most likely
be in a plaster cast.
An unstructured covariance pattern for the correlation between the observations for a participant over time
was specified in the final model based on Akaike information criterion (AIC)77 (smaller value preferred).
An estimate of the difference between treatment groups in total PRWE score was extracted from the
repeated measures model for each time point, and overall, with a 95% CI and p-value. The primary end
point was the treatment effect estimate at 52 weeks. Estimates for the treatment effect at other time
points (6, 12 and 26 weeks) and overall served as secondary outcomes. This repeated-measures approach
is more efficient and parsimonious than conducting separate linear regressions for each time point, and
also allows for the ‘overall’ (across the whole 52 weeks) effect to be investigated using the same model.
The analysis takes advantage of the extra information provided at, and the correlation between, all
post-randomisation time points. The standard errors for treatment effects at individual time points were
calculated using information from all time points and were hence more robust and accurate than standard
errors calculated from separate analyses at each time point. An additional advantage of the mixed model
approach is that the presence of missing data across time points does not cause a problem under the
assumption that they are missing at random. For the estimates at a single time point, say at 52 weeks,
it is primarily the observations at that time point that determine the treatment effect and power; however,
owing to the covariance between the post-randomisation time points, greater power and precision is
obtained than that from a comparison using only the 52-week data.78
Model assumptions were checked as follows: the normality of the standardised residuals was checked
using a quantile–quantile plot and homoscedasticity was assessed by means of a scatterplot of the
standardised residuals against fitted values.
Sensitivity analyses
Missing data
Any response bias was partially minimised by using a mixed-effect, repeated measures model, which allows
the inclusion of intermittent responders in the primary analysis. Multiple imputation by chained equations
was also used to handle missing PRWE outcome data. Missing outcome and covariate data were predicted
by age, fracture displacement, hand dominance and available PRWE data at other follow-up time points.
A ‘burn-in’ of 10 was used and 20 imputed data sets were created. Separate linear regressions were then
run on the multiply imputed data set to compare the PRWE between the two groups at 6, 12, 26 and
52 weeks, adjusting for age, displacement and dominance of injured wrist. Estimates were combined using
Rubin’s rules via the ‘mi estimate’ command in Stata.79
Handling multisite data
Participants were recruited from multiple sites. To investigate whether or not site affects the outcome, a
sensitivity analysis was conducted including site as a random effect (within which participants were nested)
in the model as described for the primary analysis.80
Timing of data collection
The primary analysis model was repeated including only data collected 1 week either side of the 6-week
time point, 2 weeks either side of the 12-week time point, 6 weeks either side of the 26-week time point
and 8 weeks either side of the 52-week time point.
Post hoc sensitivity analysis including smoking status
Current smoking status (yes/no) was included as a covariate in the primary analysis model in a post hoc
sensitivity check, as this factor was found to be imbalanced by chance at baseline between the randomised
groups and thought to be associated with healing and complications. The decision to conduct this sensitivity
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analysis was taken after the primary analysis results were known; this decision was not prespecified in the
statistical analysis plan.
Displacement and lack of fracture as assessed by independent review of baseline
imaging data
Discrepancies were reported between the displacement of the fracture (< 1 mm or 1–2 mm inclusive) as
judged by the treating clinician on plain radiographs and as used for the randomisation and the judgement
agreed on by three independent reviewers using the baseline CT scans and radiographs. The primary
analysis model was rerun including a variable indicating the level of displacement judged by the three
raters instead of that on which randomisation was based.
We report the numbers of cases in which a consensus was reached between the three raters that (1) there
was no fracture or (2) displacement of the fracture was > 2 mm, based on their assessment of the baseline
radiographs/CT scans, as these were exclusion criteria. Separate sensitivity analyses of the primary outcome
model were conducted excluding these patients.
Complier-average causal effect analysis
To account for non-compliance (surgery to plaster cast) and contamination (plaster cast to surgery), a
complier-average causal effect (CACE) analysis was conducted. A two-stage least squares instrumental
variable approach81,82 was used with randomised treatment as the instrumental variable (implemented
using the ‘ivregress’ command in Stata) to compare PRWE scores at 52 weeks, adjusting for age, fracture
displacement and hand dominance. For this analysis, it was assumed that, had they been offered surgery,
participants allocated to the plaster cast group would have the same probability of non-compliance as
those allocated to the surgery group; likewise, it was assumed that, had they been offered non-surgical
management, participants allocated to the surgery group would have the same probability of contamination
as those allocated to the plaster cast group. Finally, it was assumed that simply being offered the allocated
treatment has no effect on the outcome. These assumptions were plausible under randomisation, which
should balance covariates across the two groups.
Subgroup analysis
In total, three subgroup analyses were undertaken: one exploring patient treatment preferences as
expressed at baseline and two exploring fracture displacement. Owing to the errors in classification of
fracture displacement at randomisation, two approaches for the displacement subgroup analysis were
taken: one using displacement as defined at randomisation and one using the classification given on the
study eligibility forms. Total PRWE scores are summarised by randomised group and time point, stratified
by the levels of the baseline factor of interest. To investigate whether the treatment effect varied across
the levels of these baseline factors, the factor was included in the primary analysis model alongside an
interaction between randomised treatment allocation and baseline factor, using a two-sided p-value of 0.05.
Interpretation of these models was made cautiously, as the trial was not powered for interactions.83,84
Descriptive summaries of baseline participant and fracture data and PRWE scores are presented for:
l participants in the plaster cast arm stratified by whether or not they needed surgery owing to
non-union
l participants in the surgery arm stratified by whether or not the surgical screw used was too long and
caused cartilage damage, as determined on the CT scans by the three independent raters.
There were two feasibility requirements for this trial: (1) that a CT scan was performed within 2 weeks of
a patient’s injury (or before surgery if this occurred earlier) and (2) that, for patients in the surgery arm,
surgery was performed within 2 weeks after presentation to A&E or another clinic. It was considered a
protocol deviation if these tasks were performed outside these parameters. A linear regression for the
surgery arm only investigated whether the time from injury to surgery in days was predictive of total PRWE
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score at 52 weeks, adjusted for age, fracture displacement and hand dominance. Descriptive summaries
of baseline participant and fracture data and PRWE scores are presented for:
l participants stratified by whether or not their CT scan was performed within 2 weeks of the injury
(or before surgery if this occurred earlier)
l participants in the surgery arm stratified by whether or not their surgery was performed outside the
target 2-week period from first presenting at A&E or another clinic.
Secondary analysis
Secondary outcomes
The secondary outcomes, namely the pain and function subscales of the PRWE, the physical and mental
health component summaries of the SF-12 and grip strength, were summarised descriptively for each
time point by treatment group and overall, and were analysed using the same method as for the primary
outcome, adjusting for the same covariates. The most appropriate choice of covariance structure was
identified separately for use with each outcome, which was always an unstructured pattern.
Union
Plain radiographs at 6, 12 and 52 weeks and CT images at 52 weeks were reviewed by three independent
raters at the end of the trial for union of the fracture. Union, as reviewed on CT images at 52 weeks,
was measured as a percentage (0–100%) and categorised as 0% (non-union), > 0–20% (slight union),
> 20–70% (partial union), > 70–100% (but not including 100%; mostly united) and 100% (complete
union). The same categories of union were used for radiograph images at 6, 12 and 52 weeks. The extent
of union was presented for each time point by randomised group. Participants were dichotomised at each
time point as ‘probably need surgery’ (non-union and slight union) and ‘probably do not need surgery’
(partial to complete union) and analysed using a logistic regression model (52-week data only). It was
originally planned that a mixed-effect logistic regression model would also be conducted to compare the
treatment groups at 52 weeks, with participant as a random effect to account for the repeated measures
of union at 6, 12 and 52 weeks, adjusting for age, displacement and dominance of injured wrist as fixed
effects. However, this model did not converge. As an alternative sensitivity check, multiple imputation
was used to impute the dichotomised union variables at 6, 12 and 52 weeks (imputation included union
variables, age, displacement, dominance of injured wrist and allocation). A ‘burn-in’ of 10 was used and
20 imputed data sets were created. A logistic regression was run on the multiply imputed data set to
compare union between the two groups at 52 weeks, adjusting for age, displacement and dominance
of injured wrist.
The 52-week PRWE scores for patients overall and for patients who did and did not attend imaging at
52 weeks were summarised by treatment group.
Malunion
Scaphoid height and length were measured by the three independent raters of the CT images and plain
radiographs. Malunion was defined using a ratio of scaphoid height to length of > 0.6. During the study,
literature was published that suggested that a threshold ratio of 0.7 might be more appropriate85 than 0.6.64
Rates of malunion at the 0.6 and 0.7 thresholds are presented overall and for each treatment group at
6, 12 and 52 weeks.
Complications
Complications were defined as medical, surgical and plaster cast related, and were assessed by clinical
examination at 6, 12 and 52 weeks. The number of patients who experienced a complication of a certain
type was summarised by randomised group. The presence of any medical, surgical or cast complication
recorded on the complications form up to 52 weeks was analysed by logistic regression, adjusting for age,
hand dominance and fracture displacement.
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Cases in which two out of the three raters agreed, based on the imaging, that there was a complication
were reported.
Adverse events
All serious and non-serious adverse events (AEs) were summarised by treatment group.
Agreement analysis
A descriptive analysis of agreement between the three raters was performed. Radiographs provide categorical
grades of fracture, displacement and union and these were summarised by cross-tabulating the results from
each pair of raters and calculating their percentage agreement. The CT scans provide continuous measures
of displacement and of the percentage of union. Agreement between these continuous measures was
summarised in Bland–Altman plots that compared each pair of raters, and the limits of agreement were
calculated. For all numerical summaries, 95% CIs were provided.
Data management
All hospital forms, imaging compact discs and participant questionnaires were sent from and returned
to YTU. A central database at YTU was used to prompt the sending out and return of participant
questionnaires and hospital case report forms (CRFs). This included automated e-mail reminders sent to
participating sites to help ensure the timely return of hospital CRFs.
Essential trial documentation, which individually and collectively permits evaluation of the conduct of a
clinical trial and the quality of the data produced, was kept with the Trial Master File and Investigator Site
Files. This documentation will be retained for a minimum of 5 years after the conclusion of the trial in
accordance with Good Clinical Practice. The postal questionnaires and hospital CRFs will be stored for a
minimum of 5 years after the conclusion of the trial as paper records and for a minimum of 20 years in
electronic format.86
Design of patient questionnaires and hospital case report forms
The patient questionnaires and hospital CRFs were designed using TeleForm software (version 10; Cardiff
Software, Cambridge, UK). Specification CRFs were populated with variable names and appropriate scoring.
To maximise data quality, when hospital CRFs were returned to YTU, key variables required for the statistical
analysis were reviewed for completion and accuracy by a trial co-ordinator/research data administrator who
resolved any queries with the research nurse at the site. The hospital sites were reimbursed according to a
payment schedule for the completion of CRFs and provision of research imaging up to a total of £430.30.
This was agreed between each trust and trial sponsor using a Clinical Trial Agreement. No checks regarding
the data quality of the postal questionnaires were made on immediate return to YTU. A trial co-ordinator
did, however, as a duty of care, check if a participant had responded with the extreme answers to the
following: questions 4a, 4b, 6a and 6b of the SF-12 and the final EQ-5D-3L question. The trial co-ordinator
also checked free-text responses to see if the participant could be at harm. When this occurred, the PI and
research nurse at the recruiting site were notified by e-mail.
After this initial check, all postal questionnaires and hospital CRFs were prepared for scanning by a research
data administrator using the TeleForm software. When a form would not scan, the data were manually
entered. When a form was scanned, the data were then verified depending on what TeleForm identified as
requiring correction. The verified data were then temporarily held in the download database and available
for second checking. This involved each hard copy of all forms being compared against the entry stored in
the download database and correcting the electronic data as necessary. All data were scanned, downloaded
and second checked in the validate database. The automated data validation was undertaken by the data
manager who applied predetermined rules to check for agreed variables to see if the data were recorded
correctly. Data that had been validated were then held in the survey database and were available on a
formal request from the trial statistician and health economist.
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Strategies to follow up patients
Participants at the 6-, 12-, 26- and 52-week follow-ups were notified by post to expect the questionnaire
(see Report Supplementary Material 15) 2 weeks before it was due. Reminder letters were sent 2 and 4 weeks
after the due letter was sent out. When there was no response to reminder letters, a trial co-ordinator at YTU
contacted participants by telephone, who were invited to provide answers for, as a minimum, the primary
outcome (PRWE) and EQ-5D-3L. At 52 weeks only (the primary time point for the study), in addition to the
telephone call at 6 weeks, a letter was sent to non-responding participants requesting that they complete
the PRWE only. At 26 weeks, if participants did not attend a hospital appointment, an unconditional incentive
of £5 was included with the postal questionnaire. At 52 weeks, a £40 payment was made to participants
who attended the clinic. For the final 11 months of the follow-up period of the study, participants were
also offered up to £40 to cover their travel expenses, or more if this was agreed with the trial team. The
participants could complete the follow-up questionnaires during the clinic visits.
Various techniques were used to minimise loss to follow-up. This included regular participant newsletters,
which publicised the progress of the study on the trial website (www.swifft.co.uk). A trial ‘tagline’ was
placed on postal envelopes sent to participants to highlight the importance of their involvement in the
research (i.e. ‘SWIFFT Study: Patients helping to improve healthcare through research’). As the return of
postal questionnaires can be improved when participants are included in a prize draw,87 anyone who
returned their questionnaire at 26 weeks could win an iPad® (Apple Inc., Cupertino, CA, USA) worth £500.
Participants who attended their hospital clinic appointment at 52 weeks were also entered into a prize
draw to win an iPad worth £500. If, at 52 weeks, it was difficult to arrange the hospital appointment,
a letter was sent from the hospital to the participant along with a leaflet to encourage their attendance.
Other strategies to collect follow-up data on participants who did not return their questionnaire or attend
clinics included using a participating hospital’s Picture Archiving Communication System (PACS) for the
local area/region to retrieve imaging of patients; accessing Summary Care Records to view participants’
addresses and/or the general practitioner (GP) they were registered with to help contact them; and asking
a participant’s GP if they have had an operation on their scaphoid fracture.
A trial participant could withdraw from the study at any time for any reason, but any data collected up to
that point was used in the analysis. A participant could withdraw from all data collection, or from postal
questionnaire collection or hospital data collection only, which was recorded using a change in status form
(see Report Supplementary Material 16).
Data management for the review of imaging
The forms used to capture assessments of the scaphoid fracture and conduct measurements on the imaging
collected were created using the ‘Design’ module in Formic Fusion® software (5.5.1; Formic Limited, Middlesex,
UK) and include the SWIFFT master radiograph form, SWIFFT baseline CT form and SWIFFT 52-week CT form.
Once completed by reviewers, variables within each form were checked visually for completeness and
for whether or not measurements were within an expected range. Completed forms were then scanned
using the Formic ‘Capture & Process’ module and responses were reviewed. The Formic scanning software
flagged hand-written text and those checkboxes with no mark or more than one mark; these were manually
corrected to reflect the entry on the form. The scanned image of the form was also held within the database
to permit independent verification. Once exported to the ‘SWIFFT logging database’ (Microsoft Access®,
Microsoft Corporation, Redmond, WA, USA), the data then went through a final electronic check to
ensure all measurements were within the limits assigned by the chief investigator and to check for errors
in measurements (e.g. cm instead of mm). The data were then checked for these rules in Stata v15 and
potential problems were flagged and checked by each reviewer.
Data from the three reviewers were assessed and any classification conflicts on fracture displacement at
baseline and state of the union at 52 weeks were identified and resolved in ‘conflict resolution meetings’
using specific forms (SWIFFT conflict CT form, SWIFFT conflict radiograph form and SWIFFT 52-week
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inter-observer conflict forms), which were used when conflicts were resolved. Predefined agreement rules
were used to generate the final data based on all three reviewers’ assessments.
All conflicts identified were reviewed by all reviewers at face-to-face/teleconference meetings. All reviewers
looked at the images together and a collective decision was made and recorded. From the 439 baseline
radiographs reviewed, 106 were taken back to a conflict meeting. Of the 431 CT images reviewed at
baseline, 155 were taken back to a conflict meeting to agree displacement thresholds. These baseline
conflicts were reviewed over 26 meetings between September 2013 and February 2018. At 52 weeks,
297 radiographs and 292 CT scans were reviewed. All radiographs and CT scans at 52 weeks that were
classified as a ‘non-union’ by any one reviewer were brought back to the conflict resolution meeting for
confirmation. Of both radiographs and CT scans, only 17 were taken back to three conflict meetings to
agree the state of the union.
Finally, the reviewers also agreed the cases that did not have an identifiable fracture on baseline radiographs
(one) and CT scans (five). There were also a total of 52 conflicts identified on the categorical data at
baseline. For baseline radiographs, 15 conflicts were identified from the categorical classification of the
orientation of the fracture line. These were reviewed by all reviewers and were resolved. For baseline CT
scans, 37 conflicts were identified involving the fracture line (27) and fracture location (10). All of these
were reviewed at a conflict meeting in January 2018 and all were resolved.
Adverse event management
Adverse events were defined as any untoward medical occurrence in a trial participant that did not
necessarily have a causal relationship with the treatment. Serious AEs (SAEs) were defined as any untoward
medical occurrence that:
l resulted in death
l were life-threatening
l required hospitalisation or prolongation of existing inpatient hospitalisation
l resulted in persistent or significant disability or incapacity
l was a congenital anomaly or birth defect.
In addition, SAEs included any other important medical condition that, although not included in the above,
may have required medical or surgical intervention to prevent one of the outcomes listed. (S)AEs related
to scaphoid fracture and its treatment during the 12 months after randomisation were recorded by site PIs
on a CRF (see Report Supplementary Materials 17 and 18). The trial office was notified of any SAEs within
24 hours of the PI becoming aware of them, and of any AEs within 5 days. The categorisation of causality
and expectedness was confirmed by the chief investigator. AEs that were expected with this injury to
the wrist and related to anaesthesia and/or surgery were infection, CRPS, screw-related complications,
chondrolysis, delayed wound healing, nerve or vessel events, fracture of scaphoid tuberosity, and nausea
and/or disorientation. AEs specific to the plaster cast were soft cast/broken cast that led to movement of
the wrist, CRPS, pressure sores, nerve compression or pain due to a tight cast. Movement in a cast was
considered untoward, as it could mean that the fracture was not properly immobilised and could result in
failure to unite.
All (S)AEs were routinely reported to the Trial Management Group (TMG), Trial Steering Committee (TSC),
Data Monitoring Committee (DMC) and sponsor. SAEs that were related to the research and unexpected
were reported to the Research Ethics Committee (REC). The chief investigator reviewed all (S)AEs that were
unresolved at initial reporting a month later. This was to ensure that adequate action had been taken.
Additional reviews at 1-month intervals were conducted until the chief investigator confirmed that no
further monitoring was required.
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The chief investigator was also informed, by the reviewers of the radiographs/CT scans collected for the
study, of any abnormalities identified. The chief investigator judged whether or not the abnormality was
clinically important and could affect patient safety (e.g. a protruding screw). The need to notify the PI
of the site, and whether or not to record this as an AE, was also considered. No actions or treatments
were discussed with the PI.
Ethics approval and monitoring
Standard NHS cover for negligent harm was available. There was no cover for non-negligent harm.
Ethics committee approval and any changes to the project protocol
SWIFFT was approved by Derby Research Ethics Committee – East Midlands on 21 May 2013 (REC reference
13/EM/0154). NHS permission was given by the research and development department of each participating
site. A summary of the changes made to the protocol since the original REC approval are listed in Appendix 2.
The trial protocol was published in BMC Musculoskeletal Disorders.48
Trial Management Group
The day-to-day management of the trial was overseen by the TMG, which met on a quarterly basis. A
representative of the sponsor attended when available. These meetings monitored the progress as regards
recruitment (e.g. enrolment, consent and eligibility), allocation to study groups, adherence of the trial
interventions to the protocol, retention of trial participants, monitoring of (S)AEs and reasons for participant
withdrawal. The review of progress was undertaken at the level of the participating site and, as necessary,
feedback was given to the PI and research nurses at each site.
Trial Steering Committee
A TSC was appointed by the funding body to provide overall supervision of the trial and to advise on its
continuation. Membership is listed in the Acknowledgements.
Data Monitoring Committee
The DMC was appointed by the funding body with access to the unblinded comparative data as provided
by a statistician at YTU who was independent of the trial team. The DMC monitored the data and notified
the TSC of whether or not there were any ethical or safety reasons why the trial should not continue.
Membership is listed in the Acknowledgements.
Patient and public involvement
A patient who had a fracture of their left wrist and was treated at the sponsor site commented on the
study documentation and was invited to TMG meetings. Alternatively, their opinion was sought outside
these meetings. This patient also contributed to a video that was posted on the trial website, which
was publicised in a newsletter to participants, to encourage completion of postal questionnaires and
attendance at hospital visits. In Leicester, a group of eight individuals [six of whom had experience of a
scaphoid fracture and two who had not but were typical of the patient population (i.e. male and aged
under 30 years)] met to advise the TMG on strategies to maximise the retention of trial participants; these
individuals were also contacted by e-mail for advice.88 This meeting was led by the chief investigator, a
senior qualitative researcher and the patient representative on the TMG. This group will also advise on the
summary of the findings for trial participants and other dissemination activities. In one of our newsletters
to participants, a photograph and positive feedback about their involvement in the trial was included
from the participant who won the prize draw of the iPad at the 26-week follow-up. Two members of the
Patient Liaison Group of the British Orthopaedic Association were independent members of the TSC and
advised on strategies to maximise recruitment and retention.
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Chapter 3 Clinical effectiveness results
Recruitment
Site recruitment
In our original protocol, we estimated that we would need 17 sites to recruit patients into SWIFFT. The
number of sites was increased to meet the slightly lower than planned recruitment rate. Forty sites were
approached to take part in SWIFFT between May 2013 and March 2015 and, in total, 34 sites were set up
and opened to recruitment, the last of which commenced screening/recruitment in June 2015. Thirty-three
sites screened at least one patient and 31 sites recruited at least one participant (median 10, range 1–61).
Two of the three sites that did not recruit any participants screened one and two patients, respectively,
one of which was eligible but non-consenting. The lead site, Leicester Royal Infirmary within the University
Hospitals of Leicester NHS Trust, recruited the highest number of patients of all sites (n = 61). Table 1
presents the number of patients recruited by each site, ordered by when each site was set up to recruit
(Leicester first), with sites identified at trust level. One hospital from each trust took part in SWIFFT.
All sites agreed to recruit an average of one patient per month, but only two sites achieved this.
TABLE 1 The SWIFFT recruitment by hospital site
Site Date opened
Months
open
Number
recruited
Average
number of
recruits
per month
University Hospitals of Leicester NHS Trust 1 July 2013 37 61 1.6
South Tees Hospitals NHS Foundation Trust 17 August 2013 36 10 0.3
University Hospitals Coventry and Warwickshire NHS Trust 9 September 2013 35 24 0.7
Nottingham University Hospitals NHS Trust 25 September 2013 35 27 0.8
Chelsea and Westminster Hospital NHS Foundation Trust 19 November 2013 11a 0 0.0
Southport and Ormskirk Hospital NHS Trust 21 November 2013 13a 0 0.0
Bolton NHS Foundation Trust 2 December 2013 32 17 0.5
Northumbria Healthcare NHS Foundation Trust 6 February 2014 30 5 0.2
Oxford University Hospitals NHS Trust 7 February 2014 30 35 1.2
University Hospital Southampton NHS Foundation Trust 10 February 2014 30 17 0.6
Royal Berkshire NHS Foundation Trust 10 February 2014 30 9 0.3
Salford Royal NHS Foundation Trust 10 February 2014 30 4 0.1
Brighton and Sussex University Hospitals NHS Trust 26 February 2014 30 5 0.2
Worcestershire Acute Hospitals NHS Trust 10 March 2014 8a 0 0.0
Hampshire Hospitals NHS Foundation Trust 17 March 2014 29 6 0.2
Royal United Hospitals Bath NHS Trust 17 March 2014 29 23 0.8
Poole Hospital NHS Foundation Trust 22 April 2014 28 5 0.2
Royal Cornwall Hospitals NHS Trust 9 May 2014 27 24 0.9
Cardiff and Vale University Health Board 12 May 2014 27 22 0.8
Maidstone and Tunbridge Wells NHS Trust 21 May 2014 27 5 0.2
continued
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Patient recruitment
Our required sample size was 438 participants, which we aimed to achieve by the end of March 2016;
however, recruitment was slightly slower than anticipated in the final few months and we agreed with the
trial sponsor, the trial funder and the REC (February 2016) to extend recruitment beyond March 2016 until
the 438 patients had been recruited.
The first participant was randomised on 23 July 2013. As of 31 July 2016, 439 patients had been enrolled in
the trial and sites were notified that recruitment should cease; thus, patients were recruited over 37 months.
Figures 3 and 4 demonstrate our final recruitment figures.
Characteristics of screened patients
A total of 1047 patients who met the inclusion criteria (aged 16 years or over and skeletally mature, presenting
within 2 weeks of injury with a radiologically confirmed clear and bicortical fracture of the scaphoid waist
that does not include the proximal pole) were assessed for participation in the trial from July 2013 to
July 2016, of which 775 (74.0%) were eligible and 439 (41.9%) were eligible and consenting, the latter
all being randomised. The number of participants screened per site ranged from 1 to 133 (median 23) and
the percentage of screened participants who were eligible per site ranged from 0 to 100% (median 83.3%).
Table 2 displays the characteristics of the different populations. Eligible patients tended to be younger and
were more likely to be male and have a displaced fracture than ineligible patients. There were no marked
differences between consenting and non-consenting patients in gender, age or time since injury; however,
there was an indication that consenting patients were more likely to have a displaced fracture than non-
consenting patients. The numbers of patients for whom each type of radiograph was used to determine
eligibility, along with the percentage of those screened, are as follows: elongated scaphoid view (n = 910,
86.9%), posterior–anterior view (n = 1024, 97.8%), 45° semisupine view (n = 610, 58.3%), lateral view
(n = 1017, 97.1%) and 45° semiprone view (n = 834, 79.7%). Screened patients had a median of four
scaphoid radiographic views taken.
TABLE 1 The SWIFFT recruitment by hospital site (continued )
Site Date opened
Months
open
Number
recruited
Average
number of
recruits
per month
Taunton and Somerset NHS Foundation Trust 1 June 2014 26 7 0.3
University Hospitals Plymouth NHS Trust 9 June 2014 26 20 0.8
North West Anglia NHS Foundation Trust 12 June 2014 26 17 0.7
Cambridge University Hospitals NHS Foundation Trust 16 June 2014 26 5 0.2
The Royal Liverpool and Broadgreen University Hospitals
NHS Trust
17 June 2014 26 5 0.2
Barts Health NHS Trust 20 June 2014 26 24 0.9
Gloucestershire Hospitals NHS Foundation Trust 10 July 2014 25 15 0.6
North Bristol NHS Trust 1 September 2014 23 13 0.6
University Hospitals Bristol NHS Foundation Trust 6 October 2014 22 10 0.5
Newcastle upon Tyne Hospitals NHS Foundation Trust 10 November 2014 21 11 0.5
Medway NHS Foundation Trust 12 November 2014 21 2 0.1
Lancashire Teaching Hospitals NHS Foundation Trust 24 November 2014 21 1 0.05
University Hospitals Birmingham NHS Foundation Trust 16 February 2015 18 6 0.3
King’s College Hospital NHS Foundation Trust 22 June 2015 14 4 0.3
a Withdrew interest in recruiting to SWIFFT.
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FIGURE 4 Recruitment targets of participants into SWIFFT.
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Reasons for exclusion
A total of 272 (26.0%) of the 1047 patients screened were ineligible for the trial for one or more reasons
(Table 3). Twenty-nine of these should strictly never have been screened for participation in the trial, as
they did not fulfil the inclusion criteria: their injury was more than 2 weeks old (n = 15), they did not have
a radiologically confirmed bicortical fracture (n = 7), their fracture included the proximal pole (n = 6) or they
were skeletally immature (n = 1). A further 156 patients failed at least one of the exclusion criteria, most
commonly having a concurrent other injury in the same limb (n = 70). The remaining 87 were ineligible for
other reasons: the site did not think it was feasible for the patient’s surgery (if allocated) to be scheduled
within 2 weeks from presentation (n = 30), the patient was not approached about study (e.g. they
presented at the weekend when there was no clinician available to confirm eligibility) (n = 21), the patient
was deemed to be unsuitable for surgery (n = 16), the fracture was seen on radiography but not on the
subsequent CT scan (n = 8) or other miscellaneous/unknown reasons (n = 12).
Patient consent
The percentage of eligible patients who consented to take part in the trial varied in the 31 sites that
recruited a patient from 13.9% to 100% (median 63.2%). A reason was provided for 325 of the 336
(96.7%) patients who did not consent to the study, despite being eligible: patient had a preference for
non-operative treatment (n = 206), patient had a preference for surgery (n = 40), patient was unable to
commit to follow-ups (n = 24), patient did not want to take part in research and/or was unhappy with
the concept of random treatment allocation (n = 13), consent was not given in time to allow surgery
TABLE 2 Patient baseline characteristics of different populations
Characteristic
Screened
(N= 1047)
Ineligible
(N= 272)
Eligible (N= 775)
Non-consenting
(N= 336)
Consenting
(N= 439)
Gender, n (%)
Male 834 (79.7) 203 (74.6) 268 (79.8) 363 (82.7)
Female 210 (20.1) 66 (24.3) 68 (20.2) 76 (17.3)
Missing 3 (0.3) 3 (1.1) 0 (0.0) 0 (0.0)
Age (years)
n 1040 266 335 439
Mean (SD) 33.7 (14.8) 36.6 (17.5) 32.5 (14.6) 32.9 (12.7)
Median (min., max.) 29.2 (16.0, 94.8) 30.0 (16.2, 94.8) 28.2 (16.0, 79.7) 29.3 (16.1, 80.6)
Time since injury (days)a
n 1044 269 336 439
Mean (SD) 1.0 (1.8) 1.2 (2.5) 1.0 (1.5) 0.8 (1.4)
Median (min., max.) 0 (0, 14) 0 (0, 14) 1 (0, 9) 1 (0, 10)
Displacement involvement,b n (%)
Displacement 342 (32.7) 61 (22.4) 111 (33.0) 170 (38.7)
No displacement 651 (62.2) 160 (58.8) 222 (66.1) 269 (61.3)
Missing 54 (5.2) 51 (18.8) 3 (0.9) 0 (0.0)
Max., maximum; min., minimum; SD, standard deviation.
a Time from injury to first contact with the NHS (presentation at A&E or other); this is consistent with the inclusion
criterion for patients to present at a participating site within 2 weeks of injury.
b As recorded on the study eligibility form.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
(if allocated) to be conducted within 2 weeks of presentation at A&E or another clinic (n = 13), patient
circumstances did not allow for surgery (if allocated) to be conducted within 2 weeks of presentation at
A&E or another clinic (e.g. planned holiday or exams) (n = 7) and other miscellaneous reasons (e.g. patient
trying to become pregnant, patient having multiple comorbidities, etc.) (n = 22).
Treatment preference data were collected for 320 of the 336 eligible but non-consenting patients: 30
(9.4%) had no treatment preference, 57 (17.8%) had a preference for surgery and 233 (72.8%) preferred
not to have surgery. A response to the treatment that the surgeon advised the patient to have was
provided for 325 patients: no surgery (n = 191, 58.8%), surgery (n = 32, 9.9%) and uncertain (n = 102,
31.4%). The agreed treatment for 328 of these patients was recorded: surgery (n = 45, 13.7%) and no
surgery (n = 283, 86.3%).
In total, the median time spent obtaining consent from each participant to participate in the trial was
20 minutes. In general, approximately 10 more minutes were spent with participants who went on to
be randomised than those who did not [randomised: mean [standard deviation (SD)] = 31.6 minutes
(18.9 minutes), median = 30 minutes; not randomised: mean (SD) = 19.5 minutes (12.7 minutes),
median = 20 minutes].
TABLE 3 Reasons for patient ineligibility for SWIFFT
Reason for ineligibility
Number of (%)
ineligible patients
(N= 272)
Exclusion criteria (N = 156) – reasons not mutually exclusive
Fracture displaced by > 2mm 43 (15.8)
Concurrent wrist fracture in the opposite limb 12 (4.4)
Trans-scaphoid perilunate dislocation 8 (2.9)
Multiple injuries in the same limb 70 (25.7)
Patient not a resident in the trauma centre catchment area of the participating site 21 (7.7)
Previous injury or disease in the same wrist 2 (0.7)
Patient lacks the mental capacity and is unable to understand the trial and instructions for treatment 11 (4.0)
Patient is pregnant 6 (2.2)
Other reasons (N = 116)
Patient did not meet the inclusion criteria to be approached about the trial 29 (10.7)
Presenting > 2 weeks after injury 15
No radiologically confirmed bicortical fracture 7
Fracture includes proximal pole 6
Aged < 16 years and/or skeletally immature 1
No fracture seen on CT scan prior to randomisation 8 (2.9)
Surgery not feasible within 2 weeks of injury 30 (11.0)
Patient not suitable for surgery 16 (5.9)
Study not discussed with patient (e.g. patient presented at the weekend) 21 (7.7)
Othera 12 (4.4)
a No reason provided (n = 6), patient currently in prison or a young offenders’ institute (n = 2), hospital records show that
patient did not attend six times to visits so patient deemed unreliable (n = 1), clinician deemed fracture ‘would fix irrespective
of study’ (n = 1), scapholunate disruption likely (n = 1), patient previously approached about SWIFFT for right scaphoid
fracture but declined as did not want surgical intervention, so patient not approached for left scaphoid fracture (n = 1).
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Participant flow
The flow of patients through the trial is summarised in a CONSORT flow diagram in Figure 5. Of the 439
randomised participants, 408 (92.9%) were eligible for inclusion in the primary analysis model (surgery arm:
203/219, 92.7%; non-surgery arm: 205/220, 93.2%). The trial was designed to allow for 20% attrition.
Baseline characteristics of randomised participants
The 439 participants were randomised using equal allocation to surgery (n = 219) or plaster cast
management (n = 220) of their fractures. The allocation of participants was stratified by fracture
displacement at enrolment (< 1 mm or 1 to 2 mm inclusive). On 24 occasions, the incorrect displacement
stratum was used in the randomisation: 16 participants with no fracture displacement were randomised
within the displacement stratum and eight participants with displacement were randomised within the
no displacement stratum [see Chapter 2, Primary outcome (Patient-Rated Wrist Evaluation) analysis].
A baseline questionnaire was not received from two participants (both allocated to the surgery group).
The recruited participants were predominantly male (82.7%) and the average age was 32 years (range
16–80 years). Just over half of the participants (53.6%) had injured their left wrist and their non-dominant
side (56.8%). Nearly half of the participants stated that they did not have a treatment preference at
enrolment to the trial (47.6%), but, of the other 230 participants, most (84.3%) expressed a preference
for surgery. This trend is substantially different from that observed in the population of eligible but non-
consenting participants, who predominantly stated a preference to not receive surgery. The treatment
groups as randomised and as analysed appear to be balanced on all measured baseline participant
characteristics and fracture details (see Tables 4 and 5), with the exception of ethnicity, education
and smoking status. Participants in the plaster cast group were more likely to have a degree or higher
qualifications and were less likely to be smokers and to be white than those in the surgery group, both as
randomised and as analysed. No formal statistical comparisons were conducted and so we cannot see if
these differences are statistically significant, but these differences are consistent with a chance imbalance.
The trial team considered these imbalances post hoc and it was decided that a sensitivity analysis would
be included with an adjustment to the primary analysis model for smoking status, as this is likely to be
associated with outcome. It was not felt that ethnicity and education status were likely to be associated
with outcome and so no sensitivity analyses were conducted with these factors.
Follow-up
Participant questionnaires
In total, follow-up participant questionnaires were returned for 359 (81.8%), 349 (79.5%), 313 (71.3%)
and 364 (82.9%) of the 439 randomised participants at 6, 12, 26 and 52 weeks, respectively (Table 6).
Return rates were lower in the plaster cast group at all time points, except at 6 weeks, when they were
similar between the two groups.
The participant questionnaires were primarily returned by post (50% or more at each time point). At 6,
12 and 52 weeks, when participants were invited to attend a hospital visit, there was the opportunity to
complete the questionnaire in clinic. This occurred in 46.0%, 41.6% and 34.3% of cases at weeks 6, 12
and 52, respectively. Questionnaire data were completed by telephone as a last resort for hard-to-reach
participants in 84 instances.
The numbers of days from the date that the questionnaire was due (e.g. the 6-week questionnaire was
due 42 days after randomisation) to the completion of the questionnaire as recorded by the patient
(‘Days to complete’) and the return of the questionnaire to the YTU (‘Days to return’) are presented in
Table 6. If the questionnaire was completed/returned before the due date (i.e. if it was completed during
a clinic visit rather than having been posted by the YTU on the due date), the number of days was
recorded as zero. Medians and IQRs are presented, as the data had a right-skewed distribution because
most patients completed and returned their forms promptly. There was no obvious difference between
the two groups in time to completion or time to return.
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Withdrew from questionnaires (n = 5)
Died (n = 0)
Centres performing surgery (n = 29/31)
   Number of patients for each centre
   (median = 6, minimum = 0, maximum = 29)
Surgeons (n = 95)
   Number of patients for each surgeon
   (median = 1, minimum = 1, maximum = 6)
6-week questionnaire (n = 214)
Analysed (n = 176)
Excluded from analysis (n = 2)
• Partial response, n = 2
• All responses missing, n = 0
No response (n = 36)
12-week questionnaire (n = 212)
Analysed (n = 178)
Excluded from analysis (n = 4)
• Partial response, n = 4
• All responses missing, n = 0
No response (n = 30)
26-week questionnaire (n = 212)
Analysed (n = 156)
Excluded from analysis (n = 7)
• Partial response, n = 6
• All responses missing, n = 1
No response (n = 49)
52-week questionnaire (n = 212)
Analysed (n = 186)
Excluded from analysis (n = 0)
• Partial response, n = 0
• All responses missing, n = 0
No response (n = 26)
Withdrew from questionnaires (n = 2)
Died (n = 0)
Withdrew from questionnaires (n = 0)
Died (n = 0)
Withdrew from questionnaires (n = 0)
Died (n = 0)
Allocated to surgery (n = 219)
Received surgery (n = 188)
• No fracture on CT scan, n = 10
• Participant choice, n = 9
• Not bicortical scaphoid waist fracture, n = 8
• Other, n = 4
   • surgery inappropriate, n = 2
   • surgery could not be arranged, n = 1
   • participant had pericarditis, n = 1
Received non-surgical treatment (n = 31)
• Patient received plaster cast/splint, n = 30
• Patient received no treatment as subsequent 
   CT scan indicated no injury, n = 1
Withdrew from questionnaires (n = 3)
Died (n = 0)
Centres providing plaster cast treatment (n = 30/31)
   Number of patients for each centre
   (median = 5, minimum = 0, maximum = 32)
6-week questionnaire (n = 217)
Analysed (n = 172)
Excluded from analysis (n = 9)
• Partial response, n = 9
• All responses missing, n = 0
No response (n = 36)
12-week questionnaire (n = 217)
Analysed (n = 163)
Excluded from analysis (n = 4)
• Partial response, n = 4
• All responses missing, n = 0
No response (n = 50)
26-week questionnaire (n = 216)
Analysed (n = 146)
Excluded from analysis (n = 3)
• Partial response, n = 3
• All responses missing, n = 0
No response (n = 67)
52-week questionnaire (n = 213)
Analysed (n = 176)
Excluded from analysis (n = 2)
• Partial response, n = 2
• All responses missing, n = 0
No response (n = 35)
Withdrew from questionnaires (n = 0)
Died (n = 0)
Withdrew from questionnaires (n = 1)
Died (n = 0)
Withdrew from questionnaires (n = 3)
Died (n = 0)
Allocated to plaster cast (n = 220)
Received non-surgical treatment only (n = 195)
Received immediate surgical fixation (n = 6)
• Participant choice, n = 4
• CT scan showed displacement, n = 1
• Radiographs reviewed again and displacement
   deemed > 2 mm, n = 1
Received surgery due to treatment failure of
plaster cast (n = 1)
Received surgery following plaster cast treatment
(n = 18)
Randomised (n = 439)
Eligible (n = 775)
Assessed for eligibility (n = 1047)
Patient non-consent (n = 336)
Ineligible (n = 272)
Reason(s) for exclusion as the result of meeting one or more exclusion criteria:
• Multiple injuries in the same limb, n = 70
• Fractures displaced by > 2 mm, n = 43
• Patient not resident in trauma centre area, n = 21
• Concurrent wrist fracture in the opposite limb, n = 12
• Lack of mental capacity, n = 11
• Trans-scaphoid perilunate dislocation, n = 8
• Patient was pregnant, n = 6
• Previous injury or disease in same wrist, n = 2
Reason(s) for exclusion as the result of not meeting one or more of the
inclusion criteria:
• Surgery infeasible within 2 weeks of injury, n = 30
• Study not discussed with patient, n = 21
• Patient not suitable for surgery, n = 16
• Presenting > 2 weeks from injury, n = 15
• No fracture seen on CT scan prior to randomisation, n = 8
• No radiologically confirmed bicortical fracture, n = 7
• Fracture includes proximal pole, n = 6
• Aged < 16 years and/or skeletally immature, n = 1
• Other, n = 12
FIGURE 5 The SWIFFT CONSORT flow diagram. Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C,
Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast immobilisation for adults with a bicortical fracture
of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label, randomised superiority trial, pp. 390–401,89
Copyright (2020), with permission from Elsevier.
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TABLE 4 Baseline characteristics of trial participants as randomised and as included in the primary analysis model
Characteristic
As randomised As analysed
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
Surgery
(N= 203)
Plaster cast
(N= 205)
Total
(N= 408)
Gender, n (%)
Male 180 (82.2) 183 (83.2) 363 (82.7) 168 (82.8) 169 (82.4) 337 (82.6)
Female 39 (17.8) 37 (16.8) 76 (17.3) 35 (17.2) 36 (17.6) 71 (17.4)
Age (years)
n 219 220 439 203 205 408
Mean (SD) 32.9 (13.2) 32.9 (12.2) 32.9 (12.7) 33.2 (13.2) 32.9 (12.4) 33.1 (12.8)
Median (min., max.) 28 (16, 80) 29 (16, 76) 29 (16, 80) 29 (16, 80) 29 (16, 76) 29 (16, 80)
Ethnicity, n (%)
White 205 (93.6) 195 (88.6) 400 (91.1) 191 (94.1) 180 (87.8) 371 (90.9)
Black 0 (0.0) 5 (2.3) 5 (1.1) 0 (0.0) 5 (2.4) 5 (1.2)
Asian 7 (3.2) 10 (4.5) 17 (3.9) 7 (3.4) 10 (4.9) 17 (4.2)
Other 5 (2.3) 10 (4.5) 15 (3.4) 5 (2.5) 10 (4.9) 15 (3.7)
Missing 2 (0.9) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Education, n (%)
No formal qualifications 24 (11.0) 27 (12.3) 51 (11.6) 22 (10.8) 25 (12.2) 47 (11.5)
Some qualifications/no degree 151 (68.9) 129 (58.6) 280 (63.8) 139 (68.5) 120 (58.5) 259 (63.5)
Degree or higher 41 (18.7) 64 (29.1) 105 (23.9) 41 (20.2) 60 (29.3) 101 (24.8)
Missing 3 (1.4) 0 (0.0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2)
Employment status, n (%)
Part-time 20 (9.1) 18 (8.2) 38 (8.7) 20 (9.9) 18 (8.8) 38 (9.3)
Full-time 127 (58.0) 120 (54.5) 247 (56.3) 119 (58.6) 111 (54.1) 230 (56.4)
Self-employed 21 (9.6) 36 (16.4) 57 (13.0) 19 (9.4) 31 (15.1) 50 (12.3)
Student 20 (9.1) 21 (9.5) 41 (9.3) 19 (9.4) 21 (10.2) 40 (9.8)
Retired 7 (3.2) 5 (2.3) 12 (2.7) 7 (3.4) 5 (2.4) 12 (2.9)
Looking after family/home 1 (0.5) 6 (2.7) 7 (1.6) 0 (0.0) 5 (2.4) 5 (1.2)
Not employed but seeking work 9 (4.1) 5 (2.3) 14 (3.2) 8 (3.9) 5 (2.4) 13 (3.2)
Other 11 (5.0) 9 (4.1) 20 (4.6) 10 (4.9) 9 (4.4) 19 (4.7)
Missing 3 (1.4) 0 (0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2)
Type of employment, n (%)
Unskilled manual 25 (11.4) 23 (10.5) 48 (10.9) 24 (11.8) 20 (9.8) 44 (10.8)
Skilled manual 63 (28.8) 60 (27.3) 123 (28.0) 56 (27.6) 56 (27.3) 112 (27.5)
Unskilled non-manual 19 (8.7) 12 (5.5) 31 (7.1) 19 (9.4) 11 (5.4) 30 (7.4)
Skilled non-manual 33 (15.1) 46 (20.9) 79 (18) 32 (15.8) 44 (21.5) 76 (18.6)
Professional 20 (9.1) 19 (8.6) 39 (8.9) 20 (9.9) 17 (8.3) 37 (9.1)
Other 19 (8.7) 30 (13.6) 49 (11.2) 18 (8.9) 28 (13.7) 46 (11.3)
Missing 40 (18.3) 30 (13.6) 70 (15.9) 34 (16.7) 29 (14.1) 63 (15.4)
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TABLE 4 Baseline characteristics of trial participants as randomised and as included in the primary analysis model
(continued )
Characteristic
As randomised As analysed
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
Surgery
(N= 203)
Plaster cast
(N= 205)
Total
(N= 408)
Current smoker, n (%)
Yes 73 (33.3) 56 (25.5) 129 (29.4) 64 (31.5) 50 (24.4) 114 (27.9)
No 143 (65.3) 163 (74.1) 306 (69.7) 138 (68.0) 154 (75.1) 292 (71.6)
Missing 3 (1.4) 1 (0.5) 4 (0.9) 1 (0.5) 1 (0.5) 2 (0.5)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (1, 40) 10 (1, 30) 10 (1, 40)
Number of years,
median (min., max.)
10 (1, 50) 10 (1, 36) 10 (1, 50) 10 (1, 50) 10 (1, 36) 10 (1, 50)
Past smoker, n (%)
Yes 116 (53.0) 109 (49.5) 225 (51.3) 110 (54.2) 99 (48.3) 209 (51.2)
No 85 (38.8) 101 (45.9) 186 (42.4) 81 (39.9) 96 (46.8) 177 (43.4)
Missing 18 (8.2) 10 (4.5) 28 (6.4) 12 (5.9) 10 (4.9) 22 (5.4)
Diabetes, n (%)
Yes 7 (3.2) 4 (1.8) 11 (2.5) 6 (3.0) 4 (2.0) 10 (2.5)
No 209 (95.4) 216 (98.2) 425 (96.8) 196 (96.6) 201 (98.0) 397 (97.3)
Missing 3 (1.4) 0 (0.0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2)
Steroid use, n (%)
Yes 6 (2.7) 4 (1.8) 10 (2.3) 6 (3.0) 4 (2.0) 10 (2.5)
No 210 (95.9) 216 (98.2) 426 (97.0) 196 (96.6) 201 (98.0) 397 (97.3)
Missing 3 (1.4) 0 (0.0) 3 (0.7) 1 (0.5) 0 (0.0) 1 (0.2)
Max., maximum; min., minimum.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
TABLE 5 Baseline fracture details of trial participants as randomised and as included in the primary analysis model
Characteristic
As randomised As analysed
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
Surgery
(N= 203)
Plaster cast
(N= 205)
Total
(N= 408)
Time since injury, daysa
n 219 220 439 203 205 408
Mean (SD) 5.1 (3.1) 5.3 (3.3) 5.2 (3.2) 4.9 (3.0) 5.4 (3.3) 5.2 (3.2)
Median (min., max.) 5 (1, 14) 5 (0, 14) 5 (0, 14) 4 (1, 14) 5 (0, 14) 5 (0, 14)
Affected wrist, n (%)
Left 115 (52.5) 118 (53.6) 233 (53.1) 110 (54.2) 110 (53.7) 220 (53.9)
Right 104 (47.5) 102 (46.4) 206 (46.9) 93 (45.8) 95 (46.3) 188 (46.1)
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TABLE 5 Baseline fracture details of trial participants as randomised and as included in the primary analysis model
(continued )
Characteristic
As randomised As analysed
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
Surgery
(N= 203)
Plaster cast
(N= 205)
Total
(N= 408)
Affected wrist is dominant hand, n (%)
Yes 100 (45.7) 95 (43.2) 195 (44.4) 92 (45.3) 89 (43.4) 181 (44.4)
No 117 (53.4) 125 (56.8) 242 (55.1) 111 (54.7) 116 (56.6) 227 (55.6)
Missing 2 (0.9) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Displacement (eligibility), n (%)
No displacement 135 (61.6) 134 (60.9) 269 (61.3) 123 (60.6) 123 (60) 246 (60.3)
Displacement 84 (38.4) 86 (39.1) 170 (38.7) 80 (39.4) 82 (40) 162 (39.7)
Displacement (randomisation), n (%)
No displacement 131 (59.8) 130 (59.1) 261 (59.5) 119 (58.6) 119 (58) 238 (58.3)
Displacement 88 (40.2) 90 (40.9) 178 (40.5) 84 (41.4) 86 (42) 170 (41.7)
Radiographs,b n (%)
Elongated scaphoid view 209 (95.4) 210 (95.5) 419 (95.4) 193 (95.1) 195 (95.1) 388 (95.1)
Posterior–anterior view 215 (98.2) 218 (99.1) 433 (98.6) 200 (98.5) 203 (99.0) 403 (98.8)
45° semisupine view 159 (72.6) 166 (75.5) 325 (74.0) 144 (70.9) 156 (76.1) 300 (73.5)
Lateral view 218 (99.5) 217 (98.6) 435 (99.1) 203 (100.0) 202 (98.5) 405 (99.3)
45° semiprone view 198 (90.4) 196 (89.1) 394 (89.7) 184 (90.6) 183 (89.3) 367 (90.0)
Previous wrist problems on same side, n (%)
Yes 43 (19.6) 45 (20.5) 88 (20.0) 43 (21.2) 42 (20.5) 85 (20.8)
No 173 (79.0) 173 (78.6) 346 (78.8) 159 (78.3) 161 (78.5) 320 (78.4)
Missing 3 (1.4) 2 (0.9) 5 (1.1) 1 (0.5) 2 (1.0) 3 (0.7)
If yes, what injury?, n (%)
Previous fracture 23 (53.5) 28 (62.2) 51 (58.0) 23 (53.5) 25 (59.5) 48 (56.5)
Arthritis 2 (4.7) 1 (2.2) 3 (3.4) 2 (4.7) 1 (2.4) 3 (3.5)
Ligament, tendon or nerve injury 10 (23.3) 8 (17.8) 18 (20.5) 10 (23.3) 8 (19.1) 18 (21.2)
Other 6 (14.0) 8 (17.8) 14 (15.9) 6 (14.0) 8 (19.1) 14 (16.5)
Missing 2 (4.7) 0 (0.0) 2 (2.3) 2 (4.7) 0 (0.0) 2 (2.4)
Injury mechanism, n (%)
Fall
Standing 28 (12.8) 29 (13.2) 57 (13.0) 26 (12.8) 26 (12.7) 52 (12.7)
Walking 24 (11.0) 24 (10.9) 48 (10.9) 22 (10.8) 23 (11.2) 45 (11.0)
Running 40 (18.3) 38 (17.3) 78 (17.8) 37 (18.2) 33 (16.1) 70 (17.2)
From height 28 (12.8) 34 (15.5) 62 (14.1) 26 (12.8) 31 (15.1) 57 (14.0)
From moving object 42 (19.2) 31 (14.1) 73 (16.6) 41 (20.2) 31 (15.1) 72 (17.6)
Hit on palm of hand
Object striking palm 16 (7.3) 15 (6.8) 31 (7.1) 15 (7.4) 15 (7.3) 30 (7.4)
Handle whipping back 9 (4.1) 11 (5.0) 20 (4.6) 8 (3.9) 11 (5.4) 19 (4.7)
Other sudden extension 11 (5.0) 8 (3.6) 19 (4.3) 11 (5.4) 8 (3.9) 19 (4.7)
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TABLE 5 Baseline fracture details of trial participants as randomised and as included in the primary analysis model
(continued )
Characteristic
As randomised As analysed
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
Surgery
(N= 203)
Plaster cast
(N= 205)
Total
(N= 408)
Punched something 4 (1.8) 12 (5.5) 16 (3.6) 4 (2.0) 10 (4.9) 14 (3.4)
Road traffic accident 9 (4.1) 8 (3.6) 17 (3.9) 9 (4.4) 7 (3.4) 16 (3.9)
Other 6 (2.7) 10 (4.5) 16 (3.6) 4 (2.0) 10 (4.9) 14 (3.4)
Missing 2 (0.9) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Place of injury,b n (%)
Sport 88 (40.2) 78 (35.5) 166 (37.8) 85 (41.9) 72 (35.1) 157 (38.5)
Home 27 (12.3) 43 (19.5) 70 (15.9) 24 (11.8) 38 (18.5) 62 (15.2)
Work 22 (10) 18 (8.2) 40 (9.1) 19 (9.4) 17 (8.3) 36 (8.8)
Road traffic accident 26 (11.9) 34 (15.5) 60 (13.7) 25 (12.3) 33 (16.1) 58 (14.2)
Public place 49 (22.4) 48 (21.8) 97 (22.1) 46 (22.7) 46 (22.4) 92 (22.5)
Other 3 (1.4) 0 (0) 3 (0.7) 3 (1.5) 0 (0.0) 3 (0.7)
Missing 4 (1.8) 2 (0.9) 6 (1.4) 3 (1.5) 2 (1.0) 5 (1.2)
Treatment preference, n (%)
Surgery 93 (42.5) 101 (45.9) 194 (44.2) 89 (43.8) 96 (46.8) 185 (45.3)
No surgery 13 (5.9) 19 (8.6) 32 (7.3) 11 (5.4) 16 (7.8) 27 (6.6)
No preference 110 (50.2) 99 (45.0) 209 (47.6) 102 (50.2) 92 (44.9) 194 (47.5)
Missing 3 (1.4) 1 (0.5) 4 (0.9) 1 (0.5) 1 (0.5) 2 (0.5)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
TABLE 6 Follow-up participant questionnaire return rates
Time point Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
6 weeks
Sent, n (%)a 214 (97.7) 217 (98.6) 431 (98.2)
Returned, n (%)b 178 (83.2) 181 (83.4) 359 (83.3)
Days to complete, median (IQR) 5 (1–11) 2 (0–9) 4 (0–11)
Days to return, median (IQR) 13 (8–24) 12 (5–24) 13 (6–24)
Completed within 1 week, n (%)c 119 (66.9) 118 (65.2) 237 (66.0)
Mode of completion, n (%)
Post 99 (55.6) 93 (51.4) 192 (53.5)
In clinic 78 (43.8) 87 (48.1) 165 (46.0)
Telephone 1 (0.6) 1 (0.6) 2 (0.6)
12 weeks
Sent, n (%)a 212 (96.8) 217 (98.6) 429 (97.7)
Returned, n (%)b 182 (85.9) 167 (77.0) 349 (81.4)
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Hospital data collection forms
The return of hospital forms is summarised in Table 7. Treatment confirmation forms were collected at
6 and 12 weeks post randomisation; at least one treatment confirmation form was completed for all but
one participant (who was allocated to surgery but withdrew on the day of randomisation). A complications
form was completed for over 84% of the randomised participants at each of the 6-, 12- and 52-week time
points. Wrist range of movement and grip strength forms were received for 389 (88.6%), 336 (76.5%) and
309 (70.4%) participants at 6, 12 and 52 weeks, respectively. At 52 weeks, there appears to be a difference
in the percentage of grip and range forms returned between the two groups (surgery, 74.4%; plaster cast,
66.4%), otherwise there are no obvious differences between the two groups in the return rates of hospital
forms. The return of treatment confirmation and complications forms was higher than for the grip and
range forms, as completion of these forms did not require the participant to attend the hospital visit.
TABLE 6 Follow-up participant questionnaire return rates (continued )
Time point Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Days to complete, median (IQR) 7 (2–21) 5 (0–19) 6 (0–20)
Days to return, median (IQR) 15 (8–31) 13 (7–35) 14 (7–33)
Completed within 2 weeks, n (%)c 122 (67.0) 110 (65.9) 232 (66.5)
Mode of completion, n (%)
Post 97 (53.3) 77 (46.1) 174 (49.9)
In clinic 70 (38.5) 75 (44.9) 145 (41.6)
Telephone 15 (8.2) 15 (9.0) 30 (8.6)
26 weeks
Sent, n (%)a 212 (96.8) 216 (98.2) 428 (97.5)
Returned, n (%)b 163 (76.9) 149 (69.0) 313 (72.9)
Days to complete, median (IQR) 10 (5–27) 10 (4–30) 10 (5–28)
Days to return, median (IQR) 20 (10–38) 19 (10–37) 20 (10–37)
Completed within 6 weeks, n (%)c 136 (83.4) 131 (87.9) 267 (85.6)
Mode of completion, n (%)
Post 165 (92.7) 165 (91.2) 330 (91.9)
Telephone 13 (7.3) 16 (8.8) 29 (8.1)
52 weeks
Sent, n (%)a 212 (96.8) 213 (96.8) 425 (96.8)
Returned, n (%)b 186 (87.7) 178 (83.6) 364 (85.7)
Days to complete, median (IQR) 5 (0–16) 7 (2–26) 6 (2–22)
Days to return, median (IQR) 12 (7–33) 17 (8–36) 14 (7–35)
Completed within 8 weeks, n (%)c 170 (91.4) 157 (88.2) 327 (89.8)
Mode of completion, n (%)
Post 103 (57.9) 110 (60.8) 213 (59.3)
In clinic 67 (37.6) 56 (30.9) 123 (34.3)
Telephone 8 (4.5) 15 (8.3) 23 (6.4)
a Percentage of randomised participants.
b Percentage of questionnaires sent.
c Percentage of questionnaires returned by the due date.
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Patient withdrawals
Five participants (surgery, n = 2; plaster cast, n = 3) withdrew from hospital follow-up but agreed to continue
completing participant questionnaires; three of these were before the 6-week visit (no hospital visits attended)
and two were following the 6-week visit (12- and 26-week visits not attended). The reasons provided were
work commitments (surgery, n = 1; plaster cast, n = 1), the participant moved away from the trial catchment
area (surgery, n = 1), the participant was too ill to commit to extra hospital visits (plaster cast, n = 1) and the
participant sought further opinions at an alternative hospital, with surgical fixation and follow-ups completed
there instead of at the recruiting site (plaster cast, n = 1).
A further 14 participants were withdrawn completely from the trial; eight before the 6-week time point
(surgery, n = 5; plaster cast, n = 3), two between the 6- and 12-week time points (surgery, n = 2), one
between 12 and 26 weeks (plaster cast, n = 1) and three between 26 and 52 weeks (plaster cast, n = 3). The
reasons for these withdrawals were the participant no longer wanted to take part in the study, for example
was too busy or was sick of the questionnaires (surgery, n = 2; plaster cast, n = 3); no fracture present on
the CT scan (surgery, n = 4; plaster cast, n = 1); the participant was unhappy with their treatment allocation
(surgery, n = 1; plaster cast, n = 2); and the participant emigrated (plaster cast, n = 1).
Hospital visits
Baseline participant and fracture data are summarised according to whether patients attended hospital visits
at 6, 12 and 52 weeks (see Appendix 3, Tables 46–51). Non-smokers and participants in employment were
more likely to attend than smokers and those not in employment, respectively, at all time points. Participants
with fracture displacement at baseline were more likely to attend their 6- and 52-week hospital visits, but
were equally likely to attend at 12 weeks.
Compliance with random allocation and treatment received
For all but four of the randomised participants, their affected wrist was recorded as being immobilised at
enrolment, largely by a plaster cast (n = 328, 74.7%), but alternatively by a splint (n = 80, 18.2%) or a
backslab (n = 27, 6.2%). From the treatment confirmation and surgery forms, we were able to ascertain
the further treatment received for each participant within the 12 months following randomisation.
TABLE 7 Follow-up hospital form return rates
Hospital form Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Wrist range of movement and grip strength form, n (%)
6 weeks 189 (86.3) 200 (90.9) 389 (88.6)
12 weeks 172 (78.5) 164 (74.6) 336 (76.5)
52 weeks 163 (74.4) 146 (66.4) 309 (70.4)
Treatment confirmation form, n (%)
6 weeks 200 (91.3) 211 (95.9) 411 (93.6)
12 weeks 202 (92.2) 195 (88.6) 397 (90.4)
At least one 219 (99.5) 220 (100.0) 438 (99.8)
Complications form, n (%)
6 weeks 197 (90.0) 206 (93.6) 403 (91.8)
12 weeks 181 (82.7) 189 (85.9) 370 (84.3)
52 weeks 199 (90.9) 196 (89.1) 395 (90.0)
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Allocated to receive surgery
Of the 219 patients allocated to surgery, 188 (85.8%) received treatment as allocated (Table 8). Surgery
took place, on average, 10.2 days (median 11 days, range 3–20 days) after injury, 9.5 days (median 10 days,
range 1–20 days) after presenting at A&E or another clinic and 4.5 days (median 5 days, range 0–15 days)
after randomisation. Of the 188 participants who underwent surgery, 39 (20.7%) received routine treatment
(i.e. surgery and no subsequent plaster cast or splint), 141 (75%) had further routine treatment with a
plaster cast or splint only after surgery (not recorded as being due to a treatment failure) and 8 (4.3%)
had at least one other surgery within the 12 months (seven had one other surgery and one had two).
TABLE 8 Treatment received: surgery group (n= 219)
Treatment
pathway Definition of pathway n (%) Further details
Crossover Participant immediately switched to
plaster cast following consent and
randomisation, no surgery
31 (14.2) l Thirty participants received plaster cast
(n = 16), splint (n = 3) or a combination of
both (n = 11) for a median of 52 days
(range 9–84 days) post randomisation
l One participant did not receive any treatment,
as no fracture was observed on CT scan
Routine
treatment
Participant had one surgery within the
12 months from randomisation and no
subsequent plaster cast and/or splint
24 (11.0) l Surgery took place a median of 4 days (range
0–9 days) post randomisation, no subsequent
treatment recorded except bandaging
Treatment
failure
Participant had surgery and subsequent
plaster cast and/or splint due to
treatment failure (e.g. poor stability
from surgery)
0 (0.0) –
Further routine
treatment
Participant had surgery and subsequent
plaster cast and/or splint following
routine practice
156 (71.2) l Surgery took place a median of 4 days
(range 0–15 days) post randomisation
l All received plaster cast (n = 23), splint (n = 40)
or a combination of both (n = 93) for a
median of 37 days (range 2–89 days)
following surgery
Participant had index surgery but there
was subsequent evidence of non-union,
so was offered further surgery
2 (0.9) l One participant received two surgeries within
12 months from randomisation (259 days
after initial surgery); plaster cast worn for
17 days after surgery, followed by a splint
l One participant underwent three surgeries
within 12 months from randomisation, the
second taking place 176 days after the index
surgery and the third taking place 125 days
after the second surgery
Participant had index surgery and
received further surgery (not for
non-union)
6 (2.7) l Revision surgery (n = 1) or for removal of
screw (n = 5)
l All received a splint (n = 2) or a combination
of plaster cast and splint (n = 4) for a median
of 44 days (range 22–105 days) following
index surgery
l All underwent only one further surgery within
12 months from randomisation; this took
place a median of 235 days (range 97–347 days)
after index surgery
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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The reasons for repeat surgeries (for the seven patients with only one extra surgery within 12 months
of randomisation) were removal of the screw due to (1) protrusion (n = 3), (2) experiencing pain and poor
flexion of wrist (n = 1) or (3) the scaphoid screw breaching the cortex of the scaphoid at the capitate
articulation owing to mispositioning of the screw (n = 1); revision surgery owing to pain/prominent metal
work (n = 1); or persistent non-union (n = 1). For the participant who underwent two further surgeries,
the first was to remove the screw and perform iliac bone graft/k-wire stabilisation owing to non-union
of the scaphoid fracture; the second was for persistent non-union.
The remaining 31 (14.2%) participants allocated to receive surgery were treated non-surgically. It should be
noted that the participant with no treatment confirmation form was allocated to the surgery group but
withdrew on the day of randomisation and provided no follow-up data. However, one of the reasons provided
for withdrawal was that the participant wanted conservative treatment; therefore, this patient is assumed not
to have received surgery. The reasons for participants being treated non-surgically are as follows: no fracture
was observed on the CT scan subsequent to randomisation (n = 10), the participant’s choice was not to have
surgery (n = 9), the participant did not have a bicortical scaphoid waist fracture [n = 8; these fractures were
instead described as a waist plus distal pole fracture (n = 2), a radial styloid fracture (n = 1), a unicortical
fracture (n = 1), a lunate fracture (n = 1), a Y-shaped waist fracture involving the tubercle (n = 1), an associated
scaphoid tubercle fracture (n = 1) and an incomplete fracture (n = 1)]; and other reasons [n = 4; the surgeon
felt that surgery was inappropriate/unnecessary following a review of the CT scan but no further information is
available (n = 2), no appropriate time for surgery was available for either the surgeon or the patient (n = 1) and
the patient was admitted to hospital with pericarditis (n = 1)]. Of these, 30 received a plaster cast and/or splint
following randomisation, while one did not receive any treatment because the treating clinician deemed that
their subsequent CT scan indicated no injury (see Table 8).
Following randomisation, 41 participants did not report wearing any plaster cast/splint and 65 were reported
to be wearing only a splint (for a median of 40 days post randomisation, range 4–97 days – although the
upper range may not be accurate, as the final date of splint wearing was often not recorded/known and
the splint may have been worn for longer than the 12-week reporting period of the treatment confirmation
forms). Of the remaining 113 participants, 29 had a cast (with thumb incorporated) for a median of 21 days
(range 2–60 days) following randomisation [of whom two then had a cast (with thumb free) applied for a
median of 37 days] and 84 had a cast (with thumb free) for a median of 18 days (range 1–63 days) following
randomisation [of whom two then had a cast (with thumb incorporated) for a median of 9 days]. Overall,
103/219 (47.0%) participants allocated to the surgery group were still in a plaster cast or splint 6 weeks post
randomisation and 13 (5.9%) still had a cast or splint at 12 weeks.
Allocated to receive plaster cast intervention
Of the 220 patients allocated to not receive immediate surgical fixation, the majority (n = 195, 88.6%) were
treated conservatively and did not receive surgery (Table 9), although two of these were considered for
surgical fixation owing to non-union. Six (2.7%) participants immediately crossed over to surgery following
randomisation with no cast applied before this, for the following reasons: participant choice (n = 4), the CT
scan showed displacement (n = 1) and the radiographs were reviewed again at a later date and displacement
was judged to be > 2 mm (n = 1). For these six participants, surgery took place, on average, 13.5 days (median
12 days, range 5–32 days) after injury, 12.8 days (median 11.5 days, range – 31 days) after presenting at
A&E or another clinic and 8.8 days (median 8.5 days, range 0–24 days) after randomisation. None of these
six participants underwent further surgery within 12 months from randomisation.
One (0.5%) participant had a plaster cast applied but received surgery 29 days after randomisation owing
to treatment failure, as their fracture was displacing with the plaster cast. This participant received a
revision surgery to remove the screw 3 months after initial fixation.
One (0.5%) participant received surgery within 6 months of randomisation at a non-participating hospital
to fix what the treating surgeon deemed to be a historic fracture. This was noted by the participant on a
participant questionnaire. Limited information is available for this participant, as they withdrew from
hospital follow-up at their recruiting site.
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TABLE 9 Treatment received: plaster cast group (n= 220)
Treatment pathway Definition of pathway n (%) Further details
Crossover Patient immediately switched to
surgery following randomisation
6 (2.7) l Surgery took place a median of 9 days
(range 0–24 days) post randomisation
l Participants received a plaster cast
(n = 3), a splint (n = 1) or a combination
of both (n = 2) for a median of 41 days
(range 35–74 days) following surgery
Routine treatment Participant treated conservatively –
no surgery
193 (87.7) l 192 participants received a plaster cast
(n = 109) or a combination of plaster
cast and splint (n = 83) for a median
of 43 days (range 7–101 days)
post randomisation
l One participant was followed up at a
different hospital, so treatment was
unknown, but was immobilised in
plaster cast at enrolment to the trial
Treatment failure Surgery was undertaken to
stabilise the fracture (before
5 weeks from randomisation).
This is not a crossover because
the patient did have a plaster
cast applied
1 (0.5) l Plaster cast was worn following
randomisation but the fracture was
seen to be displacing so surgical
fixation was undertaken 29 days post
randomisation and a splint was worn
thereafter (unknown length of time)
l Surgery was undertaken to remove the
screw 96 days after initial fixation
Further routine treatment –
surgery (after 5 weeks post
randomisation)
Surgery was undertaken after
5 weeks from randomisation –
not owing to a failure to unite
1 (0.5) l One participant received surgery
within 6 months of randomisation at
a non-participating hospital to fix a
historic fracture
Further routine treatment –
surgery recommended (after
5 weeks post randomisation)
as per the specified treatment
pathway because of a failure
to unite
Surgery was not received 2 (0.9) l Operation was scheduled but then
delayed; participant self-discharged
after waiting and declined all further
treatment/offers of surgery
l Non-union suspected at 12 weeks but
the surgeon decided not to operate
One surgery was performed
within 12 months of
randomisation
16 (7.3) l 13 participants received urgent fixation
of non-union (within 6 months
of randomisation)
l Three participants received late fixation,
between 6 and 12 months after
randomisation. The reasons for two
of these are unknown; one participant
opted to attend a private hospital for
their fixation as they were told there
would be a 4- to 5-month wait for
surgery at the treating centre
Two or more surgeries were
performed within 12 months of
randomisation
1 (0.5) l Patient received initial surgical fixation
within 3 months of randomisation,
a further surgery 6 months later for
persistent non-union and surgery to
remove the wires from the second
operation a month later
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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The remaining 17 (7.7%) participants received surgery as part of their expected treatment pathway
when the treating surgeon judged that the bone had failed to unite with conservative treatment. Sixteen
of these received only one surgery in the 12 months following randomisation and one received three
surgeries (the second one for persistent non-union and the third to remove the wires from the second
operation). The initial surgery took place, on average, 159.0 days (median 161 days, range 68–358 days)
after injury, 157.0 days (median 156 days, range 67–358 days) after presenting at A&E or another clinic
and 151.6 days (median 153 days, range 61–350 days) after randomisation. Fourteen participants met the
protocol definition of the control condition by receiving early surgical fixation of their fractures following
detection of persistent non-union after plaster cast management (defined here as surgery within 6 months
of randomisation, although only five had their surgery within 12 weeks), while three had delayed surgical
fixation, one of whom opted to attend a private hospital for their fixation, as they were told there would
be a 4- to 5-month wait for surgery at the treating centre.
There were two participants who were deemed to have a suspected non-union at 12 weeks and for whom
surgical fixation was recommended, but who did not receive surgery. These participants did not fully
comply with the anticipated control condition for the trial. The limited information we have about these
participants is as follows: for one, the operation was scheduled but then delayed and the participant
self-discharged after waiting and declined all further treatment, including offers of surgery; for the second,
it was the surgeon’s decision not to operate.
Following randomisation, two participants did not report wearing any plaster cast/splint and two were
reported to be wearing only a splint (for a median of 44 days post randomisation). Of the remaining
216 participants, 45 had a cast (with thumb incorporated) for a median of 42 days (range 7–84 days)
following randomisation [of which eight then had a cast (with thumb free) for a median of 25 days
(range 14–42 days)] and 171 had a cast (with thumb free) for a median of 42 days (range 7–98 days) following
randomisation [of which five then had a cast (with thumb incorporated) for a median of 44 days (range
12–69 days)]. Overall, 187/220 (85.0%) participants allocated to the plaster cast group were still in a
plaster cast or splint 6 weeks post randomisation and 47 (21.4%) still had a cast or splint at 12 weeks.
Surgical fixation details
A surgery form was received for 210 of the 213 participants in the trial who received surgical fixation of
their fracture (surgery group, n = 187/188, 99.5%; plaster cast group, n = 23/25, 92.0%). Surgery was
performed by 102 surgeons across 30 sites. Each surgeon performed between one and six operations
(median 1). Details of the operation, for initial surgical fixation procedures only, are provided in Table 10.
TABLE 10 Details of initial surgical fixation
Surgery details Surgery (N= 210)
Lead surgeon grade, n (%)
Consultant 139 (66.2)
Staff grade/associate specialist 22 (10.5)
Specialist trainee 49 (23.3)
Total number of surgeons present in theatre
Mean (SD) 2.0 (0.9)
Median (min., max.) 2 (1, 9)
Duration of surgery, minutes (n = 197)
Mean (SD) 59.0 (23.6)
Median (min., max.) 55 (15, 140)
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TABLE 10 Details of initial surgical fixation (continued )
Surgery details Surgery (N= 210)
Surgery type, n (%)
Percutaneous 164 (78.1)
Open 43 (20.5)
Both 1 (0.5)
Missing 2 (1.0)
Incision, n (%)
Palmar 171 (81.4)
Dorsal 33 (15.7)
Both 2 (1.0)
Missing 4 (1.9)
Type of screw used, n (%)
Acutrak 152 (72.4)
Medartis® (Basel, Switzerland) 33 (15.7)
Twinfix® (Stryker Corporation, Kalamazoo, MI, USA) 10 (4.8)
Headless compression screw 10 (4.8)
Herbert™ (Zimmer Biomet, Warsaw, IN, USA) 1 (0.5)
Missing 4 (1.9)
Second screw, n (%)
Yes 2 (1.0)
No 202 (96.2)
Missing 6 (2.9)
K-wire used, n (%)
Yes 39 (18.6)
No 168 (80.0)
Missing 3 (1.4)
Placement of screw, n (%)
Central position
Yes 148 (70.5)
No 55 (26.2)
Missing 7 (3.3)
Position less than perfect but acceptable
Yes 74 (35.2)
No 131 (62.4)
Missing 5 (2.4)
Uncertain bone hold
Yes 2 (1.0)
No 201 (95.7)
Missing 7 (3.3)
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Surgery lasted a median of 55 minutes (range 15–140 minutes) with a mean (SD) of 2 (0.9) surgeons in
attendance. Most commonly, the main operating surgeon was a consultant (n = 39, 66.2%), followed by
a specialist trainee (n = 49, 23.3%) and a staff grade/associate specialist (n = 22, 10.5%). When the main
operating surgeon was a specialist trainee, an assisting consultant was recorded as being present in 33 of
49 (67.4%) surgeries. Acutrak® screws (Acumed LLC, Hillsboro, OR, USA) were the most frequently used
type and a second screw was used for two (1.0%) participants. There were no reported intraoperative
complications and most participants (n = 113, 53.8%) were treated with a plaster cast postoperatively.
Primary outcome (Patient-Rated Wrist Evaluation) analysis
The PRWE (pre and post injury) was assessed at baseline and at 6, 12, 26 and 52 weeks post randomisation.
The PRWE total score is a value between 0 and 100, where a higher score indicates worse pain and
functioning. The pain and function subscale scores are each out of a maximum of 50 (50 being the worst
score). The trial was powered to detect an effect size of 0.3 (assuming a SD of 20); this is equivalent to a
difference in total PRWE score of 6 points.
Primary end point analysis
There was no evidence of a difference in PRWE score between the surgery and plaster cast groups at the
52-week time point, with an adjusted mean difference of –2.1 in favour of the surgery group (95% CI
–5.8 to 1.6; p = 0.27).
This result was extracted from a multilevel model in which participant was treated as a random effect and
observations over time (6, 12, 26 and 52 weeks) were nested within participant. The effect of randomised
treatment group was assessed while adjusting for time, group-by-time interaction, age, fracture displacement
and hand dominance. The predicted means and associated 95% CIs for each group and time point are
presented in Table 11 and displayed in Figure 6.
Different covariance structures were applied to the model. An unstructured pattern that models all
variances and covariances separately resulted in the lowest AIC and so was used in the final model.
Diagnostics of model fit revealed that the standardised residuals demonstrated only a minor deviation from
normality and were uniform against fitted values; therefore, analyses were carried out on untransformed
values. Model coefficients for the covariates with 95% CIs are provided as the software output in Appendix 4
to aid understanding of the fitted model.
TABLE 10 Details of initial surgical fixation (continued )
Surgery details Surgery (N= 210)
Intraoperative complications, n (%)
Fracture around screw 0 (0.0)
Nerve injury 0 (0.0)
Vascular injury 0 (0.0)
Tendon injury 0 (0.0)
Postoperative management, n (%)
Cast 113 (53.8)
Bandage 65 (31.0)
Splint 31 (14.8)
Missing 1 (0.5)
Unexpected procedure,a n (%) 2 (1.0)
a Trapezium trimmed.
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Valid data
The primary analysis included data from 408 patients (surgery, n = 203; plaster cast, n = 205) with a valid
PRWE score for at least one follow-up time point and complete baseline covariates. A valid response is
defined here as sufficient data (maximum of one missing PRWE item in each of the two subscales) to allow
the calculation of the total score. The number of participants with valid PRWE data at each time point is
presented by randomised group in Table 12, with reasons for missing data.
The percentage of randomised participants with valid PRWE data ranged from 68.8% (26 weeks) to 82.5%
(52 weeks) for the post-randomisation time points. Overall, 408 participants (surgery, n = 203, 92.7%;
plaster cast, n = 205, 93.2%) had valid PRWE data for at least one post-randomisation time point and so
were included in the primary analysis model.
Demographic and injury characteristics at baseline for participants who provided valid PRWE data at each
time point are presented by randomised group in Appendix 3, Tables 52–55.
TABLE 11 Difference in adjusted mean PRWE scores over time by randomised group from the primary analysis
model (N= 408: surgery, n= 203; plaster cast, n= 205)
Time point Surgery, mean (95% CI) Plaster cast, mean (95% CI) Difference (95% CI) p-value
6 weeks 35.6 (32.6 to 38.6) 39.8 (36.8 to 42.8) –4.2 (–8.5 to 0.1) 0.06
12 weeks 21.0 (18.1 to 24.0) 26.6 (23.6 to 29.6) –5.6 (–9.8 to –1.4) 0.01
26 weeks 16.2 (13.5 to 18.9) 16.5 (13.8 to 19.2) –0.3 (–4.1 to 3.6) 0.89
52 weeks 11.9 (9.2 to 14.5) 14.0 (11.3 to 16.6) –2.1 (–5.8 to 1.6) 0.27
Overall 21.3 (18.9 to 23.6) 24.4 (22.0 to 26.7) –3.0 (–6.3 to 0.3) 0.07
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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FIGURE 6 Adjusted mean PRWE scores (with 95% CIs) over time by randomised group for primary analysis.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery
versus cast immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic,
multicentre, open-label, randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission
from Elsevier.
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TABLE 12 Valid PRWE data by randomised group and time point, with reasons for missing data
Time point Response type
Surgery
(N= 219), n (%)
Plaster cast
(N= 220), n (%)
Total
(N= 439), n (%)
Baseline (pre injury) Valid response 205 (93.6) 203 (92.3) 408 (92.9)
No or partial responsea
Partial response 0 (0) 2 (0.9) 2 (0.5)
All responses missing 12 (5.5) 15 (6.8) 27 (6.2)
Did not return questionnaire 2 (0.9) 0 (0.0) 2 (0.5)
Baseline (post injury) Valid response 213 (97.3) 209 (95) 422 (96.1)
No or partial responsea
Partial response 4 (1.8) 11 (5) 15 (3.4)
All responses missing 0 (0.0) 0 (0.0) 0 (0.0)
Did not return questionnaire 2 (0.9) 0 (0.0) 2 (0.5)
6 weeks Valid response 176 (80.4) 172 (78.2) 348 (79.3)
No or partial responsea
Partial response 2 (0.9) 9 (4.1) 11 (2.5)
All responses missing 0 (0.0) 0 (0.0) 0 (0.0)
Did not return questionnaire 36 (16.4) 36 (16.4) 72 (16.4)
Withdrawn from questionnaires 5 (2.3) 3 (1.4) 8 (1.8)
12 weeks Valid response 178 (81.3) 163 (74.1) 341 (77.7)
No or partial responsea
Partial response 4 (1.8) 4 (1.8) 8 (1.8)
All responses missing 0 (0.0) 0 (0.0) 0 (0.0)
Did not return questionnaire 30 (13.7) 50 (22.7) 80 (18.2)
Withdrawn from questionnaires 7 (3.2) 3 (1.4) 10 (2.3)
26 weeks Valid response 156 (71.2) 146 (66.4) 302 (68.8)
No or partial responsea
Partial response 6 (2.7) 3 (1.4) 9 (2.1)
All responses missing 1 (0.5) 0 (0.0) 1 (0.2)
Did not return questionnaire 49 (22.4) 67 (30.5) 116 (26.4)
Withdrawn from questionnaires 7 (3.2) 4 (1.8) 11 (2.5)
52 weeks Valid response 186 (84.9) 176 (80) 362 (82.5)
No or partial responsea
Partial response 0 (0.0) 2 (0.9) 2 (0.5)
All responses missing 0 (0.0) 0 (0.0) 0 (0.0)
Did not return questionnaire 26 (11.9) 35 (15.9) 61 (13.9)
Withdrawn from questionnaires 7 (3.2) 7 (3.2) 14 (3.2)
a Questionnaire returned but missing response data to PRWE items.
DOI: 10.3310/hta24520 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 52
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dias et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
Overall, 249 patients (56.7%) had a valid PRWE response at all post-randomisation follow-up time points
(complete responders: surgery, n = 130, 59.4%; plaster cast, n = 119, 54.1%) and a further 159 patients
(intermittent responders: surgery, n = 73, 33.3%; plaster cast, n = 86, 39.1%) had a valid PRWE response
at one or more, but not all, post-randomisation time points. Table 13 provides the descriptive PRWE total
scores for complete and intermittent responders and the baseline PRWE scores for those who had no valid
post-randomisation PRWE data. Complete responders had, on average, better PRWE outcomes (lower
mean scores) than intermittent responders pre injury and at 52 weeks post randomisation, but had similar
outcomes at baseline (post injury) and at 6, 12 and 26 weeks post randomisation.
TABLE 13 Unadjusted total PRWE scores for complete responders, intermittent responders and non-responders to
post-randomisation follow-ups, by time point
Total PRWE score
Responders
Complete (n= 249) Intermittent (n= 159) Non (n= 31)
Baseline (pre injury)
Mean (SD) 2.7 (9.3) 4.8 (14.7) 1.1 (2.3)
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0)
Min., max. (0, 85) (0, 90.5) (0, 8)
Baseline (post injury)
Mean (SD) 74.4 (16.8) 72.4 (21.5) 72.1 (16.5)
Median (IQR) 77.5 (65.3–77.5) 76.8 (62–76.8) 74.5 (63.8–74.5)
Min., max. (0, 100) (0, 100) (35, 96.5)
6 weeks
Mean (SD) 37.3 (19.7) 37.0 (24.6) –
Median (IQR) 37 (22.5–37) 30.5 (17.5–30.5) –
Min., max. (0, 85.9) (0, 100) –
12 weeks
Mean (SD) 22.9 (20.0) 23.9 (23.0) –
Median (IQR) 17. (8–17.5) 17 (5–17) –
Min., max. (0, 90) (0, 80.5) –
26 weeks
Mean (SD) 15.4 (17.1) 15.3 (21.7) –
Median (IQR) 10.5 (3.5–10.5) 5 (0–5) –
Min., max. (0, 84) (0, 91.5) –
52 weeks
Mean (SD) 11.7 (17.5) 15.0 (19.6) –
Median (IQR) 4.5 (0–4.5) 4 (0–4) –
Min., max. (0, 96) (0, 88) –
Max., maximum; min., minimum.
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Descriptive Patient-Rated Wrist Evaluation statistics
Total mean PRWE scores pre injury and at enrolment (post injury) were similar between the two groups
(Table 14). Total mean PRWE scores improved (decreased) over time following injury in both groups, but
were higher (worse) in the plaster cast group than in the surgery group at all post-randomisation time
points except at 26 weeks. At 52 weeks, the unadjusted mean difference was –2.8 points (95% CI –6.5 to
1.0 points) favouring the surgery group.
TABLE 14 Unadjusted PRWE total and subscale scores by randomised group and time point
PRWE score Surgery Plaster cast Total
Baseline (pre injury)
Pain subscale
Mean (SD) 2.2 (6.6) 2.5 (6.9) 2.4 (6.7)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Min., max. (0, 50) (0, 41) (0, 50)
Function subscale
Mean (SD) 1.0 (5.1) 1.1 (5.7) 1.0 (5.4)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Min., max. (0, 43) (0, 49.5) (0, 49.5)
Total
Mean (SD) 3.1 (10.8) 3.6 (11.8) 3.4 (11.3)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Min., max. (0, 85) (0, 90.5) (0, 90.5)
Baseline (post injury)
Pain subscale
Mean (SD) 34.7 (10.8) 34.3 (9.7) 34.5 (10.2)
Median (IQR) 36.0 (30.0–42.0) 35.0 (28.4–42.0) 36.0 (29.0–42.0)
Min., max. (0, 50) (0, 50) (0, 50)
Function subscale
Mean (SD) 39.1 (10.4) 38.5 (10.0) 38.8 (10.2)
Median (IQR) 41.8 (34.0–47.0) 40.5 (33.5–46.0) 41.0 (33.5–46.5)
Min., max. (0, 50) (0, 50) (0, 50)
Total
Mean (SD) 73.9 (19.8) 73.2 (17.4) 73.5 (18.6)
Median (IQR) 78.5 (65.5–87.5) 76.0 (63.5–86.5) 77.5 (64.0–87.0)
Min., max. (0, 100) (0, 100) (0, 100)
6 weeks
Pain subscale
Mean (SD) 18.9 (10.5) 18.4 (10.7) 18.6 (10.6)
Median (IQR) 19.0 (10.0–27.0) 17.0 (10.0–26.0) 18.0 (10.0–26.3)
Min., max. (0, 44) (0, 50) (0, 50)
continued
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TABLE 14 Unadjusted PRWE total and subscale scores by randomised group and time point (continued )
PRWE score Surgery Plaster cast Total
Function subscale
Mean (SD) 16.8 (12.8) 20.1 (12.4) 18.5 (12.7)
Median (IQR) 13.5 (6.5–25.5) 19.0 (9.8–27.3) 17.0 (8.0–26.5)
Min., max. (0, 47) (0, 50) (0, 50)
Total
Mean (SD) 35.7 (21.4) 38.8 (21.0) 37.2 (21.2)
Median (IQR) 33.8 (18.8–49.0) 38.3 (22.5–52.3) 35.4 (19.5–51.5)
Min., max. (3, 85.5) (0, 100) (0, 100)
12 weeks
Pain subscale
Mean (SD) 12.8 (11.0) 14.6 (11.2) 13.7 (11.1)
Median (IQR) 10.0 (4.5–18.0) 12.0 (6.0–21.0) 11.0 (5.0–19.0)
Min., max. (0, 45) (0, 47) (0, 47)
Function subscale
Mean (SD) 7.9 (9.3) 11.2 (11.5) 9.5 (10.5)
Median (IQR) 5.0 (1.0–11.0) 7.5 (2.5–16.0) 6.0 (1.5–13.0)
Min., max. (0, 44.5) (0, 46.5) (0, 46.5)
Total
Mean (SD) 20.7 (19.6) 25.9 (21.8) 23.2 (20.8)
Median (IQR) 15.0 (6.0–27.0) 20.0 (8.7–35.5) 17.5 (7.0–31.5)
Min., max. (0, 89.5) (0, 90) (0, 90)
26 weeks
Pain subscale
Mean (SD) 10.5 (10.6) 9.9 (10.0) 10.2 (10.3)
Median (IQR) 7.0 (3.0–15.0) 8.0 (2.0–13.0) 8.0 (2.0–15.0)
Min., max. (0, 43) (0, 44) (0, 44)
Function subscale
Mean (SD) 5.3 (8.3) 5.4 (8.7) 5.4 (8.5)
Median (IQR) 1.8 (0.0–5.8) 2.0 (0.0–6.0) 2.0 (0.0–6.0)
Min., max. (0, 41) (0, 47.5) (0, 47.5)
Total
Mean (SD) 15.7 (18.1) 15.1 (17.8) 15.4 (18.0)
Median (IQR) 9.0 (3.5–20.5) 10.5 (2.0–18.0) 9.5 (3.0–19.0)
Min., max. (0, 84) (0, 91.5) (0, 91.5)
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Patient-Rated Wrist Evaluation at the secondary time points
Adjusted PRWE means and group differences for the primary analysis model are presented in Table 11 and
displayed in Figure 6. The analysis showed a statistically significant difference between treatment groups at
week 12 (p = 0.01) and a borderline result at week 6 (p = 0.06) but not at week 26 (p = 0.89) or at the
primary end point of 52 weeks (p = 0.27). There was no overall effect of treatment group (difference of
3.0 points in favour of the surgery group; p = 0.07). Although statistically significant, the mean difference
observed at 12 weeks was lower than our minimum clinically important difference of 6 points, although
the confidence interval does include this difference.
Sensitivity analyses
Missing data
Adjusted PRWE means and group differences for the separate linear regression analysis models, for each
time point, run on the multiply imputed data set are presented in Table 15. Analyses showed very similar
results to the primary analysis, that is, a statistically significant difference between treatment groups at
weeks 6 (p = 0.049) and 12 (p = 0.01) but not at week 26 (p = 0.93) or the primary end point of 52 weeks
(p = 0.28). The adjusted mean difference at 52 weeks was –2.0 (95% CI –5.7 to 1.6) in favour of the
surgery group. Although separate linear regressions were performed for these analyses, as opposed to a
repeated measures model, there is no estimate for the overall treatment effect over time.
Handling multisite data
Adjusted PRWE means and group differences are presented in Table 15 for the analysis in which the primary
outcome model also included site as a random effect (within which participants were nested). An unstructured
covariance pattern was specified for this model. The analysis showed no statistically significant differences
between treatment groups post randomisation, except at week 12 (p = 0.01). The adjusted mean difference
at 52 weeks was –1.9 (95% CI –5.6 to 1.8). There was no overall effect of treatment group (difference of
2.8 points in favour of the surgery group; p = 0.09).
TABLE 14 Unadjusted PRWE total and subscale scores by randomised group and time point (continued )
PRWE score Surgery Plaster cast Total
52 weeks
Pain subscale
Mean (SD) 7.7 (10.1) 9.2 (11.3) 8.4 (10.7)
Median (IQR) 4.0 (0.0–10.0) 4.0 (0.0–14.0) 4.0 (0.0–12.0)
Min., max. (0, 42) (0, 48) (0, 48)
Function subscale
Mean (SD) 3.7 (7.2) 4.9 (9.0) 4.3 (8.1)
Median (IQR) 0.5 (0.0–3.5) 0.5 (0.0–5.0) 0.5 (0.0–4.5)
Min., max. (0, 43.5) (0, 48) (0, 48)
Total
Mean (SD) 11.4 (16.6) 14.2 (19.8) 12.8 (18.2)
Median (IQR) 4.0 (0.0–14.0) 4.5 (0.0–19.3) 4.5 (0.0–16.5)
Min., max. (0, 85.5) (0, 96) (0, 96)
Max., maximum; min., minimum.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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TABLE 15 Difference in adjusted mean PRWE scores over time by randomised group for sensitivity analyses
Time point Surgery, mean (95% CI) Plaster cast, mean (95% CI) Difference (95% CI) p-value
Missing dataa (N = 439; surgery, n = 219; plaster cast, n = 220)
6 weeks 35.1 (32.1 to 38.1) 39.8 (36.7 to 42.9) –4.7 (–9.0 to –0.5) 0.03
12 weeks 20.7 (17.9 to 23.6) 26.6 (23.7 to 29.5) –5.9 (–9.9 to –1.9) < 0.01
26 weeks 16.1 (13.4 to 18.8) 16.4 (13.7 to 19.2) –0.3 (–4.2 to 3.5) 0.87
52 weeks 12.0 (9.3 to 14.6) 14.1 (11.4 to 16.8) –2.1 (–5.9 to 1.6) 0.26
Handling multisite data (N = 408; surgery, n = 203; plaster cast, n = 205)
6 weeks 36.2 (32.6 to 39.8) 40.2 (36.6 to 43.8) –4.0 (–8.2 to 0.3) 0.07
12 weeks 21.6 (18.1 to 25.1) 27.0 (23.4 to 30.6) –5.4 (–9.5 to –1.2) 0.01
26 weeks 16.8 (13.5 to 20.1) 16.9 (13.6 to 20.3) –0.1 (–3.9 to 3.7) 0.96
52 weeks 12.5 (9.2 to 15.7) 14.4 (11.1 to 17.7) –1.9 (–5.6 to 1.8) 0.31
Overall 21.9 (18.8 to 24.9) 24.8 (21.7 to 27.8) –2.8 (–6.1 to 0.4) 0.09
Timing of data collection (N = 380; surgery, n = 190; plaster cast, n = 190)
6 weeks 37.3 (33.9 to 40.7) 37.7 (34.2 to 41.2) –0.4 (–5.3 to 4.4) 0.86
12 weeks 20.6 (17.5 to 23.8) 26.4 (23.1 to 29.7) –5.7 (–10.3 to –1.2) 0.01
26 weeks 15.2 (12.5 to 17.9) 15.4 (12.7 to 18.1) –0.2 (–4.0 to 3.6) 0.93
52 weeks 10.8 (8.2 to 13.3) 13.8 (11.2 to 16.5) –3.1 (–6.7 to 0.6) 0.10
Overall 19.9 (17.6 to 22.2) 22.2 (19.9 to 24.5) –2.4 (–5.6 to 0.9) 0.16
Adjusted for smoking status (N = 406; surgery, n = 202; plaster cast, n = 204)
6 weeks 35.3 (32.3 to 38.3) 40.0 (36.9 to 43.0) –4.7 (–9.0 to -0.4) 0.03
12 weeks 20.7 (17.8 to 23.7) 26.8 (23.8 to 29.8) –6.0 (–10.2 to –1.8) 0.01
26 weeks 15.9 (13.2 to 18.6) 16.7 (14.0 to 19.5) –0.8 (–4.7 to 3.0) 0.67
52 weeks 11.3 (8.8 to 13.9) 14.2 (11.5 to 16.8) –2.8 (–6.5 to 0.9) 0.14
Overall 20.9 (18.6 to 23.2) 24.6 (22.2 to 26.9) –3.6 (–6.9 to –0.3) 0.03
Including displacement as agreed by three independent raters (N = 408; surgery, n = 203; plaster cast, n = 205)
6 weeks 35.5 (32.5 to 38.5) 39.8 (36.8 to 42.8) –4.3 (–8.5 to –0.0) 0.05
12 weeks 21.0 (18.0 to 23.9) 26.6 (23.6 to 29.6) –5.6 (–9.8 to –1.4) 0.01
26 weeks 16.2 (13.6 to 18.9) 16.5 (13.8 to 19.2) –0.3 (–4.1 to 3.6) 0.89
52 weeks 11.9 (9.3 to 14.5) 13.9 (11.3 to 16.6) –2.1 (–5.8 to 1.6) 0.27
Overall 21.2 (18.9 to 23.5) 24.4 (22.0 to 26.7) –3.1 (–6.3 to 0.2) 0.07
Excluding those with no fracture (N = 407; surgery, n = 202; plaster cast, n = 205)
6 weeks 35.7 (32.6 to 38.7) 39.8 (36.8 to 42.8) –4.1 (–8.4 to 0.1) 0.06
12 weeks 21.1 (18.1 to 24.0) 26.6 (23.6 to 29.6) –5.5 (–9.7 to –1.3) 0.01
26 weeks 16.3 (13.6 to 19.0) 16.5 (13.8 to 19.2) –0.2 (–4.1 to 3.6) 0.91
52 weeks 11.9 (9.3 to 14.6) 14.0 (11.3 to 16.6) –2.0 (–5.8 to 1.7) 0.29
Overall 21.3 (19.0 to 23.6) 24.4 (22.0 to 26.7) –3.0 (–6.3 to 0.3) 0.08
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Timing of data collection
The primary analysis model was repeated including only data collected 1 week either side of the 6-week
time point (surgery, n = 118; plaster cast, n = 112), 2 weeks either side of the 12-week time point (surgery,
n = 121; plaster cast, n = 108), 6 weeks either side of the 26-week time point (surgery, n = 133; plaster
cast, n = 128) and 8 weeks either side of the 52-week time point (surgery, n = 170; plaster cast, n = 155).
A total of 380 participants were included in this analysis (190 in each group).
Adjusted PRWE means and group differences for the model as specified above are presented in Table 15.
The analysis showed no statistically significant differences between treatment groups post randomisation,
except at week 12 (p = 0.01). The adjusted mean difference at 52 weeks is in this population was –3.1
(95% CI –6.7 to 0.6). There was no overall effect of treatment group (difference of 2.4 points in favour
of the surgery group; p = 0.16).
Post hoc sensitivity analysis including smoking status
Smoking status (yes/no) was included as a covariate in the primary analysis model in a sensitivity check,
as this factor was found to be imbalanced by chance at baseline (smokers: 33% in the surgery group,
26% in the plaster cast group) and thought to be associated with poorer bone healing and complications.
The analysis showed similar results to the primary analysis, that is, a statistically significant difference
between treatment groups at week 12 (p = 0.01), but at not at week 26 (p = 0.67) or the primary end
point of 52 weeks (p = 0.14). Week 6 was now statistically significant at the 5% level (p = 0.03). However,
there was evidence of an overall effect of treatment group (difference of 3.6 points in favour of the
surgery group; p = 0.03). The magnitude of the effect at 52 weeks increased compared with the primary
analysis (from 2.1 to 2.8 points in favour of the surgery group) and the 95% CI includes the minimum
clinically important difference of 6 points (see Table 15).
Displacement and lack of fracture as assessed by independent review of baseline
imaging data
The randomisation for the trial was stratified by presence (or not) of displacement of a scaphoid fracture
(< 1 mm or 1–2 mm inclusive) as seen on the plain radiographic views taken at baseline and used by
the treating clinician to determine eligibility (although the discrepancies discussed in Chapter 3, Baseline
characteristics of randomised participants, should be noted). This judgement of displacement is included
as a covariate in the primary analysis model. The extent of fracture displacement was also subsequently
assessed and agreed on by three independent raters who reviewed all available participant baseline
imaging data (CT scans and radiographs) throughout the trial.
TABLE 15 Difference in adjusted mean PRWE scores over time by randomised group for sensitivity analyses
(continued )
Time point Surgery, mean (95% CI) Plaster cast, mean (95% CI) Difference (95% CI) p-value
Excluding those with displacement > 2mm (N = 383; surgery, n = 191; plaster cast, n = 192)
6 weeks 35.0 (31.9 to 38.0) 39.8 (36.7 to 42.9) –4.8 (–9.2 to -0.5) 0.03
12 weeks 20.7 (17.6 to 23.7) 26.2 (23.1 to 29.3) –5.6 (–9.9 to –1.3) 0.01
26 weeks 15.7 (13.0 to 18.3) 16.3 (13.6 to 19.0) –0.6 (–4.4 to 3.2) 0.76
52 weeks 11.4 (8.8 to 13.9) 13.7 (11.0 to 16.3) –2.3 (–6.0 to 1.4) 0.22
Overall 20.7 (18.4 to 23.0) 24.1 (21.7 to 26.4) –3.3 (–6.6 to 0.0) 0.05
a Separate linear regression analysis models for each time point run on the multiply imputed data set.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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Baseline radiographic images were available and reviewed for all but one participant (in the surgery arm).
Baseline CT images were available and reviewed for 431 participants (surgery, n = 214, 97.3%; plaster cast,
n = 217, 99.1%). Both baseline and CT images were reviewed for 431 (98.2%) participants, radiographs
were reviewed for only seven participants (1.6%) and neither were reviewed for one participant (0.2%).
The maximum fracture displacement, in millimetres, observed on either the CT or the radiographic images
was identified and used to categorise the participant’s fracture displacement as < 1 mm, 1–2 mm inclusive
or > 2 mm. Overall, 213 (81.6%) of the 261 fractures that were deemed by the treating clinician to not be
displaced at baseline were classified as not displaced (< 1 mm) on review, 39 (14.9%) were classified as
displaced 1–2 mm, eight (3.1%) were classified as displaced > 2 mm and one (0.4%) was missing (see
Appendix 3, Table 56). Of the 178 fractures that were deemed to be displaced (1–2 mm) by the treating
clinician at baseline, 112 (62.9%) were classified as not displaced (< 1 mm) on review, 47 (26.4%) were
classified as displaced 1–2 mm and 19 (10.7%) were classified as displaced > 2 mm.
The primary analysis model was rerun, replacing displacement as used in the randomisation as a covariate
with the variable indicating the extent of displacement agreed by the three raters (see Table 15) providing
very similar results to the primary analysis (see Table 11).
Consensus was reached between the three raters that displacement of the fracture was > 2 mm, based on
their assessment of the baseline radiography/CT scans, for 27 (6.2%) randomised participants. A fracture
could be seen on radiographic imaging for all but one of the 438 participants (n = 437, 99.8%) for whom
these data were available and on CT imaging for 426 (98.8%) of 431 participants. In five participants no
fracture could be seen on the CT scan, but in four of these participants the fracture could be seen on the
radiographic images; thus, consensus was reached between the three raters that only one participant did
not actually have a fracture (participant allocated to surgery group). Sensitivity analyses of the primary
outcome model were conducted that excluded these participants (see Table 15).
The quality of the radiographic imaging in the participant who was deemed not to have a fracture was
considered to be ‘good’. In the five cases in which a fracture could not be seen on CT images, the quality
of the images was deemed to be ‘good’ in three cases and ‘fair’ in the other two.
In addition, for patients for whom raters thought there was no fracture on the CT scan, later images were
reviewed for evidence of bone healing to confirm whether there had been a fracture. For the participant
for whom the baseline radiographic images also indicated there was no fracture, this was confirmed in
all other images. In the four others, the radiographic images indicated a fracture: one only had baseline
images, so later images could not be reviewed; one had only baseline and 52-week images and, at
52 weeks, the fracture was interpreted as having united; one had baseline, 6-week and 52-week images
and in all subsequent images the fracture was considered to be united; and one had only 6-week images,
in which the fracture was considered to have united. However, union cannot be said to confirm that a
fracture was initially present.
Complier-average causal effect analysis
The CACE analysis considers the effect of receiving early surgical fixation compared with no surgical fixation
of the fracture, and as such does not account for the ‘partial’ compliers in the plaster cast group [i.e. the two
participants for whom surgery was considered for non-union after a period of plaster cast management,
and the three participants who received delayed surgical fixation (6 months after randomisation) of their
non-united fracture]. We have considered these a pragmatic aspect of the ‘control’ condition. Six (2.7%)
participants in the plaster cast group crossed over to the surgery group and received immediate surgical
fixation of their fractures (contamination), while 31 (14.2%) participants in the surgery group did not
receive surgery but instead were managed conservatively (non-compliance). The CACE estimate of the
treatment effect with adjustment for non-compliance and contamination is a difference of –3.1 (95% CI
–7.3 to 1.1; p = 0.15) in 52-week total PRWE score. This difference is in favour of the surgery group and is
larger than the ITT treatment effect estimate at 52 weeks, demonstrating a greater, but not statistically
significant, benefit of surgery among participants who complied with their treatment allocation. The 95% CI
is –7.3 to 1.1; therefore, we cannot rule out a clinically meaningful difference or no effect.
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Subgroup analysis
Patient preference for treatment
The first subgroup analysis was undertaken to test the hypothesis that participants who expressed a
preference for surgery at baseline would benefit more from surgery than participants who expressed a
preference against surgery or who had no particular treatment preference.
Descriptive summary statistics for the PRWE total score are presented in Appendix 3, Table 57, and
displayed in Appendix 3, Figure 14, by treatment group stratified by baseline treatment preference. No
notable differences between the two groups are observed at any time point within the subgroup who did
not express a treatment preference at baseline. Unadjusted mean scores are lower (better) in the surgery
group at all time points, except 26 weeks in the subgroup who expressed a preference for surgery. In the
subgroup who preferred no surgery, unadjusted mean scores are lower (better) in the surgery group at all
time points, except baseline (post injury) in the subgroup who expressed a preference for surgery, and the
differences between the groups are larger at 6, 12 and 26 weeks than in the subgroup with a preference
for surgery.
No significant interaction was observed between randomised allocation and treatment preference (surgery
group and preference for surgery, p = 0.54; surgery group and preference for no surgery, p = 0.65). At
52 weeks, the adjusted mean difference in total PRWE score between the surgery and plaster cast groups
was –0.9 (95% CI –6.0 to 4.2; p = 0.72) in the no preference subgroup, –3.0 (95% CI –8.2 to 2.2; p = 0.25)
in the surgery preference subgroup and –4.2 (95% CI –17.2 to 8.9; p = 0.53) in the no-surgery preference
subgroup.
Fracture displacement (randomisation)
The second subgroup analysis tested the hypothesis that patients with a displaced fracture at baseline would
benefit more from surgery than those with a non-displaced fracture. The relationship between fracture
displacement (as stratified on in the randomisation) and randomised group in terms of PRWE is illustrated
in Appendix 3, Table 58 and Figure 15. Overall, participants with a displaced fracture tended to have higher
post-randomisation PRWE scores than those with no or minimal displacement, and scores in the surgery
group were lower than in the plaster cast group at 6, 12, 26 and 52 weeks for this subgroup. There was no
statistically significant interaction effect (p = 0.35); at 52 weeks, the adjusted mean difference between the
surgery and plaster cast groups was –0.8 (95% CI –5.4 to 3.8; p = 0.73) in the no displacement subgroup
and –4.0 (95% CI –9.3 to 1.4; p = 0.15) in the displaced subgroup, both favouring the surgery group.
Fracture displacement (study eligibility form)
A third subgroup analysis tested the same hypothesis as above using displacement as recorded on the study
eligibility form. The relationship between fracture displacement (as recorded on the study eligibility form)
and randomised group in terms of PRWE is illustrated in Appendix 3, Table 59 and Figure 16. Overall,
participants with a displaced fracture tended to have higher post-randomisation PRWE scores than those
with no or minimal displacement, and scores in the surgery group were lower than in the plaster cast group
at 6, 12, and 52 weeks for this subgroup. There was no statistically significant interaction effect (p = 0.70);
at 52 weeks, the adjusted mean difference between the surgery and plaster cast groups was –1.6 (95% CI
–6.1 to 3.0; p = 0.50) in the no displacement subgroup and –2.9 (95% CI –8.4 to 2.6; p = 0.30) in the
displaced subgroup, both favouring the surgery group.
Surgery patients for whom the screw caused cartilage damage
A total of 188 (85.8%) participants allocated to the surgery group received treatment as allocated. For 142
(75.5%) of these, CT images at 52 weeks were assessed by three independent raters for surgical screw
penetration. No screw penetration was observed for 49 (34.5%) participants. The extent of the penetration
was measured for the remaining 93 participants (mean 1.6 mm, SD 0.95 mm, range 0.2–4.7 mm), and was
categorised as minor (< 1 mm), which is unlikely to have an effect on articular cartilage (n = 25/93, 26.9%);
moderate (1–2mm inclusive), which will probably have an effect on cartilage, causing damage (n = 44, 47.3%);
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or severe (> 2 mm), which will definitely cause lasting damage to articular cartilage (n = 24, 25.8%). Descriptive
summaries of baseline participant and fracture data and PRWE scores for these participants, stratified by
whether or not the surgical screw used was too long and caused cartilage damage (none plus minor versus
moderate plus severe) as determined on the CT scans, are provided in Appendix 3, Tables 58–60. Participants
with displaced fractures at baseline were less likely to suffer from cartilage damage caused by the screw.
At 52 weeks, those who did not have significant surgical screw protrusion tended to perform better on the
PRWE (total unadjusted mean: 8.9 versus 10.8).
Plaster cast patients who required surgery for non-union
Of the 220 participants allocated to the plaster cast group, six crossed over to receive immediate surgical
fixation while, of the remaining 214, 19 (8.9%) were deemed to require surgical fixation of a non-united
fracture following plaster cast management (although two participants did not receive the surgery,
see Allocated to receive plaster cast intervention). Descriptive summaries of baseline participant and fracture
data and PRWE scores for the 214 plaster cast participants stratified by whether or not they needed surgery
owing to non-union are presented in Appendix 3, Tables 60–62. Participants with displaced fractures at
baseline were more likely to require surgery for non-union than those with < 1-mm displacement. Other risk
factors include being female and a smoker. In addition, those that required surgery had had their injuries for
slightly longer at enrolment to the trial than those who did not require surgery (median: 6 versus 4 days).
At 52 weeks, those who did not require surgery for non-union tended to perform better on the PRWE
(total unadjusted mean: 12.8 vs. 29.1).
Feasibility requirements
There were two feasibility requirements for this trial: (1) that a CT scan was performed within 2 weeks
(14 days) of a patient’s injury (and before surgery if this occurred earlier) and (2) for patients in the surgery
arm, that surgery was performed within 2 weeks of presentation to A&E or another clinic.
The majority of participants had a CT scan within 2 weeks of their injury (and before surgery if this was
earlier) (surgery group, n = 216, 98.6%; plaster cast group, n = 196, 89.1%; see Appendix 3, Tables 63–65).
Three participants in the surgery group did not meet this feasibility requirement: two crossed over treatment
and received neither a CT scan nor surgery and one had their CT scan 15 days after their injury, but this
was before their surgery which occurred 5 days later. Twenty-four participants in the plaster cast group did
not meet this feasibility requirement: five received routine treatment and did not receive a CT scan; one
immediately crossed over to surgery, which took place 7 days after injury, but did not receive a CT scan; and
18 had their CT scan between 15 and 47 days after injury (three of whom received surgery at a later date as
part of their further routine treatment for non-union).
Among participants allocated to the surgery group, 182 (83.1%) had surgical fixation of their fracture within
14 days of presenting at A&E or another clinic. Of the remaining 37 participants, 31 did not receive surgery
and six had their surgery between 15 and 20 days after presentation (see Appendix 3, Tables 63–65).
A linear regression for the surgery arm indicated that time from injury to surgery in days may be predictive
of PRWE score at 52 weeks, such that a 1-day delay in surgery is associated with a 0.78-point increase in
PRWE score (95% CI –0.01 to 1.57; p = 0.054).
Secondary analysis
Patient-Rated Wrist Evaluation subscales: pain and function
The PRWE subscale scores for pain and function are summarised in Table 14. Adjusted PRWE pain and
function subscale means and group differences are presented in Table 16 and displayed in Appendix 3,
Figure 17. The pain subscale analysis included data from 409 participants (surgery, n = 203, 92.7%; plaster
cast, n = 206, 93.6%) and the function analysis included data from 408 participants (surgery, n = 203,
92.7%; plaster cast, n = 205, 93.2%). The analysis of the pain subscale showed no statistically significant
difference between treatment groups overall or at any individual post-randomisation time point. The adjusted
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mean difference at 52 weeks was –1.1 (95% CI –3.3 to 1.0) in favour of the surgery group. However, a
statistically significant difference in function subscale score, favouring the surgery group, was seen at 6 and
12 weeks. This difference did not persist to 26 or 52 weeks, but there is an overall statistically significant
difference between the two groups over time.
Short Form questionnaire 12-items: physical and mental health component scores
Mean mental component summary (MCS) and physical component summary (PCS) scores of the SF-12
improved (increased) over time following randomisation in both groups (except between 26 and 52 weeks
in PCS in the plaster cast arm) (Table 17). At 52 weeks, the unadjusted mean difference in MCS was
–1.1 points (95% CI –3.2 to 1.0 points) favouring the plaster cast group, but in PCS was 1.8 points
(95% CI 0.2 to 3.3 points) favouring the surgery group.
TABLE 16 Difference in adjusted mean PRWE pain and function subscale scores over time by randomised group
Time point Surgery, mean (95% CI) Plaster cast, mean (95% CI) Difference (95% CI) p-value
PRWE pain subscale (N = 409; surgery, n = 203; plaster cast, n = 206)
6 weeks 18.8 (17.3 to 20.4) 19.0 (17.5 to 20.5) –0.1 (–2.3 to 2.0) 0.89
12 weeks 13.1 (11.5 to 14.6) 15.0 (13.4 to 16.6) –2.0 (–4.2 to 0.3) 0.09
26 weeks 11.0 (9.4 to 12.5) 10.6 (9.0 to 12.2) 0.4 (–1.8 to 2.6) 0.75
52 weeks 7.9 (6.4 to 9.5) 9.1 (7.5 to 10.6) –1.1 (–3.3 to 1.0) 0.31
Overall 12.7 (11.5 to 14.0) 13.5 (12.2 to 14.8) –0.7 (–2.5 to 1.1) 0.44
PRWE function subscale (N = 408; surgery, n = 203; plaster cast, n = 205)
6 weeks 16.7 (14.9 to 18.5) 20.5 (18.7 to 22.3) –3.8 (–6.3 to -1.3) < 0.01
12 weeks 8.1 (6.6 to 9.5) 11.5 (10.0 to 13.0) –3.4 (–5.6 to –1.3) < 0.01
26 weeks 5.4 (4.1 to 6.6) 6.0 (4.7 to 7.3) –0.6 (–2.4 to 1.2) 0.52
52 weeks 3.9 (2.7 to 5.1) 4.9 (3.7 to 6.1) –1.0 (–2.6 to 0.7) 0.25
Overall 8.6 (7.5 to 9.7) 10.8 (9.7 to 12.0) –2.2 (–3.8 to –0.6) 0.01
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
TABLE 17 Summaries and differences in the adjusted mean of the SF-12 MCS and PCS scores over time by
randomised group
SF-12 Surgery Plaster cast Total
6 weeks
MCS
Mean (SD) 49.5 (11.4) 49.3 (10.8) 49.4 (11.1)
Median (IQR) 52.4 (41.2–58.1) 51.3 (43.9–57.0) 51.5 (42.5–57.3)
Min., max. (12.8, 67.8) (16.0, 68.8) (12.8, 68.8)
PCS
Mean (SD) 43.7 (8.6) 43.9 (8.1) 43.8 (8.3)
Median (IQR) 44.0 (38.6–50.3) 43.9 (38.0–49.9) 43.9 (38.3–50.1)
Min., max. (21.1, 62.1) (23.6, 63.7) (21.1, 63.7)
continued
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TABLE 17 Summaries and differences in the adjusted mean of the SF-12 MCS and PCS scores over time by
randomised group (continued )
SF-12 Surgery Plaster cast Total
12 weeks
MCS
Mean (SD) 50.9 (11.1) 51.5 (10.2) 51.2 (10.7)
Median (IQR) 52.8 (44.7–59.4) 53.2 (45.7–59.3) 53.0 (45.3–59.3)
Min., max. (16.4, 67.9) (15.6, 66.4) (15.6, 67.9)
PCS
Mean (SD) 49.9 (7.5) 47.7 (8.5) 48.9 (8.1)
Median (IQR) 51.9 (45.0–55.9) 49.3 (42.6–53.5) 50.2 (43.9–54.8)
Min., max. (21.5, 62.1) (21.4, 64.6) (21.4, 64.6)
26 weeks
MCS
Mean (SD) 50.9 (12.1) 52.2 (9.9) 51.5 (11.1)
Median (IQR) 54.2 (46.2–58.4) 54.4 (47.9–59.1) 54.2 (47.5–59.1)
Min., max. (8.2, 67.9) (11.4, 68.2) (8.2, 68.2)
PCS
Mean (SD) 51.8 (7.4) 52.0 (7.6) 51.9 (7.5)
Median (IQR) 54.5 (48.9–56.3) 54.2 (49.5–56.7) 54.3 (49.1–56.7)
Min., max. (25.9, 63.0) (17.8, 62.5) (17.8, 63.0)
52 weeks
MCS
Mean (SD) 51.4 (10.1) 52.5 (10.0) 51.9 (10.1)
Median (IQR) 54.2 (46.8–57.6) 55.8 (47.6–59.3) 54.8 (47.5–58.2)
Min., max. (15.3, 64.7) (13.0, 68.5) (13.0, 68.5)
PCS
Mean (SD) 53.2 (6.3) 51.5 (8.1) 52.3 (7.3)
Median (IQR) 55.9 (49.3–57.2) 53.5 (48.4–56.2) 54.8 (49.0–56.7)
Min., max. (33.6, 65.7) (22.2, 69.4) (22.2, 69.4)
Time point Surgery, mean (95% CI) Plaster cast, mean (95% CI) Difference (95% CI) p-value
SF-12 MCS subscale (N = 408; surgery, n = 202; plaster cast, n = 206)
6 weeks 49.7 (48.1 to 51.3) 49.1 (47.5 to 50.7) 0.5 (–1.7 to 2.8) 0.63
12 weeks 50.6 (49.0 to 52.1) 50.7 (49.1 to 52.3) –0.2 (–2.4 to 2.1) 0.88
26 weeks 51.0 (49.4 to 52.6) 51.6 (49.9 to 53.3) –0.6 (–3.0 to 1.7) 0.60
52 weeks 51.0 (49.6 to 52.5) 52.3 (50.8 to 53.7) –1.2 (–3.3 to 0.8) 0.24
Overall 50.6 (49.3 to 51.8) 50.9 (49.7 to 52.2) –0.4 (–2.2 to 1.4) 0.69
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Adjusted SF-12 means and group differences for the models are presented in Table 17 and displayed
in Appendix 3, Figure 18. Both analysis models included data from 408 participants (surgery, n = 202,
92.2%; plaster cast, n = 206, 93.6%). The analysis of the MCS subscale showed no statistically significant
difference between treatment groups overall or at any individual post-randomisation time point. The adjusted
mean difference at 52 weeks was –1.2 (95% CI –3.3 to 0.8) in favour of the plaster cast group. However,
a statistically significant difference in PCS subscale score, favouring the surgery group, was seen at 12 and
52 weeks, but not at 6 or 26 weeks or overall (p = 0.08). The adjusted mean difference at 52 weeks was 1.6
(95% CI 0.2 to 3.1) in favour of the surgery group.
Wrist range of movement and grip strength: affected wrist
Measures of wrist range of movement and grip strength for the affected wrist are presented in Table 18.
Similar mean values were observed across these variables in the two groups at baseline. These were
assessed at hospital visits at baseline and at 6, 12 and 52 weeks post randomisation.
TABLE 17 Summaries and differences in the adjusted mean of the SF-12 MCS and PCS scores over time by
randomised group (continued )
SF-12 Surgery Plaster cast Total
SF-12 PCS subscale (N = 408; surgery, n = 202; plaster cast, n = 206)
6 weeks 43.9 (42.7 to 45.1) 43.4 (42.2 to 44.6) 0.5 (–1.2 to 2.2) 0.59
12 weeks 49.8 (48.7 to 50.9) 47.6 (46.5 to 48.8) 2.2 (0.6 to 3.8) 0.01
26 weeks 51.6 (50.5 to 52.7) 51.6 (50.5 to 52.8) –0.0 (–1.6 to 1.5) 0.95
52 weeks 53.1 (52.1 to 54.2) 51.5 (50.5 to 52.6) 1.6 (0.2 to 3.1) 0.03
Overall 49.6 (48.8 to 50.4) 48.5 (47.7 to 49.3) 1.1 (–0.1 to 2.2) 0.08
Max., maximum; min., minimum.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
TABLE 18 Grip and range measures by randomised group and time point
Wrist range of movement and grip strength measures Surgery Plaster cast Total
Baseline
Beighton laxity score
Mean (SD) 1.1 (2.0) 0.9 (1.7) 1.0 (1.8)
Median (IQR) 0.0 (0.0–2.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Min., max. (0.0, 10.0) (0.0, 8.0) (0.0, 10.0)
Extension (degrees)
Mean (SD) 32.0 (18.6) 28.9 (17.2) 30.4 (17.9)
Median (IQR) 30.0 (20.0–42.0) 30.0 (18.0–40.0) 30.0 (20.0–40.0)
Min., max. (0.0, 135.0) (–15.0, 90.0) (–15.0, 135.0)
Flexion (degrees)
Mean (SD) 35.0 (25.5) 34.9 (21.7) 35.0 (23.6)
Median (IQR) 30.0 (20.0–45.0) 35.0 (22.0–44.0) 32.0 (20.0–45.0)
Min., max. (0.0, 160.0) (0.0, 162.0) (0.0, 162.0)
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TABLE 18 Grip and range measures by randomised group and time point (continued )
Wrist range of movement and grip strength measures Surgery Plaster cast Total
Radial deviation (degrees)
Mean (SD) 14.3 (9.5) 14.3 (9.6) 14.3 (9.6)
Median (IQR) 13.0 (10.0–20.0) 14.0 (9.0–20.0) 13.0 (9.0–20.0)
Min., max. (0.0, 60.0) (0.0, 70.0) (0.0, 70.0)
Ulnar deviation (degrees)
Mean (SD) 18.0 (10.9) 18.6 (11.0) 18.3 (10.9)
Median (IQR) 17.0 (10.0–22.5) 18.0 (10.0–25.0) 18.0 (10.0–25.0)
Min., max. (0.0, 70.0) (0.0, 60.0) (0.0, 70.0)
Forearm rotation supination (degrees)
Mean (SD) 66.9 (26.7) 63.6 (27.8) 65.3 (27.3)
Median (IQR) 75.0 (56.5–85.0) 70.0 (50.0–85.0) 73.0 (50.0–85.0)
Min., max. (0.0, 124.0) (–10.0, 118.0) (–10.0, 124.0)
Forearm rotation pronation (degrees)
Mean (SD) 72.2 (23.1) 71.2 (25.0) 71.7 (24.0)
Median (IQR) 80.0 (67.5–90.0) 80.0 (68.5–90.0) 80.0 (68.0–90.0)
Min., max. (0.0, 100.0) (0.0, 105.0) (0.0, 105.0)
Grip strength (kg)
Mean (SD) 9.6 (10.0) 9.8 (10.6) 9.7 (10.3)
Median (IQR) 6.0 (2.0–15.3) 7.0 (2.0–12.7) 6.7 (2.0–14.4)
Min., max. (0.0, 61.7) (0.0, 58.0) (0.0, 61.7)
6 weeks
Extension (degrees)
Mean (SD) 51.0 (20.2) 40.0 (18.3) 45.4 (20.0)
Median (IQR) 50.0 (38.0–60.0) 40.0 (28.0–50.0) 45.0 (30.0–56.0)
Min., max. (5.0, 135.0) (0.0, 90.0) (0.0, 135.0)
Flexion (degrees)
Mean (SD) 51.6 (28.3) 40.1 (23.4) 45.7 (26.5)
Median (IQR) 49.0 (30.0–65.0) 35.0 (25.0–50.0) 40.0 (30.0–60.0)
Min., max. (5.0, 162.0) (–5.0, 158.0) (–5.0, 162.0)
Radial deviation (degrees)
Mean (SD) 21.7 (10.7) 21.3 (12.8) 21.5 (11.8)
Median (IQR) 20.0 (15.0–28.0) 20.0 (11.0–28.0) 20.0 (13.0–28.0)
Min., max. (0.0, 60.0) (0.0, 70.0) (0.0, 70.0)
Ulnar deviation (degrees)
Mean (SD) 29.3 (12.1) 23.5 (13.0) 26.3 (12.9)
Median (IQR) 30.0 (20.0–38.0) 20.0 (15.0–30.0) 25.0 (18.0–35.0)
Min., max. (1.0, 60.0) (0.0, 70.0) (0.0, 70.0)
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TABLE 18 Grip and range measures by randomised group and time point (continued )
Wrist range of movement and grip strength measures Surgery Plaster cast Total
Forearm rotation supination (degrees)
Mean (SD) 82.4 (15.7) 74.9 (20.3) 78.5 (18.6)
Median (IQR) 90.0 (80.0–90.0) 80.0 (65.0–90.0) 85.0 (72.0–90.0)
Min., max. (0.0, 131.0) (0.0, 108.0) (0.0, 131.0)
Forearm rotation pronation (degrees)
Mean (SD) 82.8 (14.4) 80.1 (15.5) 81.4 (15.0)
Median (IQR) 90.0 (80.0–90.0) 85.0 (75.0–90.0) 90.0 (80.0–90.0)
Min., max. (0.0, 110.0) (10.0, 104.0) (0.0, 110.0)
Grip strength (kg)
Mean (SD) 24.1 (12.7) 20.1 (14.0) 22.0 (13.5)
Median (IQR) 23.3 (15.3–32.7) 18.2 (9.3–28.7) 20.0 (11.3–30.7)
Min., max. (0.0, 77.3) (0.0, 81.7) (0.0, 81.7)
12 weeks
Extension (degrees)
Mean (SD) 61.1 (17.7) 56.9 (19.5) 59.1 (18.7)
Median (IQR) 60.0 (50.0–70.0) 55.0 (43.5–70.0) 60.0 (45.0–70.0)
Min., max. (13.0, 125.0) (2.0, 125.0) (2.0, 125.0)
Flexion (degrees)
Mean (SD) 62.0 (23.7) 55.3 (22.3) 58.7 (23.2)
Median (IQR) 60.0 (45.0–75.0) 55.0 (41.0–70.0) 58.0 (45.0–72.0)
Min., max. (15.0, 144.0) (5.0, 144.0) (5.0, 144.0)
Radial deviation (degrees)
Mean (SD) 26.1 (12.7) 26.2 (14.5) 26.1 (13.6)
Median (IQR) 25.0 (18.0–30.0) 23.0 (15.0–32.0) 24.0 (18.0–30.0)
Min., max. (5.0, 80.0) (0.0, 80.0) (0.0, 80.0)
Ulnar deviation (degrees)
Mean (SD) 35.4 (12.7) 31.6 (13.7) 33.5 (13.3)
Median (IQR) 35.0 (28.0–40.0) 30.0 (22.0–40.0) 31.0 (25.0–40.0)
Min., max. (10.0, 80.0) (0.0, 80.0) (0.0, 80.0)
Forearm rotation supination (degrees)
Mean (SD) 87.1 (13.8) 82.3 (18.2) 84.7 (16.3)
Median (IQR) 90.0 (85.0–90.0) 90.0 (80.0–90.0) 90.0 (80.0–90.0)
Min., max. (10.0, 140.0) (0.0, 126.0) (0.0, 140.0)
Forearm rotation pronation (degrees)
Mean (SD) 86.5 (8.5) 83.4 (13.8) 85.0 (11.5)
Median (IQR) 90.0 (85.0–90.0) 90.0 (80.0–90.0) 90.0 (80.0–90.0)
Min., max. (26.0, 104.0) (0.0, 120.0) (0.0, 120.0)
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TABLE 18 Grip and range measures by randomised group and time point (continued )
Wrist range of movement and grip strength measures Surgery Plaster cast Total
Grip strength (kg)
Mean (SD) 30.8 (12.5) 28.2 (14.4) 29.5 (13.5)
Median (IQR) 29.3 (22.3–39.3) 28.5 (18.7–37.8) 28.7 (20.0–38.7)
Min., max. (0.0, 82.0) (0.0, 89.0) (0.0, 89.0)
52 weeks
Extension (degrees)
Mean (SD) 68.4 (21.0) 68.8 (15.5) 68.6 (18.6)
Median (IQR) 70.0 (56.0–80.0) 70.0 (56.0–80.0) 70.0 (56.0–80.0)
Min., max. (15.0, 140.0) (40.0, 115.0) (15.0, 140.0)
Flexion (degrees)
Mean (SD) 69.8 (20.3) 68.4 (16.4) 69.1 (18.5)
Median (IQR) 70.0 (55.0–85.0) 70.0 (60.0–80.0) 70.0 (58.0–80.0)
Min., max. (20.0, 152.0) (22.0, 105.0) (20.0, 152.0)
Radial deviation (degrees)
Mean (SD) 32.2 (17.4) 32.5 (14.5) 32.4 (16.1)
Median (IQR) 28.0 (20.0–40.0) 30.0 (22.0–40.0) 30.0 (20.0–40.0)
Min., max. (6.0, 90.0) (8.0, 80.0) (6.0, 90.0)
Ulnar deviation (degrees)
Mean (SD) 40.6 (14.8) 39.9 (13.7) 40.3 (14.3)
Median (IQR) 40.0 (30.0–50.0) 40.0 (30.0–49.0) 40.0 (30.0–50.0)
Min., max. (8.0, 90.0) (12.0, 80.0) (8.0, 90.0)
Forearm rotation supination (degrees)
Mean (SD) 88.3 (13.3) 85.2 (13.9) 86.8 (13.6)
Median (IQR) 90.0 (86.0–90.0) 90.0 (80.0–90.0) 90.0 (85.0–90.0)
Min., max. (30.0, 136.0) (30.0, 122.0) (30.0, 136.0)
Forearm rotation pronation (degrees)
Mean (SD) 86.8 (10.5) 86.2 (9.5) 86.5 (10.0)
Median (IQR) 90.0 (85.0–90.0) 90.0 (85.0–90.0) 90.0 (85.0–90.0)
Min., max. (5.0, 114.0) (40.0, 109.0) (5.0, 114.0)
Grip strength (kg)
Mean (SD) 36.9 (12.7) 37.4 (14.2) 37.2 (13.4)
Median (IQR) 36.2 (28.7–44.8) 38.5 (28.7–46.2) 37.3 (28.7–45.2)
Min., max. (10.3, 109.7) (4.7, 88.3) (4.7, 109.7)
Max., maximum; min., minimum.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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Grip strength
On average, grip strength, in kilograms, increased over time in both groups and was higher in the surgery
group than in the plaster cast group at all post-randomisation time points except 52 weeks.
Adjusted grip strength means and group differences are presented in Table 19 and displayed in Appendix 3,
Figure 19. The analysis models included data from 407 participants (surgery, n = 201, 91.8%; plaster cast,
n = 206, 93.6%) and showed a statistically significant difference between treatment groups at 6 weeks
post randomisation (p < 0.001) favouring the surgery group, a borderline statistically significant result
at 12 weeks (p = 0.06) and no difference at 52 weeks. The adjusted mean difference at 52 weeks was
–1.0 (95% CI –3.7 to 1.8) favouring the plaster cast group.
Union
Assessment of union via radiographs was possible for 188 (85.8%) participants in the surgery group
and 201 (91.4%) participants in the plaster cast group at 6 weeks, of whom 13 (6.9%) and 32 (15.9%),
respectively, displayed non-union or only slight union (Table 20). At week 12, radiographic images were
available for assessment of union for fewer participants than at 6 weeks: 169 (77.2%) in the surgery group
and 163 (74.1%) in the plaster cast arm. A lower proportion of those reviewed were graded as having
non-union or slight union at this time point than at 6 weeks in both groups (surgery, n = 7, 4.1%; plaster
cast, n = 23, 14.1%).
The proportion of participants assessed for union decreased at each time point in both groups. At 52 weeks,
the grading of union was based on CT images or on radiographic images when CT was not available and
was assessed for 314 participants (surgery, n = 164, 74.9%; plaster cast, n = 150, 68.2%), of whom 13
(4.1%) were deemed to have non-union or only slight union of their fracture (surgery, n = 4, 2.4%; plaster
cast, n = 9, 6.0%). Furthermore, in Table 20, the percentages are calculated using a denominator that
includes participants with missing data. There is a substantial number of participants with missing data
(28.5% overall at 52 weeks), which may underestimate the proportion of participants with union.
The 52-week PRWE scores, where available, are summarised for the two groups according to whether or
not the participants had imaging available for union assessment at 52 weeks (see Table 20). Overall, there
is little difference in the mean PRWE scores of those who attended and did not attend imaging (12.7 vs.
13.2, respectively); however, there are differences between the two randomised groups. In the surgery
group, participants who did not attend imaging tended to have higher (worse) scores than those who did
attend imaging (mean 16.4 vs. 10.6, respectively) and so were perhaps less likely to have full union of their
fractures. However, the trend reverses in the plaster cast group, with those not attending imaging having
lower (better) scores and so more likely to have better union.
TABLE 19 Difference in adjusted mean grip strength over time by randomised group (N= 407; surgery, n= 201;
plaster cast, n= 206)
Time point Surgery, mean (95% CI) Plaster cast, mean (95% CI) Difference (95% CI) p-value
6 weeks 23.8 (22.0 to 25.6) 19.4 (17.6 to 21.2) 4.4 (1.8 to 6.9) 0.001
12 weeks 30.9 (29.0 to 32.8) 28.3 (26.4 to 30.2) 2.6 (–0.1 to 5.3) 0.06
52 weeks 37.0 (35.1 to 39.0) 38.0 (36.1 to 40.0) –1.0 (–3.7 to 1.7) 0.48
Overall 30.1 (28.5 to 31.7) 27.9 (26.3 to 29.5) 2.0 (–0.3 to 4.2) 0.08
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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Participants in the surgery group were less likely than those in the plaster cast group to have non-union
or only slight union of their fracture at 52 weeks, but this difference was not statistically significant in a
logistic regression model adjusting for age, fracture displacement and hand dominance [odds ratio (OR)
0.40, 95% CI 0.12 to 1.33; p = 0.13). Similarly, results following multiple imputation of the union variables
at 6, 12 and 52 weeks indicated that the likelihood of participants having non-union or only slight union
of their fracture at 52 weeks was lower for participants allocated to the surgery group than for those in
the plaster cast group (OR 0.51, 95% CI 0.17 to 1.57), but this difference was not statistically significant
(p = 0.24). In the surgery group, 4 out of 219 participants were deemed to have non-union or slight
union at 52 weeks (1.8%), compared with 9 out of 220 in the plaster cast group (4.1%). Based on these
figures, the increase in the number of participants who need to be offered surgery compared with the
number offered plaster cast management (followed by fixation of fractures that fail to unite with cast
immobilisation) to prevent one extra non-union or slight union at 52 weeks is 44 [number needed to
treat (NNT)]. However, data are missing in over a quarter of participants, and this calculation, by default,
assumes that all those in whom data are missing experience at least partial union. At the other extreme,
assuming that all those in whom data are missing experience slight union or non-union, the NNT is 11.
For non-union alone, the NNT is 73 and 12 in the first and second scenario, respectively.
TABLE 20 Summary of union assessment by time point and randomised group
Time pointa Union Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
6 weeks, n (%) Union 47 (21.5) 26 (11.8) 73 (16.6)
Almost full union 81 (37.0) 73 (33.2) 154 (35.1)
Partial union 47 (21.5) 70 (31.8) 117 (26.7)
Slight union 11 (5.0) 23 (10.5) 34 (7.7)
Non-union 2 (0.9) 9 (4.1) 11 (2.5)
Missing 31 (14.2) 19 (8.6) 50 (11.4)
12 weeks, n (%) Union 102 (46.6) 63 (28.6) 165 (37.6)
Almost full union 45 (20.5) 44 (20.0) 89 (20.3)
Partial union 15 (6.8) 33 (15.0) 48 (10.9)
Slight union 7 (3.2) 13 (5.9) 20 (4.6)
Non-union 0 (0.0) 10 (4.5) 10 (2.3)
Missing 50 (22.8) 57 (25.9) 107 (24.4)
52 weeks, n (%) Union 93 (42.5) 72 (32.7) 165 (37.6)
Almost full union 64 (29.2) 59 (26.8) 123 (28)
Partial union 3 (1.4) 10 (4.5) 13 (3)
Slight union 3 (1.4) 5 (2.3) 8 (1.8)
Non-union 1 (0.5) 4 (1.8) 5 (1.1)
Missing 55 (25.1) 70 (31.8) 125 (28.5)
PRWE total score,b
n [mean (SD)]
Attended imaging 161 [10.6 (15.5)] 145 [15.0 (20.1)] 306 [12.7 (18.0)]
Did not attend 25 [16.4 (22.1)] 31 [10.6 (17.7)] 56 [13.2 (19.8)]
a The 6- and 12-week data are from radiographic images and the 52-week data are from CT scans, unless missing,
in which case radiographic imaging was considered.
b Total 52-week PRWE score, where available, according to whether patients attended or did not attend imaging at
52 weeks.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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The one participant in the plaster cast group whose fracture was assessed at 52 weeks by three raters as
showing non-union underwent surgical fixation the day after randomisation, then wore a splint for 2 weeks;
no concerns about non-union were raised and recorded in the treatment confirmation form at 6 or 12 weeks.
One of the four participants in the plaster cast group whose fractures were assessed as showing non-union
had surgery to fix non-union 3 months after randomisation, a further surgery for persistent non-union
6 months after that and surgery a month later to remove the wires from the second operation. The remaining
three participants received routine treatment with a plaster cast and were not offered surgery; for two of
them, this was because non-union was not suspected by the treating clinician on review of radiography,
while the third did not attend for radiography at 6 or 12 weeks.
Malunion
Malunion was determined by calculating the ratio of the scaphoid height to length, using thresholds of both
0.6 and 0.7 (Table 21). By default, more participants are classified as having malunion using the 0.6 threshold
than 0.7. Considering those with non-missing data only, at 6 weeks, 175 (93.6%) participants in the surgery
group and 180 (90.0%) participants in the plaster cast group had malunion based on the 0.6 threshold. At
0.7, the figures are 52 (27.8%) and 51 (25.5%), respectively. Malunion at both thresholds remained reasonably
steady in both groups at 6, 12 and 52 weeks, as determined from radiographic images. However, at 52 weeks,
based on CT scans, the rate of malunion dramatically decreased to 60 (38.29%) participants in the surgery
group and 45 (33.3%) participants in the plaster cast group at the 0.6 threshold, and to seven (4.5%) and
seven (5.2%), respectively, at 0.7.
TABLE 21 Malunion assessed using scaphoid height to length ratio at thresholds of 0.6 and 0.7 by randomised
group and time point
Time point Union, n (%) Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
0.6 threshold
Baseline (radiography) No malunion 30 (13.7) 28 (12.7) 58 (13.2)
Malunion 182 (83.1) 190 (86.4) 372 (84.7)
Missing 7 (3.2) 2 (0.9) 9 (2.1)
Baseline (CT scan) No malunion 154 (70.3) 160 (72.7) 314 (71.5)
Malunion 63 (28.8) 54 (24.5) 117 (26.7)
Missing 2 (0.9) 6 (2.7) 8 (1.8)
6 weeks No malunion 12 (5.5) 20 (9.1) 32 (7.3)
Malunion 175 (79.9) 180 (81.8) 355 (80.9)
Missing 32 (14.6) 20 (9.1) 52 (11.8)
12 weeks No malunion 10 (4.6) 12 (5.5) 22 (5.0)
Malunion 159 (72.6) 151 (68.6) 310 (70.6)
Missing 50 (22.8) 57 (25.9) 107 (24.4)
52 weeks (radiography) No malunion 9 (4.1) 13 (5.9) 22 (5.0)
Malunion 148 (67.6) 128 (58.2) 276 (62.9)
Missing 62 (28.3) 79 (35.9) 141 (32.1)
52 weeks (CT scan) No malunion 97 (44.3) 90 (40.9) 187 (42.6)
Malunion 60 (27.4) 45 (20.5) 105 (23.9)
Missing 62 (28.3) 85 (38.6) 147 (33.5)
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Complications
At least one surgical complication, up to and including 52 weeks post randomisation, was experienced
by 31 (14.2%) participants randomised to the surgery group and by three (1.4%) participants in the
plaster cast group. The most common surgical complication was screw protrusion (Table 22), reported for
10 participants in the surgery group and one in the plaster cast group at 6, 12 or 52 weeks. A nerve event
(of any kind) was reported for one participant in the plaster cast group (hypoaesthesia at 52 weeks) and
for 10 unique participants in the surgery group. Table 22 presents only complications that were reported
for at least one participant throughout the course of the study; however, we also explicitly asked about the
following surgical complications, of which none were reported: superficial division of radial nerve, vessel
events and avascular necrosis.
At least one issue relating to the plaster cast, up to and including 52 weeks, was reported for five (2.3%)
participants randomised to the surgery group and for 40 (18.2%) participants in the plaster cast group
(Table 23). The most commonly reported issue was that the cast caused soreness (this was generally minor
rubbing of the skin), reported for three surgery participants and 23 plaster cast participants at 6 or 12 weeks.
At least one medical complication, up to 52 weeks, was reported for four (1.8%) participants randomised
to the surgery group and for five (2.3%) participants in the plaster cast group. These were either a chest
infection or another issue (gastric upset, depression or tenderness of the affected wrist; Table 24). We
also explicitly asked about the following medical complications, of which none were reported: myocardial
infarction, stroke, deep vein thrombosis requiring treatment and pulmonary embolism requiring treatment.
TABLE 21 Malunion assessed using scaphoid height to length ratio at thresholds of 0.6 and 0.7 by randomised
group and time point (continued )
Time point Union, n (%) Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
0.7 threshold
Baseline (radiography) No malunion 167 (76.3) 173 (78.6) 340 (77.4)
Malunion 45 (20.5) 45 (20.5) 90 (20.5)
Missing 7 (3.2) 2 (0.9) 9 (2.1)
Baseline (CT scan) No malunion 214 (97.7) 212 (96.4) 426 (97)
Malunion 3 (1.4) 2 (0.9) 5 (1.1)
Missing 2 (0.9) 6 (2.7) 8 (1.8)
6 weeks No malunion 135 (61.6) 149 (67.7) 284 (64.7)
Malunion 52 (23.7) 51 (23.2) 103 (23.5)
Missing 32 (14.6) 20 (9.1) 52 (11.8)
12 weeks No malunion 117 (53.4) 118 (53.6) 235 (53.5)
Malunion 52 (23.7) 45 (20.5) 97 (22.1)
Missing 50 (22.8) 57 (25.9) 107 (24.4)
52 weeks (radiography) No malunion 96 (43.8) 101 (45.9) 197 (44.9)
Malunion 61 (27.9) 40 (18.2) 101 (23.0)
Missing 62 (28.3) 79 (35.9) 141 (32.1)
52 weeks (CT scan) No malunion 150 (68.5) 128 (58.2) 278 (63.3)
Malunion 7 (3.2) 7 (3.2) 14 (3.2)
Missing 62 (28.3) 85 (38.6) 147 (33.5)
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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TABLE 22 Surgery-related complications as assessed by clinical examination by randomised group and time point
Surgery-related
complications, n (%)a Time point Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Surgical site infection 6 weeks 1 (0.5) 0 (0.0) 1 (0.2)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 1 (0.5) 2 (0.9) 3 (0.7)
Delayed wound healing 6 weeks 2 (0.9) 0 (0.0) 2 (0.5)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 1 (0.5) 1 (0.5) 2 (0.5)
Regional pain syndrome 6 weeks 0 (0.0) 0 (0.0) 0 (0.0)
12 weeks 1 (0.5) 0 (0.0) 1 (0.2)
52 weeks 1 (0.5) 0 (0.0) 1 (0.2)
Nerve event
Hypoaesthesia 6 weeks 2 (0.9) 0 (0.0) 2 (0.5)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 1 (0.5) 1 (0.5) 2 (0.5)
Numbness 6 weeks 3 (1.4) 0 (0.0) 3 (0.7)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 0 (0.0) 0 (0.0) 0 (0.0)
Superficial division of
median nerve
6 weeks 3 (1.4) 0 (0.0) 3 (0.7)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 0 (0.0) 0 (0.0) 0 (0.0)
Other nerve event 6 weeks 0 (0.0) 0 (0.0) 0 (0.0)
12 weeks 2 (0.9) 0 (0.0) 2 (0.5)
52 weeks 1 (0.5) 0 (0.0) 1 (0.2)
Screw-related complications
Protrusion 6 weeks 2 (0.9) 0 (0.0) 2 (0.5)
12 weeks 1 (0.5) 0 (0.0) 1 (0.2)
52 weeks 7 (3.2) 1 (0.5) 8 (1.8)
Bending 6 weeks 0 (0.0) 0 (0.0) 0 (0.0)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 1 (0.5) 0 (0.0) 1 (0.2)
Radiolucent halo 6 weeks 1 (0.5) 0 (0.0) 1 (0.2)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 2 (0.9) 0 (0.0) 2 (0.5)
Implant problem – movement 6 weeks 2 (0.9) 0 (0.0) 2 (0.5)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 3 (1.4) 0 (0.0) 3 (0.7)
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TABLE 22 Surgery-related complications as assessed by clinical examination by randomised group and time point
(continued )
Surgery-related
complications, n (%)a Time point Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Otherb 6 weeks 3 (1.4) 0 (0.0) 3 (0.7)
12 weeks 2 (0.9) 0 (0.0) 2 (0.5)
52 weeks 1 (0.5) 1 (0.5) 2 (0.5)
≥ 1 surgical complication 6 weeks 14 (6.4) 0 (0.0) 14 (3.2)
12 weeks 6 (2.7) 0 (0.0) 6 (1.4)
52 weeks 15 (6.9) 3 (1.4) 18 (4.1)
Any time point 31 (14.2) 3 (1.4) 34 (7.7)
a Number of unique participants and percentage of those randomised.
b Other includes the following: at 6 weeks (all surgery group), painful, swollen and stich sinus (n = 1), stich still in situ
(n = 1) and tingling sensation in fingers (n = 1); at 12 weeks (all surgery group), pins and needles, and problems lifting
(n = 1) and pain, stiffness and swelling (n = 1); and at 52 weeks, scar tenderness (surgery group, n = 1) and allergic
reaction to dressing (plaster cast group, n = 1).
TABLE 23 Complications related to the plaster cast as assessed by clinical examination by randomised group and
time point
Plaster cast issues, n (%)a Time point Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Cast broken 6 weeks 0 (0.0) 7 (3.2) 7 (1.6)
12 weeks 1 (0.5) 1 (0.5) 1 (0.5)
52 weeks 0 (0.0) 0 (0.0) 0 (0.0)
Cast too soft 6 weeks 1 (0.5) 9 (4.1) 10 (2.3)
12 weeks 0 (0.0) 1 (0.5) 1 (0.2)
52 weeks 0 (0.0) 1 (0.5) 1 (0.2)
Cast too tight 6 weeks 2 (0.9) 8 (3.6) 10 (2.3)
12 weeks 0 (0.0) 1 (0.5) 1 (0.2)
52 weeks 0 (0.0) 2 (0.9) 2 (0.5)
Cast caused soreness 6 weeks 3 (1.4) 20 (9.1) 23 (5.2)
12 weeks 0 (0.0) 3 (1.4) 3 (0.7)
52 weeks 0 (0.0) 0 (0.0) 0 (0.0)
Otherb 6 weeks 0 (0.0) 5 (2.3) 5 (1.1)
12 weeks 0 (0.0) 0 (0.0) 0 (0.0)
52 weeks 0 (0.0) 0 (0.0) 0 (0.0)
One or more cast complication 6 weeks 5 (2.3) 40 (18.2) 45 (10.3)
12 weeks 1 (0.5) 4 (1.8) 5 (1.1)
52 weeks 0 (0.0) 3 (1.4) 3 (0.7)
Any time point 6 (2.7) 45 (20.5) 51 (11.6)
a Number of unique participants and percentage of those randomised.
b Other includes the following: at 6 weeks (all plaster cast group), cast itchy (n = 2), mild numbness of the thumb (n = 2)
and nerve event, namely hypoaesthesia in the left first branch at median nerve (n = 1).
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There was no evidence of a difference between the two groups in the likelihood of participants experiencing
at least one surgical, medical or cast complication (as recorded on the complications form, with details in
Tables 22–24) up to 52 weeks [surgery group, n = 39, 17.8%; plaster cast group, n = 51, 23.2% (OR 0.72,
95% CI 0.45 to 1.15; p = 0.17)]. We must be careful not to overinterpret this finding to mean that the
likelihood of experiencing a surgical, cast or medical complication is similar in both groups. Cast complications
were observed more frequently among the plaster cast group and surgical complications were observed more
frequently among the surgery group. Complications related to the plaster cast tended to be relatively minor
and would not result in ongoing problems (see Table 23). However, surgery-related complications are more
severe and are more likely to have potentially long-lasting consequences for the individual (see Table 22).
As an example, Table 23 shows that, in the plaster cast group, half (30 of 58 events) of the complications
were due to the cast being broken, soft or tight, and, in the statistical analysis of the complications, are
given the same importance as CRPS or an infection. Non-union symptoms (n = 8) were recorded as AEs or
complications, even when this was an expected part of the control pathway and when non-union had been
identified. There are also some discrepancies between the reporting of events on the complications form and
on the AEs form. For example, the AEs form logs three participants as having CRPS, but the complications
form records only two. The three raters’ review of the imaging identified further complications that were not
accounted for in the AE or complications forms, particularly after surgery. This could have been influenced by
whether or not the problem had been recognised, by the surgeon’s decision on whether or not this needed
to be reported or by whether or not the complication was identified on imaging done solely for research
purposes and hence was not available to clinicians. The logistic regression included complications from the
hospital forms only and did not include those from other data sources (i.e. AE reporting or imaging).
Cases when two out of the three raters agreed that there was a complication on a review of imaging data
are reported by randomised group and time point in Table 25.
Osteoarthritis (OA) was detected at baseline on either radiographic or CT images for 25 (11.4%) participants
in the surgery group and 31 (14.1%) participants in the plaster cast group. OA was more likely to be detected
on CT images than in plain radiographic views. Of these 25 participants in the surgery group, 23 had
radiographic or CT imaging at 52 weeks and 17 were seen to have OA on either of these. OA was detected
for a further 28 participants at 52 weeks in the surgery group. Of the 31 participants in the plaster cast group
with OA at baseline, 22 had radiographic or CT imaging at 52 weeks and 20 were seen to have OA on either
of these. OA was detected for a further 22 participants at 52 weeks in the plaster cast group.
TABLE 24 Other medical complications as assessed by clinical examination by randomised group and time point
Medical complications, n (%)a Time point Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Chest infection 6 weeks 0 (0.0) 0 (0.0) 0 (0.0)
12 weeks 1 (0.5) 2 (0.9) 3 (0.7)
52 weeks 4 (1.8) 0 (0.0) 4 (0.9)
Otherb 6 weeks 0 (0.0) 2 (0.9) 2 (0.5)
12 weeks 0 (0.0) 1 (0.5) 1 (0.2)
52 weeks 0 (0.0) 0 (0.0) 0 (0.0)
One or more medical
complication
6 weeks 0 (0.0) 2 (0.9) 2 (0.5)
12 weeks 1 (0.5) 3 (1.4) 4 (0.9)
52 weeks 4 (1.8) 0 (0.0) 4 (0.9)
Any time point 4 (1.8) 5 (2.3) 9 (2.1)
a Number of unique participants and percentage of those randomised.
b Other includes the following: at 6 weeks (all plaster cast group), gastric upset, possibly caused by ibuprofen (n = 1) and
depression (n = 1); and at 12 weeks (all plaster cast group), tenderness of the affected wrist (n = 1).
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TABLE 25 Complications reported on review of imaging data at 6, 12 and 52 weeks by three independent raters by
randomised group and time point
Complication observed on
independent review of imaging data,
n (%)a Time point
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
Osteoarthritisb Baseline
(radiography)
N = 218 N = 220 N = 438
21 (9.6) 22 (10.0) 43 (9.8)
Baseline (CT scan) N = 217 N = 214 N = 431
22 (10.1) 26 (12.2) 48 (11.1)
6 weeks N = 188 N = 201 N = 389
15 (8.0) 21 (10.5) 36 (9.3)
12 weeks N = 169 N = 163 N = 332
21 (12.4) 28 (17.2) 49 (14.8)
52 weeks
(radiography)
N = 157 N = 142 N = 299
25 (15.9) 24 (16.9) 49 (16.4)
52 weeks (CT scan) N = 157 N = 135 N = 292
42 (26.8) 36 (26.7) 78 (26.7)
Avascular necrosisb,c Baseline
(radiography)
N = 218 N = 220 N = 438
None 204 (93.6) 204 (92.7) 408 (93.2)
Just 14 (6.4) 15 (6.8) 29 (6.6)
Missing 0 (0.0) 1 (0.5) 1 (0.2)
Baseline (CT scan) N = 217 N = 214 N = 431
None 197 (90.8) 187 (87.4) 384 (89.1)
Just 20 (9.2) 27 (12.6) 47 (10.9)
6 weeks N = 188 N = 201 N = 389
None 141 (75.0) 131 (65.2) 272 (69.9)
Just 46 (24.5) 61 (30.4) 107 (27.5)
Marked 1 1 (0.5) 8 (4.0) 9 (2.3)
Marked > 1 0 (0.0) 1 (0.5) 1 (0.3)
12 weeks N = 169 N = 163 N = 332
None 130 (76.9) 109 (66.9) 239 (72.0)
Just 39 (23.1) 51 (31.3) 90 (27.1)
Marked 1 0 (0.0) 1 (0.6) 1 (0.3)
Marked > 1 0 (0.0) 2 (1.2) 2 (0.6)
52 weeks
(radiography)
N = 157 N = 142 N = 299
None 135 (86.0) 110 (77.5) 245 (81.9)
Just 22 (14.0) 27 (19.0) 49 (16.4)
Marked 1 0 (0.0) 4 (2.8) 4 (1.3)
Missing 0 (0.0) 1 (0.7) 1 (0.3)
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TABLE 25 Complications reported on review of imaging data at 6, 12 and 52 weeks by three independent raters by
randomised group and time point (continued )
Complication observed on
independent review of imaging data,
n (%)a Time point
Surgery
(N= 219)
Plaster cast
(N= 220)
Total
(N= 439)
52 weeks (CT scan) N = 157 N = 135 N = 292
None 80 (51.0) 57 (42.2) 137 (46.9)
Just 72 (45.9) 69 (51.1) 141 (48.3)
Marked 1 5 (3.2) 5 (3.7) 10 (3.4)
Marked > 1 0 (0.0) 3 (2.2) 3 (1.0)
Fragmented 0 (0.0) 1 (0.7) 1 (0.3)
Screw penetrationd 6 weeks N = 172 N = 6 N = 178
57 (33.1) 1 (16.7) 58 (32.6)
12 weeks N = 156 N = 6 N = 162
55 (35.3) 2 (33.3) 57 (35.2)
52 weeks
(radiography)
N = 135 N = 15 N = 150
52 (38.5) 5 (13.3) 57 (38.0)
52 weeks (CT scan) N = 136 N = 11 N = 147
75 (55.1) 8 (72.7) 83 (56.5)
Screw lucencyd 6 weeks N = 172 N = 6 N = 178
None 139 (80.8) 4 (66.7) 143 (80.3)
< 1 mm 32 (18.6) 2 (33.3) 34 (19.1)
1–2 mm 1 (0.6) 0 (0.0) 1 (0.6)
12 weeks N = 156 N = 6 N = 162
None 113 (72.4) 6 (100.0) 119 (73.5)
< 1 mm 41 (26.3) 0 (0.0) 41 (25.3)
1–2 mm 2 (1.3) 0 (0.0) 2 (1.2)
52 weeks
(radiography)
N = 135 N = 15 N = 150
None 99 (73.3) 7 (46.7) 106 (70.7)
< 1 mm 32 (23.7) 8 (53.3) 40 (26.7)
1–2 mm 4 (3.0) 0 (0.0) 4 (2.7)
52 weeks (CT scan) N = 136 N = 11 N = 147
None 108 (79.4) 7 (63.6) 115 (78.2)
< 1mm 22 (16.2) 3 (27.3) 25 (17.0)
> 1mm 4 (2.9) 1 (9.1) 5 (3.4)
Uneven 2 (1.5) 0 (0.0) 2 (1.4)
a Number of unique participants and percentage of those randomised.
b N represents those with imaging.
c > 1 indicates density observed on more than one view or MPR.
d N represents the number for which the screw was observed on imaging.
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Penetration of the screw (used during surgical fixation) of the radioscaphoid joint (RSJ), the scaphotrapezium
joint (STJ) or another joint was reported for a total of 104 unique participants at 6, 12 or 52 weeks (surgery,
n = 94, 42.9%; plaster cast, n = 10, 4.6%). At 52 weeks, the CT scans of 80 participants in the surgery group
were reported to show screw penetration in one or more joints (RSJ, n = 44/80, 55.0%; STJ, n = 48/80,
60.0%; another joint, n = 19/80, 23.8%. For the plaster cast group, of which a smaller proportion underwent
surgery, the CT scans of nine participants were reported to show screw penetration in one or more joints (RSJ,
n = 4/9, 44.4%; STJ, n = 6/9, 66.7%; another joint, n = 0/9, 0.0%). On CT scans at 52 weeks, the maximum
screw protrusion was measured and seen to be, on average, 1.7 mm (SD 0.9 mm, range 0.4–4.7 mm) and
was similar in both groups. Overall, maximum screw protrusion was categorised as < 1 mm (20.7%), 1–2 mm
(52.4%) or > 2 mm (26.8%).
Lucency was assessed based on each of these categories on follow-up radiographic images (worst of each
view available) and the 52-week CT scan (worst of each of three MPRs available) agreed by three observers
using agreement rules. This was considered only when an implant was present. In the surgery group,
serious lucency (1–2 mm) was observed on radiography for only one participant at 6 weeks, for two
participants (including the one at 6 weeks) at 12 weeks and for four participants (including the one at
12 weeks who did not display lucency at 6 weeks) at 52 weeks. No serious lucency was observed on
radiographs for any participant in the plaster cast group.
The prevalence of avascular necrosis (which is also known as osteonecrosis) is summarised for the two
groups in Table 25; prevalence appears to be similar in both groups at baseline but, at later time points,
the plaster cast group has a higher proportion of more significant cases of avascular necrosis.
Adverse events
At least one non-serious AE was reported for 24 (11.0%) participants in the surgery group and for 29 (13.2%)
participants in the plaster cast group (difference of –2.2%, 95% CI –8.3% to 3.9%; Table 26). Of those who
experienced at least one event, most reported only one event (surgery group, n = 19, 79.2%; plaster cast
group, n = 23, 79.3%) but participants reported up to three events each. In total, 30 events were reported
for participants in the surgery group and 36 events were reported for participants in the plaster cast group,
of which, respectively, 24 (80.0%) and four (11.1%) were related to receiving anaesthesia and/or surgery,
three (3.0%) and 23 (63.9%) were related to cast treatment and three (3.0%) and nine (25.0%) were other
events. Sixteen events (surgery group, n = 5, 16.7%; plaster cast group, n = 11, 30.6%) were deemed to be
unexpected by the reporting clinician.
TABLE 26 Non-serious AEs by randomised group
Non-serious AEs, n (%) Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Participants reporting ≥ 1 AEs 24 (11.0) 29 (13.2) 53 (12.1)
Total number of non-serious AEs 30 36 66
Number of non-serious events per participant
0 195 (89.0) 191 (86.8) 386 (87.9)
1 19 (8.7) 23 (10.5) 42 (9.6)
2 4 (1.8) 5 (2.3) 9 (2.1)
3 1 (0.5) 1 (0.5) 2 (0.5)
AEs related to anaesthesia and/or surgerya
Screw-related complication 9 (30.0) 1 (2.8) 10 (15.2)
Nerve or vessel event 4 (13.3) 1 (2.8) 5 (7.6)
Infection 2 (6.7) 2 (5.6) 4 (6.1)
CRPS 3 (10.0) 0 (0.0) 3 (4.6)
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Three SAEs were reported among three (1.4%) participants in the surgery group (Table 27). All three were
related to anaesthesia and/or surgery and two were deemed to be unexpected at the time of reporting.
Agreement analysis
Descriptive analyses of the agreement between the three independent raters on review of radiographic
and CT imaging are presented in Appendix 5.
TABLE 26 Non-serious AEs by randomised group (continued )
Non-serious AEs, n (%) Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Symptoms consistent with non-union 1 (3.3) 0 (0.0) 1 (1.5)
Other 5 (16.7) 0 (0.0) 5 (7.6)
Any of the above 24 (80.0) 4 (11.1) 28 (42.4)
AEs related to cast treatmenta
Pain related to the cast 2 (6.7) 6 (16.7) 8 (12.1)
Symptoms consistent with non-union 0 (0.0) 8 (22.2) 8 (12.1)
Pressure sores 0 (0.0) 5 (13.9) 5 (7.6)
Pain due to a tight cast 1 (3.3) 2 (5.6) 3 (4.6)
Soft cast/broken cast leading to movement of wrist 0 (0.0) 2 (5.6) 2 (3.0)
Any of the above 3 (3.0) 23 (63.9) 26 (39.4)
Othera
Reinjury 2 (6.7) 7 (19.4) 9 (13.6)
Allergy to dressing 0 (0.0) 2 (5.6) 2 (3.0)
Substance abuse 1 (3.3) 0 (0.0) 3 (1.5)
Any of the above 3 (3.0) 9 (25.0) 12 (18.2)
Gradingb
Mild 22 (73.3) 28 (77.8) 50 (75.8)
Moderate 7 (23.3) 7 (19.4) 14 (21.2)
Severe 1 (3.3) 0 (0.0) 1 (1.5)
Missing 0 (0.0) 1 (2.8) 1 (1.5)
Causalityb
Not related 2 (6.7) 8 (22.2) 10 (15.2)
Unlikely to be related 2 (6.7) 2 (5.6) 4 (6.1)
Possibly related 10 (33.3) 2 (5.6) 12 (18.2)
Probably related 4 (13.3) 1 (2.8) 5 (7.6)
Definitely related 12 (40.0) 23 (63.9) 35 (53.0)
Expectednessb
Expected 25 (83.3) 25 (69.4) 50 (75.8)
Unexpected 5 (16.7) 11 (30.6) 16 (24.2)
a Retrospectively and independently classified by two clinicians, with disagreements discussed and resolved.
b Classifications as provided on the AE initial report form by the reporting clinician.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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Participant use of home exercises to care for wrist
When entered into the study, participants should have been provided with written advice about home
exercises to perform to care for their wrist. Participants were asked on the 12-week participant questionnaire
how they found doing these exercises. Responses to these questions are provided in Appendix 3, Table 66.
Of those who provided a response to the question, 151/176 (85.8%) in the surgery group and 123/155
(79.4%) in the plaster cast group reported that they found the exercises very or quite useful. Among those
who performed the exercises, the exercises were reported to have been performed on a median of 41 days
(range 1–168 days) in the surgery group and on a median of 35 days (range 2–137 days) in the plaster cast
group. On the 52-week complication form, data were collected on whether or not the participant was
referred for physiotherapy for the treatment of their wrist injury during the previous year. Approximately
twice as many participants allocated to the surgery group had been referred for physiotherapy (n = 58, 26.5%)
as in the plaster cast group (n = 30, 13.6%).
Participant perceptions of their wrist and treatment preference at 52 weeks
On the 52-week questionnaire, participants were asked about the state of their wrist at present in
comparison with a year ago (see Appendix 3, Table 67). Of those who provided a response to the question,
a very similar proportion in the two groups reported that their wrist felt much or slightly better (surgery
group, n = 166/181, 91.7%; plaster cast group, n = 156/174, 89.7%). Participants were also asked, based
TABLE 27 Serious adverse events by randomised group
SAEs, n (%) Surgery (N= 219) Plaster cast (N= 220) Total (N= 439)
Participants reporting ≥ 1 SAE 3 (1.4) 0 (0.0) 0 (0.0)
Total number of SAEs 3 0 0
Number of serious events per participant
0 216 (98.6) 220 (100.0) 436 (99.3)
1 3 (1.4) 0 (0.0) 3 (0.7)
Type of eventb
Hospitalisation 2 (66.7) 0 (0.0) 2 (66.7)
Persistent or significant disability/incapacity 1 (33.3) 0 (0.0) 3 (33.3)
AEs related to anaesthesia and/or surgerya
Anaesthetic complication 2 (66.7) 0 (0.0) 2 (66.7)
Symptoms consistent with non-union 1 (33.3) 0 (0.0) 1 (33.3)
Causalityb
Definitely related 3 (100.0) 0 (0.0) 3 (100.0)
Expectednessb
Expected 1 (33.3) 0 (0.0) 1 (33.3)
Unexpected 2 (66.7) 0 (0.0) 2 (66.7)
Durationb
≤ 24 hours 2 (66.7) 0 (0.0) 2 (66.7)
> 24 hours 1 (33.3) 0 (0.0) 1 (33.3)
a Retrospectively and independently classified by two clinicians, with disagreements discussed and resolved.
b Classifications as provided on the AE initial report form by the reporting clinician.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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on their experiences of the treatment received as part of the trial, if they were to again injure their wrist to
the same extent as they did 52 weeks ago, which treatment they would prefer. Of those who provided a
response to the question, in the surgery group, three-quarters reported that they would have surgery again
(n = 137/181, 75.7%), 36 (19.9%) participants did not have a preference and eight (4.4%) participants
reported that they would not have surgery. In the plaster cast group, there was a reasonably equal split among
the three categories (surgery, n = 59/175, 33.7%; no preference, n = 68, 38.9%; no surgery, n = 48, 27.4%).
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Chapter 4 Economic evaluation
The role of economic evaluation is to consider the relative merits of competing treatment alternativesweighed against their costs, using a consistent analytical perspective. This chapter investigates the
possible impact of available treatments for adults with bicortical, minimally displaced fractures of the
scaphoid waist on the health of the patient and the costs to the NHS and personal social services (PSS),
in both the short and the long term.
This is achieved in two ways; first, the short-term effect on patients’ health and costs to the NHS of the
treatment are considered through a within-trial analysis, using direct results of the clinical trial up to
52 weeks of follow-up. This analysis focuses on the short-term health implications of treatment and
the immediate period of rehabilitation, as well as the associated costs of this care. Second, as persistent
non-union of the fracture and the development of OA have potentially lifelong implications, it is necessary
to consider the long-term implications of treatment. This is achieved through an extrapolated analysis, in
which mathematical modelling of the expected future health of the patients is used to estimate the health
and resource use implications beyond the time frame of this SWIFFT report.
Within-trial analysis: methods
A rich array of information was collected from both patients and clinicians on health and resource use
during and after treatment. This within-trial analysis will consider quality of life (QoL), as reported by the
EQ-5D-3L, and the level of NHS costs, estimated through the treatment received and the patient-reported
estimates of interaction with the NHS, at a per patient level for the 52 weeks after randomisation into the
trial (the ‘within analysis period’). This analysis was conducted using the Stata software package.
The base case is an ITT analysis. An additional scenario of per protocol is presented, whereby any patients
who were deemed to cross over from one treatment allocation to another are excluded from the analysis.
Missing data are imputed for both cost and QoL components, as detailed later in this section. Relevant
summary statistics and estimates of the QoL and costs associated with patients are reported both at a
complete case level (i.e. dropping all cases of missing data) and after imputation. Regression analyses
are also conducted on total QoL and costs in the within-trial period to consider the impact of key patient
characteristics on QoL and costs, beyond the treatment allocation. The approach taken to missing data and
the regression analyses conducted on QoL and costs in this chapter are consistent with those outlined for
the PRWE in Chapter 2, Statistical methods.
The primary clinical justification for surgical intervention is the reduced future risk of OA and other
long-term AEs that may not become evident until after the within-trial period. Therefore, considering the
cost-effectiveness of the treatment options with only a within-trial time frame would be misleading. As a
result, conclusions about the cost-effectiveness of the treatment options will be limited to the presentation
of a within-trial point estimate incremental cost-effectiveness ratio (ICER), namely the difference in average
costs between two treatment pathways divided by the difference in average QoL for the within-trial period.
Quality of life: EuroQol-5 Dimensions, three-level version
The EQ-5D-3L is a validated questionnaire to assess the generic health status or QoL of a patient, consisting
of questions covering five dimensions of health: mobility, self-care, usual activity, pain/discomfort and anxiety/
depression.90 It is the most widely used means of consistently estimating the general health of a patient and
is used by the National Institute for Health and Care excellence (NICE) as its preferred measure.91 While other
disease-specific questionnaires are available, such as the PRWE, they do not allow for comparison across
disease areas and they cannot be used to determine the optimal allocation of limited NHS resources. A score
of 0 is equivalent to death and 1 represents perfect health; negative scores are considered worse than death.
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Under the UK preference weighting, achievable scores range from –0.594 (worst response across all five
dimensions) to 1 (best responses).
The responses to EQ-5D-3L questionnaires were collected at baseline and then at 6, 12, 26 and 52 weeks
after randomisation. In this section, the combined EQ-5D-3L scores using the preference weighting are
presented, such that each patient who completed a questionnaire at each time point has a single EQ-5D-3L
QoL ‘score’ given to them based on their responses to the questionnaire. These scores are carried forward to
the missing data analysis discussed later in this section and the within-trial analyses.
After having imputed for any missing questionnaires (see later section), the QoL scores are combined to
estimate a score for the patient across the full within-trial period, using the equation below, where ti is the
time in days at which questionnaire ‘i’ was conducted and QoLi is the QoL score reported at time ‘i’:
QoLwithin trial =

QoLbaseline ×
t6wk − tbaseline
2
+ QoL6wk ×
 t6wk − tbaseline
2
+
t12wk − t6wk
2

+ QoL12wk
×
 t12wk − t26wk
2
+
t26wk − t12wk
2

+ QoL26wk ×
 365− t26wk
2
+
t26wk − t52wk
2

+ QoL52wk ×
365−t26wk
2

/365.
(1)
This combined QoL score is used to inform the regression analysis conducted to estimate the impact of
patient characteristics, including treatment allocation, on QoL.
Resource use and unit costs
Costs to the NHS are considered in two ways: those reported by clinical staff and those reported by patients
at 6, 12, 26 and 52 weeks during the trial (see the trial CRFs in Report Supplementary Material 15). As the
trial did not directly seek to report the costs of care, but instead reported the frequency of various interactions
and care provision, all elements reported have to be linked with an appropriate unit cost to estimate total
costs. We assumed that all interactions with the NHS were captured by the trial CRFs.
Relevant resource use is reported from the time of randomisation into the trial and does not include the
cost of initial presentation with the injury or the care that might have occurred prior to the randomly
allocated treatment, typically immobilisation with a cast or splint. Randomisation should ensure that these
initial treatment options and costs are balanced between the two groups.
For the purpose of the costing of the within-trial analysis, only those interactions reported as being related
to the patient’s wrist are included. Unrelated interactions reported by the patients should not affect the
incremental cost, but risk introducing bias if patients had high cost but completely unrelated health care.
An investigation into the level of NHS and PSS interactions for reasons other than the wrist injury confirmed
that there was no statistically significant difference between the randomised group (mean number of
interactions: 5.65 for plaster immobilisation, 5.91 for surgical fixation; p = 0.828).
The unit costs associated with each component of the within-trial analysis are presented in Table 28.
Patient-reported costs are estimated at 6, 12, 26 and 52 weeks for the purpose of the missing data
analysis, and treatment and imaging costs are estimated for the full within-trial period.
After imputation for patient-reported costs at the four time points and imaging costs, costs are combined
into an estimate of the total patient-level cost for the within-trial period.
Patient-reported medications, aids and out-of-pocket costs such as private health care related to the initial
injury are excluded from this analysis. In the case of medications, all reported cases were identified as
being low-cost painkillers, which either cost less than the patient prescription cost or could have been
purchased by patients over the counter. Aids are not routinely provided to patients on the NHS, as
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TABLE 28 Unit costs associated with the within-trial analysis
Stage Cost item Value (£) Source of estimation
Treatment and
imaging
Cost of casts, both the initial
cast at diagnosis and additional
casts
10 Consistent with NICE NG3888
Assumes costs of hospital attendance, etc.,
are covered in patient-reported activity
Cost of primary surgery (patients
randomised to surgical arm)
1632 Weighted average of adult HT44 (intermediate
hand procedures for trauma, mapped from all
open OPCS codes), reference costs 2015/1692
Cost of secondary surgery
(repeat surgery for surgery
group and surgery for plaster
cast group)
2509 Weighted average of adult HT43 (major hand
procedures for trauma, mapped from all closed
OPCS codes), reference costs 2015/1692
Cost of radiography 30 Reference costs 2015/16, direct access plain film
Cost of CT scans 94 Reference costs 2015/16, RD20A, CT scan of
one area, without contrast, 19 years and over92
Cost of magnetic resonance
imaging
145 Reference costs 2015/16, RD01A, magnetic
resonance imaging scan of one area, without
contrast, 19 years and over92
Follow-up care – from
trial patient-reported
questionnaires, only
for those ‘about your
wrist’ rather than
‘other reasons’
GP – at practice 37 Based on estimates from PSSRU (11.7-minute
consultation)93
GP – at home 74 Based on estimates from PSSRU (11.4-minute
consultation plus 12 minutes of travel)93
GP – by phone 22 Based on estimates from PSSRU (7.1-minute
consultation)93
Physiotherapist – at GP’s
practice
49 Reference costs 2015/16, A08A1
(physiotherapist, adult, one to one, community)92
Nurse – at GP’s practice 12 Based on estimates of duration of contact and
cost per hour of face-to-face time from PSSRU93
District/community nurse 38 Reference costs 2015/16 (N02AF, district nurse,
adult, face to face, community)92
Occupational therapist 79 Reference costs 2015/16 (A06A1, occupational
therapist, adult, one to one, community)92
Hospital – physiotherapist 46 Reference costs 2015/16, WF01A, non-admitted
face-to-face attendance, physiotherapy92
Hospital – occupational therapist 58 Reference costs 2015/16, WF01A, non-admitted
face-to-face attendance, occupational therapist92
Hospital – A&E 157 Reference costs 2015/16, WF01B, non-admitted
face-to-face attendance, first, A&E92
Hospital – fracture clinic 110 Reference costs 2015/16, WF01A, non-admitted
face-to-face attendance, trauma and
orthopaedics92
Hospital – pain management
clinic
131 Reference costs 2015/16, WF01A, non-admitted
face-to-face attendance, pain management92
Hospital – in-patient stay 269 per day Weighted average of reference costs 2015/16,
HE41 hand fracture without intervention, excess
bed-days92
OPCS, Office of Population Censuses and Surveys; PSSRU, Personal Social Services Research Unit.
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reflected by the trial data, and as such reflect a private cost that, alongside out-of-pocket costs, fall outside
the NHS and PSS perspective taken in this chapter.
Missing data
Missing data were imputed across the patient-reported questionnaires related to QoL and resource use in
addition to imaging. Using the framework described by Faria et al.,94 the missing data were assumed to be
missing at random. Imputation was conducted across all nine cost and QoL variables identified as having
missing data (i.e. costs at 6, 12, 26 and 52 weeks and QoL at baseline and at 6, 12, 26 and 52 weeks).
Consistent with the missing data approach outlined in the PRWE analysis in the previous chapter, these
missing variables were assumed to be correlated to each other as well as to treatment allocation, age
at randomisation, whether or not the patient’s dominant hand was fractured and displacement of the
fracture. The number of imputations was set equal to the proportion of missing values in the variable with
the largest level of missingness, presented in Results in this chapter. Imputation was conducted using the
‘ICE’ multiple imputation package in Stata and reporting using the ‘MIM’ package.95,96
Impact of lost employment and unpaid activities
In addition to considering the costs to the NHS and PSS and the QoL of patients, this within-trial analysis
reports the impact of treatment allocation on days of lost employment and unpaid activities. The method
of this analysis is reported in Appendix 6, Impact of lost employment and unpaid activities.
Extrapolated model: methods
As the implications, in terms of both NHS costs and patient health, of the different treatment options and
associated AEs can persist beyond the 52-week follow-up of the trial, an extrapolation model is required to
estimate cost-effectiveness over a lifetime. These beyond-trial implications were discussed in Chapter 1 and
can be broadly categorised by the future burden of OA, SNAC and long-term pain or limited mobility that
occur as a direct result of the initial injury and its treatment.
Systematic review of existing cost-effectiveness evidence
A literature review was conducted to determine if previous economic evaluations had sufficiently determined
the cost-effectiveness of surgical fixation versus plaster cast immobilisation for bicortical, minimally displaced
fractures of the scaphoid waist in adults. A secondary aim of the search was to determine if previous
mathematical models could be adapted to estimate the long-term cost-effectiveness, and thus remove the
need to construct a de novo mathematical model. Full details and results of the search strategy and results
are given in Appendix 6, Systematic review of previous cost-effectiveness studies.
The review found no suitably robust cost-effectiveness analysis. Therefore, we determined that a de novo
mathematical model was required to investigate the long-term cost-effectiveness of surgical fixation
compared with cast immobilisation.
Cost-effectiveness analysis: analytical methods and model inputs
This section details the scope of the de novo extrapolated model and provides details on its structure,
the base-case inputs and the scenarios considered.
Analytical approach
The analysis presented here uses a methodology consistent with the NICE Guide to the Methods of
Technological Appraisal91 and Decision Modelling for Health Economic Evaluation.97 In brief, real-world
observations from trial data, published literature and expert opinion were used to estimate the expected
lifetime health and resource use per patient for each treatment comparator.
The conventional outcomes of these models that were used to determine the cost-effectiveness of the different
treatment pathways are lifetime cost, expected life-years and expected QALYs. These estimates are compared
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across treatment pathways by estimating the ICER. A cost-effectiveness threshold of £20,000/QALY is used as
the base-case value to estimate the net health benefit (NHB) of each of the treatment options,98 calculated
using the following equation:
NHB = expected mean QALYs of intervention – (mean cost of treatment option/
cost-effectiveness threshold).
(2)
To incorporate the uncertainty present in the estimation of such models, two approaches are used:
(1) probabilistic sensitivity analysis (PSA) and (2) scenario analysis. PSA explicitly incorporates the uncertainty
present in parameter estimates by using the range of values over which these estimates exist (characterised
by an informative distribution), rather than single point estimates, as inputs into the mathematical models.97
Scenario analyses are used to test the structural uncertainty of the models, with the underlying structure
and sources of evidence changed to explore the impact of such uncertainty on the results of the models.
A value of information analysis explored the population expected value of perfect information (EVPI), an
assessment of the benefit of resolving all uncertainty in the parameter estimates of the base-case model.
Analytical perspective
Consistent with the within-trial analysis, the full, extrapolated analysis takes as its primary perspective the
health outcomes for the patient, expressed in QALYs, and the costs to the NHS, expressed in GBP at 2017
prices. A lifetime time horizon is used in the base-case analysis to reflect the full duration of impact of
potential AEs including OA and SNAC. Both costs and outcomes are discounted using a 3.5% annual
discount rate consistent with current guidelines.91 The model was developed using Microsoft Excel® 2013
(Microsoft Corporation, Redmond, WA, USA).
Decision problem
Consistent with the SWIFFT protocol, this analysis seeks to estimate the most cost-effective treatment
pathway for adults presenting with an undisplaced (< 1 mm step or gap) or minimally displaced
(1–2 mm inclusive) bicortical fracture of the scaphoid waist.
An important element of any analysis that seeks to determine the most cost-effective treatment is the full
incorporation of all possible treatment alternatives, including those beyond the two considered in SWIFFT.
A brief review of the literature, using the framework outlined in Appendix 6, Systematic review of previous
cost-effectiveness studies, and discussions with the SWIFFT TMG highlighted that no active treatments
beyond combinations of cast and surgical fixation were considered relevant to an NHS setting, with the
only other treatment identified, pulsed electromagnetic fields, rarely used in the UK. To ensure the
extrapolated model includes all possible treatment options the following four are considered (the first two
are extensions of SWIFFT):
1. No treatment – all patients who experience a scaphoid waist fracture are left untreated. While unlikely
to happen in practice, and considered unethical to include in SWIFFT, this is an important anchor point
to ensure that all active treatments are well demonstrated to be effective and cost-effective compared
with providing no intervention, and a means of model validation. Furthermore, the TMG confirmed that
some patients choose to not have treatment, often not attending diagnosis or refusing the recommended
treatment. This arm is therefore important for exploring the validity of patients’ decisions.
2. Cast immobilisation only – all patients are treated with cast immobilisation alone, such that patients who
are identified as having non-union are not able to progress to surgery. While not incorporated into SWIFFT,
this allows the analysis to test whether the addition of surgical fixation for non-union patients is cost-
effective compared with casting alone. Furthermore, it represents the historic treatment option in many
cases, before fixation surgery was routinely offered. In this and all other similar cases, ‘cast’ refers to all
forms of non-surgical immobilisation, including casts with thumb incorporated and excluded, and splints.
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3. Cast immobilisation followed by immediate surgery – in line with the SWIFFT population, patients are
initially treated with casting with immediate surgical fixation soon after cast removal offered to all patients
in whom non-union is detected.
4. Surgical fixation – in line with SWIFFT, patients are initially treated with surgical fixation; if primary fixation
is unsuccessful (due to either implant problems or failure of union), patients are offered additional surgery.
The assumptions related to each are considered later in this chapter.
Population
The population considered in the extrapolated model is consistent with SWIFFT, as described in Chapter 2.
Inevitably, when an economic evaluation model has to use evidence from the existing literature to inform an
extrapolation, there are some differences between the analysed population and that considered in the relevant
literature. These are identified and discussed later in this chapter, with biases explored where possible.
Model structure
The model itself has two components: (1) a short-term decision model, which characterises the first 52 weeks
after initial presentation, consistent with the SWIFFT period; and (2) a long-term element, over which the
implications of the treatment and union status on long-term outcomes and costs are considered. These two
components are presented separately below for clarity but are intricately linked.
The model takes as a starting point the time at which a treatment decision is made, such that patients
have already experienced the injury and attended hospital for their initial assessment. As a result, the
nature of the fracture is known and the patient has been identified as within this population.
Short-term decision model
Covering the first year since treatment, the short-term element closely matches the within-trial analysis by
drawing directly from the findings of SWIFFT, with the additional treatment pathways of no treatment and
primary cast immobilisation only. Figure 7 provides an overview of the short-term element of the model
through this 52-week period, from the treatment decision to the 52-week time point, at which point patients
enter the long-term ‘Markov’ model, symbolised by the ‘M’ in the figure. The key features of each treatment
arm in the short-term element are as follows:
l No treatment – after having been identified as within the population considered in this analysis, all
patients receive no active treatment (i.e. neither cast nor surgery). As a result, no short-term treatment
costs are incurred, but patients are assumed in the base-case analysis to never achieve union of the
fracture. While it is expected that some untreated fractures would unite, as the literature provides
examples of such cases,99,100 it is not possible to estimate this as a proportion of all cases and, as such,
the base case assumes no cases of union. This assumption is explored in a later scenario.
l Cast immobilisation only – primary cast immobilisation is assumed to be the only treatment available to
patients, such that all are initially immobilised in a cast but, should the fracture fail to unite, no subsequent
surgery is available. Treatment characteristics and rates of union are drawn directly from the SWIFFT primary
cast immobilisation arm, but all those offered post-cast surgery for non-union are assumed to remain as
non-unions.
l Cast immobilisation with immediate surgery for non-union – this treatment arm is consistent with the
cast-only arm, except that patients who fail to achieve union are offered surgical fixation (like in SWIFFT),
a proportion of whom will opt for it. The patients who failed to achieve union with the cast and chose to
not have surgery are assumed to end the short-term component while still having non-union, while patients
who opted for surgical fixation can achieve union or non-union at a rate determined by SWIFFT results.
l Primary surgery – like the surgery group of SWIFFT, patients are treated with surgical fixation as their
primary treatment; many patients initially receive a cast, which is then removed and surgery is performed.
After surgery, patients can achieve union or non-union. A small proportion determined by SWIFFT have
multiple rounds of surgery if the primary surgery is unsuccessful or there are complications. Furthermore,
most patients are provided with a cast after surgery as part of routine therapy.
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All cost and QoL impacts that occur within this first year are included in the estimates presented later in this
section. Mortality within the first year is not explicitly modelled, as scaphoid-related death is not expected to
occur and the primary population is young, with no related or unrelated deaths observed in SWIFFT.
Long-term Markov model
The long-term cost and health outcomes extrapolated beyond the 52-week short-term model are
estimated using two Markov models, presented in Figures 8 and 9. In a Markov model, patients reside in
one out of a set of mutually exclusive health states at particular points in time.101 During discrete time
intervals, these patients can either remain in a particular health state or move to a separate health state,
typically because they have experienced a particular clinical event.
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FIGURE 7 Schematic of the short-term element of the economic evaluation model.
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FIGURE 8 Long-term Markov model for successful union.
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As shown in Figures 8 and 9, the Markov model that patients enter is dependent on their union status at
the end of the short-term decision model, with patients who achieve union entering the model outlined in
Figure 8 and non-union patients entering the model outlined in Figure 9. This is consistent with the very
different long-term clinical expectations associated with the two groups, as discussed in Chapter 1, with
union patients likely to regain usual health and function, but those with non-union likely to have long-term
health concerns.
The treatment pathway that a patient experienced to get to their union status is informative to their
rate of transition through the model. In other words, while a patient’s prior treatment is assumed to not
affect the set of long-term health states they can achieve, it does affect the likelihood with which they
achieve them.
Patients achieving successful union at the end of the short-term element are placed into one of two starting
states in the union Markov model: ‘no OA or other AEs’ or ‘no OA but long-term AEs’. This distinction is
made because of the prevailing evidence that a number of patients experience lifelong symptomatic AEs
associated with the original injury and treatment that are not related to the development of OA. Specifically,
Lindström and Nyström102 reported the presence of pain and weakness not associated with OA in their
long-term follow-up study of patients treated with cast immobilisation. Limitations in the available evidence
on the long-term transitions necessitated the assumption that these patients represent a separate group
from those who will go on to develop OA.
Patients who experience permanent long-term symptomatic AEs without OA remain in this state until they
die of other causes, as the treatment or related events are unlikely to cause death. We also assumed that
these non-OA AEs are fixed for the patient’s remaining lifetime, with all time-limited AEs being resolved
within the short-term element of the model (i.e. within a year of injury).
Patients who enter the long-term model in an AE-free state (i.e. no OA or other AEs) can similarly stay in this
state until they die of other causes, or they may develop OA, which is modelled as being either symptomatic
or non-symptomatic, again informed by the literature. As is discussed later, limitations in the data mean
we are unable to model the potential development of OA from non-symptomatic to symptomatic, or the
potential for different levels of symptomatic presentation. From each of the OA states, patients stay in that
state until they die of other causes.
The dearth of evidence relating to the development and transition between AEs in this population
necessitated the assumption that patients do not transit between the three AE states. As a result, the
Non-union
SNAC
Death
No
SNAC
FIGURE 9 Long-term Markov model for non-union.
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analysis assumes that patients experience at most only one lifelong AE. As there is no difference in the
cost and no utility difference between the two symptomatic states, discussed later in this section, and the
asymptomatic OA state is based on long-term observational data, this model assumption does not affect
the result of the analysis.
In contrast, patients who end the short-term element in a non-union state are modelled based on their risk
of developing SNAC, as shown in Figure 9. As discussed in Chapter 1, SNAC represents a SAE that results
from non-union, whereby the proximal carpal row can no longer stabilise the distal carpal row, and hence
the wrist. The resulting abnormal loading leads to carpal collapse, cartilage degeneration and arthritis.
Owing to a dearth of evidence relating to the natural history of events associated with non-union, we
were not able to model separate states reflecting the development of OA and other symptoms within the
non-union Markov model. Patients in this Markov model enter in the ‘no SNAC’ state and throughout
their lifetime face a risk of progressing to SNAC or dying from unrelated causes. As with OA in the union
Markov model, SNAC is modelled as being a binary disease state, but, unlike OA, is assumed to always
be symptomatic as a result of the severity of the condition. Owing to the challenging nature of treating
SNAC, and the lifetime implications even if treatment is successful, patients are modelled as remaining in
the SNAC state for the rest of their life if it develops. Unlike the union model, patients are not modelled as
separately having non-OA-related long-term symptoms and non-symptomatic OA. This assumption is the
result of the observation by Dias et al.103 that almost all patients (9 of 10) had pain or stiffness after a
mean of 2.1 years. Therefore, our base-case model assumes that all non-union patients had some QoL
decrement, incorporating a range of AEs including low-grade OA and non-OA AEs.
Model inputs
Much of the evidence defining the patient cohort and the short-term element is sourced directly from
SWIFFT. As SWIFFT currently has only 52 weeks of patient follow-up, all long-term model inputs are
informed by the wider literature.
Consistent with SWIFFT, the base-case patient cohort is modelled as being 33 years old, with 84% being
male. A patient’s age is assumed to affect only the rate of mortality, as, while there is likely to be a
correlation between age and OA and other AEs, there was insufficient evidence to incorporate such a
correlation. Similarly, the gender mix affects only the mortality rate.
Short- and long-term element transition estimates
The short- and long-term model transition estimates are reported in Table 29. The base-case mean
estimates are reported alongside the 95% CI and the informative distribution used to inform the PSA.
The distributions are reported in terms of the distribution selected, conforming to conventional approaches,97
and the parameters required to describe the distribution.
The parameters required for the short-term element of the model are derived from SWIFFT, with the exception
of the assumption that all untreated patients have a non-union. This assumption biases against a no-treatment
scenario and, while some of the literature suggests rates of union in an untreated population,99,100 there is
insufficient evidence to determine a rate of non-union in the population considered here.
The long-term Markov models are reliant on published literature until the 5-year follow-up of SWIFFT is
completed. In the base-case model, the choice and frequency of the different treatment options affects a
patient’s long-term health only through its ability to effect union of the fracture; this core assumption is
relaxed in a series of scenarios. The model parameters for which this assumption applies are presented in
Table 29.
Base-case estimates of the probability of having long-term adverse symptoms that are not OA related are
drawn from the study by Lindström and Nyström,102 who reported the presence of pain and weakness not
associated with OA in their long-term follow-up study of patients treated with cast immobilisation, finding
that 4.8% of patients had long-term non-OA AEs.
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TABLE 29 Probabilities applied in the model
Parameter Base-case value (95% CI) Distribution (informative parameters) Source
Short-term element of the model
Probability of being
identified as requiring
surgery/repeat surgery after
initial treatment
Cast immobilisation 0.090 (0.005 to 0.130) Beta (alpha 20, beta 200) SWIFFT; 20 cases including 17 participants who had
surgery plus three participants who did not have
surgery at 52 weeks but had an identification of
non-union
Surgery as initial
treatment
0.037 (0.016 to 0.065) Beta (alpha 8, beta 221) SWIFFT; eight participants who had secondary
surgery
Probability of having surgery post cast, non-union 0.948 (0.901 to 0.981) Beta (alpha 110, beta 6) Review of the existing literature
Probability of having repeat surgery post initial
surgery, non-union or issue
0.948 (0.901 to 0.981) Beta (alpha 110, beta 6)
Probability of non-union after second-line surgery 0.059 (0.002 to 0.206) Beta (alpha 1, beta 16) SWIFFT; 17 patients who underwent secondary
surgery and one patient who had confirmed
non-union
Probability of having non-union after no treatment 1 Fixed Assumption
Long-term element of the model – union Markov model
Probability of having long-term adverse symptoms that are not OA related
Cast immobilisation 0.048 (0.024 to 0.079) Beta (alpha 11, beta 218) Lindström and Nyström (1990)102
Surgery as last treatment provided 0.048 (0.024 to 0.079) Beta (alpha 11, beta 218) Assumed to be same as cast
Probability of developing OA
Cast immobilisation Limiting value: 0.056
Time constant: 1.5
CI: 0.035 to 0.087
Exponential decay towards a limiting value, with
limiting value characterised as a beta distribution
(see Appendix 6, Probability of developing
osteoarthritis)
Lindström and Nyström (1990);102 5.6% of
218 patients had OA after primary healing with
a minimum follow-up of 7 years
Surgery as initial treatment Limiting value: 0.056
Time constant: 1.5
CI: 0.035 to 0.087
Exponential decay towards a limiting value, with
limiting value characterised as a beta distribution
Assumed to be same as cast
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Parameter Base-case value (95% CI) Distribution (informative parameters) Source
Probability that developed OA is symptomatic
Cast 0.992 (0.918 to 1.00) Beta (alpha 11.9, beta 0.1) Lindström and Nyström (1990)102
Surgery 0.992 (0.918 to 1.00) Beta (alpha 11.9, beta 0.1) Assumed to be same as cast
Mortality from all causes As per published tables Fixed ONS National Life Tables, England and Wales,
2014–16104
Long-term element of the model – non-union Markov model
Survival function of no SNAC to SNAC Lambda 0.0069
Gamma 1.77
Weibull Weibull function fitted to time-to-event data from
Moritomo et al. (1999)105
Mortality from all causes As per published tables Fixed ONS National Life Tables, England and Wales,
2014–16104
ONS, Office for National Statistics.
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The probability of developing OA as a result of the initial injury and treatment is modelled as an exponential
decay. It is estimated by fitting an exponential function to three time points extracted from Lindström and
Nyström102 (presented in more detail in Appendix 6, Probability of developing osteoarthritis): time 0, when no
patients had developed related OA; year 1, when 2.6% had radiological OA; and year 7, when 5.6% had
radiological OA,. We assume that no OA, which can directly be linked to the original fracture and treatment,
occurs beyond 10 years. Some authors report a prevalence of OA in patients with united fractures with greater
follow-up. For example, Düppe13 reported that, 36 years after the initial event, 15% had OA. However, there
was no significant difference between the rate of OA in the injured and uninjured wrists assessed, suggesting
that much of the identified OA was unrelated to the original fracture. While the literature does suggest that
repeat intervention and surgery may exacerbate rates of OA,27 we found insufficient evidence to support this
theory. Therefore, the probability of developing OA is assumed to be treatment independent, as discussed
earlier. This assumption is justified by limited data on the rate of OA collected during SWIFFT, which showed
no statistically significant difference in the rate of early OA between the two randomised groups.
Once developed, the probability of OA being symptomatic is modelled as a time-invariant probability
applied at the point of development. In the base-case analysis, the probability is estimated from Lindström
and Nyström,102 who found that all those who developed OA (12 of 229 patients) were symptomatic.
Scenarios exploring the treatment independence of this parameter and alternative estimates are explored.
For the non-union patients, the probability of developing SNAC is modelled as a Weibull function fitted
to time-to-event patient-level data reported by Moritomo et al.,105 using only those patients reported as
having a fracture to the middle third. The Weibull function represented the best-fitting function to the
extracted Kaplan–Meier of those tried based on AIC; details of the regressions explored are presented in
Appendix 6, Probability of developing scaphoid non-union advanced collapse. The Cholesky decomposition
method was used to reflect uncertainty in the analysis.97 One major limitation of the Moritomo et al. study
is that it considers a symptomatic population alone, albeit one in which some non-union patients have
symptoms but not radiologically detectable SNAC. Findings similar to those of Moritomo et al. can be
found elsewhere in the literature; for example, Mack et al.,12 again looking only at patients presenting
symptomatically, found that arthritis is likely to develop if sufficient time passes after the time of non-union
development. Similarly, Dias et al.103 identified that after a mean review period of only 2.1years, 5 of 10
patients with non-union had signs of OA and dorsal intercalated segment instability, suggesting significant
degeneration. Vender et al.15 also conducted a retrospective radiological review of 64 participants with
symptomatic non-union among an untreated population, finding a similar time to arthritis onset.
In both the union and non-union Markov models, patients are subject to a mortality risk throughout,
conditional on the cohort age and gender mix alone, such that non-union, OA, SNAC and all other modelled
factors were assumed to have no impact on the rate of mortality. The required estimates were drawn from
Office for National Statistics National Life Tables, England and Wales, 2014–16.104
We assume that patients are at risk of developing OA caused by the initial injury or subsequent treatment
only for 10 years; this assumption is made to reduce the potential impact of conflation of OA caused by
the injury with that due to other causes. In addition, we assume that all OA detected in the informative
studies for 10 years after injury is a direct result of the initial injury and treatment.
In the base case, we assumed that the patient populations, treatments used and clinical definitions
(e.g. union and OA) evaluated in each of the informative studies match with those analysed in this study
or, where they do vary, do not introduce any bias so large as to make them uninformative or misleading.
A review of the key characteristics and definitions, including all studies pertinent to the base-case and
scenario analyses, is given in Appendix 6, Systematic review of previous cost-effectiveness studies. Table 69
in Appendix 6 shows that many of the characteristics appear consistent, with some limitations regarding
insufficient detail, for example displacement of the original fracture. The potentially inconsistent definitions
relate to symptoms, with some of the key studies considering only pain, while others consider pain
and weakness.
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Resource use and cost estimates
The costs used in the mathematical model are presented in Table 30. Consistent with the model structure,
the costs incurred by the NHS during the first year, as described by the short-term model, are directly taken
from SWIFFT, with the additional two treatment arms (no treatment and cast immobilisation only). The
short-term model costs are composed of the initial cost of each treatment alongside treatment-specific
costs incurred for the first year post injury and any additional treatments within that period (i.e. secondary
surgery). The no-treatment option is assumed to have no costs in this first year, as no interactions with the
NHS are expected until patients progress into the extrapolated model. The arm involving casting without
surgery is assumed to have the same cost as the SWIFFT arm involving casting with surgery for non-union
with the exclusion of any surgical interventions.
The costs associated with the long-term model, also reported in Table 30, reflect the structure of the Markov
model, shown in Figure 8, taking into consideration the occurrence of OA, symptomatic AEs that are not
related to OA and events related to non-union. In the base-case union model, patients in the ‘healthy group’
of no AEs including OA, as well as those in the non-symptomatic OA group, are assumed to not be associated
with any costs to the NHS, as both groups are categorised by the lack of symptoms with which they would
present to an NHS setting for investigation and treatment. Similarly, the non-union base case assumes that
patients in the non-SNAC state will be associated with no additional regular cost to the NHS, under the
assumption that all suitable interventions would have been attempted, and thus costed, prior to the diagnosis
TABLE 30 Cost considered in short- and long-term sections of the mathematical model
Parameter
Base-case value
(£) (95% CI) Distribution Source
Short-term costs modelled (first year)
Follow-up cost for cast as
first treatment (not including
any surgery costs)
587 (504 to 672) Gamma Estimated from the trial data; includes the cost
of all recasting, NHS interactions and imaging,
but not surgery, using the ITT population, after
imputation for missing values as detailed later
Cost of initial surgical
treatment (not including
follow-up)
1632 Fixed As per the within-trial analysis (see Table 28)
Cost of secondary surgery
(not including follow-up)
2509
Follow-up cost after surgery
(not including any surgery
costs)
618 (551 to 648) Gamma Estimated from the trial data; includes the cost
of all recasting, NHS interactions and imaging,
but not surgery, using the ITT population, after
imputation for missing values as detailed later
Long-term costs modelled (52 weeks to end of analysis)
Cost of diagnosis of
symptomatic OA
74 Fixed Assumption of two GP visits with no radiological
investigation; cost drawn from Personal Social
Services Research Unit, 2015 (11.7-minute
consultation)93
Annual cost of treating
symptomatic OA
38 (10 to 83) Gamma Assumption of a mean of one GP visit per
year with no investigation or treatment cost
(as treated with over-the-counter medication);
standard error assumed to be half of the meanAnnual cost of treating
non-OA symptomatic AEs
38 (10 to 83) Gamma
Cost of SNAC 2551 (695 to 5592) Gamma Modelled as one-off cost, assuming half of patients
receive very major surgery (£3440, reference cost
HN42A)92 and half receive casting, both with
associated costs per year of care from trial;
standard error assumed to be half of the mean
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of non-union. Once a patient progresses to SNAC, a one-off treatment cost is applied to reflect any active
interventions attempted to resolve or reduce the impact of the collapse. Little evidence was identified relating
to the range and frequency of treatments for SNAC. Shah and Stern106 describe highly personalised treatment
of SNAC, including initial non-surgical treatment, wrist immobilisation with splints, anti-inflammatory
medication and corticosteroid injections, coupled with surgical options for refractory cases. In calculating costs,
we assumed that half of the patients would be treated with immobilisation, with the other half progressing to
major surgery, in addition to the associated 52-week follow-up costs estimated from the trial data. A standard
error equal to half of the mean SNAC cost is assumed to reflect the lack of certainty around the variable.
Health-related quality of life inputs
As with the estimation of cost for the mathematical model, the HRQoL inputs into the short-term model
are determined by SWIFFT, such that patients have a QoL score for the first year of the analysis, which is
estimated from the trial data described earlier in this chapter. In the base-case analysis, patients in both the
no-treatment arm and the cast immobilisation only arm are assumed to have the same QoL as those in the
cast plus surgery for non-union arm of SWIFFT as a conservative estimate of their QoL.
In the long-term model, the QoL impact of being in a state associated with adverse health (e.g. symptomatic
OA, SNAC and non-union) is applied as decrements to the expected QoL that a ‘normal’ patient who is
otherwise free of associated problems would expect to experience. These QoL norms are drawn from
extensive surveys of the general public using the EQ-5D-3L by Ara and Brazier107 and are stratified by age
and gender. Patients in the ‘no OA or other permanent adverse events’ category of the union Markov
model are assumed to achieve this QoL norm.
Evidence on the QoL of OA and SNAC relevant to this analysis is limited and diverse. Our review of the
literature identified four relevant studies: Kovács et al.,108 Neuprez et al.,109 Slatkowsky-Christensen et al.110
and the economic evaluation by Davis et al.43 The base-case analysis uses the QoL decrement of OA estimated
by Slatkowsky-Christensen et al.110 to represent the QoL of patients in the symptomatic OA, non-OA related
AEs and non-union ‘no SNAC’ states under the assumption that all represent, on average, a similar level of
QoL decrement. While we were unable to identify any evidence that explored the QoL impact of non-union
prior to the development of SNAC, we believe this assumption is the most appropriate in the base case,
as patients would not be expected to regain full QoL with non-union. This is one of the many uncertainties
that will be explored during the 5-year follow-up.
In contrast, the severe state of SNAC is estimated by applying the Kovács et al.108 QoL score as a
decrement using the Slatkowsky-Christensen et al.110 ‘healthy’ population baseline to ensure a consistent
baseline. The Kovács estimate is used here, as it represents a more severe patient population, which we
believe to be the best fit to a SNAC outcome. While the use of QoL scores estimated using different tools
(i.e. the Short Form Six Dimension and EQ-5D-3L) is discouraged in current best guidance91 owing to risks
of inconsistency, we believe that, given available evidence, this is the optimal approach. As with other
parameters in the model, these are subject to PSA and exploration through sensitivity analysis.
All QoL decrements are applied for the duration of a patient’s time in each state, as, while treatment may
alleviate some symptoms, the progressive nature of many of these AEs will have the opposite effect. As a
result, it was not possible, given existing evidence, to model changes in the QoL within each state over
time, as reflected in the structural model assumptions discussed earlier in this chapter.
To reflect the QoL implications of additional surgery, patients who required surgery as a secondary line of
treatment received an additional QoL decrement equal to that observed in the first year after surgery from
SWIFFT. This assumption is relaxed in a scenario.
The full set of informative QoL estimates are reported in Table 31. All uncertain QoL parameters are
characterised as gamma distributions for the PSA to reflect the bounding of possible QoL scores.97
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Scenario analyses
To develop the mathematical model into the form presented above, a number of simplifying assumptions and
interpretations of the available evidence were necessary, as is true of all mathematical models.97 While the
assumptions made in the base-case analysis are considered to be the most reasonable, given the evidence
available, it is important to test the impact of different approaches on the results of the analysis. A number of
scenarios, detailed in Appendix 6, Extrapolated model scenario analyses, have been constructed to conduct
these tests; as far as possible, other sources of evidence are used to inform the scenarios.
Results
Within-trial analysis: results
In this section, we present the results of the within-trial analysis. This section is structured around four
different scenarios relating to an ITT or per-protocol analysis and whether a complete-case approach or
after multiple imputation approach is taken. The ITT analysis is presented as the base case and the summary
statistics relating to QoL and costs are reported only for this analysis. The majority of within-trial analyses
results are presented in Appendix 6, Within-trial analysis results, with the focus here on the regression
analyses conducted across the QoL and cost outcomes.
Regression analyses
The dependent variables for both regressions are total cost and average QoL over the within-trial period.
Additional regressions are reported, adjusting for QoL at baseline (Tables 32 and 33).
TABLE 31 The HRQoL model inputs
Parameter Base-case value (95% CI) Distribution Source
Short-term HRQoL modelled (first year)
QoL for first year
post cast
0.812 (0.780 to 0.844) Gamma Directly drawn from the trial data, using the ITT
population, after imputation for missing values
as detailed later
QoL for first year
post surgery
0.834 (0.788 to 0.843) Gamma Directly drawn from the trial data, using the ITT
population, after imputation for missing values
as detailed later
QoL for first year for
those who are untreated
0.812 (0.780 to 0.844) Gamma Assumed to be the same as cast, as the least
invasive intervention
Long-term HRQoL modelled (52 weeks to end of analysis), all applied as decrements to population norms107
Union and no OA or
other AEs decrement
0 Fixed Assumption
Symptomatic OA
decrement
–0.130 (–0.120 to –0.140) Gamma Decrement estimated from
Slatkowsky-Christensen et al. (2007)110
Non-OA symptomatic
AEs decrement
–0.130 (–0.120 to –0.140) Gamma Assumed to be the same as decrement for OA
Non-symptomatic OA
decrement
0 Fixed Assumption that a lack of symptoms implies no
HRQoL decrement
Non-union (no SNAC
state) decrement
–0.130 (–0.120 to –0.140) Gamma Assumed to be the same as decrement for OA
SNAC decrement –0.275 (–0.0689 to –0.4811) Gamma Modelled as being from the time of development
to end of life. Estimated by comparing the
response in Kovács et al. (2012)108 (0.495) to the
‘healthy’ control used in Slatkowsky-Christensen
et al. (2007)110 (0.77)
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TABLE 32 Cost regression results for the four within-trial scenarios, adjusted and unadjusted for baseline QoL
Adjusted for
baseline QoL Scenario Regression constant Surgical allocation QoL at baseline Fracture displacement Dominant wrist injured Age
Unadjusted Complete case ITT 589.96 (0.120) 1580.27 (0.000) N/A 180.06 (0.490) –16.66 (0.934) 1.48 (0.833)
With MI ITT 882.80 (0.002) 1228.13 (0.000) N/A 225.47 (0.168) 74.39 (0.622) 1.58 (0.767)
Complete case PP 678.06 (0.072) 1770.87 (0.000) N/A 128.68 (0.595) 141.08 (0.467) 4.27 (0.535)
With MI PP 799.81 (0.004) 1549.14 (0.000) N/A 190.84 (0.252) 86.87 (0.578) 2.72 (0.624)
Adjusted Complete case ITT 939.86 (0.001) 1308.11 (0.000) –530.67 (0.022) 183.41 (0.223) 32.24 (0.804) –0.08 (0.984)
With MI ITT 1160.66 (0.000) 1294.53 (0.000) –593.71 (0.015) 212.60 (0.164) 1.86 (0.989) 0.19 (0.964)
Complete case PP 911.11 (0.002) 1615.50 (0.000) –519.08 (0.055) 143.33 (0.340) –17.04 (0.904) 1.73 (0.692)
With MI PP 1091.85 (0.000) 1594.40 (0.000) –562.63 (0.036) 173.21 (0.255) –28.19 (0.841) 1.39 (0.764)
MI, multiple imputation; N/A, not applicable; PP, per protocol.
Values in brackets are the p-values for each coefficient.
TABLE 33 The QoL regression output for the four within-trial scenarios, unadjusted for baseline QoL
Adjusted for
baseline QoL Scenario Regression constant Surgical allocation QoL at baseline Fracture displacement Dominant wrist injured Age
Unadjusted Complete case ITT 0.8162 (0.000) 0.0208 (0.319) N/A –0.0283 (0.176) –0.0285 (0.163) –0.0011 (0.091)
With MI ITT 0.8042 (0.000) 0.0182 (0.304) N/A –0.0350 (0.047) –0.0399 (0.027) –0.0016 (0.010)
Complete case PP 0.8112 (0.000) 0.0257 (0.233) N/A –0.0342 (0.118) –0.0348 (0.101) –0.0012 (0.076)
With MI PP 0.7984 (0.000) 0.0173 (0.331) N/A –0.0423 (0.021) –0.0433 (0.018) –0.0015 (0.026)
Adjusted Complete case ITT 0.6947 (0.000) 0.0250 (0.289) 0.2895 (0.000) –0.0202 (0.371) 0.0046 (0.826) –0.0020 (0.020)
With MI ITT 0.6733 (0.000) 0.0158 (0.379) 0.2732 (0.000) –0.0261 (0.164) 0.0229 (0.203) –0.0020 (0.005)
Complete case PP 0.6761 (0.000) 0.0238 (0.315) 0.3272 (0.000) –0.0168 (0.494) 0.0033 (0.884) –0.0021 (0.018)
With MI PP 0.6690 (0.000) 0.0118 (0.505) 0.2823 (0.000) –0.0265 (0.175) 0.0218 (0.227) –0.0019 (0.009)
MI, multiple imputation; N/A, not applicable; PP, per protocol.
Values in brackets are the p-values for each coefficient.
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The regression analyses highlight a number of interesting findings. First, as expected, across all scenarios,
allocation to the surgical arm of the trial is associated with greater incremental costs and greater QoL.
However, while the correlation with costs is found to be statistically significant, the correlation with QoL is
not significant across any of the scenarios considered. The per-protocol analyses find a larger impact on
cost and QoL, as they remove the crossover patients whose inclusion reduces the reported benefit of
surgical allocation.
Also consistent to a priori expectations, increased fracture displacement [i.e. minimally (1–2 mm inclusive)
compared with undisplaced (< 1 mm step or gap)] was associated with a lower QoL (statistically significant
also in the two multiple imputation scenarios) and a higher cost. Age was also found to be associated with
a decrease in QoL and an increase in costs, while those who had injured their non-dominant hand had
increased QoL but had no consistent impact on costs.
Adjusting for baseline QoL using a regression approach had only a relatively small impact on the treatment
allocation regression estimate, with no consistent direction across the different scenarios. The scale of this
change, while surprising given the relative size of the incremental mean difference in baseline reported in
Table 34, is due to many of the differences being already explained by the existing explanatory variables in
the unadjusted regressions and the random component of the variable. The impact of QoL at baseline on
the cost regression is expected to be the result of adjusting for some level of comorbidities or patients’
willingness to interact with the NHS.
Clearly, using the limited time scale of the within-trial analysis, the use of surgical fixation is not cost-
effective, especially if the difference in baseline QoL is adjusted for. However, as discussed, such a limited
timescale overlooks many of the outcomes correlated with the choice of treatment for scaphoid waist
fractures, primarily the impact of non-union after this period of treatment on the incidence of arthritis,
SNAC and other related AEs.
Impact of lost employment
The summary statistics of the patient-reported days of lost employment are reported in Table 35. Primarily,
the table shows that the majority of patients experienced some days of lost employment in the first
6 weeks of the analysis period (with only 21.6% and 31.3% reporting no lost days over that period in
the surgery and cast group, respectively), but from 12 weeks onwards most were back to full-time work
(with medians of 0 for all other periods). There did, however, remain a number of patients who were
forced to continue missing work because of their wrist fracture, characterised by the persistent mean
number of days lost, despite close to 90% reporting no lost days. There were very few cases of patients
having to miss work for all, or even most, of the period covered by the questionnaire.
A detailed description of this table and the estimation methods are provided in Appendix 6, Impact of lost
employment and unpaid activities, which also includes details of the impact on unpaid work.
Extrapolated model: results
In this section, the results of the extrapolated mathematical model are reported. First, we report the
headline cost-effectiveness results (i.e. the expected costs, QALYs and resultant ICER and NHB), alongside a
consideration of how the NHB accumulates over time. We then go on to consider the decision uncertainty
present in the decision model. This is reported in two ways: the probability of each of the four strategies
being cost-effective at a given cost-effectiveness threshold represented by the cost-effectiveness
acceptability curve (CEAC) and a series of scenario analyses exploring the impact of structural uncertainty
on the result.
Base-case analysis
Table 36 reports the cost-effectiveness results for the base-case analysis in terms of each treatment
option’s expected costs and QALYs, alongside a range of ICERs and the NHBs at thresholds of £20,000/
QALY and £30,000/QALY.
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TABLE 34 Incremental costs, QoL estimates and ICER
Adjusted for baseline QoL Scenario Incremental cost (95% CI) Incremental QALYs (95% CI) ICER: surgery versus cast
Unadjusted Complete case ITT £1580 (£1282 to 1879) 0.0208 (–0.0200 to 0.0616) £75,962/QALY
With MI ITT £1228 (£1011 to 1445) 0.0182 (–0.0165 to 0.0530) £67,473/QALY
Complete case PP £1771 (£1490 to 2052) 0.0257 (–0.0165 to 0.0678) £68,910/QALY
With MI PP £1549 (£1344 to 1754) 0.0173 (–0.0176 to 0.0522) £89,538/QALY
Adjusted Complete case ITT £1308 (£1063 to 1609) 0.0250 (–0.0240 to 0.0694) £52,320/QALY
With MI ITT (base case) £1295 (£1084 to 1504) 0.0158 (–0.0221 to 0.0570) £81,962/QALY
Complete case PP £1616 (£1314 to 1988) 0.0238 (–0.0247 to 0.0649) £67,899/QALY
With MI PP £1594 (£1296 to 1961) 0.0118 (–0.0123 to 0.0529) £135,085/QALY
MI, multiple imputation; PP, per protocol.
TABLE 35 Summary statistics for days of lost employment reported since last questionnaire
Questionnaire period Treatment allocation Number of responses Mean days lost Median days lost (95% percentile) Percentage reporting 0 days
6 weeks Surgery 148 12.07 6 (40) 21.6
Cast 150 12.13 4 (42) 31.3
12 weeks Surgery 159 2.38 0 (21) 76.7
Cast 145 3.90 0 (30) 69.0
26 weeks Surgery 140 1.34 0 (5) 91.4
Cast 135 3.72 0 (32) 88.9
52 weeks Surgery 164 1.51 0 (4) 91.5
Cast 160 1.94 0 (6) 91.8
Total, complete case Surgery 102 16.62 9.5 (51) 13.7
Cast 91 17.57 5 (67) 28.6
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The results show that, by taking a lifetime perspective, surgery is the most expensive option, followed by no
treatment, cast plus surgery for non-union and finally cast only. The high cost of the surgery arm is driven
by the high upfront cost of the initial treatment, in contrast to the no-treatment cost, which is the result of
high future costs. These different cost accumulations are shown in Figure 10, which shows the cumulative
discount costs and clearly shows the large costs in the non-treatment arm after the initial treatment period,
which result from the large costs that result from the long-term implications of non-union.
The total QALYs for the no-treatment arm are much lower than for any of the active treatment arms
owing to the lifetime impact of AEs related to non-union. Surgery was found to result in the highest total
QALYs, followed by cast plus surgery and cast only.
The ICERs and NHBs show that, at their expected values (i.e. not taking into account any uncertainty), cast plus
surgery is the most cost-effective option, with the highest NHB at a conventional threshold of £20,000/QALY,
followed by primary surgery, cast only and, finally, no treatment.
The accumulation of NHB over time can be seen in Figure 11, which shows the cumulative incremental NHB
over the analysis period at a threshold of £20,000/QALY, compared with no treatment. It shows that, with
the exception of the first year, all three active treatment options have a positive cumulative incremental NHB
throughout. The closeness of the primary surgery and cast plus surgery lines show that there is a very small
absolute difference between the two over time, with the impact of the higher upfront cost in the surgery
treatment never being overcome by future health or cost gains, such that, at any time point in the analysis,
cast plus surgery is the most cost-effective treatment when considering mean values at a threshold of
£20,000/QALY.
TABLE 36 Discounted expected cost-effectiveness of all treatments per patient treated
Treatment Cost (£) QALYs
ICER (£/QALY) versus . . . NHB at threshold of . . .
Lowest cost
(cast only)
Next least effective
non-dominated £20,000/QALY £30,000/QALY
Cast only 836 18.72 – – 18.68 18.70
Cast plus surgery 921 19.07 243 243 19.02 19.04
No treatment 1749 14.75 Dominated Dominated 14.67 14.70
Surgery 2404 19.12 3952 29,660 19.00 19.04
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FIGURE 10 Cumulative costs.
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There are a number of ways of reporting the parametric uncertainty associated with the base-case analysis
(i.e. how much the modelled uncertainty in each of the parameters affects our decision). Figure 12 provides
the conventional CEAC, which reports the probability of each of the four arms being the most cost-effective
option for a range of cost-effectiveness thresholds. The CEAC shows that, at very low threshold values, below
£300/QALY, the cast-only treatment is the most cost-effective. This swaps to cast plus surgery for thresholds
between £300 and 29,660/QALY, after which surgery becomes the most cost-effective for all higher
thresholds. As the threshold increases to extreme values, primary surgery becomes the more cost-effective
option owing to its slightly higher estimated lifetime QALYs, but there remains a large level of uncertainty in
the decision.
The CEAC further shows that, if a threshold of £13,000/QALY was used, as indicated by recent research,111
cast plus surgery would remain the most cost-effective option, with 79% of the simulations favouring it,
with the expected incremental NHB when compared with primary surgery increasing to 0.07.
Another important factor to consider is the relative rank of each treatment option, as it is important to
understand the situation when a treatment option is not the most cost-effective. Table 37 provides the
probability of each treatment option being ranked at each place at a cost-effectiveness threshold of
£20,000/QALY. It shows that surgery and cast plus surgery are always the top two treatment options.
In addition, cast only is almost always ranked third and no treatment is always last. This distribution
becomes more marked at higher threshold values. This, combined with the base-case result and CEAC,
allow us to conclude that the cast plus surgery option results in the highest NHB and is the most likely to
be cost-effective at a range of conventional threshold values; in addition, even when it is not the most
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FIGURE 11 Cumulative incremental NHB in relation to no treatment (QALY).
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FIGURE 12 Cost-effectiveness acceptability curve.
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cost-effective, it is almost always the second most cost-effective option. Table 37 also shows the large level
of uncertainty in the decision at conventional thresholds, with the parametric uncertainty in our analysis
resulting in two-thirds of simulations favouring cast plus surgery over initial surgical fixation.
Furthermore, Appendix 6, Extended model results, reports the cost-effectiveness scatterplots generated
from the PSA, alongside predictions made by the model for the rate of OA and SNAC at 1, 5 and 10 years
to facilitate future validation of this analysis.
Value of information analysis
In addition to considering which treatment option is the most cost-effective and the probabilities of
cost-effectiveness as we have done so far, it is also important to consider the implications of that decision
uncertainty. For example, if a treatment is estimated as being the most cost-effective 80% of the time
but, when it is incorrect, the resultant NHB is catastrophic, it may not be deemed the best option by
decision-makers until further research can be used to reduce this level of uncertainty.
To calculate the population EVPI, estimates of the population size and time frame are required. We
assumed a 10-year time frame and a per annum population of 4650. The per annum population was
estimated by using the 7265 total scaphoid fractures reported by Garala,4 with 64%4 estimated as being
located in the waist.
The population EVPI is presented in Figure 13, showing how the value of generating additional information
varies as the threshold varies. The figure shows that, at lower threshold values, there is a relatively low
level of EVPI, associated with a high value of additional information, as there is a low level of uncertainty
about the most cost-effective treatment option, as shown earlier in this section. However, the value of
perfect information increases at an increasing rate as the threshold increases, as both the probability and
the implications of an incorrect decision increase. The ‘kink’ in the curve is the point at which primary
TABLE 37 Probability of cost-effectiveness by rank (threshold of £20,000/QALY)
Rank No treatment Cast plus surgery for non-union Surgery Cast only
1 0.00 0.61 0.39 0.00
2 0.00 0.39 0.60 0.01
3 0.00 0.00 0.01 0.99
4 1.00 0.00 0.00 0.00
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FIGURE 13 Population EVPI across different threshold values.
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surgery becomes the treatment that is most likely to be cost-effective, but, as the level of uncertainty
remains high, the value of resolving it continues to increase. One approach to interpreting population
EVPI is as a framework to measure conditions under which future research is potentially cost-effective.97
Scenario analyses
A number of scenarios were conducted to explore some of the elements of uncertainty not well captured
by the PSA. The full methods and results of these scenarios are presented in Appendix 6, Extrapolated
model scenario analyses. In brief, the scenarios show that the headline result of the analysis is not sensitive
to the majority of parameter changes but is sensitive to changes in how union is defined (scenario 1) and
the assumption made regarding what happens to the patients who failed to achieve initial union with
cast immobilisation only (scenario 2). These sensitivities are because the model result is almost completely
driven by the rate of non-union between the treatment options, which were very similar in SWIFFT at the
52-week follow-up.
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Chapter 5 Qualitative study
Introduction
Context of the qualitative study
A number of factors suggest the value of integrating qualitative research within SWIFFT. The fact that
fractures of the scaphoid waist are most common in a younger, active (and economically active) population
suggests that the impact of the injury may be wide-reaching and significant. A failure rate of 10–12% for
plaster cast management, the potential for complications associated with surgery and the fact that cast
and surgical treatments are of different orders (one invasive, one conservative) might suggest that patients
will have opinions about the appropriateness of (and a preference for) the treatment options available.
Furthermore, a comparison of medical and surgical treatments creates its own challenge of trial delivery,
in ensuring equipoise, managing expectations of treatment and ensuring long-term engagement with
trial procedures.
This nested study will seek to generate personalised, contextualised and specific insight about participants’
experience of a scaphoid fracture and about their involvement in SWIFFT. It will generate additional insight
that will complement the findings of the main trial and it will offer insight that will support the design and
delivery of future surgical trials.
Aims and objectives
The aim of this study is to provide complementary, detailed and person-centred insight that will inform the
interpretation of trial findings and that might support future clinical decision-making.
The study objectives were to:
l explore participant experience of a fracture of the scaphoid waist
l explore participant experience of treatment of a scaphoid waist fracture
l consider preferences for treatment options and those factors that might be pertinent in this
l consider involvement in a surgical, randomised clinical trial.
Fracture and recovery: a patient’s perspective
With the exception of hip fracture, qualitative investigation of patient experience of fracture is limited, with
only a small number of papers that address injury of the hand, wrist or arm.112–119 Despite some variation
(‘wrist fracture’, ‘wrist disorder’, ‘hand injury’, ‘hand disability’, ‘finger fracture’, ‘flexor tendon surgery’),
this body of work points to a number of common themes that are likely to be pertinent to a fracture
of the scaphoid waist: functional ability, relationships with others, perceptions of treatment/recovery and
recovery goals.
Functional ability
Functional ability was addressed in all studies.112–119 ‘Wrist disorders’ are described as affecting all aspects of life
(including domestic, recreational and economic) and spanning activities that require fine motor skills as well
as those that require strength.117 Employment was presented as an area in which limitations might have a
significant impact, namely in changed roles, reliance on others and challenges to self-confidence.112,115,119
The financial consequences of absence from work were a further potential consequence of a wrist injury.117,118
These and other limitations might lead individuals to feel anxious, frustrated, emotionally distressed or even
depressed;114,116,117,119 some authors propose a holistic approach to managing injuries (which incorporates both
psychological and clinical therapy).112,114,116,118
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Watson et al.118 are alone in their assessment that the nature and extent of limitations might vary among a
heterogeneous patient population, with factors such as single-parent status and self-employment associated
with an increased impact. They also propose that the time spent in a cast might be associated with how
limitations are perceived – a longer period in a cast increasing the experience of limitations associated with
the injury.118
Relationships with others
Functional limitations associated with immobilised hands or wrists may lead individuals to become more
reliant on others for practical help and support;117–119 husbands/wives, friends or family might all play
an important role in helping an individual to maintain normal activities.117 Such support, while generally
perceived positively, might have some negative consequences for those who find a lack of independence
or a reliance on others emotionally challenging.116 Schier and Chan112 describe how social roles (as a spouse,
caregiver, worker) might be fundamentally changed after a hand injury and that a ‘sense of loss’ for
‘previous social roles’ is conceivable.
A more positive perspective is offered by Chan and Spencer,114 who identify that supportive relationships can
be a motivator for patients to make positive adaptive behaviours (e.g. adhering to rehabilitation programmes
so as to resume parenting activities). Supportive relationships might also provide moral (rather than practical)
support at clinic appointments and in gathering information about the injury and treatment.118
Perceptions of treatment/recovery
A potential disconnect between how an injury is perceived and the complexity/duration of treatment can
have consequences for adherence to rehabilitation programmes113 and for remaining optimistic about
recovery.119 The fact that a treatment might feel excessive when compared with how the injury is understood
(simple, uncomplicated, minor?) offers conceptual challenges in accepting treatment and imagining recovery.
Removal of a cast was associated with ‘a sense of relief, improved function and the start of recovery’
(emphasis added);118 this demonstrates the pertinence of lay conceptions of treatment and highlights that a
patient’s own sense of recovery might be at odds with their clinical recovery, in other words that perceptions
of recovery might be more about regaining normality than about the clinical/physical repair of the fracture
or injury. In the same study, participants describe uncertainty and anxiety about the removal of a cast,
concerned by the loss of protection and uncertainty about the status of the wrist repair.118 A lack of
feedback and information about recovery is a source of anxiety for some patients,119 and elsewhere patients
describe the importance of feeling confident that they are receiving the right care and feeling certain about
their recovery trajectory.118
It seems that patient understanding of injury and recovery is influential in shaping their experience of
treatment and their satisfaction with it.
Recovery goals
Uncertainty about achievable levels of functionality,116 acceptance about possible longer-term limitations114
and ‘readjusting expectations and accepting limitations’119 all point to some sense of uncertainty about
what long-term recovery might look like. The fact that such concerns are less common in this body of
work and less present in initial clinical consultations118 reinforces the assessment that ‘wrist fracture is
perceived too trivial to warrant [detailed/longer-term concern]’.118
Amman et al.115 suggest that patients ‘had an inner drive to strive for normality’, which mirrors a concern
for ‘regaining normality’ demonstrated in orthopaedic trauma patients (which includes wrist, elbow and
shoulder injuries).120 Pre-injury wrist status might be important in establishing some sense of what this
might mean,117 although, to borrow from the hip fracture literature, notions of ‘normality’ will be shaped
by broader conceptions of prior health and by what is considered acceptable with regard to natural
deterioration (such as that associated with ageing).121
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Summary and assessment of literature
It is evident that hand or wrist injuries can have wide-ranging impacts on functional abilities in domestic,
leisure and employment environments and that such difficulties can lead to a greater reliance on other
people. A lack of clarity about longer-term goals and the potential for dissonance between how injury
(minor) and treatment (complex/long-term) are conceived may lead to uncertainty about recovery. A
patient’s (subjective) ‘sense of recovery’ may thus be important in their level of satisfaction with treatment.
The fact that subjective experience is influenced by clinical, personal, social or even economic factors
suggests a wide variation in how recovery might be managed.
It should be noted that this assessment is based on limited literature and that the existing evidence base
varies in scope and method, from detailed reviews of two or three interviews112,114,116 to more structured
assessment of larger data sets.117 Differences in focus (hand, wrist or finger) and reach (from one-off interviews
to longitudinal studies) also make synthesis and confident extrapolation difficult. Little has been written about
wrist fracture,118,119 and fracture of the scaphoid waist is not explicitly identified in these papers. Surgical
treatment is not explicitly explored and an investigation of patient preference for treatment is lacking.
Randomised trials in surgery
Difficulties recruiting to randomised clinical trials are well documented,122–127 with issues of participant
retention gaining increased consideration.128–132 For clinical trials in which surgery is compared with a
non-surgical treatment, these difficulties are recognised as being more pronounced,47 and McCulloch et al.46
identify a range of factors that they consider as inhibiting surgical trial delivery. Among these are surgeons’
equipoise, patients’ equipoise, surgical learning curves, issues with blinding, life-threatening and urgent
conditions, definitions (of procedures) and quality control monitoring.46
A more general assessment highlights the relevance of contextual and specific characteristics in trial
delivery; the setting of a study, the population of interest and specific procedures may all pose challenges
to the appeal or completion of a study.128,133 For SWIFFT, the younger, active male population suggests
some challenge to trial delivery. Previous research has demonstrated that females are more likely to
participate in research134 and that older people are more likely to fulfil their commitment to a study.135
Insight generated in this qualitative research might provide further insight into the challenges of delivering
a trial with this population and might point to factors that enhance or inhibit success.
Methods
Study design
A nested interview study was conducted to explore participants’ experience of the fracture of the scaphoid
waist, its treatment and their experience (or opinion about) involvement in clinical research. This study
involved both individuals recruited to the SWIFFT pragmatic RCT, as well as a small number of individuals
who declined to participate in the trial. Interviews were conversational (semistructured rather than structured)
and analysed using an inductive, thematic approach.
Participants
A purposive sample136 of those SWIFFT participants who indicated a willingness to be interviewed were
recruited to this study. Interviewees were purposively selected to ensure that both men and women,
experiencing different treatments and of different ages and occupations, were interviewed. A predefined
sampling frame (Table 38) was constructed to guide participant selection and to ensure that the sample
broadly reflected general patterns in the incidence of scaphoid fractures, that is, to prioritise younger
people (under 30 years of age) and to prioritise male participants. The sampling frame also distinguishes
between manual and non-manual occupations to enable this comparison in the analysis.
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Those who declined to participate in SWIFFT were also invited to take part in this interview study. This
second group was recruited to support a broader consideration of patient preference for treatment, that is,
to reflect that those who declined may have different attitudes about treatment from those who took part.
Again, a sampling frame was constructed to prioritise interviews with male participants and with those
under 30 years of age (Table 39).
Recruitment to this element of SWIFFT research was also informed by concerns for data saturation, that is,
the point at which no new insight is generated in the undertaking of additional data collection.137 Prior
assessment has suggested that core topics and themes might be established with as few as six interviews
and that more complete data saturation is commonly achieved with 10–13 interviews.138–140 Here, 18 in-trial
interviews per treatment arm were proposed as sufficient to reach data saturation and as sufficient to be
confident of the interpretation of combinations such as male/cast (n = 12) or surgery/under 30 years (n = 12).
In total, 36 in-trial interviewees and nine interviews with those who declined to participate in SWIFFT
were proposed.
All interviewees were separately consented for this element of the SWIFFT research.
Data collection
All participants were interviewed within 6 weeks of randomisation and those in the trial were interviewed
again at 52 weeks. Earlier and later interviews covered similar topics and were organised in three parts:
(1) wrist fracture and its impact, (2) treatment of fracture and (3) participation in clinical research. Interviews
at 6 weeks were intended to capture an immediate response to the scaphoid injury; interviews at 52 weeks
were intended to reflect on treatment options and individual recovery. At both time points, questions about
clinical research were included to generate general (understanding and perceptions) and specific (to support
the delivery of SWIFFT) insight.
The same interview schedule was used for all interviews at 6 weeks, with some adjustment in the prompts
used and how questions were phrased for those who declined participation in the trial. Interview schedules
are included here as Report Supplementary Material 19.
Where possible, interviews were undertaken face to face at a time and location convenient to the participant.
In other cases, when it was the participant’s preference or when geography made a face-to-face meeting
impractical, interviews were undertaken via the telephone. Interview questions and prompts were used as a
guide for discussion only (rather than as a strict script)141–144 and interviewees were encouraged to develop
TABLE 38 Target sample: within trial
Group
Gender (n) Age (n) Occupation (n)
Male Female Under 30 years Over 30 years Manual Non-manual
Surgery 12 6 12 6 9 9
Cast 12 6 12 6 9 9
Total 24 12 24 12 18 18
TABLE 39 Target sample: declined participation in SWIFFT
Group
Gender (n) Age (n) Occupation (n)
Male Female Under 30 years Over 30 years Manual Non-manual
Total 6 3 6 3 – –
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issues that they felt were important and to introduce new topics that had not otherwise been considered. In
this way, these interviews were intended to be discursive, generating personalised and contextualised accounts
of injury and treatment. Therefore, the body of data generated was intended to capture the range of different
individual experiences.
All interviews were digitally recorded and transcribed in full; transcripts were anonymised with all personal
identifying data removed. Data were stored on a password-protected, networked drive and handled using
the NVivo (version 11) software package (QSR International, Warrington, UK).
Data analysis
The discursive nature of the data generated (i.e. guided, but not restricted, by an interview schedule)
suggests a thematic approach to data analysis.137,145 Furthermore, the exploratory nature of the study would
suggest an inductive, thematic approach, as described by Braun and Clarke.146 This approach describes a
systematic and structured method undertaken in a series of iterative steps. It is a form of qualitative analysis
that explores data on their own terms and that prioritises the organic insight generated therein.
Interview transcripts were read and reread in an initial stage of data familiarisation. Next, open (inductive)
coding was used to identify points of interest in a process of generating initial codes. This process was
managed independently by a study researcher, with the qualitative study lead ensuring the consistency
and validity of the coding.
In stage 3, these initial codes were merged and grouped according to topic or sentiment in the identification
of themes. Here, themes and subthemes were organised within three broad topic areas that reflect the aims
and objectives of the study, that is, injury, treatment and research. These early stages (1–3) were undertaken
alongside data collection, with emergent findings presented to the SWIFFT TMG at its regular meetings.
In stage 4, themes were reviewed and refined to ensure their internal and external coherence. At this stage,
themes were also interrogated to establish their utility in serving the aims and objectives of the research.
Following this, themes were finalised in a stage entitled ‘definition and name’ and were connected to form
broad narratives, providing insight into (1) the injury and its impact, (2) cast treatment, (3) surgical treatment
and (4) research. Themes and thematic models were validated by the study chief investigator and other
members of the SWIFFT TMG.
Braun and Clarke146 suggest that producing the report is the final stage of thematic analysis, stressing that
interpretation continues as data are organised in an authored form. The final narratives (presented below)
were validated by the SWIFFT TMG and author groups.
Results
Data overview and code book
A total of 64 interviews were undertaken with 49 individuals.
At 6 weeks, 36 in-trial interviews were carried out and, at 52 weeks, 19 interviews were carried out; in addition,
nine interviews with individuals who declined the main trial were carried out at 6 weeks (Tables 40–42 describe
the demographics of the sample). Of the 49 individuals interviewed, 36 in-trial participants were recruited
at baseline, nine individuals who declined participation in SWIFFT were recruited at baseline and four in-trial
participants were recruited at 52 weeks (to compensate for dropout). Of these, 35 were male (14 female)
and 26 were under the age of 30 years. Approximately half of all interviews were with our key demographic:
males under the age of 30 years (17/36 at 6 weeks, 9/19 at 52 weeks and 5/9 who declined participation).
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The initial analysis was structured around three broad topics (injury, treatment and research) with codes
subsequently organised within 11 core themes and 37 subthemes (Table 43). This represents stages 1–4 of
the inductive thematic analysis.146 Stages 5 and 6 are presented from the Thematic analysis section onwards.
Topics, themes and subthemes were consistent across the sample; data collection ceased following the
addition of four young, male interviewees who were interviewed at 52 weeks only (to ensure data
saturation for this key population).
Participants were recruited from 13 centres: Bath, Bolton, Cardiff, Coventry, Leicester, Newcastle,
Nottingham, Oxford, Peterborough, Plymouth, Royal London, Southampton and Teesside.
Interviews varied in length from 14 to 73 minutes at 6 weeks and from 13 to 41 minutes at 52 weeks.
Interviews were typically 40–45 minutes in length at 6 weeks and 20–25 minutes at 52 weeks.
Thematic analysis
The convention for identifying participants is as follows: plaster cast (P) or surgery (S) + participant ID
number, gender, age (years), 6- or 52-week interview; an asterisk indicates an interview with someone
who declined to participate in the main trial.
TABLE 40 Interviews at 6 weeks with trial participants
Group
Gender (n) Age (n) Occupation (n)
Male Female Under 30 years Over 30 years Manual Non-manual
Surgery 13 4 9 8 7 10
Cast 12 7 10 9 7 12
Total 25 11 19 17 14 22
TABLE 41 Interviews at 52 weeks with trial participants
Group
Gender (n) Age (n) Occupation (n)
Male Female Under 30 years Over 30 years Manual Non-manual
Surgery 8 1 6 3 5 4
Cast 5 5 4 6 6 4
Total 13 6 10 9 11 8
TABLE 42 Interviews with those who declined participation in SWIFFT
Group
Gender (n) Age (n)
Male Female Under 30 years Over 30 years
Total 6 3 5 4
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TABLE 43 The SWIFFT code book for qualitative data
Topic Theme Subtheme
Injury A minor injury? Delayed seeking medical help
Not worthy of serious treatment
Practical difficulties Driving
Leisure pursuits
Washing
Domestic chores
Difficulties at work
Psychosocial difficulties Loss of independence
Mood
Relationships with others
Other difficulties Employment
Money and finances
Treatment Plaster cast Inconvenient and immobilising
Passive
Safe and natural
Preference for plaster cast
Surgery Preference for surgery
Active
Quicker recovery
Risks
Factors in preference The need for speed – employment and money
The need for speed – familial responsibilities
The need for speed – lifestyle and other events
Access to practical support
Prior clinical experience
Recovery Return to normal
Progress made
Long-term concerns
Research Reasons for participating Access to treatment options
Clinical benefits
Money as incentive
Positive assessment of research Research processes acceptable
Research nurses
Facilitators of research
Negative assessment of research Barriers to research processes
Research processes unacceptable
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Model 1: the injury and its impact
Thematic model: fracture of the scaphoid waist is often initially considered a relatively minor injury. It can,
however, have a wide-reaching impact in limiting function. Limited function may be associated with a
greater reliance on other people and may have other psychosocial consequences.
An inconsequential injury?
For many, the fracture was the result of what they considered to be an inconsequential incident – a trip,
a clash on the football pitch, a bang at work or falling off a bike. Few considered the injury serious and
many continued what they were doing: ‘[S]trapped it up, checked I could still catch and pass the ball, and
then went back on’ (P1121, male, under 30, 6 weeks); ‘I carried on working . . . I had to make the job safe
before I walked away, so I worked for probably an hour after’ (S1008, male, under 30, 6 weeks); ‘oh yeah
I carried on dancing, it didn’t hurt at the time’ (P1245, female, under 30, 6 weeks). Even an assessment
that some damage might have been done did not necessarily mean that immediate action was taken:
I knew as soon as I’d landed, it was obvious . . . I could tell it was more than a sprain . . . I thought I’d
damaged it . . . [but] I did what I needed to do, I just finished the delivery, and drove the van to where
it was needed . . . by the time I got back here it was 9 o’clock [at night] . . . So I went down the
hospital first thing on Saturday morning.
P1451, male, over 30, 6 weeks
In the few cases in which more immediate medical attention was sought, it was often because of multiple
injuries, with the wrist commonly considered the least of these: ‘I went because of the blood gushing
from my chin . . . I did my tooth, my chin, everything else as well’ (P1023, male, under 30, 6 weeks*); ‘the
ladders slipped underneath me . . . it was my back . . . I didn’t know I’d hurt my wrist’ (P1282, male, under
30, 6 weeks).
For most, swelling, pain or bruising prompted them to seek medical attention within 24 hours, although
for some it was a number of days before they sought any treatment: P1823 (female, under 30, 6 weeks)
went to A&E 3 days after her fall and P1161 (male, over 30, 6 weeks) went to hospital 6 days after a trip.
Even when seeking medical attention, some still suspected that they had only sprained their wrist and a
number were surprised at the fracture diagnosis. The severity of the consequences of the injury (and the
potential for surgery) were surprising to some:
I think when you initially do it, you always think, well, your wrists are nothing and it’s not until
somebody sits down and explains to you just exactly how complicated a wrist or a foot or hand is that
you suddenly realise, hang on a minute.
S1175, male, over 30, 52 weeks
I was like, well, it didn’t really hurt so how can it be that bad . . . [the hospital] said ‘it could be 6 to
10 weeks in a cast and then an operation’ . . . I was like ‘oh no, I don’t want any of this! I only just
went ice-skating and accidentally got pushed over’ . . . I didn’t realise the severity of it, kind of thing,
well, I just didn’t, I still can’t quite believe it now to be fair.
S1244, female, over 30, 6 weeks
Practical difficulties associated with the injury
Despite any initial thoughts that the fracture might be a minor injury, all interviewees described some
degree of practical limitation, from work to washing and dining to driving.
The impact on leisure pursuits was telling for some: ‘the only real impact it’s had is my leisure activities,
so I haven’t really felt that I’m comfortable going to play football just in case I fall again’ (P1201, male,
under 30, 6 weeks); ‘my leisure time is somewhat disrupted, I’m a church bell-ringer, which involves my
hands, and I can’t really do that so much now’ (P1856, male, under 30, 6 weeks); ‘I do quite a bit of
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cycling. I haven’t been on the bike since just because of grabbing the handlebar might be quite difficult,
so I haven’t been able to do that’ (P1360, male, under 30, 6 weeks).
The impact on work was more important for others, especially when pay is affected by an absence from
work: ‘[W]ell I’d just gone self-employed, so I’m not going to be earning now. I’m out of pocket in that
respect’ (P1451, male, over 30, 6 weeks) and:
The worse thing was knowing that I had to have time off work . . . [I’m] classed as self-employed so
. . . it was just the thought of not being able to work really . . . knowing that there’s kind of a month’s
pay that’s going to be missing.
P1327, male, under 30, 6 weeks
Driving was a common area of discussion, with interviewees often concerned by advice not to drive and
about what this might mean for their independence: ‘3 months of not driving for me would be 3 months
of hell really . . . it would have affected my work so much, not being able to drive for 3 months’ (S2097,
male, under 30, 52 weeks) and:
I live right in the middle of nowhere really, so in terms of getting the bus to work that’d be impossible . . .
I was relying on my girlfriend for lifts and friends picking me up . . . But in terms of getting to places,
yeah I was just really reliant on people giving me lifts, which was awful.
S1691, male, under 30, 6 weeks
Psychological and social impact of the injury
The final quotation in Practical difficulties associated with the injury highlights the fact that practical
difficulties often translated into reliance on others and potential changes to relationships. Some (younger
individuals, often students) described becoming more reliant on (or even moving back in with) parents
or other family members. Others described being unable to contribute at home and relying on wives,
husbands or partners for practical support. In response to the interviewer asking ‘[H]ow did your wife
cope?’, one individual responded as follows:
With great difficulty because I was someone who was very active and I turned into someone who . . .
wasn’t able just to take the mower out of the shed and mow the lawn or take my daughter to the
park on the swings . . . So I couldn’t drive so it meant me not being able to take my son to sports . . .
Everything was kind of left to her.
P1020, male, over 30, 52 weeks
Few suggested that this was problematic, although some indicated feeling low about the injury: ‘I need
to find other things to do with my time . . . I feel really bad, I feel depressed . . .’ (S2284, male, under 30,
52 weeks); ‘I started to get very depressed and it affected me badly. I wasn’t coming out of my room’
(P1023, male, under 30, 6 weeks*); ‘Saturday was the day I felt a bit low . . . I was just a bit, like, I hate
relying on everyone . . . I felt “oh my God this is crap” ’ (S1244, female, over 30, 6 weeks).
Less remarkable complaints about frustration and boredom were common: ‘So I just had to sit there and
watch TV and in the end it was getting boring to the point where I was just going out for a walk randomly,
just to try and get out‘ (S1008, male, under 30, 6 weeks); ‘I’ve definitely been frustrated with it yeah.
Because it’s just so well so silly falling off my bike. And then having like everything, everything changes you
know just because of that really’ (S1691, male, under 30, 6 weeks).
Model 2: plaster cast treatment
Thematic model: in comparison with surgery, initial treatment in a plaster cast is recognised as less risky
and possibly more ‘natural’. It is, however, perceived to be more limiting and more limiting for a longer
period of time. The fact that repair beneath the cast is unseen is a concern for some.
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A more natural option
For some interviewees, plaster cast treatment was perceived as more natural and less risky than surgery.
This assessment was of course informed by concerns about surgery – about anaesthesia, scarring, surgical
error, etc. – but also seemed to reflect an attitude that there is benefit in allowing the body to heal
naturally (P1986, female, over 30*; P1023, male, under 30*; P1360, male, under 30; among others).
Plaster cast was considered a convenient and straightforward option by some:
[When allocated to plaster cast treatment] I thought ‘oh flipping heck’. But now, in hindsight, I’m so
pleased I had the plaster because you’ve no scar or anything. You risk infection don’t you if you have
an operation? I’ve no scar or anything, it’s perfectly healed, so no, I’m quite happy, I would have the
plaster again I think.
P1617, female, over 30, 52 weeks
It is pertinent to note that these assessments reflect participants whose recovery was positive and
straightforward. Not all those who were interviewed experienced such outcomes and their assessment
acknowledged that plaster cast treatment might be more or less attractive, given the nature and severity
of the injury and different lifestyles and commitments:
I prefer non-intervention if possible . . . my upfront view was never do surgical intervention if you don’t
need to . . . [cast is better] assuming that the bits are all in the right position . . . but I’m starting to
wonder if I’ve done more damage [than I thought].
P1542, female, over 30, 6 weeks
And who’s to say if I was entering a different situation in a different time, I’d be like, oh I really do
hope that I do get the surgery because I cannot be in a cast for more than 2 weeks, you know.
P1030, male, over 30, 6 weeks
An inconvenience
More common in the data were comments about the inconvenience of wearing a plaster cast:
The worst thing . . . restricted movement. That’s it you know. That’s all it is. That’s even worse than
[the original injury and pain] . . . just being restricted from doing what you’d normally do . . .. I think
just that, just being restricted you know . . . That to me, that’s the main one, just the restriction of
the cast.
P1161, male, over 30, 6 weeks
When I had the cast on, being a bit limited for stuff you know. Which was a bit awkward, doing
buttons up on shirts and stuff you know because it did used to hurt at the start. But because I used to
do running and couldn’t really run with the cast on, that was a bit of a pain.
P1161, male, over 30, 52 weeks
An inability to work, difficulties at work and difficulties driving were all associated with the restrictive
nature of the cast and, while these complaints varied from person to person, the consequences for some
were significant and long term (for a few, these were still evident at 52 weeks). Feelings of being disabled
and about losing independence were associated with this:
I’ve become more reliant on other people . . . In a sense I’ve learnt how to sort of let people do more
things . . . I try and do what I usually do and I get annoyed ‘cause I can’t do it, I sort of just sit back
and faff about and then try and sort of relinquish that duty to someone else . . . err, so I’ve become
more submissive I suppose in that sense, and sort of wait for someone to help out.
P1485, male, under 30, 6 weeks
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Other complaints focused on more mundane, personal, everyday activities. Some experienced difficulties
going to the toilet: ‘I couldn’t flush the toilet normal, I couldn’t wipe my backside’ (P1020, male, over 30,
6 weeks). Difficulties using cutlery were mentioned: ‘[eating] would be a struggle, I can’t use a knife and
fork’ (P1245, female, under 30, 6 weeks). Difficulties sleeping were reported: ‘I’m quite fidgety when I
sleep, then I sleep on my side quite a bit so the arm gets in the way quite a lot’ (P1575, male, under 30,
6 weeks). In addition, issues with clothing were also mentioned: ‘it’s ruined so many clothes, the plaster
rubbing up against your dress or blouse’ (P1316, female, over 30, 52 weeks).
Difficulties washing could be added to this list, with regard to both keeping the cast dry and the dexterity
required to wash with one hand and/or with a non-dominant hand: ‘I’ve got one nice-smelling armpit,
one less so’ (P1451, male, over 30, 6 weeks). The itching associated with a plaster cast was distracting to
some, and individuals described using knives, knitting needles, pens and forks, among other things, to
scratch beneath the cast. The state of the cast and the potential for it to become ‘manky’ (P1121, male,
under 30, 6 weeks) was described by some who were concerned about hygiene: ‘it’s not the nicest
smelling thing in the world – as much as you try wash your hands, it really does smell like cheese’ (P1485,
male, under 30, 6 weeks); ‘I don’t like the fact that there’s one thing on my arm for 6 weeks you know.
I’m a bit of a clean freak and it’s quite annoying’ (P1823, female, under 30, 6 weeks). Others mentioned
how the cast might appear to others: ‘I don’t wear short sleeve when I’ve got the cast . . . like it’s not
exactly the most pleasant looking’ (P1575, male, under 30, 6 weeks).
Uncertain recovery
Around half of those treated in a plaster cast interviewed at 52 weeks expressed some ongoing concerns
about their recovery. P1020 (male, over 30, 52 weeks) described his recovery as being at 70%. Others
described feeling some weakness in their wrist (P1560, female, over 30, 52 weeks; P1245, female, under
30, 52 weeks), wearing a wrist support (P1542, female, over 30, 52 weeks) and hoping for some further
improvement: ‘I’m hoping that it isn’t going to be like this forever, I’m hoping that it’s going to be one of
those things that’ll sort itself out one day’ (P1121, male, under 30, 52 weeks). Of those describing a more
positive recovery, there was some disappointment at how they had been incapacitated: ‘because it hadn’t
fully healed after the 6 weeks, I had to have it on for another 6 weeks and 12 weeks is kind of pushing it
really, for how long I was to wear this thing for’ (P1807, male, under 30, 52 weeks) and:
I was probably a bit surprised with how long it took to heal . . . [when the cast came off] it wasn’t
completely healed . . .. I do remember them saying it hadn’t completely healed. I don’t know, I think it
was probably around 70% or something.
P1161, male, over 30, 52 weeks
A common observation was that cast treatment requires a long period for healing to take place: ‘a bit of
disappointment that I was going to have to be stuck in the cast for so much longer . . . it’s going to be on
for a longer time than it would have been for surgery’ (P1856, male, under 30, 6 weeks). A less common,
but perhaps equally pertinent, observation was that the period in a cast is an uncertain period, a time
during which improvement and outcome are unclear. These two elements combined (duration and
uncertainty) might make cast treatment less attractive to some: ‘being in a cast for maybe 4 to 6 weeks
and then maybe another decision being made . . . I think, you know, kind of 6 to 12 weeks of uncertainty’
(P1360, male, under 30, 6 weeks) and:
[It would be good] if you could see the healing process before the 6 weeks [when the cast is removed],
because I think 6 weeks is a hell of a long time for somebody to kind of stop doing 50% of the things
that they’d normally do, to then still not be any better off. It’s kind of a kick in the teeth. I mean if you
was in the cast for 3 weeks and your healing [could be checked] or just to know something halfway
through probably would have been a little bit better.
P1020, male, over 30, 52 weeks
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Model 3: surgical treatment
Thematic model: in comparison with cast treatment, initial surgery is perceived as a more active form of
treatment. The benefits of a more quickly removed cast are important to those whose personal, economic
or familial circumstances exaggerate the impact of limited functionality.
A preference for surgery
The opportunity for surgical treatment was an important factor affecting the willingness of some patients
to participate in the trial. These individuals felt that surgery was the right option for them. For some, this
was an intuitive preference based on previous fractures; for others, it was an assessment reached through
discussion with their consultant and the nurses recruiting to the trial. Speed of recovery, strength of repair
and certainty of treatment were all factors in this; employment circumstances, family commitments, leisure
pursuits and even holidays were also identified as being pertinent to surgery being more attractive:
My mind was already sort of going towards the surgery side anyway . . . me and a friend of mine we
run an events catering business and June and July are the busiest months of the year . . . if I’d have
been stuck in a cast, you know, I was able to come to work but my skill level dropped off when it
comes to using knives.
S1345, male, over 30, 6 weeks
I said, to be honest, I’d just like to have the option of the operation if it will be quicker . . . . Because
we were buying this house and we needed the money to be coming in . . . . I’ve got no such thing as
light duties. It’s either all in or all out and I’ve had to put a few jobs off.
S1008, male, under 30, 6 weeks
A need for speed: a quicker recovery
At the most basic level, the inconvenience of a cast was a push factor for favouring surgery:
But for someone like me who is very independent and I have to work and drive and, you know, do all
of these things, the thought of being in a cast for 8 to 10 weeks, maybe longer . . . that was quite scary.
S1749, female, over 30, 6 weeks
For others, a slow, delayed recovery might lead them to do more than they should, potentially aggravating
or reinjuring their fracture:
[In a cast] I would have wanted to become independent again and I would have done other stuff, you
know, I wouldn’t have been able to just sit around with a cast on, I would have been doing other
stuff. So I would have probably have put myself at risk by wanting to become independent again.
S1658, female, over 30, 6 weeks
They said it could be 6 weeks but after those 6 weeks you could still need surgery . . . To be out of
work for so long I’d then run the risk of, you know, trying to get back quicker and then ending up
[hurting myself again] and being twice as long. So you know, it seemed like a smarter option . . .
I did feel as though it [surgery] was probably the best treatment for the injury.
S1759, male, under 30, 52 weeks
The risk of the fracture not healing while in a cast was also present in other individuals’ assessments:
Yeah that’s what they said, if we just put the cast on it, it could end up, like, having surgery later on,
so I thought I might as well have the surgery done now . . . I thought, oh well, it’s best to have the
surgery done now and then avoid [more problems later].
S2097, male, under 30, 52 weeks
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After 6 to 10 weeks [in a cast] you still might need an operation anyway because it might not have
healed . . . I was thinking, oh no, I don’t want that, well I don’t want to go through doing that and
then having the operation anyway, so that’s the other reason, I thought, well, you’re just better off
going for the operation anyway.
S1244, female, over 30, 6 weeks
The fact that surgery following the failure of cast treatment was perceived to be a more complex
procedure reinforced the appeal of immediate surgical treatment: better to have straightforward surgery
immediately than to risk a more challenging procedure later.
A need for speed: a more active form of treatment
In coming to the decision that surgery offered a quicker and more certain recovery, many perceived that
the more invasive and interventional nature of surgery offered benefits to the healing process. By this way
of thinking, surgery was doing something beneficial, rather than simply waiting for healing to take place.
Surgery was seen as offering a more certain treatment pathway, was considered to involve a more active
repair of the wrist and was considered beneficial in kick-starting the healing process: ‘I suppose you feel
[it is a] more involved healing process . . . The fact that you’re going to hospital and getting it treated
rather than just waiting for it to heal in a cast’ (S1339, male, under 30, 6 weeks); ‘Yeah. I think there’s just
a lot more certainty in the [surgery] treatment . . . . there’s just some sense that the surgery would just feel
like something’s happening. It’s happening now, I’m going to be getting better’ (P1360, male, under 30,
6 weeks).
The insertion of a pin was intuitively appealing to some, adding strength to the fractured bone. This
assessment was particularly important to those who were concerned about manual or physically demanding
activities: ‘If I was to knock it again, it wasn’t just going to break because the screw would hold it in
place . . . The operation would be better in my circumstances [self-employed joiner] because it will be a
stronger fix’ (S1008, male, under 30, 6 weeks); ‘because it’s got a screw in it, for me, mechanically minded
[motocross cyclist], it’s going to be stronger, so, I don’t know, I think that’s why I liked it a lot more’ (S1265,
male, under 30, 6 weeks).
Assessment of surgical procedures
Those exposed to surgery expressed few concerns about the appropriateness of the procedure. The fact
that the surgeons expressed confidence in the procedure was important, but the surgery being commonly
offered within the NHS was particularly important. All were generally content with their initial recovery and
those interviewed at 52 weeks (n = 9) indicated that their recovery had exceeded expectations (in both
speed and completeness). Those interviewed at 52 weeks also indicated that they would recommend
surgery to others:
The fact that it is pretty much back to exactly the way it was, obviously there’s just a pin in there,
or a screw, whatever it is, you know, I mean there’s no loss of movement, there’s no stiffness in the
movement, so I am quite surprised in the fact that I’ve had an injury like that and there’s no . . .
you know, to be honest you kind of almost wouldn’t really know it had happened in a way.
S1345, male, over 30, 52 weeks
There were some minor concerns about scarring and some comments about pain following surgery, but
none of these was considered a barrier to the appeal of surgery. The only barrier identified by some was
a reluctance to undergo surgery under a local (rather than a general) anaesthetic:
[As regards local anaesthetic] I suppose it’s more, a bit modern and a bit . . . it just didn’t appeal to me
really . . . I know that you can’t feel it or whatever and you probably couldn’t see what’s going on,
I was just like ‘oh no’ and she said instantly in my face she could see how I weren’t up for that!
S1244, female, over 30, 52 weeks
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They said to me at first they was going to like knock me out, but then when they got there they said
they wasn’t, they was going to do it on the local anaesthetic. And that’s when I started to get a bit
worried. I didn’t really want to hear it. I asked them straight away, well, what about, would I be able
to see it? And they said no, they’d put a screen up. And then eventually I asked for some sedative and
I had it and went straight to sleep.
S1452, male, under 30, 52 weeks
Model 4: research
Thematic model: surgical treatment made participation more appealing to some, although for others
surgery (and randomisation) was a reason for not taking part in the wider study. The study burden was
considered acceptable and some felt that taking part in a clinical trial might improve their clinical care.
The appeal of research
Individuals in both arms of the trial expressed similar opinions about agreeing to participate because of the
possibility of being randomised to the surgical treatment arm:
I was approached to join the study and, yeah, I was fully willing to join and I thought it would
probably be the best . . . I wanted surgery from the start, I know it was randomised, but I told them
I wanted surgery.
S1452, male, under 30, 52 weeks
I think she explained to me that with the operation it could heal quicker I think . . . I said to her ‘Look,
OK, fair enough. Whatever’s quicker’, you know, but I mean obviously it came that I’ve got to have
the cast on.
P1161, male, under 30, 6 weeks
In contrast, some of those who declined the main trial expressed uncertainty about the surgical procedure.
At least one trial decliner indicated feeling ‘scared of surgery’ (P1774, male, under 30, 6 weeks*); another
suggested that surgery felt quite serious for a relatively minor injury:
I just felt [surgery is] a more drastic approach for something which is fairly common . . . . I was a little
bit shocked, to be honest, when they offered me surgery . . . I think of surgery as something more,
for more serious injuries, I think I could probably heal without and, like I say, all the side effects put
me off.
P1023, male, under 30, 6 weeks*
In addition, a number of interviewees speculated that participating in a major clinical study might bring
with it other benefits, with regard to either improved clinical care or simply less waiting at appointments:
You get seen quite quickly when you’re doing it . . . Actually I think you get treated a bit better when
you’re doing it!
P1245, female, under 30, 52 weeks
And the other thing is, because it’s research, when it comes to the treatment, everything has to be
within a certain period for that information to be relevant . . . So I thought everything will be pushed
through quicker than just being on a waiting list as well.
S1008, male, under 30, 6 weeks
More commonly, participants indicated altruistic reasons (benefiting other patients, contributing to the NHS)
for taking part in the trial.
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Research processes
A few of those who declined to participate pointed to study burden as a factor in their decision, although
for those involved in the study this was rarely commented on. More likely, interviewees would confirm
their commitment to fulfilling their involvement as a point of principle: ‘you know, it’s just a mindset really
and I said I would do it, so I was quite happy to go ahead with it . . . I wouldn’t have stopped’ (P1617,
female, over 30, 52 weeks). Some gripes about the questionnaires (long, repetitive) and about follow-up
appointments (parking, timing, etc.) were mentioned, but these were rarely described as serious problems.
Continuity of contact and support from the research nurses was commended by some and described as a
key factor in their fulfilment of the study requirements:
I think that my experience of all the follow-ups and stuff was absolutely spot on. I had the same nurse
that I saw the first day . . . she kept in contact with me, she told me everything I need to know, always
there if I needed to speak to someone . . . I think that I was very well looked after and always kept
informed and very helpful at all times.
S1452, male, over 30, 52 weeks
We’ve actually been treated really nicely and it was – obviously the research nurse that I went to in the
hospital, or who I’d spoken to, she was lovely. She rings me about my appointments and stuff and . . .
things like that. And I know what’s going on.
P1245, female, under 30, 6 weeks
Most interviewees indicated that they had a reasonable comprehension of randomisation, although in
some cases this included notions that individual circumstances would be considered (S1008, male, under
30, 6 weeks) and that the process might be modified according to the doctor’s opinion (S1175, male,
over 30, 6 weeks). The fact that both treatments were established and safe was important in accepting
randomisation and, while many had an initial preference for one treatment or the other, all demonstrated
a willingness to adhere to the randomised treatment. Among those who declined to take part in the main
trial, an uncertainty about randomisation was the most clearly expressed reason for not wanting to take
part. These individuals were unhappy with their clinical care being compromised by research procedures:
I just didn’t like the fact it was not the doctor giving me the best advice that he would normally give
you . . . You know, they’d say this is what I recommend. I didn’t at all like the fact [that] . . . something
else would then decide which way to do it, and I didn’t like that at all and it wasn’t what I was
expecting . . . I didn’t think it’s really appropriate . . .. I’d rather have the doctor telling me what he
thought I should do.
P1464, female, under 30, 6 weeks*
I personally don’t like the big question mark as to whether you’re [getting surgery or plaster cast] . . .
Not with health issues, you know, I don’t like the lottery effect . . . I like to know what is happening
rather than a random number out of a hat.
P1986, female, over 30, 6 weeks*
Some of those who declined to participate in the main trial indicated that being provided with more
information about the benefits of surgery might have changed their opinion about taking part:
If someone then had taken time at that point and sit me down and, say, talk me through the benefits
of what having a screw would give . . . I would have been extremely open to go on the trial.
P1263, male, over 30, 6 weeks*
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Discussion
Summary of key results
A number of points can be made about a scaphoid waist fracture:
l The initial assessment is often that this is a minor injury.
l Functional limitations associated with the fracture may have impacts across domestic, employment,
familial and social activities.
l Individuals may become more reliant on others because of these limitations.
l Individual circumstances may exaggerate or mitigate the impact of a fracture – personal, familial or
other contextual circumstances (including the severity of the fracture, dominant/non-dominant hand)
may influence how limitations are experienced.
A number of points can be made about how treatment options are viewed:
l Cast treatment is recognised as conservative and less risky. It is, however, associated with an extended
period of immobilisation.
l Uncertainty about healing may exaggerate concerns about the duration of immobilisation.
l Surgery is associated with a more active repair and is perceived as offering a speedier recovery.
l Again, individual circumstances may inform treatment preference – if personal, familial or other
contextual circumstances require a quicker recovery, surgery may be perceived as advantageous.
A number of points can be made about the delivery of this trial:
l The potential for surgery was appealing to many of those interviewed. Conversely, among those who
declined to take part in SWIFFT, concerns were expressed about surgery.
l Trial procedures were not considered burdensome and there was recognition that trial processes may
enhance navigation and experience of clinical processes.
Reflections on the results
This work contributes to the limited literature on patient experience of hand, wrist or arm injury. It
reinforces and extends a number of themes in this literature – specifically, the wide-ranging functional
impact of an injury,112–119 the relevance of an individual’s subjective ‘sense of recovery’117–119 and the
potential for personal or contextual factors to shape these.118 It also adds insight into how treatments are
perceived and into the personal and contextual characteristics that may shape this.
Fracture of the scaphoid waist
Data generated here reinforce the fact that a wrist fracture can have far-reaching consequences117–119
and that these might exceed any initial assessment that this is a trivial injury.118 Impacts on functional
limitations112–119 were commonly reported and interviewees described (to a greater or lesser degree)
limitations in all aspects of their life. Impacts in employment were commonly reported and concerns for the
financial distress118 were evident when interviewees described being self-employed. Changes to domestic
and employment responsibilities suggest social role changes previously described.112
Moving in with parents, relying on others for lifts, help tying shoe laces and help cutting food all illustrate
a need for practical support that has been reported previously.117–119 They also suggest a challenge to
independence that Fitzpatrick and Finlay116 identify. Complaints about boredom, frustration and depression
mirror those concerns for the psychological consequences of a hand or wrist injury.114,116,117,119
The fact that individual reports of functional limitation varied significantly – from those continuing as normal
to those feeling significantly disabled – reminds us that this is a heterogeneous population. This reinforces
the importance of establishing what patients deem to be normal,115,121 reflecting on pre-injury wrist function119
and considering those contextual factors that exaggerate or mediate disability.118 In this, the data generated
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here take us beyond a simple comparison of men and women and manual and non-manual occupations and
support the relevance of specific circumstances,118 such as occupation, familial responsibilities, access to
familial (or other social) support and leisure/lifestyle pursuits (among many others).
Assessment of treatment options
The fact that surgery is often uncritically assessed as a quicker, stronger and more active repair overlooks
important clinical facts, namely that casts are 90% successful, that surgery can be marked by complications
(and poses a risk of non-union), that bone repair takes the same amount of time irrespective of treatment,
etc. However, despite this, the appeal of surgery is clear; a number of things might help us to understand this.
First, the appeal of surgery reiterates and reinforces Watson’s118 recognition that an individual’s ‘sense
of recovery’ might be distinct from the repair of the bone and actual (objective) recovery. The fact that
non-union following conservative treatment (plaster cast) is possible (irrespective of how likely this is) informs
a subjective judgement that the relative risks/complications of surgery are consequently less important.
In addition, the fact that, in Watson’s118 work, the removal of the plaster cast represents the ‘start of
recovery’ also suggests a confusion between the removal of a cast with a more abstract sense of personal
recovery. This interpretation suggests that participants perceive an initial remedial phase (either in surgery
or in a cast) as preceding a phase of more active recovery, in which normal function is regained. The fact
that this remedial phase takes longer in a plaster cast means that returning to normal115,120 is consequently
perceived as taking longer to achieve. The fact that this overlooks the clinical reality would seem less
important if we accept that understanding treatment is, in part at least, a subjective assessment.
As with functional limitations, it is pertinent to reflect that individual assessment of treatment may also
be influenced by contextual factors that demand a speedier return to normality. This might help us to
understand why the student who was able to return to their parental home (P1023) found surgery to be
less appealing than the self-employed caterer (S1345). Again, we should reflect that our data have moved
us beyond those simple dichotomies (male/female, younger/older) to recognise that the experience of,
and preference for, a particular treatment will be shaped by a complex set of personal circumstances.
Concerns about clarity in treatment118 were important to interviewees. A dislike about not knowing
and about uncertainty118,119 may also help us to understand why some interviewees found plaster cast
treatment challenging. Surgery may offer no more certain outcomes, but the fact that this outcome might
be known more quickly better satisfies our impatience and (for some at least) lessens the likelihood that
impetuous behaviour may lead to further injury.
One final set of circumstances should be highlighted. Owing to participant dropout, our data are skewed
towards interviews undertaken at 6 weeks. At this point, the worst aspects of cast treatment and the best
attributes of surgery might be seen – on one side, participants might be bored by ongoing immobility or
frustrated by a dirty plaster cast; on the other, they might be surprised by their mobility and pleased at
how quickly normality has been regained. While we might expect these trends to even out over the longer
term, it is unfortunate that, among those interviewed at 52 weeks, 5 of the 10 treated in a plaster cast
demonstrated some form of ongoing concern.
Irrespective of this, it is evident that assessment of treatment (and consequent preference) is shaped by
an individual’s own sense of recovery and that this is, in turn, informed by their personal circumstances.
The fact that cast removal and a return to more normal functioning are perceived as significant thresholds
perhaps helps us to understand the appeal of surgery to those interviewed here.
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Recruitment and retention in surgical clinical trials
The challenge of recruiting to a surgical trial47 is demonstrated here in an almost contradictory fashion –
surgery both attracted and discouraged participation. Among those interviewed, the appeal of surgery was
often commented on as a motivating factor; however, for those who declined to participate in the trial,
surgery was considered a reason not to take part. This, of course, points to the challenge of patient
equipoise46 and might suggest that the SWIFFT population favours those eager for surgery. Other elements
of the SWIFFT data will address this issue more directly.
This also places pressure on clinical equipoise46 and reinforces the importance of how a trial is introduced
to a potential participant. The fact that some of those who declined to take part in SWIFFT subsequently
(when given more information) suggested that they might have changed their mind demonstrates the
complexity of getting this right.
The challenge of retaining young male participants134,135 is demonstrated here, with the reduction in this
population exceeding that for other demographics. Among younger females, older males and older
females, approximately 50% declined or were unavailable for interview at 52 weeks; for younger males,
this proportion increased to 70%. We have commented on the challenge of this elsewhere,132 but it is
worth reiterating that comments about a positive experience, continuity of contact and accessibility of
research nurses suggest the softer-type strategies and the ‘valuing of a study’ that we have previously
described.132
Closing comments and recommendations
The insight generated here points to the importance of a patient’s subjective experience of scaphoid
fracture and treatment and highlights the pertinence of their own sense of recovery in this. This has a
number of implications for clinical practice:
l It suggests that clinical consultations might include a more detailed consideration of a patient’s
circumstances. We have argued here that a patient’s experience is shaped not simply by age, gender
and occupation, but by a range of specific personal, familial and economic circumstances that influence
how immobilisation is experienced.
l It suggests that tailored information about a patient’s fracture and recovery might be beneficial. Here
we have argued that a participant’s sense of recovery and treatment preference were often based on
an incomplete (and possibly inaccurate) understanding of their injury.
l Finally, it suggests that earlier removal of a cast, supported by the use of alternative forms of immobilisation,
might facilitate a stronger sense of recovery for patients. We have argued that functional limitation was a
common complaint and that cast removal was perceived to be an important threshold in this.
This study has also offered insight into the delivery of the clinical trial, specifically highlighting issues of patient
and clinician equipoise. For future trials in which medical and surgical treatments are being compared,
the following recommendations could be taken into account:
l Those who recruit participants should have knowledge of all of the treatments being investigated.
This may mean that research nurses are drawn from pertinent specialties and/or that participants have
access to clinicians who have experience of treatments. This will lessen the potential for stereotypical
comparisons (conservative/progressive, simple/complex, quicker/slower) and support a more informed
commentary on treatment options.
l All information provided should demonstrate equipoise, both in fact and in impression. It is evident here
that some participants understood surgery to be a quicker solution and that this impression shaped
how they experienced their recovery.
l When there are issues with retention (such as with a young, male population), there is value in building
in retention strategies from the outset. In this study, the introduction of an iPad lottery132 might have
had a greater effect had it been established sooner.
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The insight generated here points to a number of uncertainties, which might benefit from further
investigation:
l Further qualitative research with young, male patients could respond to the high dropout rate in this
group seen in this trial. Exploring if those in this group have their own distinctive sense of recovery or
display certain commonalities in treatment experience and expectation would provide insight for
shaping clinical consultations. It may also help to reduce reinjury associated with impulsive or impatient
behaviour that some predict.
l Exploring the reasons for late clinical presentation of a scaphoid fracture would support awareness
raising of this injury and would complement prior work that has demonstrated gendered patterns in
health care-seeking behaviour.147 Such research might challenge those initial assessments that this is an
inconsequential injury and might also offer insight into whether or not late presentation is significant in
expectations for recovery and treatment experience.
l Research that considers the provision of information about the treatment of a scaphoid fracture might
similarly inform clinical consultations and inform a patient’s sense of recovery. Research in this area
might could follow two routes: first, the development of the content of the information and
mechanisms for delivery and, second, testing whether or not such information improves the experience
of, and satisfaction with, treatment.
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Chapter 6 Discussion and conclusion
Outcomes
This report is based on the assessment of primary and secondary outcomes at 52 weeks (the primary time
point) after 439 participants with a clear bicortical scaphoid waist fracture were randomised to have the
control treatment, namely immobilisation in a plaster cast and early identification of non-union followed
by urgent surgical fixation (n = 220), or to have early surgical fixation using CE-marked headless screws
(n = 219).
Primary outcome
Patient-Rated Wrist Evaluation at 52 weeks
The main finding of this pragmatic trial is that there is no statistically significant difference in pain and
function assessed by the PRWE at 52 weeks between participants randomised to receive initial cast
treatment and those randomised to immediate fixation of clear and bicortical fractures of the scaphoid
with 2 mm or less displacement. The adjusted mean difference in the total PRWE score was –2.1 in favour
of those in the surgical fixation group (95% CI –5.8 to 1.6; p = 0.27). This difference is unlikely to be
considered important by patients, as the CIs of the adjusted mean difference exclude the clinically relevant
difference of 6 points in PRWE scores.
In the early period at 6 and 12 weeks, the difference, which favours surgery, is statistically significant and,
although the mean difference is below the clinically relevant difference of 6 points, the lower CI is below
–6 points in some analyses (indicating the possibility that the true treatment effect might be an increase of
6 points on the PRWE in the surgery group). Therefore, these differences are statistically significant but of
borderline clinical importance. Importantly, 47% and 6% of participants in the surgery group, respectively,
were still in plaster cast or a splint at 6 and 12 weeks post randomisation. This compares with 85% and
21% of patients still in plaster cast in the non-surgical group at these time points. Therefore, participants
in the plaster cast group were more likely to still be in a cast and have consequential functional limitations.
This is corroborated when looking at the pain and function components of the PRWE: there is no difference
between groups in pain but there is a difference in function at these early time points. After 12 weeks,
there is no statistically significant difference between the groups.
Sensitivity analyses of the Patient-Rated Wrist Evaluation
The sensitivity analyses using multiple imputation, checking for an influence of the recruiting site, investigating
those scores that were obtained within the time-point windows, adjusting for smoking status and displacement
of the fracture, and the CACE analysis all broadly support the primary analysis. Subgroup analyses of baseline
treatment preference, and displacement, also support the results of the primary analysis.
Secondary outcomes of bone union, grip strength and SF-12 support the primary analysis findings.
Immobilisation of the broken scaphoid in different types of casts has been compared with immediate fixation
using a headless screw in at least eight reported trials18,23–28,75 and one cohort study.148 These studies (Table 44)
used different methods of assessing function and disability [three used the Disabilities of the Arm, Shoulder
and Hand questionnaire (DASH), one used the Patient Evaluation Measure (PEM) and another used PRWE; the
other four studies used a variety of assessments including their own questionnaire, a satisfaction questionnaire
and the modified Green and O’Brien score] and at different time points (4–144 months). The studies reported
are small, with different time points, and some reviews29 and meta-analyses have also included case
series.24,44,149,150 The data from these studies have been extracted systematically and meta-analysed on
numerous occasions.29–34,36,37
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TABLE 44 Randomised trials of treatments for fracture of the scaphoid bone
Author Year
Participants, n
Follow-up,
months
Patient-reported outcome measure
used
Non-union, n
Conclusion summarised from textN Surgery
Plaster
cast Surgery
Plaster
cast
Saedén27 2001 62 32 30 144 Own questionnaire, no difference 1 0 Surgery allows early return of function and is an
alternative to conservative treatment
Bond25 2001 25 11 14 25 Satisfaction questionnaire, no difference 0 0 Surgery for undisplaced fractures resulted in faster
union and return to military duty than plaster cast
Adolfsson23 2001 53 25 28 4 None 1 0 Surgery resulted in better movement at 16 weeks
but similar grip strength. Early surgery allows early
mobilisation without adverse effects on fracture
healing
Dias3 2005 88 44 44 12 PEM, no difference; at 8 weeks
surgery better
0 2 Plaster cast treatment, carefully assessing fracture
healing with plain radiographs and CT scans after
6–8 weeks and recommending surgery at that time
if non-union is confirmed, achieved fracture union in
over 95%
Dias75 2008 88 44 44 93 PEM, no difference; at 8 weeks
surgery better
0 2 No medium-term difference in function or
radiological outcome between surgery and
plaster cast
Arora24 2007 47 23 24 6 DASH, surgery better 1 0 Surgery for non-displaced scaphoid fractures had
faster union and quicker return to work. Although
surgery is more expensive, the total cost was
not higher
Vinnars28 2008 83 43 42 120 PRWE, no difference 0 0 No long-term benefit of surgery, compared with
plaster cast, for acute non-displaced or minimally
displaced fractures. The long-term risks of surgery
should be considered
McQueen18 2008 60 30 30 12 Green and O’Brien score, no difference;
surgery better before 1 year
1 4 Surgery was associated with faster return of
function, sport and work than plaster cast. Surgery
had a low complication rate. All active patients
should be offered surgery
Clementson26 2015 45 21 24 72 DASH, no difference; at 6 and
10 weeks surgery better
0 0 Non-displaced and minimally displaced scaphoid waist
fractures are best treated in a plaster cast. Surgery may
provide improved function in the short term, but there
is an increased risk of arthritis in the long term
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One study reported PRWE score at 10 years in 75 of 83 patients randomised to scaphoid cast treatment or
surgical fixation with a Herbert headless screw and the mean score was 6 in each group.28 No data were
available for the 52-week time point. Two studies reported a patient-reported outcome measure score at
52 weeks. One3 used the PEM score, which ranges from 0 to 100, with 100 being worse, and reported
an unadjusted mean difference of –1.3 favouring surgery, although the difference was not statistically
significant. The second18 reported on 60 patients randomised to either a below-elbow cast leaving the
thumb free or an Acutrak headless screw; authors used the Mayo modification of the Green and O’Brien
score151 to assess function (pain and function) and impairment (range of wrist movement and grip strength)
and noted that this score was 13% better (higher) in those having surgery, but this difference was not
statistically significant. This finding is not reflected in the present study.
As the non-union rate for displaced fractures is 14%, compared with 10% for transverse undisplaced
fractures,8,10,39 randomisation was stratified by the presence or not of displacement (< 1 mm or 1–2 mm
inclusive) of a scaphoid fracture as seen on radiographs10,39 and used by the treating clinician to determine
eligibility. The three raters identified displacement of the fracture > 2 mm in 27 (6.2%) participants.
When these patients were excluded, the difference in PRWE score between treatment groups at 52 weeks
was –2.1 favouring surgery. The difference was not significant (p = 0.07) and was below the clinically
meaningful threshold.
Complications
Treating clinicians at the recruiting sites noted that 31 (14.2%) participants randomised to the surgery
group experienced a complication, while the rate was much lower in the plaster cast group (n = 3, 1.4%).
The review of radiographs identified penetration of joints by the screw in 94 participants in the surgery
group (42.9%) compared with 10 (4.6%) participants in the plaster cast group. In half of these the screw
protruded 1–2 mm into the joint and in a quarter there was significant protrusion of over 2 mm. The
concern about such screw protrusion is that articular cartilage will be damaged irreversibly, leading to early
degenerative arthritis in the involved joint.
Cast complications, in contrast, were minor, had no lasting consequence and were reported in six (2.7%)
participants allocated to the surgery fixation group, probably reflecting the frequent changes of cast to
inspect the wound and the initial application of the cast by the surgeon. Cast problems (soft, tight or
broken cast, skin soreness) were reported for 45 (20.5%) participants in the plaster cast group; it is likely
that the cast was applied by experienced fracture clinic staff and not changed as frequently.
Malunion of the scaphoid was assessed using the height to length ratio on radiographs and on the
baseline and 52-week CT scans. ten Berg et al.85 noted a ratio of 0.69 as the upper 95% CI of a normal
population, so we used this to define malunion, rather than the ratio of 0.6 we had proposed in our
protocol. At 52 weeks, using the 0.7 threshold (i.e. the ratio of the scaphoid height to length), malunion
increased between baseline and 52 weeks on CT scans and the rate of malunion was similar (3.2%) in
both treatment groups. The rate of malunion based on radiographs was higher and, again, tended to
increase over time and to be higher in the surgery group.
Reoperations
Eight participants in the surgery group had 11 reoperations subsequent to their initial fixation; in six of
these participants, the reoperations were for implant-related problems and, for the other two participants,
the reoperations were for non-union, with one requiring scaphoid excision and a four-corner fusion.
One participant required reoperation for persistent non-union following fixation of non-union after initial
cast fixation. The overall rate of reoperation for all causes (assuming that none of those who were not
followed up required reoperation) was 8 of 219 (3.7%) after early surgery and 1 of 220 (0.5%) after initial
cast treatment and surgery to fix non-union.
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Secondary outcomes
Union
The aim of immobilising a broken scaphoid is to get it to unite. Failure of union, if left untreated, mostly
results in wrist arthritis,12,99,105 as there is abnormal loading between the distal scaphoid and the radius.152
Therefore, an important outcome after treatment is to establish the state of fracture union on imaging. In
clinical practice, union is commonly assessed on radiographs of the scaphoid in different projections. Bony
continuity on all radiographic views is interpreted as trabeculae crossing the fracture line, and sometimes
there may be sclerosis at the fracture line. Both of these features suggest union, especially if there are no
adverse features, namely (1) a gap at the fracture line on any view, (2) progressive displacement of the
fracture or (3) if implants are used, lucency around the implant, which may suggest failure of union.59 The
usual advice is that radiological union is considered to have occurred only when ‘bridging trabeculae’ are
seen across the whole cross-section of the scaphoid on radiographs or a CT scan,153 with the latter being
more reliable.
The bone may unite partially, with a gap seen across part of the fracture site and bony continuity identified
across the remainder of the fracture. This can be identified on the scaphoid radiographic views but can
also be quantified on a CT scan.61 Partial union has been reported in around 42% of scaphoid fractures
and usually consolidates in time, but the wrist may need protection for a while.61
Non-union is the absence of radiographic signs of healing with a clear gap on radiographs on any view
and confirmed on a CT scan.153–155 A high-quality CT scan (fine cut, bone window) helps establish that the
fracture has not united. An un-united scaphoid fracture will eventually lead to collapse of the carpus and
degenerative OA termed as SNAC.99
Clinically, there would be a concern if union was < 20% at 52 weeks and this would suggest the need for
treatment, namely a bone graft to stabilise the fracture, although this partial union threshold has not been
formally investigated. On radiographs, this extent of union is likely to be interpreted as a ‘non-union’ by
the treating clinician.
The rate of non-union recorded in this study is very low for both groups. In the 188 participants who had
screw fixation in the surgery group, there was one case of non-union. In the 198 participants in the plaster
cast group who fully complied with the control pathway (treated in a cast and surgery to fix a non-union),
there was also just one case of non-union. This study has not identified evidence that the rate of non-union
and slight union is statistically significantly different between surgical fixation and cast immobilisation in an
ITT logistic regression model that adjusted for age, fracture displacement and hand dominance (OR 0.40,
95% CI 0.12 to 1.33; p = 0.13). We observed this state in four participants (three with slight union and one
with non-union) in the surgery group and nine participants (five with slight union and four with non-union)
treated in a plaster cast. Three meta-analyses30,36,37 reported on union rates; two36,37 found no difference
and one30 reported a significant difference in favour of surgery. These meta-analyses reviewed four to seven
small trials comparing surgical fixation with plaster cast treatment for scaphoid fractures.
The control treatment pathway in SWIFFT was initial cast treatment with early identification of failure of
union and early fixation of un-united fractures. Of the 18 participants who had surgery for early identified
non-union, 15 had the surgery early (i.e. within 6 months from randomisation) and a further three were
treated after 6 months. The reasons for this have been described in Chapter 3.
The union rate after early fixation of less than 20% after initial cast immobilisation is high. Four papers3,148,149,156
report prospectively collected data and present results of early identification of non-union after cast treatment
and early fixation of these. One is a RCT3 and the other three are prospective comparative case series. These
papers reported on a total of 166 scaphoid fractures treated in a below-elbow cast. Nineteen non-unions
were identified when the cast was discontinued. Seventeen of these had early surgery and two declined the
offer of surgery and had a persisting non-union at 52 weeks. Of the 17 that were fixed, all united (100%).
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Two retrospective studies157,158 also reported on 210 acute scaphoid fractures treated in a cast with 12
non-unions, 11 of which were fixed early and all of which united (100%). One 80-year-old man was not
offered surgery. There is only one retrospective case series159 that reported on 308 acute fractures, of which 27
did not unite. Of these, 24 had fixation and 21 united; of the three that did not join (87.5% union), two were
reoperated and one healed. Overall, the reported rate of union after early identification of failure to unite and
fixation is very high. Our study confirms that it is unlikely that the risk of non-union following surgery for non-
union after initial cast immobilisation is greater than if surgery is carried out in the first 14 days after the injury.
In SWIFFT, 18 patients in the plaster cast group were also offered and had surgery, as the clinicians treating
them were concerned about the state of union after cast treatment. Only one had a persistent non-union at
52 weeks. In these patients, the total PRWE score was worse [mean 29.1 (SD 32.4) points] than in those who
did not need surgery [mean 12.8 (SD 17.4) points]. This may reflect the delay in fixation of the non-union.
The numbers of scaphoid fractures we would need to fix to avoid one additional non-union or slight union
is 44. All of these patients would be exposed to the risks of surgery.
Range of wrist movement
One year after the fracture, there is no difference between groups for range of wrist movement. This
confirms that the treatment method does not have a measurable effect on the range of wrist movement
at 52 weeks. At 6 weeks, when participants treated in a plaster cast are likely to still be immobilised, the
range is worse than those left out of a cast after surgery and screw fixation. Wrist movement returns to
normal and most studies that compared cast with surgery were unable to establish a difference between
groups at time points later than 52 weeks.
One study36 found that there was no difference between groups after 6 months and others34,160 found no
difference between groups at any time point. Another meta-analysis30 highlighted the observation that
several trials24,27,28 had noted a better range of wrist movement after treatment in a plaster cast.
Grip strength
The strength of the hand, assessed using a Jamar® dynamometer (The Jamar Company, Inc., Duluth, MN,
USA), was similar between groups. Grip strength, measured in kilograms, in those treated in a cast was
slightly worse at 6 weeks (by around 4 kg) and 12 weeks after injury (by around 2.6 kg) but better at
52 weeks (cast 37.4 kg (SD 14.2) than in those in the surgery group [36.2 kg (SD 12.7 kg)]. The cast is
usually removed between 6 and 12 weeks, so this was an expected difference at these time points.
Five meta-analyses30,31,34,36,160 have commented on the recovery of grip strength, reporting on various
combinations of several small trials.3,18,23–25,27,28 One of these36 found that patients who underwent surgery
had better grip strength than those initially given a cast up to a year after surgery. The same study36
also reported that the difference between groups was greatest at 8 weeks, combining the results of two
studies.3,18 The authors of another study30 felt that they were unable to conduct a meta-analysis because of
the different ways of recording grip strength. This study collated the results from seven studies3,18,23–25,27,28
in a table. The authors noted a consistent trend in that those having early surgery had better strength, but
recommended caution in interpretation. Another meta-analysis found no difference between groups.160
Return to work and unpaid activities
This study, in contrast with most previous trials, found little difference in days of lost employment. On
average, the time that those treated in a cast were off work was 21.7 days, while those who had their
broken scaphoid fixed were off work for 17.3 days. Of note was that the time off work was the same in
the first 6 weeks and was only 12 days.
Five meta-analyses29,31,34,36,37 reviewed RCTs and reported on the time to return to work. One study29
included a prospective comparative study,149 which was not randomised. All five, extracting data from
different combinations of studies, noted that patients who had their scaphoid fracture fixed returned to
work quicker (range 1.6–7 weeks earlier) than those treated in a cast.
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This study finds little difference in time off work, especially in the early period, and this may reflect the
common practice of immobilising the operated fracture in a plaster cast or splint. One reason may be that
around 77.7% were treated initially in a cast that did not include the thumb and therefore permitted early
resumption of hand function. Another may be that patients may have felt more secure working in a cast.
Finally, patients may have had direct reassurance regarding return to work in a cast and were encouraged
to do so.
The overall days of lost unpaid activity was also similar in the two groups. There was a larger impact on
lost unpaid activity in the surgery group for the 6 weeks after randomisation. For all time points after this,
patients allocated to the surgical arm reported a smaller impact on unpaid activities than those in the
plaster cast group, which is consistent with the findings for days of lost employment.
Short Form questionnaire 12-items
The SF-12 was completed to measure the potential broader consequences of a scaphoid fracture on the
participants’ physical and mental health, along with EQ-5D-3L. The analyses of the MCS scores reassuringly
showed that participants’ mental health improved in both treatment groups at each time point and overall.
The between-group differences in the MCS were not statistically different at any time point, with an
adjusted mean difference at 52 weeks of –1.2 points (95% CI –3.3 to 0.8 points) in favour of the plaster
cast group. A statistically significant difference in the PCS score favouring the surgery group was seen at
12 and 52 weeks, but not at 6 or 26 weeks or overall (p = 0.08). The adjusted mean difference at 52 weeks
was 1.6 points (95% CI 0.2 to 3.1 points) in favour of the surgery group. These findings corroborate the
overall PRWE results and the PRWE function subscale, but appear inconsistent across time points and the
differences are below that considered clinically meaningful (range 3.3–12.6 points) in other musculoskeletal
(spine and knee) disorders.161–164
Trial validity and minimising bias
Various measures were taken to ensure trial validity and minimise bias or to explore the potential for bias,
some of which are discussed here.
The secure randomisation method helped to ensure that there was comparability in the characteristics
of the two treatment groups, with the exception of ethnicity, education and smoking status, by chance.
The imbalance in the number of smokers, with participants in the plaster cast group less likely to be smokers,
was examined in a post hoc sensitivity analysis. Adjusting for smoking status (yes/no) found similar results
to the primary analysis, except at 12 weeks, when a clinically relevant 6-point improvement in the PRWE
score in favour of the surgery group could not be ruled out. In addition, at baseline, it was important that
the series of five radiographic views were performed to ensure the correct diagnosis of the fracture for
inclusion of a patient in the trial. Except for one view (45° semisupine), nearly all randomised patients
were enrolled based on the series of radiographs taken at baseline. The three raters agreed that 6% of
randomised participants had displacement of the fracture at baseline that was > 2 mm, which was a reason
to exclude a patient. The raters agreed that only one participant did not have a fracture (in the surgery
group). Sensitivity analyses of the primary outcome model that excluded these participants supported the
findings of the primary analysis. A further sensitivity analysis also provided reassurance that the perceived
threat to validity of low recruitment at sites did not affect the results on the PRWE. In addition, the subgroup
analyses found participant treatment preferences at baseline; if there was a preference, it was in favour of
surgery, but this did not affect the results of the PRWE at 52 weeks. However, participants with a preference
for surgery or in treatment equipoise were dominant (n = 403, 91.8%), and those preferring cast treatment
(n = 32, 7.3%) were under-represented. This helps, in part, to mitigate concerns that a lack of blinding can
introduce bias in participant self-reported completion of the primary outcome.
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Although it was not possible to blind assessing clinicians to the treatment allocations, this multicentre
study with its pragmatic design had multiple clinicians assessing objective outcomes. The statisticians and
health economists were presented with data only after collection and cleaning was completed and the
statistician undertaking the analyses was different from the one monitoring the study data collection
processes. The DMC and the TSC also provided independent advice and support throughout the conduct
of this study.
To help ensure a good standard of care, surgeons were advised to use techniques with which they were
familiar, which also helped to avoid learning-curve problems. The majority of operations were conducted
by consultant surgeons, who were also present for the majority of operations when the main operating
surgeon was a specialist trainee. Predominantly, a percutaneous approach with a palmar incision was
performed, which is consistent with current practice. No intraoperative complications were reported. All
participants were provided with standardised, written physiotherapy advice detailing the exercises they
needed to perform. At 12 weeks, the majority of participants in both treatment groups self-reported that
the written advice was quite or very useful and that they had performed home exercises.
The high rate of return of participant questionnaires at the primary end point of the trial reflects the
success of the extensive measures taken to achieve the required retention rates. Critically, this included
continuous engagement and advice from three involved groups (patients, research nurses and clinicians),
as explained elsewhere.132 The participant questionnaire return rates were lower in the plaster cast
group than in the surgery group, except at 6 weeks, when they were similar between the two groups.
The baseline characteristics of participants who completed a valid primary outcome at 52 weeks were
comparable between the two groups, except for the continued difference in ethnicity, education and
smoking status. Any response bias that could be introduced from these imbalances in the return rates
and characteristics of responders was minimised by using a mixed-effect, repeated-measures model that
included intermittent responders. Consequently, only 7% of participants were not included in the primary
analysis model, with an almost identical number of participants included for each treatment group. The
use of this statistical model had the benefit of increasing the statistical power of the analyses, compared
with the use of a two-sample test for the sample size calculation. Multiple imputation analyses to explore
the effect of these minimal missing data helped to ensure that this did not have an effect on the results
of the PRWE. There were, however, missing data on imaging for nearly 30% of participants at 52 weeks.
There were quite marked differences in the PRWE score in those participants who did or did not attend
imaging between groups. Participants in the surgery group who attended imaging tended to have better
scores than those who attended in the plaster group. This may have contributed to lower reporting of
non-union in the surgery group. Furthermore, the lower than expected non-union rate reported for both
groups could be attributed to the participation of largely specialist hand units in this study and a more
rigorous assessment of non-union than in previous studies.3,18,23–28 The other finding on imaging was that
43% of participants in the surgery group had penetration of the screw into the adjacent joint; this was
1 mm or greater on the 52-week CT scan in 68 participants. It was considered likely that this would have
an adverse effect on the joint cartilage and this therefore probably explains the worse PRWE score in
this participant group. This emphasises the need for imaging during surgery. In our study, imaging was
reviewed by three independent raters, two senior radiologists and one surgeon not involved in the clinical
care processes, with robust methods of identification and resolution of conflicts. The senior clinicians
reviewing imaging could identify participants whose fracture was stabilised with a screw, but did not
know the allocation after randomisation. Having three reviewers independently reviewing the imaging
and performing measurements also helped to mitigate any bias in measurements.
Finally, a potential threat to study validity is non-compliance. This is when the treatment was not delivered
as planned, which could have potentially diluted the treatment effect observed in the ITT primary analysis.
Thirty-one patients (14%) in the surgery group did not have surgery and six patients (3%) in the plaster
cast group immediately switched to surgery following randomisation. There were various reasons why
participants did not get their allocated surgery. These included a fracture not being seen on the baseline
CT scan, the surgeon deciding that the participant had a different type of fracture on further review of
DOI: 10.3310/hta24520 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 52
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dias et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
imaging/further imaging at baseline, and the participant changing their mind. ITT analysis was used throughout,
which includes all participants in the group to which they were randomly assigned. This preserves the original
random allocation and reflects the pragmatic nature of administering treatment in clinical practice. CACE
analysis was also conducted to explore the potential dilution of the treatment effect of the six participants
(3%) in the plaster cast group who crossed over to surgery and the 31 participants (14%) in the surgery
group who were managed conservatively. The CACE analysis reproduced a difference in favour of surgery
among participants who complied with their treatment that was larger than the ITT treatment effect on
the total PRWE score at 52 weeks. Although it remained a non-statistically significant result and was not a
clinically important treatment effect, the upper confidence limit now included the clinically important effect.
In terms of further non-compliance in the control pathway, of the 17 participants in the plaster cast group
who had surgery for early identified non-union, 14 had the surgery within 6 months from randomisation
and three were treated after 6 months. Three of the four participants in the plaster cast group who had
non-union or slight union at 52 weeks were also not offered surgery. Therefore, 6 of 21 participants in the
plaster cast group did not have the expected immediate surgical fixation when there was non-union.
Applicability of results
Characteristics of the trial population
The review of the baseline characteristics of the trial participants and the fact that the three raters agreed,
based on the baseline imaging, that only one participant did not actually have a fracture at enrolment
helped to confirm the inclusion of appropriate participants in SWIFFT.
The application of the eligibility criteria meant that a quarter of the population of patients considered for
the trial were excluded for genuine clinical reasons, predominantly because the inclusion of these patients
meant that the surgeon would not be in equipoise about how to treat a patient. A further third of the
population screened did not consent to take part. Therefore, just over 40% of the patients screened for
participation were randomised. A comparison of the four key baseline characteristics revealed that eligible
patients tended to be a few years younger than those excluded and were marginally more likely to be
male and to have a displaced fracture. The characteristics of consenting and non-consenting patients were
comparable, except that consenting patients were more likely to have a displaced fracture. As previously
discussed, the statistical method used to analyse the primary outcome meant that only 7% of consenting
participants were not included in the primary analysis. Multiple imputation analysis to explore the effect of
these minimal missing data confirmed that this did not bias the treatment effect in the PRWE.
Applicability of the trial findings
The pragmatic design of SWIFFT helped to ensure that there was immediate application to the NHS.
The criteria used to enrol participants in the trial were minimised as much as possible. There were also no
stringent criteria regarding which surgeons could operate on participants. Those surgeons who did operate,
or were present during the operation, were mostly consultants, as would be expected. The provision of
standardised, written physiotherapy advice detailing the exercises that participants needed to perform may
not be entirely reflective of NHS practice. It did, however, help to ensure that a good standard of practice
was applied consistently across both groups, as was confirmed when participants self-reported this at
12 weeks. The follow-up clinics that were organised at 6 and 12 weeks were also consistent with routine
clinical practice. The follow-up clinic at 52 weeks, which was the primary end point, was to ensure to the
extent feasible that participants in both treatment groups had the time to complete the treatment pathway
being delivered. The findings are also applicable to participants with both undisplaced and minimally
displaced fractures, with the subgroup analysis showing that participants with a displaced fracture did not
statistically significantly benefit more from surgery than those with an undisplaced fracture.
Most of the previous small trials addressing this research question involved a single centre. In contrast,
SWIFFT recruited participants from 30 NHS hospitals in England and one in Wales, which reflected a variety
of geographical locations, improving the generalisability of the results. There were also 95 surgeons who
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operated on participants. While the large number of hospitals and surgeons involved improves generalisability,
there could be concerns about how the limited number of participants operated on by a single surgeon could
influence patient outcome. Including the adjustment of hospital site in the primary model produced similar
findings. Importantly, unlike previous RCTs, a thorough and detailed economic evaluation was undertaken to
assess the relative cost-effectiveness of the two treatment options within the trial follow-up period and the
lifetime implications of treatment decisions made. The primary analysis is that of the NHS and will therefore
have direct applicability to informing future policy and commissioning decisions.
Cost-effectiveness of early surgery compared with initial cast treatment
Incremental cost-effectiveness ratio
The within-study analysis, an assessment of the costs associated with treatment and QoL of patients in the
first year post randomisation, found that, up to 52 weeks, early fixation was not cost-effective, with an
ICER of £67,473 to £135,085 per QALY. This range of values was based on the approach taken to the trial
population, missing data and adjustment for baseline QoL. The most reasonable scenario is considered to
be £81,962 per QALY, a scenario of an ITT population with multiple imputation for missing values and
adjustment for baseline QoL.
Long-term model
Initial use of cast with immediate fixation of confirmed non-union was associated with a 61% probability
of being cost-effective. The extrapolated model is driven by the relatively and absolutely small numbers
of non-unions, alongside the uncertain long-term estimates.
This result was influenced by the relatively low cost of initial cast immobilisation compared with surgery
and the finding that, if cast immobilisation was unsuccessful, surgical fixation was offered, accepted by
almost all and then highly likely to result in uniting.
The long-term Markov model was based on data from small retrospective case series and was driven
mainly by the very small difference in union rate at 52 weeks between the two groups, highlighting the
considerable uncertainty surrounding the model. The uncertainty in this model will be addressed after the
medium-term 5-year review, as this will help improve our assumptions and hence the confidence in such
a model.
Health economic summary
The key finding is that, if initial cast immobilisation is unsuccessful but surgical intervention is offered soon
after confirming non-union, this is highly likely to be the most cost-effective treatment, as it avoids the
high upfront cost of fixing all broken scaphoids but still avoids a long-term non-union and the risks of both
high surgical rate and poor QoL for patients who develop SNAC.
Health economics: strengths and limitations
The economic evaluation of the treatment of these types of scaphoid fractures, described in Chapter 4,
was associated with a number of strengths and weaknesses.
It was the first evaluation of this area not only to provide an analysis of the cost and QoL implications of
the treatments available using evidence from a RCT, but also to combine these with a long-term model,
using evidence from the literature to consider the lifetime implications of treatment decisions made. The
‘within-trial’ model provided a methodologically rigorous exploration of the cost and QoL of patients in
both arms of SWIFFT, including extensive missing data estimation alongside a series of regression analyses
seeking to explore the role of confounding factors. The mathematical model presented extends the findings
of SWIFFT by not only considering the lifetime implications of the two treatments, but also incorporating
treatment scenarios of cast immobilisation only and no treatment, not considered in the trial. This allows
for a complete evaluation of all possible treatment options available and the long-term implications of
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each. This structure, alongside the PSA and extensive scenario analyses, allowed a detailed exploration
and presentation of the significant role of uncertainty in this decision problem, owing to both the small
incremental differences between the outcomes of the two arms of the trial and the limited long-term
evidence available in the literature.
However, as with any such evaluation, there are also weaknesses of the analysis, including those as a
consequence of the available evidence, and these are detailed in Chapter 4. The primary weaknesses relate
to the potential oversimplification of the mathematical model and the limited connection between the trial
data and the long-term model. The insensitivity of the decision tree to the explicit role of the time lag
between the observation of potential non-union after cast immobilisation and the occurrence of surgical
fixation is also a weakness and, while it would not be expected to change the base-case result, it limits our
ability to explore the impact of changes to such a parameter. For example, some time threshold is expected
to exist at which, unless surgery occurs before it, the cast plus surgery arm becomes less cost-effective than
initial surgery for all patients. Similarly, the simplistic approach to OA, AEs related to non-OA, and SNAC in
the long-term model, while necessitated by the available evidence, risks incorrectly specifying the risks and
benefits of each treatment arm. Finally, the use of the rate of non-union as the link between the short- and
long-term models and the use of literature-based estimates of adverse event profiles, rather than estimates
from the trial, make the result of the analysis highly sensitive to the rate of non-union estimates from the
trial. This results in the model being highly sensitive to factors such as the assumption made about the three
patients who had non-union at 52 weeks but were yet to have surgery, and the definition of slight union as
indicative of non-union or not. However, given the available evidence and the level of clinical understanding,
the models should represent the most robust base-case scenario.
The Markov model was limited by the assumptions made and the data available. The data were from very
small case series that were historic. We have addressed the uncertainty using many scenarios but feel that
the 5-year study of SWIFFT participants will help resolve much of the uncertainty in the Markov model.
Nested qualitative study: patients’ treatment preferences and their
experience of treatment
The nested qualitative study explored the impact of a scaphoid fracture and patients’ experience of
treatment and treatment preference. The study offers detailed, contextualised insight, with each interviewee
offering a distinct and personalised narrative. These data complement the clinical and other data generated
elsewhere in SWIFFT and provide an additional perspective to support the implementation of trial findings.
The qualitative data generated here provide a valuable, subjective viewpoint that will aid clinicians in
understanding their patients’ experiences and in shaping their discussions about clinical options.
Sense of recovery
The insight generated here highlights that a patient’s understanding of fracture and their sense of recovery
is important in assessing treatment success. It also shows that an individual’s sense of recovery is shaped
by specific personal, familial and economic circumstances; employment, social responsibilities or even
hobbies and leisure pursuits will shape how they feel recovery is progressing. A broader consideration of
a patient’s personal circumstances might shape more productive clinical consultations and might enhance
the management of recovery.
Certainty
The act of plaster cast removal is an important threshold in a patient’s return to normal. Patients did not
appreciate the uncertainty of the duration of immobilisation or the possible need for further treatment,
even though the rate of this was very low.
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Preference
A broadly positive assessment of surgery among those interviewed reflects a more general trend among
those recruited to the study: of the 780 eligible patients, only 12% of those preferring cast treatments
consented to take part, compared with 77% of those preferring surgery and 87% of those with no
preference. Consequently, it is difficult to assess treatment preference based on the comments and
insights offered here.
Disability
One interesting observation was the feeling of some wrist weakness, described by several of the women
interviewed. This was experienced to an extent that some chose to use an external wrist support to help
accommodate this. Some also expressed concern that this impairment could be permanent.
Return to normality while healing
Two elements of cast treatment concerned participants: the duration of immobilisation and the possibility
that some participants could need further treatment (no matter how small the rate of further treatment was).
Many suggestions were made: one participant suggested that clinicians could check the state of healing
halfway through immobilisation to identify failure earlier, although assessment of union is unreliable at
earlier time points, especially on radiographs.62 There was also a sense that patients regarded surgery as
‘doing something’ rather than ‘just waiting’ and regarded it as more active, with many readily assuming
that the risks and failures would not happen to them. A small number of participants understood and
verbalised that, if the fracture was displaced, fixing it would reduce the displacement and make it heal in a
better and reduced position.
The main reflection of this chapter is that, considering that this trial confirms that the mode of initial
treatment does not have a significant impact on fracture union, clinicians should focus more on the impact of
treatment choices on the patient’s day-to-day life and their work. There is a clear need to focus on becoming
‘normal’ again. If external immobilisation is considered, then restoring independence and minimising the
impacts on activities of daily living by using removable splints at an earlier time point in the pathway may help
patients ‘recover’. This may need a careful and planned discussion at the outset when the injury is diagnosed.
Another key point is the discussion about uncertainty in the recovery after both pathways, as in the control
cast and fixing of non-union pathway one reoperation was required up to 52 weeks, while, among those
having early surgery, 11 reoperations were required in eight participants and the surgery pathway had one
significant non-salvageable consequence and a high rate of screw penetration.
Qualitative interviews: strengths and limitations
The qualitative substudy offers detailed, contextualised insight into the experiences of a fracture of the
scaphoid waist, with each interviewee offering a distinct and personalised narrative about their injury
and experience of treatment. These data complement the clinical and other data generated elsewhere
in SWIFFT and provide an additional perspective to support the implementation of trial findings. The
qualitative data generated here provide a valuable, subjective viewpoint that will aid clinicians in
understanding their patients’ experiences and in shaping their discussions about clinical options.
The fact that our sample broadly achieved its purposive aim – approximately half of all interviews were
with males under the age of 30 years – adds pertinence and credibility to the findings. The fact that the
sample is larger than other comparable qualitative investigations of patient experience of hand, wrist or
arm injury also adds credibility to the findings reached. The findings add to the current literature, with a
more explicit focus on how surgical and plaster cast treatments are perceived and experienced and on
those personal contextual factors (domestic, social and economic) that might shape an individual’s
experience of fracture and treatment.
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It is, of course, important to reflect that this substudy explores participants’ subjective experience of fracture
and their subjective understanding of treatment and recovery. It reflects how they think things are or should
be; this does not always, or automatically, translate into how things actually are.
It should also be noted that interviewees are to some extent self-selected – restricted mainly to those who
agreed to take part in the trial – and that, among this group, participants could opt out of the interview
substudy. Generalising is difficult across the different demographics included here (which includes both
students and the retired) and differences in experience (both positive and negative) also make interpretation
and generalisation difficult. It is perhaps, however, the taciturn and monosyllabic responses of some young
men that make interpretation most difficult.
A key limitation that must be acknowledged is the fact that the attrition between the 6- and 52-week
interviews exceeded that which had been predicted (50% rather than 30%) and that this limits the
potential for direct comparison and for building narrative accounts of fracture and recovery. Most often,
participants were not contactable – not responding to approaches (on at least three occasions) via telephone,
SMS messaging or e-mail – although some respondents explicitly indicated that they did not wish to take part
in a second interview. The fact that attrition was most pronounced in the young male participants is pertinent
and this led to new male interviewees (n = 4) being added at the 52-week interview point. It should also
be noted that older females are over-represented in the final interview sample – fewer younger females
consented to the interview substudy and consequently additional older females were recruited to achieve
the target for female interviewees (n = 11). The fact that these female participants were least likely to drop
out means that older females are the second largest group interviewed at 52 weeks (n = 5/19).
Recommendations for future research
Evidence from eight published meta-analyses29–32,34–37 to evaluate surgical fixation compared with conservative
treatments for acute undisplaced or minimally displaced scaphoid fractures is based on 416 patients. SWIFFT
is therefore the largest study in the world and has doubled the existing evidence base and should be used to
update the meta-analyses to further address the uncertainty and to confirm if no further trials are necessary.
The 5-year follow-up of SWIFFT participants will be important to investigate the outcome of the partial
union of scaphoid fractures and whether or not these unite over time, as well as to explore the
consequences of the progress of degenerative arthritis, malunion and screw problems (malposition and
penetration within joints) on participants’ QoL. This long-term follow-up will further inform the areas of
uncertainty in the extrapolated model.
Findings from the qualitative study suggest that, in future trials comparing medical and surgical treatments,
patients should have access to a clinician who can adequately explain the treatments to both ensure
balance in the presentation of information and lessen the potential for stereotypical comparisons of the
treatments that could affect recruitment. Extensive retention strategies should also be included from the
outset for a difficult patient population such as predominantly young males. Finally, research that considers
the nature, form and delivery of information about a scaphoid fracture and its treatment might similarly
inform future clinical consultations and inform a patient’s sense of recovery. This could include providing
the patient with a leaflet to encourage surgical fixation when non-union occurs, explaining that surgery
will help reduce the rate of future arthritis. Furthermore, detailed qualitative, longitudinal research with
younger male patients with a scaphoid fracture would also be useful in exploring their sense of recovery,
which may help to reduce reinjury associated with impulsive or impatient behaviour.
DISCUSSION AND CONCLUSION
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Conclusion
This prospective, pragmatic RCT could not identify, at the primary end point of 52 weeks, a statistically
significant or clinically meaningful difference between the offer of cast treatment with early urgent fixation
of non-unions and having all scaphoid fractures fixed surgically at the outset. The most cost-effective
pathway is definitive cast treatment, with early fixation of only those fractures that do not unite with a
cast. Patient treatment preferences following their injury reflect their desire to have a ‘sense of recovering’
and surgeons should address this at the outset.
SWIFFT provides evidence to suggest that the treatment of all undisplaced and minimally displaced scaphoid
waist fractures should be in a cast, with investigations for non-union taking place at 6 to 12 weeks and all
confirmed non-unions fixed immediately.
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Appendix 1 Participating trusts
l Barts Health NHS Trust
l Bolton NHS Foundation Trust
l Brighton and Sussex University Hospitals NHS Trust
l Cambridge University Hospitals NHS Foundation Trust
l Cardiff and Vale University Health Board
l Chelsea and Westminster Hospital NHS Foundation Trust
l Gloucestershire Hospitals NHS Foundation Trust
l Hampshire Hospitals NHS Foundation Trust
l King’s College Hospital NHS Foundation Trust
l Lancashire Teaching Hospitals NHS Foundation Trust
l Maidstone and Tunbridge Wells NHS Trust
l Medway NHS Foundation Trust
l Newcastle upon Tyne Hospitals NHS Foundation Trust
l North Bristol NHS Trust
l Northumbria Healthcare NHS Foundation Trust
l Nottingham University Hospitals NHS Trust
l Oxford University Hospitals NHS Trust
l North West Anglia NHS Foundation Trust
l Poole Hospital NHS Foundation Trust
l Royal Berkshire NHS Foundation Trust
l Royal Cornwall Hospitals NHS Trust
l Royal United Hospital Bath NHS Trust
l Salford Royal NHS Foundation Trust
l South Tees Hospitals NHS Foundation Trust
l Southport and Ormskirk Hospital NHS Trust
l Taunton and Somerset NHS Foundation Trust
l The Royal Liverpool and Broadgreen University Hospitals NHS Trust
l University Hospital Southampton NHS Foundation Trust
l University Hospitals Birmingham NHS Foundation Trust
l University Hospitals Bristol NHS Foundation Trust
l University Hospitals Coventry and Warwickshire NHS Trust
l University Hospitals of Leicester NHS Trust
l University Hospitals Plymouth NHS Trust
l Worcestershire Acute Hospitals NHS Trust.
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Appendix 2 Table of amendments
TABLE 45 Table of amendments
Type (non-substantial
or substantial) Approval date Documents amended Brief description of amendment
Non-substantial
amendment 1
13 June 2013 Update to trial protocol
(version 1.1, 5 June 2013)
Update to main trial patient
information leaflet (version 1.1,
5 June 2013)
Update to main trial consent
form (version 1.1, 5 June 2013)
Update to linked interview
consent form (version 1.1,
5 June 2013)
Update to main interview
consent form (version 1.1,
5 June 2013)
Update to linked interview
patient information leaflet
(version 1.1, 5 June 2013)
Clarification in the protocol regarding
timing of baseline CT and surgery:
l baseline research CT scan could be
performed post randomisation if
not feasible on the day of consent
l surgery should be performed
within 2 weeks of presentation to
A&E and not within 2 weeks of
their injury as originally stated
Minor changes to patient information
leaflets in response to the TSC patient
representative recommendations.
Consequently, the consent form was
updated to reflect changes in patient
information leaflet
Change to consent status form to
capture time to consent, as stated in
the protocol
Non-substantial
amendment 2
10 July 2013 Hospital poster (version 1.1,
2 July 2013)
Update of the eligibility criteria listed
on the hospital poster to match those
stated in the protocol
Non-substantial
amendment 3
29 August 2013 Update to main trial patient
information leaflet (version 1.2,
16 August 2013)
Update to main trial consent form
(version 1.2, 16 August 2013)
Update to interview consent form
(version 1.2, 16 August 2013)
Correction of Birmingham site details
Addition of new participating sites
Addition of potential radiation risks
from radiographs/CT scans in the main
trial patient information leaflet that
were not previously explained
Non-substantial
amendment 4
9 September 2013 N/A Change in PI at Liverpool site
Non-substantial
amendment 5
8 October 2013 N/A Addition of new participating sites
Substantial
amendment 1
3 December 2013 Update to trial protocol
(version 2.0, 20 October 2013)
Update to main trial patient
information leaflet (version 2.0,
20 October 2013)
Update to main trial consent form
(version 2.0, 20 October 2013)
Update to eligibility criteria in the
protocol:
l ‘Previous injury or disease in same
wrist’ removed as an exclusion
criterion
l ‘of a participating site’ added to
the criterion about excluding
patients who are not residents in
the trauma catchment area
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TABLE 45 Table of amendments (continued )
Type (non-substantial
or substantial) Approval date Documents amended Brief description of amendment
Update to interview consent form
(version 2.0, 20 October 2013)
Update to hospital poster
(version 2.0, 20 October 2013)
Update to consent status form
(version 2.0, 6 November 2013)
Update to baseline form
(version 2.0, 20 October 2013)
l Changed the phrase ‘cognitive
impairment’ to ‘lacks mental capacity’
l Added pregnancy as an exclusion
criterion because of radiation
exposure from imaging
Obtaining consent:
l Addition that consent can be
performed not only by research
nurses but also clinicians
Timing of radiographs at baseline:
l Change to allow collection of
missing baseline radiographs after
consent, if necessary
Collection of PRWE at baseline
for both:
l in the week since injury
l in the week before injury
Adjustment for baseline covariates in
the analyses plan:
l Replacement of adjustment on
baseline PRWE as a covariate with
grip strength and range, as the
latter allows for more variability as
measured without the patient’s
wrist in plaster cast
Non-substantial
amendment 6
14 January 2014 Update to trial protocol
(version 2.1, 6 January 2014)
Update to hospital poster
(version 2.1, 6 January 2014)
Change of PI at Maidstone and
Cardiff sites
Addition of new participating sites
Update to the protocol about the
referral pathway to fracture clinic
to include points of contact other
than A&E
Changes to exclusion criteria
in protocol:
l Removal of fractures of the
proximal pole as not applicable
l Addition of concurrent wrist
fracture
Addition of expected plaster cast AEs
to protocol (soft/broken cast, pressure
sores, CRPS, nerve compression, pain
due to tight cast)
Non-substantial
amendment 7
19 June 2014 N/A Change of PI at Royal London and
Alexandra Hospital sites
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TABLE 45 Table of amendments (continued )
Type (non-substantial
or substantial) Approval date Documents amended Brief description of amendment
Non-substantial
amendment 8
19 August 2014 Update to trial protocol
(version 2.2, 14 August 2014)
Minor modifications to trial protocol:
l Clarification that AEs are followed
up at 1 month only if unresolved at
initial reporting
l Primary analysis to be adjusted on
grip strength in opposite wrist to
the one fractured
l Primary analysis adjustment based
on wrist range removed
l Correction of grip strength
measurement instructions to reflect
recommendations in Trampisch et al.
(2012)72
l Addition of Beighton joint laxity
score at baseline
Submission of correct version of
consent status form
Change in PI at Birmingham site
Substantial
amendment 2
23 February 2015 Update to trial protocol
(version 3.0, 19 January 2015)
Reinstatement of patients previously
withdrawn owing to equivocal CT
scan about the presence of a fracture:
l Letter to send to previously
withdrawn ‘Randomised in error’
patients to agree to be reinstated
and followed up
Verbal consent for qualitative
substudy:
l Permission to obtain verbal consent
at time of telephone interview
with written consent gained
retrospectively
Outline of patient engagement
activities (newsletter, video, website,
postal envelope tagline) and example
documents for approval
Update to statistical analysis plan:
l Inclusion of greater detail about
planned analyses and removal of
one of the subgroup analyses that
involved a three-way interaction
Clarification regarding collection of
patient questionnaires in clinic:
l Removal of ambiguity so that it
is clear that a questionnaire is
completed by a participant, not
the research nurse
continued
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TABLE 45 Table of amendments (continued )
Type (non-substantial
or substantial) Approval date Documents amended Brief description of amendment
Substantial
amendment 3
26 November
2015
Update to trial protocol
(version 4.0, 20 October 2015)
Update to main trial
consent form (version 3.0,
20 October 2015)
Update to main trial patient
information leaflet (version 3.0,
20 October 2015)
Inclusion of letter and primary-
outcome-only questionnaire at 6 weeks
after initial 52-week follow-up
questionnaire being sent
Inclusion of prize draws at 26 weeks
for participant completion of a returning
questionnaire and at 52 weeks and
5 years for attending the hospital
clinic visit
Removal of adjustment on covariant
‘baseline grip strength of opposite
wrist’ from analysis plan
Clarification that there will be a 5-year
follow-up
Non-substantial
amendment 9
11 March 2016 N/A Extension to recruitment period
Non-substantial
amendment 10
24 August 2016 N/A Change in PI at Royal Berkshire Hospital
Substantial
amendment 4
17 October 2016 Update to trial protocol
(version 5.0, 14 September 2016)
Permission to use e-mail to contact
patients for the 52-week follow-up
Inclusion of a patient letter from the
hospital site to encourage attendance
at the 52-week clinic appointment
Payment of travel expenses to patients
attending the 52-week clinic
appointment
Permission to retrieve imaging for
participants attending other hospitals
via PACS
The use of the Summary Care Records
to check contact details for patients
who the trial team lose contact with
Permission to contact the patient’s GP
to check if they have had any further
surgery for their scaphoid fracture
Change to the categorisation of
non-union, slight union, etc., to remove
cases of overlap
Non-substantial
amendment 11
11 May 2017 N/A Change in PI at Coventry site
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Appendix 3 Tables and figures
TABLE 46 Baseline characteristics of trial participants according to whether or not they attended the 6-week
hospital clinic visit
Characteristic
Attended visit (N= 388) Did not attend visit (N= 51)
Surgery
(N= 189)
Plaster cast
(N= 199)
Total
(N= 388)
Surgery
(N= 30)
Plaster cast
(N= 21)
Total
(N= 51)
Gender, n (%)
Male 154 (81.5) 167 (83.9) 321 (82.7) 26 (86.7) 16 (76.2) 42 (82.4)
Female 35 (18.5) 32 (16.1) 67 (17.3) 4 (13.3) 5 (23.8) 9 (17.6)
Age, years
n 189 199 388 30 21 51
Mean (SD) 33.2 (13.3) 32.7 (12.4) 32.9 (12.8) 31.2 (12.6) 34.8 (10.9) 32.7 (11.9)
Median (min., max.) 29 (16, 80) 29 (16, 76) 29 (16, 80) 25 (18, 57) 34 (21, 55) 28 (18, 57)
Ethnicity, n (%)
White 179 (94.7) 174 (87.4) 353 (91.0) 26 (86.7) 21 (100.0) 47 (92.2)
Black 0 (0.0) 5 (2.5) 5 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Asian 7 (3.7) 10 (5.0) 17 (4.4) 0 (0.0) 0 (0.0) 0 (0.0)
Other 3 (1.6) 10 (5.0) 13 (3.4) 2 (6.7) 0 (0.0) 2 (3.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 2 (3.9)
Education, n (%)
No formal qualifications 18 (9.5) 24 (12.1) 42 (10.8) 6 (20.0) 3 (14.3) 9 (17.6)
Some qualifications/no degree 132 (69.8) 114 (57.3) 246 (63.4) 19 (63.3) 15 (71.4) 34 (66.7)
Degree or higher 38 (20.1) 61 (30.7) 99 (25.5) 3 (10.0) 3 (14.3) 6 (11.8)
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9)
Employment status, n (%)
Part-time 20 (10.6) 16 (8.0) 36 (9.3) 0 (0.0) 2 (9.5) 2 (3.9)
Full-time 113 (59.8) 114 (57.3) 227 (58.5) 14 (46.7) 6 (28.6) 20 (39.2)
Self-employed 18 (9.5) 26 (13.1) 44 (11.3) 3 (10.0) 10 (47.6) 13 (25.5)
Student 17 (9.0) 21 (10.6) 38 (9.8) 3 (10.0) 0 (0.0) 3 (5.9)
Retired 7 (3.7) 5 (2.5) 12 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
Looking after family/home 0 (0.0) 4 (2.0) 4 (1.0) 1 (3.3) 2 (9.5) 3 (5.9)
Not employed but seeking work 5 (2.6) 5 (2.5) 10 (2.6) 4 (13.3) 0 (0.0) 4 (7.8)
Other 8 (4.2) 8 (4.0) 16 (4.1) 3 (10.0) 1 (4.8) 4 (7.8)
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9)
continued
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TABLE 46 Baseline characteristics of trial participants according to whether or not they attended the 6-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 388) Did not attend visit (N= 51)
Surgery
(N= 189)
Plaster cast
(N= 199)
Total
(N= 388)
Surgery
(N= 30)
Plaster cast
(N= 21)
Total
(N= 51)
Type of employment, n (%)
Unskilled manual 23 (12.2) 17 (8.5) 40 (10.3) 2 (6.7) 6 (28.6) 8 (15.7)
Skilled manual 55 (29.1) 54 (27.1) 109 (28.1) 8 (26.7) 6 (28.6) 14 (27.5)
Unskilled non-manual 17 (9.0) 10 (5.0) 27 (7.0) 2 (6.7) 2 (9.5) 4 (7.8)
Skilled non-manual 30 (15.9) 44 (22.1) 74 (19.1) 3 (10.0) 2 (9.5) 5 (9.8)
Professional 19 (10.1) 15 (7.5) 34 (8.8) 1 (3.3) 4 (19.0) 5 (9.8)
Other 17 (9.0) 30 (15.1) 47 (12.1) 2 (6.7) 0 (0.0) 2 (3.9)
Missing 28 (14.8) 29 (14.6) 57 (14.7) 12 (40.0) 1 (4.8) 13 (25.5)
Current smoker, n (%)
Yes 56 (29.6) 45 (22.6) 101 (26.0) 17 (56.7) 11 (52.4) 28 (54.9)
No 132 (69.8) 153 (76.9) 285 (73.5) 11 (36.7) 10 (47.6) 21 (41.2)
Missing 1 (0.5) 1 (0.5) 2 (0.5) 2 (6.7) 0 (0.0) 2 (3.9)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (2, 20) 10 (5, 15) 10 (2, 20)
Number of years, median
(min., max.)
10 (1, 50) 10 (1, 36) 10 (1, 50) 9 (1, 44) 10 (4, 20) 10 (1, 44)
Past smoker, n (%)
Yes 99 (52.4) 94 (47.2) 193 (49.7) 17 (56.7) 15 (71.4) 32 (62.7)
No 79 (41.8) 96 (48.2) 175 (45.1) 6 (20.0) 5 (23.8) 11 (21.6)
Missing 11 (5.8) 9 (4.5) 20 (5.2) 7 (23.3) 1 (4.8) 8 (15.7)
Diabetes, n (%)
Yes 6 (3.2) 4 (2.0) 10 (2.6) 1 (3.3) 0 (0.0) 1 (2.0)
No 182 (96.3) 195 (98.0) 377 (97.2) 27 (90.0) 21 (100.0) 48 (94.1)
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9)
Steroid use, n (%)
Yes 5 (2.6) 4 (2.0) 9 (2.3) 1 (3.3) 0 (0.0) 1 (2.0)
No 183 (96.8) 195 (98.0) 378 (97.4) 27 (90.0) 21 (100.0) 48 (94.1)
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 0 (0.0) 2 (3.9)
Max., maximum; min., minimum.
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TABLE 47 Baseline fracture details of trial participants according to whether or not they attended the 6-week
hospital clinic visit
Characteristic
Attended visit (N= 388) Did not attend visit (N= 51)
Surgery
(N= 189)
Plaster cast
(N= 199)
Total
(N= 388)
Surgery
(N= 30)
Plaster cast
(N= 21)
Total
(N= 51)
Time since injury, daysa
n 189 199 388 30 21 51
Mean (SD) 4.9 (3.1) 5.3 (3.4) 5.1 (3.3) 5.9 (2.7) 5.3 (3.2) 5.7 (2.9)
Median (min., max.) 4 (1, 14) 5 (0, 14) 4 (0, 14) 6 (1, 12) 5 (1, 12) 5 (1, 12)
Affected wrist, n (%)
Left 105 (55.6) 110 (55.3) 215 (55.4) 10 (33.3) 8 (38.1) 18 (35.3)
Right 84 (44.4) 89 (44.7) 173 (44.6) 20 (66.7) 13 (61.9) 33 (64.7)
Affected wrist is dominant hand, n (%)
Yes 85 (45.0) 83 (41.7) 168 (43.3) 15 (50.0) 12 (57.1) 27 (52.9)
No 104 (55.0) 116 (58.3) 220 (56.7) 13 (43.3) 9 (42.9) 22 (43.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 2 (3.9)
Displacement (eligibility), n (%)
No displacement 113 (59.8) 117 (58.8) 230 (59.3) 22 (73.3) 17 (81.0) 39 (76.5)
Displacement 76 (40.2) 82 (41.2) 158 (40.7) 8 (26.7) 4 (19.0) 12 (23.5)
Displacement (randomisation), n (%)
No displacement 109 (57.7) 113 (56.8) 222 (57.2) 22 (73.3) 17 (81.0) 39 (76.5)
Displacement 80 (42.3) 86 (43.2) 166 (42.8) 8 (26.7) 4 (19.0) 12 (23.5)
Radiographs,b n (%)
Elongated scaphoid view 180 (95.2) 189 (95.0) 369 (95.1) 29 (96.7) 21 (100.0) 50 (98.0)
Posterior–anterior view 187 (98.9) 197 (99.0) 384 (99.0) 28 (93.3) 21 (100.0) 49 (96.1)
45° semisupine view 134 (70.9) 151 (75.9) 285 (73.5) 25 (83.3) 15 (71.4) 40 (78.4)
Lateral view 189 (100.0) 196 (98.5) 385 (99.2) 29 (96.7) 21 (100.0) 50 (98.0)
45° semiprone view 170 (89.9) 179 (89.9) 349 (89.9) 28 (93.3) 17 (81.0) 45 (88.2)
Previous wrist problems on same side, n (%)
Yes 40 (21.2) 41 (20.6) 81 (20.9) 3 (10.0) 4 (19.0) 7 (13.7)
No 148 (78.3) 158 (79.4) 306 (78.9) 25 (83.3) 15 (71.4) 40 (78.4)
Missing 1 (0.5) 0 (0.0) 1 (0.3) 2 (6.7) 2 (9.5) 4 (7.8)
If yes, what injury?, n (%)
Previous fracture 21 (52.5) 26 (63.4) 47 (58.0) 2 (66.7) 2 (50.0) 4 (57.1)
Arthritis 1 (2.5) 1 (2.4) 2 (2.5) 1 (33.3) 0 (0.0) 1 (14.3)
Ligament, tendon or nerve injury 10 (25.0) 7 (17.1) 17 (21.0) 0 (0.0) 1 (25.0) 1 (14.3)
Other 6 (15.0) 7 (17.1) 13 (16.0) 0 (0.0) 1 (25.0) 1 (14.3)
Missing 2 (5.0) 0 (0.0) 2 (2.5) 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 47 Baseline fracture details of trial participants according to whether or not they attended the 6-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 388) Did not attend visit (N= 51)
Surgery
(N= 189)
Plaster cast
(N= 199)
Total
(N= 388)
Surgery
(N= 30)
Plaster cast
(N= 21)
Total
(N= 51)
Injury mechanism, n (%)
Fall – standing 24 (12.7) 27 (13.6) 51 (13.1) 4 (13.3) 2 (9.5) 6 (11.8)
Fall – walking 20 (10.6) 22 (11.1) 42 (10.8) 4 (13.3) 2 (9.5) 6 (11.8)
Fall – running 37 (19.6) 35 (17.6) 72 (18.6) 3 (10.0) 3 (14.3) 6 (11.8)
Fall – from height 24 (12.7) 31 (15.6) 55 (14.2) 4 (13.3) 3 (14.3) 7 (13.7)
Fall – from moving object 35 (18.5) 31 (15.6) 66 (17.0) 7 (23.3) 0 (0.0) 7 (13.7)
Hit on palm of hand – object
striking palm
15 (7.9) 14 (7.0) 29 (7.5) 1 (3.3) 1 (4.8) 2 (3.9)
Hit on palm of hand – handle
whipping back
7 (3.7) 10 (5.0) 17 (4.4) 2 (6.7) 1 (4.8) 3 (5.9)
Hit on palm of hand – other
sudden extension
10 (5.3) 7 (3.5) 17 (4.4) 1 (3.3) 1 (4.8) 2 (3.9)
Punched something 4 (2.1) 9 (4.5) 13 (3.4) 0 (0.0) 3 (14.3) 3 (5.9)
Road traffic accident 9 (4.8) 6 (3.0) 15 (3.9) 0 (0.0) 2 (9.5) 2 (3.9)
Other 4 (2.1) 7 (3.5) 11 (2.8) 2 (6.7) 3 (14.3) 5 (9.8)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0) 2 (3.9)
Place of injury,b n (%)
Sport 79 (41.8) 72 (36.2) 151 (38.9) 9 (30.0) 6 (28.6) 15 (29.4)
Home 20 (10.6) 38 (19.1) 58 (14.9) 7 (23.3) 5 (23.8) 12 (23.5)
Work 18 (9.5) 17 (8.5) 35 (9.0) 4 (13.3) 1 (4.8) 5 (9.8)
Road traffic accident 24 (12.7) 32 (16.1) 56 (14.4) 2 (6.7) 2 (9.5) 4 (7.8)
Public place 44 (23.3) 42 (21.1) 86 (22.2) 5 (16.7) 6 (28.6) 11 (21.6)
Other 3 (1.6) 0 (0.0) 3 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 3 (1.6) 1 (0.5) 4 (1.0) 1 (3.3) 1 (4.8) 2 (3.9)
Treatment preference, n (%)
Surgery 80 (42.3) 92 (46.2) 172 (44.3) 13 (43.3) 9 (42.9) 22 (43.1)
No surgery 10 (5.3) 16 (8.0) 26 (6.7) 3 (10.0) 3 (14.3) 6 (11.8)
No preference 98 (51.9) 90 (45.2) 188 (48.5) 12 (40.0) 9 (42.9) 21 (41.2)
Missing 1 (0.5) 1 (0.5) 2 (0.5) 2 (6.7) 0 (0.0) 2 (3.9)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
Modified from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label,
randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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TABLE 48 Baseline characteristics of trial participants according to whether or not they attended the 12-week
hospital clinic visit
Characteristic
Attended visit (N= 338) Did not attend visit (N= 101)
Surgery
(N= 173)
Plaster cast
(N= 165)
Total
(N= 338)
Surgery
(N= 46)
Plaster cast
(N= 55)
Total
(N= 101)
Gender, n (%)
Male 143 (82.7) 134 (81.2) 277 (82.0) 37 (80.4) 49 (89.1) 86 (85.1)
Female 30 (17.3) 31 (18.8) 61 (18.0) 9 (19.6) 6 (10.9) 15 (14.9)
Age, years
n 173 165 338 46 55 101
Mean (SD) 33.7 (13.5) 34.1 (12.8) 33.9 (13.1) 30.0 (11.9) 29.1 (9.6) 29.5 (10.6)
Median (min., max.) 29 (16, 80) 31 (16, 76) 30 (16, 80) 26 (18, 57) 25 (17, 55) 25 (17, 57)
Ethnicity, n (%)
White 163 (94.2) 144 (87.3) 307 (90.8) 42 (91.3) 51 (92.7) 93 (92.1)
Black 0 (0.0) 3 (1.8) 3 (0.9) 0 (0.0) 2 (3.6) 2 (2.0)
Asian 6 (3.5) 8 (4.8) 14 (4.1) 1 (2.2) 2 (3.6) 3 (3.0)
Other 4 (2.3) 10 (6.1) 14 (4.1) 1 (2.2) 0 (0.0) 1 (1.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.3) 0 (0.0) 2 (2.0)
Education, n (%)
No formal qualifications 16 (9.2) 21 (12.7) 37 (10.9) 8 (17.4) 6 (10.9) 14 (13.9)
Some qualifications/no degree 120 (69.4) 91 (55.2) 211 (62.4) 31 (67.4) 38 (69.1) 69 (68.3)
Degree or higher 36 (20.8) 53 (32.1) 89 (26.3) 5 (10.9) 11 (20.0) 16 (15.8)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0)
Employment status, n (%)
Part-time 19 (11.0) 15 (9.1) 34 (10.1) 1 (2.2) 3 (5.5) 4 (4.0)
Full-time 106 (61.3) 93 (56.4) 199 (58.9) 21 (45.7) 27 (49.1) 48 (47.5)
Self-employed 15 (8.7) 23 (13.9) 38 (11.2) 6 (13.0) 13 (23.6) 19 (18.8)
Student 14 (8.1) 16 (9.7) 30 (8.9) 6 (13.0) 5 (9.1) 11 (10.9)
Retired 7 (4.0) 5 (3.0) 12 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
Looking after family/home 0 (0.0) 4 (2.4) 4 (1.2) 1 (2.2) 2 (3.6) 3 (3.0)
Not employed but
seeking work
3 (1.7) 4 (2.4) 7 (2.1) 6 (13.0) 1 (1.8) 7 (6.9)
Other 8 (4.6) 5 (3.0) 13 (3.8) 3 (6.5) 4 (7.3) 7 (6.9)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0)
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TABLE 48 Baseline characteristics of trial participants according to whether or not they attended the 12-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 338) Did not attend visit (N= 101)
Surgery
(N= 173)
Plaster cast
(N= 165)
Total
(N= 338)
Surgery
(N= 46)
Plaster cast
(N= 55)
Total
(N= 101)
Type of employment, n (%)
Unskilled manual 19 (11.0) 11 (6.7) 30 (8.9) 6 (13.0) 12 (21.8) 18 (17.8)
Skilled manual 51 (29.5) 44 (26.7) 95 (28.1) 12 (26.1) 16 (29.1) 28 (27.7)
Unskilled non-manual 18 (10.4) 9 (5.5) 27 (8.0) 1 (2.2) 3 (5.5) 4 (4.0)
Skilled non-manual 28 (16.2) 38 (23) 66 (19.5) 5 (10.9) 8 (14.5) 13 (12.9)
Professional 17 (9.8) 15 (9.1) 32 (9.5) 3 (6.5) 4 (7.3) 7 (6.9)
Other 16 (9.2) 23 (13.9) 39 (11.5) 3 (6.5) 7 (12.7) 10 (9.9)
Missing 24 (13.9) 25 (15.2) 49 (14.5) 16 (34.8) 5 (9.1) 21 (20.8)
Current smoker, n (%)
Yes 49 (28.3) 31 (18.8) 80 (23.7) 24 (52.2) 25 (45.5) 49 (48.5)
No 123 (71.1) 133 (80.6) 256 (75.7) 20 (43.5) 30 (54.5) 50 (49.5)
Missing 1 (0.6) 1 (0.6) 2 (0.6) 2 (4.3) 0 (0.0) 2 (2.0)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 11 (1, 36) 10 (1, 40) 10 (1, 20) 10 (4, 20) 10 (1, 20)
Number of years, median
(min., max.)
10 (1, 50) 10 (1, 40) 10 (1, 50) 10 (1, 44) 10 (2, 20) 10 (1, 44)
Past smoker, n (%)
Yes 91 (52.6) 70 (42.4) 161 (47.6) 25 (54.3) 39 (70.9) 64 (63.4)
No 72 (41.6) 88 (53.3) 160 (47.3) 13 (28.3) 13 (23.6) 26 (25.7)
Missing 10 (5.8) 7 (4.2) 17 (5.0) 8 (17.4) 3 (5.5) 11 (10.9)
Diabetes, n (%)
Yes 6 (3.5) 4 (2.4) 10 (3.0) 1 (2.2) 0 (0.0) 1 (1.0)
No 166 (96.0) 161 (97.6) 327 (96.7) 43 (93.5) 55 (100.0) 98 (97.0)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0)
Steroid use, n (%)
Yes 4 (2.3) 4 (2.4) 8 (2.4) 2 (4.3) 0 (0.0) 2 (2.0)
No 168 (97.1) 161 (97.6) 329 (97.3) 42 (91.3) 55 (100.0) 97 (96.0)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (4.3) 0 (0.0) 2 (2.0)
Max., maximum; min., minimum.
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TABLE 49 Baseline fracture details of trial participants according to whether or not they attended the 12-week
hospital clinic visit
Characteristic
Attended visit (N= 338) Did not attend visit (N= 101)
Surgery
(N= 173)
Plaster cast
(N= 165)
Total
(N= 338)
Surgery
(N= 46)
Plaster cast
(N= 55)
Total
(N= 101)
Time since injury, daysa
n 173 165 338 46 55 101
Mean (SD) 4.8 (3.1) 5.4 (3.5) 5.1 (3.3) 6.0 (3.0) 5.2 (2.9) 5.6 (3.0)
Median (min., max.) 4 (1, 14) 4 (0, 14) 4 (0, 14) 6 (1, 14) 5 (0, 12) 6 (0, 14)
Affected wrist, n (%)
Left 93 (53.8) 94 (57.0) 187 (55.3) 22 (47.8) 24 (43.6) 46 (45.5)
Right 80 (46.2) 71 (43.0) 151 (44.7) 24 (52.2) 31 (56.4) 55 (54.5)
Affected wrist is dominant hand, n (%)
Yes 76 (43.9) 68 (41.2) 144 (42.6) 24 (52.2) 27 (49.1) 51 (50.5)
No 97 (56.1) 97 (58.8) 194 (57.4) 20 (43.5) 28 (50.9) 48 (47.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.3) 0 (0.0) 2 (2.0)
Displacement (eligibility), n (%)
No displacement 107 (61.8) 101 (61.2) 208 (61.5) 28 (60.9) 33 (60.0) 61 (60.4)
Displacement 66 (38.2) 64 (38.8) 130 (38.5) 18 (39.1) 22 (40.0) 40 (39.6)
Displacement (randomisation), n (%)
No displacement 104 (60.1) 97 (58.8) 201 (59.5) 27 (58.7) 33 (60.0) 60 (59.4)
Displacement 69 (39.9) 68 (41.2) 137 (40.5) 19 (41.3) 22 (40.0) 41 (40.6)
Radiographs,b n (%)
Elongated scaphoid view 164 (94.8) 158 (95.8) 322 (95.3) 45 (97.8) 52 (94.5) 97 (96.0)
Posterior–anterior view 171 (98.8) 165 (100.0) 336 (99.4) 44 (95.7) 53 (96.4) 97 (96.0)
45° semisupine view 121 (69.9) 121 (73.3) 242 (71.6) 38 (82.6) 45 (81.8) 83 (82.2)
Lateral view 173 (100.0) 164 (99.4) 337 (99.7) 45 (97.8) 53 (96.4) 98 (97.0)
45° semiprone view 156 (90.2) 147 (89.1) 303 (89.6) 42 (91.3) 49 (89.1) 91 (90.1)
Previous wrist problems on same side, n (%)
Yes 35 (20.2) 33 (20.0) 68 (20.1) 8 (17.4) 12 (21.8) 20 (19.8)
No 137 (79.2) 131 (79.4) 268 (79.3) 36 (78.3) 42 (76.4) 78 (77.2)
Missing 1 (0.6) 1 (0.6) 2 (0.6) 2 (4.3) 1 (1.8) 3 (3.0)
If yes, what injury?, n (%)
Previous fracture 18 (51.4) 20 (60.6) 38 (55.9) 5 (62.5) 8 (66.7) 13 (65.0)
Arthritis 2 (5.7) 1 (3.0) 3 (4.4) 0 (0.0) 0 (0.0) 0 (0.0)
Ligament, tendon or nerve injury 8 (22.9) 7 (21.2) 15 (22.1) 2 (25) 1 (8.3) 3 (15.0)
Other 6 (17.1) 5 (15.2) 11 (16.2) 0 (0.0) 3 (25.0) 3 (15.0)
Missing 1 (2.9) 0 (0.0) 1 (1.5) 1 (12.5) 0 (0.0) 1 (5.0)
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TABLE 49 Baseline fracture details of trial participants according to whether or not they attended the 12-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 338) Did not attend visit (N= 101)
Surgery
(N= 173)
Plaster cast
(N= 165)
Total
(N= 338)
Surgery
(N= 46)
Plaster cast
(N= 55)
Total
(N= 101)
Injury mechanism, n (%)
Fall – standing 22 (12.7) 21 (12.7) 43 (12.7) 6 (13.0) 8 (14.5) 14 (13.9)
Fall – walking 20 (11.6) 21 (12.7) 41 (12.1) 4 (8.7) 3 (5.5) 7 (6.9)
Fall – running 33 (19.1) 28 (17.0) 61 (18.0) 7 (15.2) 10 (18.2) 17 (16.8)
Fall – from height 25 (14.5) 25 (15.2) 50 (14.8) 3 (6.5) 9 (16.4) 12 (11.9)
Fall – from moving object 34 (19.7) 27 (16.4) 61 (18.0) 8 (17.4) 4 (7.3) 12 (11.9)
Hit on palm of hand – object
striking palm
12 (6.9) 12 (7.3) 24 (7.1) 4 (8.7) 3 (5.5) 7 (6.9)
Hit on palm of hand – handle
whipping back
5 (2.9) 8 (4.8) 13 (3.8) 4 (8.7) 3 (5.5) 7 (6.9)
Hit on palm of hand – other
sudden extension
9 (5.2) 4 (2.4) 13 (3.8) 2 (4.3) 4 (7.3) 6 (5.9)
Punched something 4 (2.3) 7 (4.2) 11 (3.3) 0 (0.0) 5 (9.1) 5 (5.0)
Road traffic accident 7 (4.0) 5 (3.0) 12 (3.6) 2 (4.3) 3 (5.5) 5 (5.0)
Other 2 (1.2) 7 (4.2) 9 (2.7) 4 (8.7) 3 (5.5) 7 (6.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.3) 0 (0.0) 2 (2.0)
Place of injury,b n (%)
Sport 73 (42.2) 60 (36.4) 133 (39.3) 15 (32.6) 18 (32.7) 33 (32.7)
Home 17 (9.8) 29 (17.6) 46 (13.6) 10 (21.7) 14 (25.5) 24 (23.8)
Work 17 (9.8) 13 (7.9) 30 (8.9) 5 (10.9) 5 (9.1) 10 (9.9)
Road traffic accident 24 (13.9) 27 (16.4) 51 (15.1) 2 (4.3) 7 (12.7) 9 (8.9)
Public place 39 (22.5) 38 (23.0) 77 (22.8) 10 (21.7) 10 (18.2) 20 (19.8)
Other 2 (1.2) 0 (0.0) 2 (0.6) 1 (2.2) 0 (0.0) 1 (1.0)
Missing 3 (1.7) 1 (0.6) 4 (1.2) 1 (2.2) 1 (1.8) 2 (2.0)
Treatment preference, n (%)
Surgery 72 (41.6) 76 (46.1) 148 (43.8) 21 (45.7) 25 (45.5) 46 (45.5)
No surgery 10 (5.8) 13 (7.9) 23 (6.8) 3 (6.5) 6 (10.9) 9 (8.9)
No preference 90 (52.0) 75 (45.5) 165 (48.8) 20 (43.5) 24 (43.6) 44 (43.6)
Missing 1 (0.6) 1 (0.6) 2 (0.6) 2 (4.3) 0 (0.0) 2 (2.0)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
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TABLE 50 Baseline characteristics of trial participants according to whether or not they attended the 52-week
hospital clinic visit
Characteristic
Attended visit (N= 310) Did not attend visit (N= 129)
Surgery
(N= 164)
Plaster cast
(N= 146)
Total
(N= 310)
Surgery
(N= 55)
Plaster cast
(N= 74)
Total
(N= 129)
Gender, n (%)
Male 137 (83.5) 122 (83.6) 259 (83.5) 43 (78.2) 61 (82.4) 104 (80.6)
Female 27 (16.5) 24 (16.4) 51 (16.5) 12 (21.8) 13 (17.6) 25 (19.4)
Age, years
n 164 146 310 55 74 129
Mean (SD) 34.6 (13.7) 34.6 (13.2) 34.6 (13.4) 27.8 (10.0) 29.5 (9.4) 28.7 (9.6)
Median (min., max.) 31 (16, 80) 31 (16, 76) 31 (16, 80) 24 (18, 57) 26 (17, 55) 25 (17, 57)
Ethnicity, n (%)
White 153 (93.3) 130 (89.0) 283 (91.3) 52 (94.5) 65 (87.8) 117 (90.7)
Black 0 (0.0) 2 (1.4) 2 (0.6) 0 (0.0) 3 (4.1) 3 (2.3)
Asian 7 (4.3) 8 (5.5) 15 (4.8) 0 (0.0) 2 (2.7) 2 (1.6)
Other 4 (2.4) 6 (4.1) 10 (3.2) 1 (1.8) 4 (5.4) 5 (3.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 2 (1.6)
Education, n (%)
No formal qualifications 14 (8.5) 21 (14.4) 35 (11.3) 10 (18.2) 6 (8.1) 16 (12.4)
Some qualifications/no degree 114 (69.5) 80 (54.8) 194 (62.6) 37 (67.3) 49 (66.2) 86 (66.7)
Degree or higher 35 (21.3) 45 (30.8) 80 (25.8) 6 (10.9) 19 (25.7) 25 (19.4)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6)
Employment status, n (%)
Part-time 15 (9.1) 14 (9.6) 29 (9.4) 5 (9.1) 4 (5.4) 9 (7.0)
Full-time 105 (64.0) 86 (58.9) 191 (61.6) 22 (40.0) 34 (45.9) 56 (43.4)
Self-employed 14 (8.5) 19 (13.0) 33 (10.6) 7 (12.7) 17 (23.0) 24 (18.6)
Student 12 (7.3) 11 (7.5) 23 (7.4) 8 (14.5) 10 (13.5) 18 (14.0)
Retired 7 (4.3) 5 (3.4) 12 (3.9) 0 (0.0) 0 (0.0) 0 (0.0)
Looking after family/home 0 (0.0) 4 (2.7) 4 (1.3) 1 (1.8) 2 (2.7) 3 (2.3)
Not employed but seeking work 3 (1.8) 3 (2.1) 6 (1.9) 6 (10.9) 2 (2.7) 8 (6.2)
Other 7 (4.3) 4 (2.7) 11 (3.5) 4 (7.3) 5 (6.8) 9 (7.0)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6)
Type of employment, n (%)
Unskilled manual 17 (10.4) 10 (6.8) 27 (8.7) 8 (14.5) 13 (17.6) 21 (16.3)
Skilled manual 48 (29.3) 39 (26.7) 87 (28.1) 15 (27.3) 21 (28.4) 36 (27.9)
Unskilled non-manual 18 (11.0) 7 (4.8) 25 (8.1) 1 (1.8) 5 (6.8) 6 (4.7)
Skilled non-manual 27 (16.5) 37 (25.3) 64 (20.6) 6 (10.9) 9 (12.2) 15 (11.6)
Professional 17 (10.4) 13 (8.9) 30 (9.7) 3 (5.5) 6 (8.1) 9 (7.0)
Other 16 (9.8) 19 (13.0) 35 (11.3) 3 (5.5) 11 (14.9) 14 (10.9)
Missing 21 (12.8) 21 (14.4) 42 (13.5) 19 (34.5) 9 (12.2) 28 (21.7)
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TABLE 50 Baseline characteristics of trial participants according to whether or not they attended the 52-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 310) Did not attend visit (N= 129)
Surgery
(N= 164)
Plaster cast
(N= 146)
Total
(N= 310)
Surgery
(N= 55)
Plaster cast
(N= 74)
Total
(N= 129)
Current smoker, n (%)
Yes 49 (29.9) 27 (18.5) 76 (24.5) 24 (43.6) 29 (39.2) 53 (41.1)
No 114 (69.5) 118 (80.8) 232 (74.8) 29 (52.7) 45 (60.8) 74 (57.4)
Missing 1 (0.6) 1 (0.7) 2 (0.6) 2 (3.6) 0 (0.0) 2 (1.6)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (1, 20) 10 (4, 25) 10 (1, 25)
Number of years, median
(min., max.)
10 (1, 50) 11 (1, 36) 10 (1, 50) 9 (1, 40) 8 (2, 30) 8 (1, 40)
Past smoker, n (%)
Yes 86 (52.4) 62 (42.5) 148 (47.7) 30 (54.5) 47 (63.5) 77 (59.7)
No 68 (41.5) 78 (53.4) 146 (47.1) 17 (30.9) 23 (31.1) 40 (31.0)
Missing 10 (6.1) 6 (4.1) 16 (5.2) 8 (14.5) 4 (5.4) 12 (9.3)
Diabetes, n (%)
Yes 6 (3.7) 4 (2.7) 10 (3.2) 1 (1.8) 0 (0.0) 1 (0.8)
No 157 (95.7) 142 (97.3) 299 (96.5) 52 (94.5) 74 (100.0) 126 (97.7)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6)
Steroid use, n (%)
Yes 5 (3.0) 2 (1.4) 7 (2.3) 1 (1.8) 2 (2.7) 3 (2.3)
No 158 (96.3) 144 (98.6) 302 (97.4) 52 (94.5) 72 (97.3) 124 (96.1)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6)
Max., maximum; min., minimum.
TABLE 51 Baseline fracture details of trial participants according to whether or not they attended the 52-week
hospital clinic visit
Characteristic
Attended visit (N= 310) Did not attend visit (N= 129)
Surgery
(N= 164)
Plaster cast
(N= 146)
Total
(N= 310)
Surgery
(N= 55)
Plaster cast
(N= 74)
Total
(N= 129)
Time since injury, daysa
n 164 146 310 55 74 129
Mean (SD) 4.9 (3.1) 5.3 (3.4) 5.1 (3.3) 5.7 (3.1) 5.4 (3.2) 5.5 (3.1)
Median (min., max.) 4 (1, 14) 4 (1, 14) 4 (1, 14) 5 (1, 14) 5 (0, 14) 5 (0, 14)
Affected wrist, n (%)
Left 86 (52.4) 77 (52.7) 163 (52.6) 29 (52.7) 41 (55.4) 70 (54.3)
Right 78 (47.6) 69 (47.3) 147 (47.4) 26 (47.3) 33 (44.6) 59 (45.7)
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TABLE 51 Baseline fracture details of trial participants according to whether or not they attended the 52-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 310) Did not attend visit (N= 129)
Surgery
(N= 164)
Plaster cast
(N= 146)
Total
(N= 310)
Surgery
(N= 55)
Plaster cast
(N= 74)
Total
(N= 129)
Affected wrist is dominant hand, n (%)
Yes 73 (44.5) 69 (47.3) 142 (45.8) 27 (49.1) 26 (35.1) 53 (41.1)
No 91 (55.5) 77 (52.7) 168 (54.2) 26 (47.3) 48 (64.9) 74 (57.4)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 2 (1.6)
Displacement (eligibility), n (%)
No displacement 96 (58.5) 86 (58.9) 182 (58.7) 39 (70.9) 48 (64.9) 87 (67.4)
Displacement 68 (41.5) 60 (41.1) 128 (41.3) 16 (29.1) 26 (35.1) 42 (32.6)
Displacement (randomisation), n (%)
No displacement 94 (57.3) 83 (56.8) 177 (57.1) 37 (67.3) 47 (63.5) 84 (65.1)
Displacement 70 (42.7) 63 (43.2) 133 (42.9) 18 (32.7) 27 (36.5) 45 (34.9)
Radiographs,b n (%)
Elongated scaphoid view 157 (95.7) 138 (94.5) 295 (95.2) 52 (94.5) 72 (97.3) 124 (96.1)
Posterior–anterior view 161 (98.2) 145 (99.3) 306 (98.7) 54 (98.2) 73 (98.6) 127 (98.4)
45° semisupine view 118 (72.0) 111 (76.0) 229 (73.9) 41 (74.5) 55 (74.3) 96 (74.4)
Lateral view 164 (100.0) 144 (98.6) 308 (99.4) 54 (98.2) 73 (98.6) 127 (98.4)
45° semiprone view 148 (90.2) 132 (90.4) 280 (90.3) 50 (90.9) 64 (86.5) 114 (88.4)
Previous wrist problems on same side, n (%)
Yes 34 (20.7) 30 (20.5) 64 (20.6) 9 (16.4) 15 (20.3) 24 (18.6)
No 129 (78.7) 115 (78.8) 244 (78.7) 44 (80.0) 58 (78.4) 102 (79.1)
Missing 1 (0.6) 1 (0.7) 2 (0.6) 2 (3.6) 1 (1.4) 3 (2.3)
If yes, what injury?, n (%)
Previous fracture 16 (47.1) 18 (60.0) 34 (53.1) 7 (77.8) 10 (66.7) 17 (70.8)
Arthritis 2 (5.9) 1 (3.3) 3 (4.7) 0 (0.0) 0 (0.0) 0 (0.0)
Ligament, tendon or
nerve injury
8 (23.5) 7 (23.3) 15 (23.4) 2 (22.2) 1 (6.7) 3 (12.5)
Other 6 (17.6) 4 (13.3) 10 (15.6) 0 (0.0) 4 (26.7) 4 (16.7)
Missing 2 (5.9) 0 (0.0) 2 (3.1) 0 (0.0) 0 (0.0) 0 (0.0)
Injury mechanism, n (%)
Fall – standing 21 (12.8) 19 (13.0) 40 (12.9) 7 (12.7) 10 (13.5) 17 (13.2)
Fall – walking 19 (11.6) 20 (13.7) 39 (12.6) 5 (9.1) 4 (5.4) 9 (7.0)
Fall – running 32 (19.5) 28 (19.2) 60 (19.4) 8 (14.5) 10 (13.5) 18 (14.0)
Fall – from height 24 (14.6) 20 (13.7) 44 (14.2) 4 (7.3) 14 (18.9) 18 (14.0)
Fall – from moving object 32 (19.5) 21 (14.4) 53 (17.1) 10 (18.2) 10 (13.5) 20 (15.5)
Hit on palm of hand – object
striking palm
10 (6.1) 12 (8.2) 22 (7.1) 6 (10.9) 3 (4.1) 9 (7.0)
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TABLE 51 Baseline fracture details of trial participants according to whether or not they attended the 52-week
hospital clinic visit (continued )
Characteristic
Attended visit (N= 310) Did not attend visit (N= 129)
Surgery
(N= 164)
Plaster cast
(N= 146)
Total
(N= 310)
Surgery
(N= 55)
Plaster cast
(N= 74)
Total
(N= 129)
Hit on palm of hand – handle
whipping back
6 (3.7) 9 (6.2) 15 (4.8) 3 (5.5) 2 (2.7) 5 (3.9)
Hit on palm of hand – other
sudden extension
8 (4.9) 4 (2.7) 12 (3.9) 3 (5.5) 4 (5.4) 7 (5.4)
Punched something 2 (1.2) 6 (4.1) 8 (2.6) 2 (3.6) 6 (8.1) 8 (6.2)
Road traffic accident 7 (4.3) 3 (2.1) 10 (3.2) 2 (3.6) 5 (6.8) 7 (5.4)
Other 3 (1.8) 4 (2.7) 7 (2.3) 3 (5.5) 6 (8.1) 9 (7.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 2 (1.6)
Place of injury,b n (%)
Sport 66 (40.2) 53 (36.3) 119 (38.4) 22 (40.0) 25 (33.8) 47 (36.4)
Home 20 (12.2) 28 (19.2) 48 (15.5) 7 (12.7) 15 (20.3) 22 (17.1)
Work 16 (9.8) 13 (8.9) 29 (9.4) 6 (10.9) 5 (6.8) 11 (8.5)
Road traffic accident 20 (12.2) 22 (15.1) 42 (13.5) 6 (10.9) 12 (16.2) 18 (14.0)
Public place 40 (24.4) 31 (21.2) 71 (22.9) 9 (16.4) 17 (23.0) 26 (20.2)
Other 1 (0.6) 0 (0.0) 1 (0.3) 2 (3.6) 0 (0.0) 2 (1.6)
Missing 3 (1.8) 2 (1.4) 5 (1.6) 1 (1.8) 0 (0.0) 1 (0.8)
Treatment preference, n (%)
Surgery 71 (43.3) 67 (45.9) 138 (44.5) 22 (40.0) 34 (45.9) 56 (43.4)
No surgery 10 (6.1) 9 (6.2) 19 (6.1) 3 (5.5) 10 (13.5) 13 (10.1)
No preference 83 (50.6) 69 (47.3) 152 (49.0) 27 (49.1) 30 (40.5) 57 (44.2)
Missing 0 (0.0) 1 (0.7) 1 (0.3) 3 (5.5) 0 (0.0) 3 (2.3)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
TABLE 52 Baseline characteristics of trial participants with valid PRWE data by time point (6 and 12 weeks)
Characteristic
6 weeks 12 weeks
Surgery
(N= 176)
Plaster cast
(N= 172)
Total
(N= 348)
Surgery
(N= 178)
Plaster cast
(N= 163)
Total
(N= 341)
Gender, n (%)
Male 143 (81.3) 141 (82.0) 284 (81.6) 150 (84.3) 134 (82.2) 284 (83.3)
Female 33 (18.8) 31 (18.0) 64 (18.4) 28 (15.7) 29 (17.8) 57 (16.7)
Age, years
n 176 172 348 178 163 341
Mean (SD) 33.5 (13.3) 33.3 (12.9) 33.4 (13.1) 33.4 (13.1) 33.4 (12.8) 33.4 (13.0)
Median (min., max.) 30 (16, 80) 30 (16, 76) 30 (16, 80) 30 (16, 80) 30 (16, 76) 30 (16, 80)
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TABLE 52 Baseline characteristics of trial participants with valid PRWE data by time point (6 and 12 weeks)
(continued )
Characteristic
6 weeks 12 weeks
Surgery
(N= 176)
Plaster cast
(N= 172)
Total
(N= 348)
Surgery
(N= 178)
Plaster cast
(N= 163)
Total
(N= 341)
Ethnicity, n (%)
White 166 (94.3) 150 (87.2) 316 (90.8) 167 (93.8) 143 (87.7) 310 (90.9)
Black 0 (0.0) 5 (2.9) 5 (1.4) 0 (0.0) 3 (1.8) 3 (0.9)
Asian 6 (3.4) 7 (4.1) 13 (3.7) 7 (3.9) 7 (4.3) 14 (4.1)
Other 4 (2.3) 10 (5.8) 14 (4.0) 4 (2.2) 10 (6.1) 14 (4.1)
Education, n (%)
No formal qualifications 19 (10.8) 21 (12.2) 40 (11.5) 17 (9.6) 21 (12.9) 38 (11.1)
Some qualifications/no degree 121 (68.8) 95 (55.2) 216 (62.1) 119 (66.9) 91 (55.8) 210 (61.6)
Degree or higher 35 (19.9) 56 (32.6) 91 (26.1) 41 (23.0) 51 (31.3) 92 (27.0)
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.6) 0 (0.0) 1 (0.3)
Employment status, n (%)
Part-time 17 (9.7) 15 (8.7) 32 (9.2) 18 (10.1) 14 (8.6) 32 (9.4)
Full-time 106 (60.2) 92 (53.5) 198 (56.9) 109 (61.2) 94 (57.7) 203 (59.5)
Self-employed 15 (8.5) 25 (14.5) 40 (11.5) 17 (9.6) 21 (12.9) 38 (11.1)
Student 16 (9.1) 19 (11.0) 35 (10.1) 14 (7.9) 18 (11.0) 32 (9.4)
Retired 6 (3.4) 5 (2.9) 11 (3.2) 7 (3.9) 5 (3.1) 12 (3.5)
Looking after family/home 0 (0.0) 5 (2.9) 5 (1.4) 0 (0.0) 4 (2.5) 4 (1.2)
Not employed but seeking work 5 (2.8) 5 (2.9) 10 (2.9) 6 (3.4) 3 (1.8) 9 (2.6)
Other 10 (5.7) 6 (3.5) 16 (4.6) 6 (3.4) 4 (2.5) 10 (2.9)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 1 (0.6) 0 (0.0) 1 (0.3)
Type of employment, n (%)
Unskilled manual 20 (11.4) 13 (7.6) 33 (9.5) 19 (10.7) 12 (7.4) 31 (9.1)
Skilled manual 52 (29.5) 49 (28.5) 101 (29.0) 53 (29.8) 41 (25.2) 94 (27.6)
Unskilled non-manual 15 (8.5) 8 (4.7) 23 (6.6) 14 (7.9) 10 (6.1) 24 (7.0)
Skilled non-manual 28 (15.9) 34 (19.8) 62 (17.8) 30 (16.9) 37 (22.7) 67 (19.6)
Professional 18 (10.2) 15 (8.7) 33 (9.5) 19 (10.7) 14 (8.6) 33 (9.7)
Other 17 (9.7) 25 (14.5) 42 (12.1) 15 (8.4) 24 (14.7) 39 (11.4)
Missing 26 (14.8) 28 (16.3) 54 (15.5) 28 (15.7) 25 (15.3) 53 (15.5)
Current smoker, n (%)
Yes 50 (28.4) 37 (21.5) 87 (25.0) 53 (29.8) 31 (19.0) 84 (24.6)
No 126 (71.6) 134 (77.9) 260 (74.7) 124 (69.7) 131 (80.4) 255 (74.8)
Missing 0 (0.0) 1 (0.6) 1 (0.3) 1 (0.6) 1 (0.6) 2 (0.6)
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TABLE 52 Baseline characteristics of trial participants with valid PRWE data by time point (6 and 12 weeks)
(continued )
Characteristic
6 weeks 12 weeks
Surgery
(N= 176)
Plaster cast
(N= 172)
Total
(N= 348)
Surgery
(N= 178)
Plaster cast
(N= 163)
Total
(N= 341)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 10 (1, 30) 10 (1, 40) 10 (1, 20) 10 (1, 30) 10 (1, 30)
Number of years, median
(min., max.)
10 (1, 50) 10 (1, 30) 10 (1, 50) 10 (1, 50) 10 (1, 36) 10 (1, 50)
Past smoker, n (%)
Yes 95 (54) 80 (46.5) 175 (50.3) 95 (53.4) 69 (42.3) 164 (48.1)
No 73 (41.5) 83 (48.3) 156 (44.8) 71 (39.9) 87 (53.4) 158 (46.3)
Missing 8 (4.5) 9 (5.2) 17 (4.9) 12 (6.7) 7 (4.3) 19 (5.6)
Diabetes, n (%)
Yes 6 (3.4) 3 (1.7) 9 (2.6) 6 (3.4) 4 (2.5) 10 (2.9)
No 170 (96.6) 169 (98.3) 339 (97.4) 171 (96.1) 159 (97.5) 330 (96.8)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.3)
Steroid use, n (%)
Yes 5 (2.8) 3 (1.7) 8 (2.3) 4 (2.2) 4 (2.5) 8 (2.3)
No 171 (97.2) 169 (98.3) 340 (97.7) 173 (97.2) 159 (97.5) 332 (97.4)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.3)
Max., maximum; min., minimum.
TABLE 53 Baseline fracture details of trial participants with valid PRWE data by time point (6 and 12 weeks)
Characteristic
6 weeks 12 weeks
Surgery
(N= 176)
Plaster cast
(N= 172)
Total
(N= 348)
Surgery
(N= 178)
Plaster cast
(N= 163)
Total
(N= 341)
Time since injury, daysa
n 176 172 348 178 163 341
Mean (SD) 4.8 (3.0) 5.4 (3.5) 5.1 (3.3) 4.9 (3.0) 5.5 (3.4) 5.2 (3.2)
Median (min., max.) 4 (1, 4) 5 (0, 14) 4 (0, 14) 4 (1, 14) 5 (1, 14) 5 (1, 14)
Affected wrist, n (%)
Left 95 (54.0) 96 (55.8) 191 (54.9) 97 (54.5) 89 (54.6) 186 (54.5)
Right 81 (46.0) 76 (44.2) 157 (45.1) 81 (45.5) 74 (45.4) 155 (45.5)
Affected wrist is dominant hand, n (%)
Yes 80 (45.5) 73 (42.4) 153 (44) 80 (44.9) 69 (42.3) 149 (43.7)
No 96 (54.5) 99 (57.6) 195 (56) 98 (55.1) 94 (57.7) 192 (56.3)
Displacement (eligibility), n (%)
No displacement 109 (61.9) 107 (62.2) 216 (62.1) 106 (59.6) 102 (62.6) 208 (61.0)
Displacement 67 (38.1) 65 (37.8) 132 (37.9) 72 (40.4) 61 (37.4) 133 (39.0)
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TABLE 53 Baseline fracture details of trial participants with valid PRWE data by time point (6 and 12 weeks)
(continued )
Characteristic
6 weeks 12 weeks
Surgery
(N= 176)
Plaster cast
(N= 172)
Total
(N= 348)
Surgery
(N= 178)
Plaster cast
(N= 163)
Total
(N= 341)
Displacement (randomisation), n (%)
No displacement 105 (59.7) 103 (59.9) 208 (59.8) 104 (58.4) 100 (61.3) 204 (59.8)
Displacement 71 (40.3) 69 (40.1) 140 (40.2) 74 (41.6) 63 (38.7) 137 (40.2)
Radiographs,b n (%)
Elongated scaphoid view 168 (95.5) 163 (94.8) 331 (95.1) 168 (94.4) 155 (95.1) 323 (94.7)
Posterior–anterior view 174 (98.9) 170 (98.8) 344 (98.9) 175 (98.3) 161 (98.8) 336 (98.5)
45° semisupine view 124 (70.5) 129 (75.0) 253 (72.7) 123 (69.1) 121 (74.2) 244 (71.6)
Lateral view 176 (100.0) 169 (98.3) 345 (99.1) 178 (100.0) 160 (98.2) 338 (99.1)
45° semiprone view 158 (89.8) 154 (89.5) 312 (89.7) 161 (90.4) 145 (89.0) 306 (89.7)
Previous wrist problems on same side, n (%)
Yes 36 (20.5) 35 (20.3) 71 (20.4) 37 (20.8) 35 (21.5) 72 (21.1)
No 139 (79.0) 135 (78.5) 274 (78.7) 140 (78.7) 128 (78.5) 268 (78.6)
Missing 1 (0.6) 2 (1.2) 3 (0.9) 1 (0.6) 0 (0.0) 1 (0.3)
If yes, what injury?, n (%)
Previous fracture 21 (58.3) 20 (57.1) 41 (57.7) 20 (54.1) 21 (60.0) 41 (56.9)
Arthritis 1 (2.8) 1 (2.9) 2 (2.8) 1 (2.7) 1 (2.9) 2 (2.8)
Ligament, tendon or nerve
injury
8 (22.2) 7 (20) 15 (21.1) 9 (24.3) 8 (22.9) 17 (23.6)
Other 6 (16.7) 7 (20) 13 (18.3) 6 (16.2) 5 (14.3) 11 (15.3)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.7) 0 (0.0) 1 (1.4)
Injury mechanism, n (%)
Fall – standing 19 (10.8) 23 (13.4) 42 (12.1) 23 (12.9) 19 (11.7) 42 (12.3)
Fall – walking 21 (11.9) 20 (11.6) 41 (11.8) 22 (12.4) 17 (10.4) 39 (11.4)
Fall – running 32 (18.2) 28 (16.3) 60 (17.2) 35 (19.7) 28 (17.2) 63 (18.5)
Fall – from height 22 (12.5) 28 (16.3) 50 (14.4) 22 (12.4) 27 (16.6) 49 (14.4)
Fall – from moving object 37 (21.0) 27 (15.7) 64 (18.4) 35 (19.7) 29 (17.8) 64 (18.8)
Hit on palm of hand – object
striking palm
14 (8.0) 11 (6.4) 25 (7.2) 12 (6.7) 13 (8.0) 25 (7.3)
Hit on palm of hand – handle
whipping back
6 (3.4) 9 (5.2) 15 (4.3) 5 (2.8) 8 (4.9) 13 (3.8)
Hit on palm of hand – other
sudden extension
10 (5.7) 5 (2.9) 15 (4.3) 9 (5.1) 3 (1.8) 12 (3.5)
Punched something 3 (1.7) 7 (4.1) 10 (2.9) 4 (2.2) 6 (3.7) 10 (2.9)
Road traffic accident 9 (5.1) 6 (3.5) 15 (4.3) 9 (5.1) 6 (3.7) 15 (4.4)
Other 3 (1.7) 8 (4.7) 11 (3.2) 2 (1.1) 7 (4.3) 9 (2.6)
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TABLE 53 Baseline fracture details of trial participants with valid PRWE data by time point (6 and 12 weeks)
(continued )
Characteristic
6 weeks 12 weeks
Surgery
(N= 176)
Plaster cast
(N= 172)
Total
(N= 348)
Surgery
(N= 178)
Plaster cast
(N= 163)
Total
(N= 341)
Place of injury,b n (%)
Sport 74 (42.0) 61 (35.5) 135 (38.8) 77 (43.3) 61 (37.4) 138 (40.5)
Home 20 (11.4) 31 (18.0) 51 (14.7) 19 (10.7) 26 (16.0) 45 (13.2)
Work 17 (9.7) 16 (9.3) 33 (9.5) 18 (10.1) 14 (8.6) 32 (9.4)
Road traffic accident 23 (13.1) 27 (15.7) 50 (14.4) 21 (11.8) 29 (17.8) 50 (14.7)
Public place 39 (22.2) 38 (22.1) 77 (22.1) 39 (21.9) 36 (22.1) 75 (22.0)
Other 2 (1.1) 0 (0.0) 2 (0.6) 2 (1.1) 0 (0.0) 2 (0.6)
Missing 3 (1.7) 2 (1.2) 5 (1.4) 3 (1.7) 0 (0.0) 3 (0.9)
Treatment preference, n (%)
Surgery 75 (42.6) 76 (44.2) 151 (43.4) 77 (43.3) 75 (46.0) 152 (44.6)
No surgery 10 (5.7) 14 (8.1) 24 (6.9) 10 (5.6) 15 (9.2) 25 (7.3)
No preference 90 (51.1) 81 (47.1) 171 (49.1) 91 (51.1) 72 (44.2) 163 (47.8)
Missing 1 (0.6) 1 (0.6) 2 (0.6) 0 (0.0) 1 (0.6) 1 (0.3)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
TABLE 54 Baseline characteristics of trial participants with valid PRWE data by time point (26 and 52 weeks)
Characteristic
26 weeks 52 weeks
Surgery
(N= 156)
Plaster cast
(N= 146)
Total
(N= 302)
Surgery
(N= 186)
Plaster cast
(N= 176)
Total
(N= 362)
Gender, n (%)
Male 129 (82.7) 119 (81.5) 248 (82.1) 153 (82.3) 140 (79.5) 293 (80.9)
Female 27 (17.3) 27 (18.5) 54 (17.9) 33 (17.7) 36 (20.5) 69 (19.1)
Age (years)
n 156 146 302 186 176 362
Mean (SD) 33.2 (13.2) 34.0 (13.3) 33.6 (13.2) 33.9 (13.4) 33.9 (12.9) 33.9 (13.2)
Median (min., max.) 30 (16, 80) 30 (16, 76) 30 (16, 80) 30 (16, 80) 30 (16, 76) 30 (16, 80)
Ethnicity, n (%)
White 148 (94.9) 129 (88.4) 277 (91.7) 175 (94.1) 156 (88.6) 331 (91.4)
Black 0 (0) 3 (2.1) 3 (1) 0 (0.0) 3 (1.7) 3 (0.8)
Asian 6 (3.8) 7 (4.8) 13 (4.3) 7 (3.8) 9 (5.1) 16 (4.4)
Other 2 (1.3) 7 (4.8) 9 (3) 4 (2.2) 8 (4.5) 12 (3.3)
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TABLE 54 Baseline characteristics of trial participants with valid PRWE data by time point (26 and 52 weeks)
(continued )
Characteristic
26 weeks 52 weeks
Surgery
(N= 156)
Plaster cast
(N= 146)
Total
(N= 302)
Surgery
(N= 186)
Plaster cast
(N= 176)
Total
(N= 362)
Education, n (%)
No formal qualifications 15 (9.6) 18 (12.3) 33 (10.9) 17 (9.1) 23 (13.1) 40 (11.0)
Some qualifications/no degree 105 (67.3) 83 (56.8) 188 (62.3) 128 (68.8) 100 (56.8) 228 (63.0)
Degree or higher 35 (22.4) 45 (30.8) 80 (26.5) 40 (21.5) 53 (30.1) 93 (25.7)
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3)
Employment status, n (%)
Part-time 16 (10.3) 15 (10.3) 31 (10.3) 19 (10.2) 16 (9.1) 35 (9.7)
Full-time 91 (58.3) 81 (55.5) 172 (57) 114 (61.3) 98 (55.7) 212 (58.6)
Self-employed 13 (8.3) 20 (13.7) 33 (10.9) 16 (8.6) 27 (15.3) 43 (11.9)
Student 15 (9.6) 15 (10.3) 30 (9.9) 16 (8.6) 17 (9.7) 33 (9.1)
Retired 6 (3.8) 5 (3.4) 11 (3.6) 7 (3.8) 5 (2.8) 12 (3.3)
Looking after family/home 0 (0) 4 (2.7) 4 (1.3) 0 (0.0) 5 (2.8) 5 (1.4)
Not employed but seeking work 7 (4.5) 2 (1.4) 9 (3) 5 (2.7) 4 (2.3) 9 (2.5)
Other 7 (4.5) 4 (2.7) 11 (3.6) 8 (4.3) 4 (2.3) 12 (3.3)
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3)
Type of employment, n (%)
Unskilled manual 17 (10.9) 12 (8.2) 29 (9.6) 23 (12.4) 15 (8.5) 38 (10.5)
Skilled manual 45 (28.8) 39 (26.7) 84 (27.8) 51 (27.4) 43 (24.4) 94 (26.0)
Unskilled non-manual 13 (8.3) 9 (6.2) 22 (7.3) 19 (10.2) 10 (5.7) 29 (8.0)
Skilled non-manual 26 (16.7) 30 (20.5) 56 (18.5) 30 (16.1) 42 (23.9) 72 (19.9)
Professional 15 (9.6) 14 (9.6) 29 (9.6) 19 (10.2) 17 (9.7) 36 (9.9)
Other 13 (8.3) 19 (13) 32 (10.6) 18 (9.7) 23 (13.1) 41 (11.3)
Missing 27 (17.3) 23 (15.8) 50 (16.6) 26 (14.0) 26 (14.8) 52 (14.4)
Current smoker, n (%)
Yes 43 (27.6) 25 (17.1) 68 (22.5) 56 (30.1) 35 (19.9) 91 (25.1)
No 112 (71.8) 120 (82.2) 232 (76.8) 129 (69.4) 140 (79.5) 269 (74.3)
Missing 1 (0.6) 1 (0.7) 2 (0.7) 1 (0.5) 1 (0.6) 2 (0.6)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 10 (1, 25) 10 (1, 40) 10 (1, 40) 10 (1, 30) 10 (1, 40)
Number of years, median
(min., max.)
10 (1, 40) 8 (1, 36) 10 (1, 40) 10 (1, 50) 10 (1, 36) 10 (1, 50)
Past smoker, n (%)
Yes 78 (50) 60 (41.1) 138 (45.7) 98 (52.7) 77 (43.8) 175 (48.3)
No 66 (42.3) 80 (54.8) 146 (48.3) 76 (40.9) 92 (52.3) 168 (46.4)
Missing 12 (7.7) 6 (4.1) 18 (6) 12 (6.5) 7 (4.0) 19 (5.2)
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TABLE 54 Baseline characteristics of trial participants with valid PRWE data by time point (26 and 52 weeks)
(continued )
Characteristic
26 weeks 52 weeks
Surgery
(N= 156)
Plaster cast
(N= 146)
Total
(N= 302)
Surgery
(N= 186)
Plaster cast
(N= 176)
Total
(N= 362)
Diabetes, n (%)
Yes 5 (3.2) 4 (2.7) 9 (3) 6 (3.2) 4 (2.3) 10 (2.8)
No 150 (96.2) 142 (97.3) 292 (96.7) 179 (96.2) 172 (97.7) 351 (97.0)
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3)
Steroid use, n (%)
Yes 4 (2.6) 3 (2.1) 7 (2.3) 6 (3.2) 4 (2.3) 10 (2.8)
No 151 (96.8) 143 (97.9) 294 (97.4) 179 (96.2) 172 (97.7) 351 (97.0)
Missing 1 (0.6) 0 (0) 1 (0.3) 1 (0.5) 0 (0.0) 1 (0.3)
Max., maximum; min., minimum.
TABLE 55 Baseline fracture details of trial participants with valid PRWE data by time point (26 and 52 weeks)
Characteristic
26 weeks 52 weeks
Surgery
(N= 156)
Plaster cast
(N= 146)
Total
(N= 302)
Surgery
(N= 186)
Plaster cast
(N= 176)
Total
(N= 362)
Time since injury, daysa
n 156 146 302 186 176 362
Mean (SD) 4.7 (3.0) 5.3 (3.4) 5.0 (3.2) 4.8 (3.0) 5.3 (3.4) 5.1 (3.2)
Median (min., max.) 4 (1, 13) 4 (1, 14) 4 (1, 14) 4 (1, 14) 4 (0, 14) 4 (0, 14)
Affected wrist, n (%)
Left 82 (52.6) 82 (56.2) 164 (54.3) 101 (54.3) 94 (53.4) 195 (53.9)
Right 74 (47.4) 64 (43.8) 138 (45.7) 85 (45.7) 82 (46.6) 167 (46.1)
Affected wrist is dominant hand, n (%)
Yes 72 (46.2) 62 (42.5) 134 (44.4) 83 (44.6) 78 (44.3) 161 (44.5)
No 84 (53.8) 84 (57.5) 168 (55.6) 103 (55.4) 98 (55.7) 201 (55.5)
Displacement (eligibility), n (%)
No displacement 96 (61.5) 89 (61.0) 185 (61.3) 114 (61.3) 106 (60.2) 220 (60.8)
Displacement 60 (38.5) 57 (39.0) 117 (38.7) 72 (38.7) 70 (39.8) 142 (39.2)
Displacement (randomisation), n (%)
No displacement 92 (59.0) 88 (60.3) 180 (59.6) 110 (59.1) 103 (58.5) 213 (58.8)
Displacement 64 (41.0) 58 (39.7) 122 (40.4) 76 (40.9) 73 (41.5) 149 (41.2)
Radiographs,b n (%)
Elongated scaphoid view 147 (94.2) 138 (94.5) 285 (94.4) 177 (95.2) 167 (94.9) 344 (95.0)
Posterior–anterior view 154 (98.7) 145 (99.3) 299 (99.0) 183 (98.4) 174 (98.9) 357 (98.6)
45° semisupine view 109 (69.9) 109 (74.7) 218 (72.2) 131 (70.4) 131 (74.4) 262 (72.4)
Lateral view 156 (100.0) 144 (98.6) 300 (99.3) 186 (100.0) 173 (98.3) 359 (99.2)
45° semiprone view 139 (89.1) 133 (91.1) 272 (90.1) 169 (90.9) 158 (89.8) 327 (90.3)
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TABLE 55 Baseline fracture details of trial participants with valid PRWE data by time point (26 and 52 weeks)
(continued )
Characteristic
26 weeks 52 weeks
Surgery
(N= 156)
Plaster cast
(N= 146)
Total
(N= 302)
Surgery
(N= 186)
Plaster cast
(N= 176)
Total
(N= 362)
Previous wrist problems on same side, n (%)
Yes 34 (21.8) 35 (24.0) 69 (22.8) 37 (19.9) 37 (21) 74 (20.4)
No 121 (77.6) 111 (76.0) 232 (76.8) 148 (79.6) 138 (78.4) 286 (79.0)
Missing 1 (0.6) 0 (0.0) 1 (0.3) 1 (0.5) 1 (0.6) 2 (0.6)
If yes, what injury?, n (%)
Previous fracture 20 (58.8) 22 (62.9) 42 (60.9) 21 (56.8) 23 (62.2) 44 (59.5)
Arthritis 2 (5.9) 1 (2.9) 3 (4.3) 1 (2.7) 1 (2.7) 2 (2.7)
Ligament, tendon or nerve injury 6 (17.6) 8 (22.9) 14 (20.3) 7 (18.9) 8 (21.6) 15 (20.3)
Other 5 (14.7) 4 (11.4) 9 (13.0) 6 (16.2) 5 (13.5) 11 (14.9)
Missing 1 (2.9) 0 (0.0) 1 (1.4) 2 (5.4) 0 (0) 2 (2.7)
Injury mechanism, n (%)
Fall – standing 18 (11.5) 22 (15.1) 40 (13.2) 26 (14.0) 23 (13.1) 49 (13.5)
Fall – walking 16 (10.3) 18 (12.3) 34 (11.3) 20 (10.8) 20 (11.4) 40 (11.0)
Fall – running 32 (20.5) 26 (17.8) 58 (19.2) 36 (19.4) 28 (15.9) 64 (17.7)
Fall – from height 17 (10.9) 20 (13.7) 37 (12.3) 23 (12.4) 25 (14.2) 48 (13.3)
Fall – from moving object 35 (22.4) 26 (17.8) 61 (20.2) 36 (19.4) 29 (16.5) 65 (18.0)
Hit on palm of hand – object
striking palm
13 (8.3) 8 (5.5) 21 (7.0) 12 (6.5) 13 (7.4) 25 (6.9)
Hit on palm of hand – handle
whipping back
7 (4.5) 8 (5.5) 15 (5.0) 7 (3.8) 10 (5.7) 17 (4.7)
Hit on palm of hand – other
sudden extension
7 (4.5) 2 (1.4) 9 (3.0) 10 (5.4) 6 (3.4) 16 (4.4)
Punched something 1 (0.6) 6 (4.1) 7 (2.3) 3 (1.6) 8 (4.5) 11 (3)
Road traffic accident 8 (5.1) 4 (2.7) 12 (4.0) 9 (4.8) 6 (3.4) 15 (4.1)
Other 2 (1.3) 6 (4.1) 8 (2.6) 4 (2.2) 8 (4.5) 12 (3.3)
Place of injury,b n (%)
Sport 70 (44.9) 55 (37.7) 125 (41.4) 76 (40.9) 63 (35.8) 139 (38.4)
Home 16 (10.3) 25 (17.1) 41 (13.6) 22 (11.8) 34 (19.3) 56 (15.5)
Work 15 (9.6) 12 (8.2) 27 (8.9) 19 (10.2) 15 (8.5) 34 (9.4)
Road traffic accident 21 (13.5) 23 (15.8) 44 (14.6) 22 (11.8) 30 (17.0) 52 (14.4)
Public place 31 (19.9) 34 (23.3) 65 (21.5) 44 (23.7) 35 (19.9) 79 (21.8)
Other 2 (1.3) 0 (0.0) 2 (0.7) 2 (1.1) 0 (0.0) 2 (0.6)
Missing 3 (1.9) 0 (0.0) 3 (1.0) 3 (1.6) 2 (1.1) 5 (1.4)
Treatment preference, n (%)
Surgery 69 (44.2) 64 (43.8) 133 (44.0) 82 (44.1) 81 (46.0) 163 (45.0)
No surgery 8 (5.1) 12 (8.2) 20 (6.6) 10 (5.4) 14 (8.0) 24 (6.6)
No preference 79 (50.6) 70 (47.9) 149 (49.3) 94 (50.5) 80 (45.5) 174 (48.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.3)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
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TABLE 56 Displacement of fractures as stratified on in the randomisation (based on radiographic images at time of
enrolment) and as agreed by three independent reviews (based on baseline radiographs and CT imaging)
Displacement agreed by three
raters from baseline CT and
radiographic images, n (%)
Surgery (N= 219) Plaster cast (N= 220)
No displacement
(N= 131)
Displacement
(N= 88)
No displacement
(N= 130)
Displacement
(N= 90)
< 1mm 106 (80.9) 54 (61.4) 107 (82.3) 58 (64.4)
1–2mm, inclusive 19 (14.5) 26 (29.6) 20 (15.4) 21 (23.3)
> 2 mm 5 (3.8) 8 (9.1) 3 (2.3) 11 (12.2)
Missing 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
TABLE 57 Descriptive PRWE statistics over time by randomised group and treatment preference at baseline
Time point Surgery Plaster cast Total
No preference
Pre injury
Mean (SD) 4.5 (14.1) 3.1 (12.1) 3.8 (13.2)
Median (IQR) 0.0 (0.0–3.0) 0.0 (0.0–1.0) 0.0 (0.0–2.0)
Min., max. (0, 85) (0, 80.11111) (0, 85)
Baseline (post injury)
Mean (SD) 72.9 (20.9) 70.0 (19.7) 71.5 (20.3)
Median (IQR) 78.5 (64.0–88.0) 73.0 (59.5–84.5) 75.0 (62.0–86.5)
Min., max. (0, 100) (0, 100) (0, 100)
6 weeks
Mean (SD) 33.8 (21.1) 35.9 (19.0) 34.8 (20.1)
Median (IQR) 31.3 (18.0–46.5) 35.5 (19.5–49.0) 34.0 (19.0–48.0)
Min., max. (3, 82) (0, 80) (0, 82)
12 weeks
Mean (SD) 20.3 (20.5) 24.8 (21.5) 22.3 (21.0)
Median (IQR) 11.5 (5.5–28.5) 20.3 (8.0–31.5) 16.5 (6.0–30.5)
Min., max. (0, 89.5) (0, 90) (0, 90)
26 weeks
Mean (SD) 16.1 (18.9) 15.3 (16.7) 15.7 (17.8)
Median (IQR) 9.0 (4.0–20.0) 10.5 (4.0–18.0) 9.5 (4.0–18.5)
Min., max. (0, 84) (0, 77) (0, 84)
52 weeks
Mean (SD) 12.0 (18.1) 13.3 (18.7) 12.6 (18.3)
Median (IQR) 4.0 (0.0–13.0) 4.8 (0.3–16.3) 4.3 (0.0–15.0)
Min., max. (0, 85.5) (0, 80.5) (0, 85.5)
Preference for surgery
Pre injury
Mean (SD) 1.7 (5.5) 4.4 (12.6) 3.1 (9.9)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.0 (0.0–0.0)
Min., max. (0, 42) (0, 90.5) (0, 90.5)
Baseline (post injury)
Mean (SD) 74.5 (19.1) 76.9 (14.5) 75.7 (16.9)
Median (IQR) 77.8 (65.4–88.0) 78.5 (70.0–89.5) 78.5 (68.0–89.0)
Min., max. (0, 98) (27, 96.5) (0, 98)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
168
TABLE 57 Descriptive PRWE statistics over time by randomised group and treatment preference at baseline (continued )
Time point Surgery Plaster cast Total
6 weeks
Mean (SD) 37.0 (21.3) 40.7 (23.1) 38.8 (22.2)
Median (IQR) 34.5 (19.0–52.0) 38.8 (24.3–55.3) 37.5 (22.0–53.5)
Min., max. (4, 85.5) (0, 100) (0, 100)
12 weeks
Mean (SD) 21.7 (19.1) 26.9 (22.8) 24.2 (21.1)
Median (IQR) 17.0 (7.0–30.0) 18.5 (10.0–35.5) 18.0 (9.8–33.0)
Min., max. (0, 80.5) (0, 84.5) (0, 84.5)
26 weeks
Mean (SD) 16.0 (18.1) 13.7 (19.2) 14.9 (18.6)
Median (IQR) 10.0 (3.0–22.0) 8.0 (0.0–16.7) 9.5 (1.0–19.0)
Min., max. (0, 74) (0, 91.5) (0, 91.5)
52 weeks
Mean (SD) 10.2 (14.4) 15.0 (21.1) 12.6 (18.1)
Median (IQR) 4.5 (0.5–14.0) 4.0 (0.0–24.5) 4.5 (0.0–17.5)
Min., max. (0, 64) (0, 96) (0, 96)
Preference for no surgery
Pre injury
Mean (SD) 2.2 (5.3) 2.3 (4.9) 2.3 (5.0)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–3.0) 0.0 (0.0–2.0)
Min., max. (0, 17) (0, 19.5) (0, 19.5)
Baseline (post injury)
Mean (SD) 77.1 (15.2) 67.5 (15.2) 71.6 (15.7)
Median (IQR) 78.8 (69.8–86.0) 68.5 (62.3–78.0) 72.8 (64.3–81.5)
Min., max. (43, 100) (36, 94) (36, 100)
6 weeks
Mean (SD) 42.1 (24.8) 46.2 (17.3) 44.5 (20.4)
Median (IQR) 45.0 (23.5–54.5) 48.5 (30.0–58.5) 46.3 (28.5–57.8)
Min., max. (4, 78.5) (16.5, 72.5) (4, 78.5)
12 weeks
Mean (SD) 17.5 (16.3) 27.2 (19.0) 23.3 (18.3)
Median (IQR) 14.8 (4.5–25.0) 24.0 (8.0–45.0) 23.0 (8.0–43.5)
Min., max. (0, 54.5) (0, 57) (0, 57)
26 weeks
Mean (SD) 9.1 (8.8) 21.6 (16.4) 16.6 (15.0)
Median (IQR) 6.0 (2.5–15.0) 16.8 (11.5–30.5) 13.5 (5.0–24.3)
Min., max. (0, 25.5) (0, 51) (0, 51)
52 weeks
Mean (SD) 15.8 (19.5) 15.5 (18.7) 15.6 (18.6)
Median (IQR) 8.0 (2.0–24.5) 9.5 (2.0–27.5) 9.5 (2.0–26.0)
Min., max. (0, 60) (0, 66) (0, 66)
Max., maximum; min., minimum.
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TABLE 58 Descriptive PRWE statistics over time by randomised group and fracture displacement (as randomised)
at baseline
Time point Surgery Plaster cast Total
Fracture displaced < 1mm
Pre injury
Mean (SD) 3.6 (12.3) 3.8 (12.8) 3.7 (12.5)
Median (IQR) 0.0 (0.0–1.1) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Min., max. (0, 85) (0, 90.5) (0, 90.5)
Baseline (post injury)
Mean (SD) 73.3 (20.4) 73.3 (18.7) 73.3 (19.5)
Median (IQR) 78.0 (69.0–87.0) 76.3 (64.0–87.0) 77.5 (65.9–87.0)
Min., max. (0, 98) (0, 100) (0, 100)
6 weeks
Mean (SD) 34.4 (21.1) 38.8 (21.3) 36.5 (21.2)
Median (IQR) 32.5 (18.0–49.0) 38.0 (23.0–54.5) 35.0 (19.5–52.0)
Min., max. (3, 82) (0, 100) (0, 100)
12 weeks
Mean (SD) 18.8 (17.7) 23.0 (18.9) 20.8 (18.3)
Median (IQR) 13.8 (5.8–24.5) 18.8 (9.1–30.8) 17.0 (6.8–28.3)
Min., max. (0, 73.3) (0, 90) (0, 90)
26 weeks
Mean (SD) 14.8 (16.8) 13.2 (16.3) 14.0 (16.5)
Median (IQR) 9.4 (3.5–19.5) 8.3 (0.5–16.0) 9.1 (2.0–17.8)
Min., max. (0, 84) (0, 77) (0, 84)
52 weeks
Mean (SD) 11.0 (17.0) 13.0 (19.4) 12.0 (18.2)
Median (IQR) 4.3 (0.0–12.5) 4.0 (0.0–18.0) 4.0 (0.0–15.0)
Min., max. (0, 85.5) (0, 88) (0, 88)
Fracture displaced ≥ 1mm and ≤ 2mm
Pre injury
Mean (SD) 2.4 (8.0) 3.3 (10.4) 2.8 (9.2)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Min., max. (0, 64.7) (0, 76) (0, 76)
Baseline (post injury)
Mean (SD) 74.7 (18.9) 73.1 (15.5) 73.9 (17.3)
Median (IQR) 79.5 (61.5–90.0) 75.0 (62.9–85.0) 76.8 (62.0–87.5)
Min., max. (0, 100) (34, 99) (0, 100)
6 weeks
Mean (SD) 37.7 (21.8) 38.7 (20.6) 38.2 (21.1)
Median (IQR) 34.5 (22.5–51.5) 39.0 (19.5–50.5) 36.0 (20.5–51.0)
Min., max. (4, 85.5) (4, 90.5) (4, 90.5)
12 weeks
Mean (SD) 23.4 (22.0) 30.5 (25.3) 26.7 (23.7)
Median (IQR) 16.3 (6.5–38.5) 22.5 (8.0–49.5) 18.0 (8.0–45.0)
Min., max. (0, 89.5) (0, 84.5) (0, 89.5)
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TABLE 58 Descriptive PRWE statistics over time by randomised group and fracture displacement (as randomised)
at baseline (continued )
Time point Surgery Plaster cast Total
26 weeks
Mean (SD) 16.9 (19.9) 18.0 (19.7) 17.4 (19.8)
Median (IQR) 8.2 (3.3–23.5) 12.3 (4.0–26.0) 10.5 (3.5–25.5)
Min., max. (0, 74) (0, 91.5) (0, 91.5)
52 weeks
Mean (SD) 12.0 (16.1) 15.8 (20.2) 13.9 (18.3)
Median (IQR) 4.0 (0.3–16.3) 8.5 (1.0–21.5) 6.5 (0.5–18.5)
Min., max. (0, 64) (0, 96) (0, 96)
Max., maximum; min., minimum.
TABLE 59 Descriptive PRWE statistics over time by randomised group and fracture displacement (as recorded on
study eligibility form) at baseline
Time point Surgery Plaster cast Total
Fracture displaced < 1mm
Pre injury
Mean (SD) 3.6 (12.3) 3.2 (11.9) 3.4 (12.1)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
Min., max. (0, 85) (0, 90.5) (0, 90.5)
Baseline (post injury)
Mean (SD) 73.2 (20.1) 72.5 (18.8) 72.9 (19.4)
Median (IQR) 78.0 (68.5–87.0) 76.0 (63.0–87.0) 77.0 (64.5–87.0)
Min., max. (0, 98) (0, 100) (0, 100)
6 weeks
Mean (SD) 33.6 (20.7) 38.2 (21.5) 35.9 (21.2)
Median (IQR) 32.0 (18.0–46.5) 36.0 (21.5–54.5) 34.3 (18.8–50.8)
Min., max. (3, 82) (0, 100) (0, 100)
12 weeks
Mean (SD) 18.1 (16.9) 22.7 (19.4) 20.3 (18.3)
Median (IQR) 13.3 (5.5–24.0) 18.3 (8.0–31.0) 16.0 (6.3–27.8)
Min., max. (0, 73.3) (0, 90) (0, 90)
26 weeks
Mean (SD) 14.0 (15.1) 13.0 (16.0) 13.5 (15.5)
Median (IQR) 9.0 (3.5–18.8) 8.5 (0.0–16.0) 9.0 (2.0–17.0)
Min., max. (0, 60) (0, 77) (0, 77)
52 weeks
Mean (SD) 10.4 (15.9) 13.3 (19.5) 11.8 (17.8)
Median (IQR) 4.0 (0.0–12.5) 4.0 (0.0–18.5) 4.0 (0.0–15.0)
Min., max. (0, 85.5) (0, 88) (0, 88)
Fracture displaced ≥ 1mm and ≤ 2mm
Pre injury
Mean (SD) 2.4 (8.0) 4.2 (11.8) 3.3 (10.1)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–1.5) 0.0 (0.0–1.3)
Min., max. (0, 64.7) (0, 76) (0, 76)
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TABLE 59 Descriptive PRWE statistics over time by randomised group and fracture displacement (as recorded on
study eligibility form) at baseline (continued )
Time point Surgery Plaster cast Total
Baseline (post injury)
Mean (SD) 74.9 (19.3) 74.2 (14.9) 74.6 (17.2)
Median (IQR) 79.5 (61.5–90.0) 76.3 (65.0–85.5) 78.5 (63.0–88.0)
Min., max. (0, 100) (34, 99) (0, 100)
6 weeks
Mean (SD) 39.1 (22.1) 39.7 (20.2) 39.4 (21.1)
Median (IQR) 35.0 (22.5–53.5) 39.5 (25.0–50.5) 38.4 (23.3–51.8)
Min., max. (4, 85.5) (4, 90.5) (4, 90.5)
12 weeks
Mean (SD) 24.6 (22.6) 31.1 (24.6) 27.6 (23.7)
Median (IQR) 16.8 (6.8–38.8) 23.0 (11.5–48.5) 18.5 (9.5–45.4)
Min., max. (0, 89.5) (0, 84.5) (0, 89.5)
26 weeks
Mean (SD) 18.4 (22.0) 18.4 (20.1) 18.4 (21.0)
Median (IQR) 9.3 (3.3–24.5) 12.0 (5.0–26.0) 10.5 (3.5–25.5)
Min., max. (0, 84) (0, 91.5) (0, 91.5)
52 weeks
Mean (SD) 13.0 (17.6) 15.5 (20.2) 14.2 (18.9)
Median (IQR) 4.3 (0.5–17.5) 8.8 (1.0–21.0) 7.3 (0.5–18.5)
Min., max. (0, 72.5) (0, 96) (0, 96)
Max., maximum; min., minimum.
TABLE 60 Baseline characteristics of trial participants according to whether or not they had surgical screw
penetration likely to cause cartilage damage (surgery group only), and whether surgery was required for
non-union (plaster cast group only)
Characteristic
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery
required
(N= 19)
No surgery
required
(N= 195)
Gender, n (%)
Male 65 (87.8) 58 (85.3) 14 (73.7) 164 (84.1)
Female 9 (12.2) 10 (14.7) 5 (26.3) 31 (15.9)
Age, years
n 74 68 19 195
Mean (SD) 33.1 (13.6) 33.2 (13.4) 29.8 (10.3) 33.3 (12.4)
Median (min., max.) 30 (16, 69) 30 (16, 80) 26 (18, 51) 29 (16, 76)
Ethnicity, n (%)
White 69 (93.2) 64 (94.1) 13 (68.4) 177 (90.8)
Black 0 (0.0) 0 (0.0) 2 (10.5) 2 (1.0)
Asian 2 (2.7) 3 (4.4) 2 (10.5) 8 (4.1)
Other 3 (4.1) 1 (1.5) 2 (10.5) 8 (4.1)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
TABLE 60 Baseline characteristics of trial participants according to whether or not they had surgical screw
penetration likely to cause cartilage damage (surgery group only), and whether surgery was required for
non-union (plaster cast group only) (continued )
Characteristic
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery
required
(N= 19)
No surgery
required
(N= 195)
Education, n (%)
No formal qualifications 6 (8.1) 3 (4.4) 0 (0.0) 27 (13.8)
Some qualifications/no degree 47 (63.5) 53 (77.9) 17 (89.5) 109 (55.9)
Degree or higher 21 (28.4) 12 (17.6) 2 (10.5) 59 (30.3)
Employment status, n (%)
Part-time 6 (8.1) 7 (10.3) 2 (10.5) 16 (8.2)
Full-time 52 (70.3) 39 (57.4) 9 (47.4) 110 (56.4)
Self-employed 5 (6.8) 6 (8.8) 2 (10.5) 32 (16.4)
Student 5 (6.8) 6 (8.8) 4 (21.1) 15 (7.7)
Retired 4 (5.4) 3 (4.4) 0 (0.0) 5 (2.6)
Looking after family/home 0 (0.0) 0 (0.0) 1 (5.3) 5 (2.6)
Not employed but seeking work 1 (1.4) 2 (2.9) 0 (0.0) 5 (2.6)
Other 0 (0.0) 5 (7.4) 1 (5.3) 7 (3.6)
Missing 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
Type of employment, n (%)
Unskilled manual 6 (8.1) 8 (11.8) 4 (21.1) 19 (9.7)
Skilled manual 22 (29.7) 17 (25.0) 6 (31.6) 51 (26.2)
Unskilled non-manual 3 (4.1) 11 (16.2) 1 (5.3) 11 (5.6)
Skilled non-manual 17 (23) 7 (10.3) 2 (10.5) 43 (22.1)
Professional 9 (12.2) 8 (11.8) 1 (5.3) 18 (9.2)
Other 9 (12.2) 6 (8.8) 1 (5.3) 29 (14.9)
Missing 8 (10.8) 11 (16.2) 4 (21.1) 24 (12.3)
Current smoker, n (%)
Yes 21 (28.4) 22 (32.4) 6 (31.6) 48 (24.6)
No 52 (70.3) 46 (67.6) 13 (68.4) 146 (74.9)
Missing 1 (1.4) 0 (0.0) 0 (0.0) 1 (0.5)
If yes
Number of cigarettes per day, median
(min., max.)
10 (1, 20) 9 (2, 20) 10 (1, 12) 10 (1, 30)
Number of years, median
(min., max.)
10 (2, 50) 10 (4, 36) 20 (1, 30) 10 (1, 36)
Past smoker, n (%)
Yes 38 (51.4) 37 (54.4) 11 (57.9) 94 (48.2)
No 32 (43.2) 27 (39.7) 7 (36.8) 92 (47.2)
Missing 4 (5.4) 4 (5.9) 1 (5.3) 9 (4.6)
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TABLE 60 Baseline characteristics of trial participants according to whether or not they had surgical screw
penetration likely to cause cartilage damage (surgery group only), and whether surgery was required for
non-union (plaster cast group only) (continued )
Characteristic
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery
required
(N= 19)
No surgery
required
(N= 195)
Diabetes, n (%)
Yes 2 (2.7) 3 (4.4) 0 (0.0) 4 (2.1)
No 71 (95.9) 65 (95.6) 19 (100.0) 191 (97.9)
Missing 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
Steroid use, n (%)
Yes 3 (4.1) 1 (1.5) 1 (5.3) 3 (1.5)
No 70 (94.6) 67 (98.5) 18 (94.7) 192 (98.5)
Missing 1 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
Max., maximum; min., minimum.
a Allocated to surgery group, received surgery and had CT imaging reviewed at 52 weeks by independent raters.
b Allocated to plaster cast group and did not cross over to receive immediate surgical fixation.
TABLE 61 Baseline fracture details of trial participants according to whether or not they had surgical screw
penetration likely to cause cartilage damage (surgery group only), and whether surgery was required for
non-union (plaster cast group only)
Characteristic
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery
required
(N= 19)
No surgery
required
(N= 195)
Time since injury, daysc
n 74 68 19 195
Mean (SD) 5.1 (3.2) 4.6 (3.0) 6.8 (3.5) 5.2 (3.3)
Median (min., max.) 4 (1, 14) 4 (1, 13) 6 (1, 14) 4 (0, 14)
Affected wrist, n (%)
Left 37 (50.0) 34 (50.0) 11 (57.9) 103 (52.8)
Right 37 (50.0) 34 (50.0) 8 (42.1) 92 (47.2)
Affected wrist is dominant hand, n (%)
Yes 34 (45.9) 32 (47.1) 8 (42.1) 85 (43.6)
No 40 (54.1) 36 (52.9) 11 (57.9) 110 (56.4)
Displacement (eligibility), n (%)
No displacement 39 (52.7) 42 (61.8) 8 (42.1) 123 (63.1)
Displacement 35 (47.3) 26 (38.2) 11 (57.9) 72 (36.9)
Displacement (randomisation), n (%)
No displacement 40 (54.1) 41 (60.3) 8 (42.1) 119 (61.0)
Displacement 34 (45.9) 27 (39.7) 11 (57.9) 76 (39.0)
Radiographs,d n (%)
Elongated scaphoid view 71 (95.9) 65 (95.6) 19 (100.0) 185 (94.9)
Posterior–anterior view 74 (100.0) 66 (97.1) 19 (100.0) 193 (99.0)
45° semisupine view 54 (73.0) 45 (66.2) 15 (78.9) 146 (74.9)
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TABLE 61 Baseline fracture details of trial participants according to whether or not they had surgical screw
penetration likely to cause cartilage damage (surgery group only), and whether surgery was required for
non-union (plaster cast group only) (continued )
Characteristic
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery
required
(N= 19)
No surgery
required
(N= 195)
Lateral view 74 (100.0) 68 (100.0) 19 (100.0) 192 (98.5)
45° semiprone view 70 (94.6) 57 (83.8) 15 (78.9) 176 (90.3)
Previous wrist problems on same side, n (%)
Yes 12 (16.2) 18 (26.5) 6 (31.6) 38 (19.5)
No 62 (83.8) 49 (72.1) 12 (63.2) 157 (80.5)
Missing 0 (0.0) 1 (1.5) 1 (5.3) 0 (0.0)
If yes, what injury?, n (%)
Previous fracture 5 (41.7) 10 (55.6) 3 (50.0) 24 (63.2)
Arthritis 1 (8.3) 0 (0.0) 0 (0.0) 1 (2.6)
Ligament, tendon or nerve injury 4 (33.3) 4 (22.2) 0 (0.0) 8 (21.1)
Other 1 (8.3) 3 (16.7) 3 (50.0) 5 (13.2)
Missing 1 (8.3) 1 (5.6) 0 (0.0) 0 (0.0)
Injury mechanism, n (%)
Fall – standing 9 (12.2) 9 (13.2) 2 (10.5) 26 (13.3)
Fall – walking 6 (8.1) 7 (10.3) 0 (0.0) 23 (11.8)
Fall – running 11 (14.9) 18 (26.5) 1 (5.3) 35 (17.9)
Fall – from height 10 (13.5) 10 (14.7) 4 (21.1) 29 (14.9)
Fall – from moving object 19 (25.7) 11 (16.2) 1 (5.3) 30 (15.4)
Hit on palm of hand – object striking palm 4 (5.4) 3 (4.4) 3 (15.8) 12 (6.2)
Hit on palm of hand – handle whipping back 3 (4.1) 3 (4.4) 3 (15.8) 8 (4.1)
Hit on palm of hand – other sudden extension 5 (6.8) 3 (4.4) 0 (0.0) 7 (3.6)
Punched something 1 (1.4) 1 (1.5) 1 (5.3) 11 (5.6)
Road traffic accident 5 (6.8) 1 (1.5) 1 (5.3) 7 (3.6)
Other 1 (1.4) 2 (2.9) 3 (15.8) 7 (3.6)
Place of injury,d n (%)
Sport 31 (41.9) 32 (47.1) 7 (36.8) 68 (34.9)
Home 6 (8.1) 10 (14.7) 2 (10.5) 40 (20.5)
Work 7 (9.5) 4 (5.9) 1 (5.3) 17 (8.7)
Road traffic accident 12 (16.2) 5 (7.4) 3 (15.8) 30 (15.4)
Public place 18 (24.3) 16 (23.5) 5 (26.3) 42 (21.5)
Other 0 (0.0) 1 (1.5) 0 (0.0) 0 (0.0)
Missing 1 (1.4) 1 (1.5) 1 (5.3) 1 (0.5)
Treatment preference, n (%)
Surgery 31 (41.9) 25 (36.8) 10 (52.6) 85 (43.6)
No surgery 7 (9.5) 2 (2.9) 1 (5.3) 18 (9.2)
No preference 36 (48.6) 41 (60.3) 8 (42.1) 91 (46.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
Max., maximum; min., minimum.
a Allocated to surgery group, received surgery and had CT imaging reviewed at 52 weeks by independent raters.
b Allocated to plaster cast group and did not cross over to receive immediate surgical fixation.
c Time from injury to screening.
d Categories not mutually exclusive.
DOI: 10.3310/hta24520 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 52
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dias et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
175
TABLE 62 The PRWE total and subscale scores for the surgery group stratified by whether or not participants had a
complication caused by their surgical screw and for the plaster cast group over time stratified by whether or not
participants had to have surgery owing to non-union
PRWE score
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery required
(N= 19)
No surgery
required (N= 195)
Baseline (pre injury)
Pain subscale Mean (SD) 3.5 (9.9) 1.9 (4.6) 1.7 (4.7) 2.3 (6.3)
Median (IQR) 0.0 (0.0–2.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–1.0)
Min., max. (0, 50) (0, 24) (0, 16.3) (0, 39)
Function subscale Mean (SD) 2.0 (8.2) 0.6 (2.6) 1.3 (4.4) 0.9 (4.6)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Min., max. (0, 43) (0, 18) (0, 18.5) (0, 41.1)
Total Mean (SD) 5.5 (16.9) 2.5 (6.7) 3.0 (9.0) 3.1 (10.2)
Median (IQR) 0.0 (0.0–2.5) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–1.0)
Min., max. (0, 85) (0, 42) (0, 34.8) (0, 80.1)
Baseline (post injury)
Pain subscale Mean (SD) 34.9 (11.4) 33.8 (11.7) 36.1 (8.2) 34.0 (9.8)
Median (IQR) 39.5 (30.0–43.0) 36.0 (28.0–43.0) 39.0 (30.0–43.0) 35.0 (28.0–42.0)
Min., max. (0, 50) (0, 50) (21, 46.25) (0, 50)
Function subscale Mean (SD) 38.7 (10.9) 38.2 (11.3) 38.0 (11.2) 38.6 (10.0)
Median (IQR) 41.5 (32.5–47.0) 41.3 (33.3–46.5) 42.0 (32.0–46.5) 40.3 (33.5–46.0)
Min., max. (0, 50) (0, 50) (8.5, 49) (0, 50)
Total Mean (SD) 73.8 (21.2) 72.0 (21.2) 74.1 (16.1) 73.0 (17.5)
Median (IQR) 79.5 (69.0–89.0) 77.0 (59.5–87.4) 76.6 (58.0–86.5) 75.5 (63.8–86.3)
Min., max. (0, 98) (0, 100) (48.5, 94.5) (0, 100)
6 weeks
Pain subscale Mean (SD) 18.0 (10.1) 19.1 (10.9) 20.2 (13.1) 18.1 (10.2)
Median (IQR) 17.0 (10.0–25.0) 19.0 (10.5–27.0) 18.0 (10.0–22.0) 17.0 (10.0–26.0)
Min., max. (3, 39) (0, 44) (6, 48) (0, 47)
Function subscale Mean (SD) 17.1 (13.4) 16.2 (12.2) 23.0 (16.2) 19.9 (11.8)
Median (IQR) 15.0 (4.3–25.8) 12.5 (7.0–22.5) 19.5 (9.0–31.0) 19.0 (10.0–26.5)
Min., max. (0, 44) (0, 47) (4, 50) (0, 46.5)
Total Mean (SD) 35.1 (21.5) 35.2 (21.2) 43.1 (26.8) 38.2 (19.8)
Median (IQR) 33.3 (17.5–52.3) 32.0 (19.5–46.5) 42.5 (19.0–53.0) 38.0 (23.0–51.5)
Min., max. (4, 77) (3, 85.5) (11, 98) (0, 90.5)
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TABLE 62 The PRWE total and subscale scores for the surgery group stratified by whether or not participants had a
complication caused by their surgical screw and for the plaster cast group over time stratified by whether or not
participants had to have surgery owing to non-union (continued )
PRWE score
Surgery (N= 142)a Plaster cast (N= 214)b
No surgical screw
complication
(N= 74)
Surgical screw
complication
(N= 68)
Surgery required
(N= 19)
No surgery
required (N= 195)
12 weeks
Pain subscale Mean (SD) 11.4 (10.3) 13.7 (10.6) 21.9 (13.0) 13.9 (10.8)
Median (IQR) 8.0 (3.0–17.0) 10.0 (6.0–20.0) 22.5 (14.0–34.0) 11.0 (5.0–19.0)
Min., max. (0, 41) (0, 45) (0, 41) (0, 47)
Function subscale Mean (SD) 6.7 (8.4) 8.7 (9.9) 23.0 (13.3) 10.1 (10.7)
Median (IQR) 4.0 (0.5–10.0) 4.8 (1.5–12.0) 25.5 (12.3–31.0) 6.5 (2.0–15.0)
Min., max. (0, 34.5) (0, 44.5) (0, 46.5) (0, 45)
Total Mean (SD) 17.8 (18.0) 22.6 (20.1) 45.0 (24.5) 24.0 (20.6)
Median (IQR) 13.5 (4.0–26.0) 15.8 (8.0–36.8) 50.5 (26.3–64.8) 18.3 (8.3–31.0)
Min., max. (0, 71.5) (0, 89.5) (0, 75.5) (0, 90)
26 weeks
Pain subscale Mean (SD) 9.2 (10.0) 10.7 (10.1) 18.3 (10.1) 9.3 (9.7)
Median (IQR) 5.0 (2.0–13.0) 8.0 (4.0–15.0) 16.0 (11.0–23.0) 7.0 (1.0–12.0)
Min., max. (0, 43) (0, 39) (6, 44) (0, 44)
Function subscale Mean (SD) 3.8 (7.2) 5.7 (8.0) 14.7 (13.4) 4.6 (7.7)
Median (IQR) 1.0 (0.0–3.5) 2.0 (0.5–7.5) 12.0 (4.0–23.0) 1.5 (0.0–5.0)
Min., max. (0, 41) (0, 35) (1.5, 47.5) (0, 40)
Total Mean (SD) 13.1 (16.7) 16.4 (17.7) 33.0 (22.3) 13.6 (16.5)
Median (IQR) 6.3 (2.0–15.5) 9.5 (4.0–20.5) 32.0 (15.0–40.0) 9.8 (1.0–17.0)
Min., max. (0, 84) (0, 74) (9, 91.5) (0, 83)
52 weeks
Pain subscale Mean (SD) 6.1 (8.9) 7.2 (8.5) 16.6 (16.0) 8.5 (10.5)
Median (IQR) 3.0 (0.0–9.0) 4.0 (1.0–10.0) 10.0 (4.0–28.0) 4.0 (0.0–13.0)
Min., max. (0, 42) (0, 37) (0, 48) (0, 47.5)
Function subscale Mean (SD) 2.8 (6.9) 3.6 (5.7) 12.5 (16.7) 4.2 (7.5)
Median (IQR) 0.5 (0.0–3.0) 1.0 (0.0–4.5) 4.0 (0.5–16.5) 0.5 (0.0–4.5)
Min., max. (0, 43.5) (0, 26) (0, 48) (0, 33)
Total Mean (SD) 8.9 (15.0) 10.8 (13.9) 29.1 (32.4) 12.8 (17.4)
Median (IQR) 3.8 (0.0–11.3) 5.0 (1.0–14.5) 14.0 (4.5–47.5) 4.5 (0.0–17.8)
Min., max. (0, 85.5) (0, 58) (1, 96) (0, 76.5)
Max., maximum; min., minimum.
a Allocated to surgery group, received surgery and had CT imaging reviewed at 52 weeks by independent raters.
b Allocated to plaster cast group and did not cross over to receive immediate surgical fixation.
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TABLE 63 Baseline characteristics of all trial participants according to whether or not they had a CT scan taken
within 2 weeks of injury and of the surgery group according to whether or not their surgery was conducted within
2 weeks of presentation at A&E
Characteristic
All (N= 439) Surgery (N= 219)
CT ≤ 2 weeks
after injury
(N= 412)
CT > 2 weeks
after injury
(N= 27)
Surgery ≤ 2 weeks
after A&E presentation
(N= 182)
Surgery > 2 weeks
after A&E presentation
(N= 37)
Gender, n (%)
Male 342 (83.0) 21 (77.8) 156 (85.7) 24 (64.9)
Female 70 (17.0) 6 (22.2) 26 (14.3) 13 (35.1)
Age, years
n 412 27 182 37
Mean (SD) 32.9 (12.8) 32.3 (11.4) 32.2 (12.9) 36.2 (14.2)
Median (min., max.) 29 (16, 80) 30 (17, 59) 27 (16, 80) 31 (17, 61)
Ethnicity, n (%)
White 377 (91.5) 23 (85.2) 171 (94.0) 34 (91.9)
Black 3 (0.7) 2 (7.4) 0 (0.0) 0 (0.0)
Asian 16 (3.9) 1 (3.7) 6 (3.3) 1 (2.7)
Other 15 (3.6) 0 (0.0) 5 (2.7) 0 (0.0)
Missing 1 (0.2) 1 (3.7) 0 (0.0) 2 (5.4)
Education, n (%)
No formal qualifications 49 (11.9) 2 (7.4) 17 (9.3) 7 (18.9)
Some qualifications/no degree 263 (63.8) 17 (63.0) 126 (69.2) 25 (67.6)
Degree or higher 98 (23.8) 7 (25.9) 38 (20.9) 3 (8.1)
Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4)
Employment status, n (%)
Part-time 34 (8.3) 4 (14.8) 15 (8.2) 5 (13.5)
Full-time 237 (57.5) 10 (37.0) 108 (59.3) 19 (51.4)
Self-employed 50 (12.1) 7 (25.9) 16 (8.8) 5 (13.5)
Student 37 (9.0) 4 (14.8) 18 (9.9) 2 (5.4)
Retired 12 (2.9) 0 (0.0) 7 (3.8) 0 (0.0)
Looking after family/home 7 (1.7) 0 (0.0) 1 (0.5) 0 (0.0)
Not employed but
seeking work
14 (3.4) 0 (0.0) 7 (3.8) 2 (5.4)
Other 19 (4.6) 1 (3.7) 9 (4.9) 2 (5.4)
Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4)
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TABLE 63 Baseline characteristics of all trial participants according to whether or not they had a CT scan taken
within 2 weeks of injury and of the surgery group according to whether or not their surgery was conducted within
2 weeks of presentation at A&E (continued )
Characteristic
All (N= 439) Surgery (N= 219)
CT ≤ 2 weeks
after injury
(N= 412)
CT > 2 weeks
after injury
(N= 27)
Surgery ≤ 2 weeks
after A&E presentation
(N= 182)
Surgery > 2 weeks
after A&E presentation
(N= 37)
Type of employment, n (%)
Unskilled manual 45 (10.9) 3 (11.1) 21 (11.5) 4 (10.8)
Skilled manual 115 (27.9) 8 (29.6) 54 (29.7) 9 (24.3)
Unskilled non-manual 29 (7.0) 2 (7.4) 15 (8.2) 4 (10.8)
Skilled non-manual 76 (18.4) 3 (11.1) 29 (15.9) 4 (10.8)
Professional 37 (9.0) 2 (7.4) 18 (9.9) 2 (5.4)
Other 44 (10.7) 5 (18.5) 14 (7.7) 5 (13.5)
Missing 66 (16.0) 4 (14.8) 31 (17.0) 9 (24.3)
Current smoker, n (%)
Yes 120 (29.1) 9 (33.3) 56 (30.8) 17 (45.9)
No 289 (70.1) 17 (63) 125 (68.7) 18 (48.6)
Missing 3 (0.7) 1 (3.7) 1 (0.5) 2 (5.4)
If yes
Number of cigarettes per day,
median (min., max.)
10 (1, 40) 10 (1, 25) 10 (1, 20) 10 (1, 40)
Number of years, median
(min., max.)
10 (1, 50) 6 (1, 30) 10 (2, 50) 10 (1, 44)
Past smoker, n (%)
Yes 209 (50.7) 16 (59.3) 95 (52.2) 21 (56.8)
No 177 (43.0) 9 (33.3) 76 (41.8) 9 (24.3)
Missing 26 (6.3) 2 (7.4) 11 (6.0) 7 (18.9)
Diabetes, n (%)
Yes 11 (2.7) 0 (0.0) 5 (2.7) 2 (5.4)
No 399 (96.8) 26 (96.3) 176 (96.7) 33 (89.2)
Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4)
Steroid use, n (%)
Yes 9 (2.2) 1 (3.7) 5 (2.7) 1 (2.7)
No 401 (97.3) 25 (92.6) 176 (96.7) 34 (91.9)
Missing 2 (0.5) 1 (3.7) 1 (0.5) 2 (5.4)
Max., maximum; min., minimum.
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TABLE 64 Baseline fracture details of all trial participants according to whether or not they had a CT scan taken
within 2 weeks of injury and of the surgery group according to whether or not their surgery was conducted within
2 weeks of presentation at A&E
Characteristic
All (N= 439) Surgery (N= 219)
CT ≤ 2 weeks
after injury
(N= 412)
CT > 2 weeks
after injury
(N= 27)
Surgery ≤ 2 weeks
after A&E presentation
(N= 182)
Surgery > 2 weeks
after A&E presentation
(N= 37)
Time since injury, daysa
n 412 27 182 37
Mean (SD) 5.2 (3.2) 5.3 (3.3) 4.8 (3.0) 6.3 (3.5)
Median (min., max.) 5 (0, 14) 5 (1, 14) 4 (1, 13) 6 (1, 14)
Affected wrist, n (%)
Left 221 (53.6) 12 (44.4) 98 (53.8) 17 (45.9)
Right 191 (46.4) 15 (55.6) 84 (46.2) 20 (54.1)
Affected wrist is dominant hand, n (%)
Yes 184 (44.7) 11 (40.7) 85 (46.7) 15 (40.5)
No 227 (55.1) 15 (55.6) 97 (53.3) 20 (54.1)
Missing 1 (0.2) 1 (3.7) 0 (0.0) 2 (5.4)
Displacement (eligibility), n (%)
No displacement 253 (61.4) 16 (59.3) 111 (61.0) 24 (64.9)
Displacement 159 (38.6) 11 (40.7) 71 (39.0) 13 (35.1)
Displacement (randomisation), n (%)
No displacement 247 (60.0) 14 (51.9) 109 (59.9) 22 (59.5)
Displacement 165 (40.0) 13 (48.1) 73 (40.1) 15 (40.5)
Radiographs,b n (%)
Elongated scaphoid view 392 (95.1) 27 (100.0) 173 (95.1) 36 (97.3)
Posterior–anterior view 406 (98.5) 27 (100.0) 181 (99.5) 34 (91.9)
45° semisupine view 305 (74.0) 20 (74.1) 132 (72.5) 27 (73.0)
Lateral view 408 (99.0) 27 (100.0) 182 (100.0) 36 (97.3)
45° semiprone view 370 (89.8) 24 (88.9) 164 (90.1) 34 (91.9)
Previous wrist problems on same side, n (%)
Yes 81 (19.7) 7 (25.9) 36 (19.8) 7 (18.9)
No 328 (79.6) 18 (66.7) 145 (79.7) 28 (75.7)
Missing 3 (0.7) 2 (7.4) 1 (0.5) 2 (5.4)
If yes, what injury?, n (%)
Previous fracture 47 (58) 4 (57.1) 21 (58.3) 2 (28.6)
Arthritis 3 (3.7) 0 (0) 1 (2.8) 1 (14.3)
Ligament, tendon or
nerve injury
17 (21) 1 (14.3) 9 (25.0) 1 (14.3)
Other 13 (16) 1 (14.3) 4 (11.1) 2 (28.6)
Missing 1 (1.2) 1 (14.3) 1 (2.8) 1 (14.3)
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TABLE 64 Baseline fracture details of all trial participants according to whether or not they had a CT scan taken
within 2 weeks of injury and of the surgery group according to whether or not their surgery was conducted within
2 weeks of presentation at A&E (continued )
Characteristic
All (N= 439) Surgery (N= 219)
CT ≤ 2 weeks
after injury
(N= 412)
CT > 2 weeks
after injury
(N= 27)
Surgery ≤ 2 weeks
after A&E presentation
(N= 182)
Surgery > 2 weeks
after A&E presentation
(N= 37)
Injury mechanism, n (%)
Fall – standing 53 (12.9) 4 (14.8) 21 (11.5) 7 (18.9)
Fall – walking 45 (10.9) 3 (11.1) 18 (9.9) 6 (16.2)
Fall – running 74 (18.0) 4 (14.8) 37 (20.3) 3 (8.1)
Fall – from height 60 (14.6) 2 (7.4) 25 (13.7) 3 (8.1)
Fall – from moving object 69 (16.7) 4 (14.8) 40 (22.0) 2 (5.4)
Hit on palm of hand – object
striking palm
30 (7.3) 1 (3.7) 9 (4.9) 7 (18.9)
Hit on palm of hand – handle
whipping back
20 (4.9) 0 (0.0) 9 (4.9) 0 (0.0)
Hit on palm of hand – other
sudden extension
16 (3.9) 3 (11.1) 8 (4.4) 3 (8.1)
Punched something 15 (3.6) 1 (3.7) 4 (2.2) 0 (0.0)
Road traffic accident 15 (3.6) 2 (7.4) 7 (3.8) 2 (5.4)
Other 14 (3.4) 2 (7.4) 4 (2.2) 2 (5.4)
Missing 1 (0.2) 1 (3.7) 0 (0.0) 2 (5.4)
Place of injury,b n (%)
Sport 156 (37.9) 10 (37.0) 77 (42.3) 11 (29.7)
Home 64 (15.5) 6 (22.2) 20 (11.0) 7 (18.9)
Work 38 (9.2) 2 (7.4) 14 (7.7) 8 (21.6)
Road traffic accident 57 (13.8) 3 (11.1) 24 (13.2) 2 (5.4)
Public place 93 (22.6) 4 (14.8) 43 (23.6) 6 (16.2)
Other 3 (0.7) 0 (0.0) 3 (1.6) 0 (0.0)
Missing 5 (1.2) 1 (3.7) 3 (1.6) 1 (2.7)
Treatment preference, n (%)
Surgery 180 (43.7) 14 (51.9) 75 (41.2) 18 (48.6)
No surgery 29 (7.0) 3 (11.1) 10 (5.5) 3 (8.1)
No preference 200 (48.5) 9 (33.3) 96 (52.7) 14 (37.8)
Missing 3 (0.7) 1 (3.7) 1 (0.5) 2 (5.4)
Max., maximum; min., minimum.
a Time from injury to screening.
b Categories not mutually exclusive.
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TABLE 65 The PRWE total and subscale scores for all participants according to whether or not they had a CT scan
taken within 2 weeks of injury and for the surgery group according to whether or not their surgery was conducted
within 2 weeks of presentation at A&E
PRWE score
All (N= 439) Surgery (N= 219)
CT ≤ 2 weeks
after injury
(N= 412)
CT > 2 weeks
after injury
(N= 27)
Surgery ≤ 2 weeks
after A&E
presentation
(N= 182)
Surgery > 2 weeks
after A&E
presentation
(N= 37)
Baseline (pre injury)
Pain subscale Mean (SD) 2.3 (6.6) 3.2 (9.3) 2.2 (6.6) 2.2 (6.3)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.0 (0.0–0.0)
Min., max. (0, 50) (0, 35) (0, 50) (0, 32.5)
Function subscale Mean (SD) 1.0 (5.1) 2.4 (9.0) 0.9 (5.0) 1.3 (5.8)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Min., max. (0, 49.5) (0, 41) (0, 43) (0, 32.2)
Total Mean (SD) 3.2 (10.9) 5.7 (17.9) 3.1 (10.7) 3.4 (11.8)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.0 (0.0–0.0)
Min., max. (0, 90.5) (0, 76) (0, 85) (0, 64.7)
Baseline (post injury)
Pain subscale Mean (SD) 34.5 (10.2) 33.9 (10.8) 34.3 (11.1) 36.7 (8.8)
Median (IQR) 36.0 (29.0–42.0) 35.5 (25.0–43.0) 36.0 (28.0–42.0) 38.0 (31.0–42.0)
Min., max. (0, 50) (8.75, 47) (0, 50) (2, 50)
Function subscale Mean (SD) 39.0 (10.3) 36.7 (9.4) 38.7 (10.9) 41.3 (7.6)
Median (IQR) 41.5 (33.5–46.5) 40.0 (34.5–42.5) 42.0 (33.0–46.5) 41.0 (37.5–48.5)
Min., max. (0, 50) (15, 49) (0, 50) (20, 50)
Total Mean (SD) 73.7 (18.6) 71.6 (18.2) 73.1 (20.5) 78.0 (14.7)
Median (IQR) 77.5 (64.0–87.5) 75.5 (70.0–85.0) 78.0 (62.0–88.0) 79.0 (71.0–87.5)
Min., max. (0, 100) (35, 96) (0, 100) (22, 100)
6 weeks
Pain subscale Mean (SD) 18.5 (10.6) 21.6 (9.3) 18.7 (10.3) 20.4 (12.1)
Median (IQR) 18.0 (10.0–26.0) 21.0 (14.5–28.5) 19.0 (10.0–26.0) 18.0 (10.0–33.0)
Min., max. (0, 50) (6, 38) (0, 44) (2, 38)
Function subscale Mean (SD) 18.3 (12.6) 22.5 (14.6) 16.2 (12.4) 21.1 (15.2)
Median (IQR) 16.5 (8.0–26.5) 23.5 (14.5–32.5) 13.0 (6.1–25.0) 16.0 (9.5–32.0)
Min., max. (0, 50) (0, 46) (0, 44.5) (0, 47)
Total Mean (SD) 36.8 (21.1) 45.4 (21.3) 34.9 (20.8) 41.5 (24.6)
Median (IQR) 35.0 (19.5–51.3) 43.3 (33.0–63.3) 33.5 (18.5–48.5) 39.5 (19.5–62.0)
Min., max. (0, 100) (6, 84) (3, 85.5) (6, 82)
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TABLE 65 The PRWE total and subscale scores for all participants according to whether or not they had a CT scan
taken within 2 weeks of injury and for the surgery group according to whether or not their surgery was conducted
within 2 weeks of presentation at A&E (continued )
PRWE score
All (N= 439) Surgery (N= 219)
CT ≤ 2 weeks
after injury
(N= 412)
CT > 2 weeks
after injury
(N= 27)
Surgery ≤ 2 weeks
after A&E
presentation
(N= 182)
Surgery > 2 weeks
after A&E
presentation
(N= 37)
12 weeks
Pain subscale Mean (SD) 13.4 (10.9) 19.9 (13.3) 12.6 (10.9) 14.5 (11.6)
Median (IQR) 11.0 (5.0–18.0) 23.0 (7.5–31.5) 9.0 (4.0–17.5) 12.5 (5.0–18.0)
Min., max. (0, 47) (0, 41) (0, 45) (0, 40)
Function subscale Mean (SD) 9.1 (10.2) 17.8 (14.3) 7.7 (9.1) 9.7 (10.2)
Median (IQR) 5.5 (1.5–12.0) 17.8 (5.0–27.5) 4.3 (1.0–11.0) 7.4 (1.5–12.0)
Min., max. (0, 45) (0, 46.5) (0, 44.5) (0, 34)
Total Mean (SD) 22.5 (20.3) 37.8 (25.9) 20.2 (19.4) 24.2 (21.2)
Median (IQR) 17.0 (7.0–30.0) 38.8 (11.5–60.0) 14.1 (6.0–26.8) 18.8 (8.0–28.5)
Min., max. (0, 90) (0, 78.5) (0, 89.5) (0, 73.3)
26 weeks
Pain subscale Mean (SD) 10.0 (10.3) 15.1 (9.8) 10.1 (10.4) 12.9 (12.4)
Median (IQR) 7.0 (2.0–13.0) 13.0 (7.0–23.0) 7.0 (3.0–15.0) 8.0 (2.0–24.0)
Min., max. (0, 44) (0, 35) (0, 43) (0, 36)
Function subscale Mean (SD) 5.3 (8.5) 7.5 (8.4) 5.0 (8.0) 7.9 (10.5)
Median (IQR) 1.5 (0.0–5.6) 4.4 (1.5–10.5) 1.5 (0.3–5.3) 4.0 (0.0–13.0)
Min., max. (0, 47.5) (0, 24) (0, 41) (0, 41)
Total Mean (SD) 15.1 (18.0) 21.0 (15.6) 15.2 (17.9) 19.4 (19.8)
Median (IQR) 9.5 (2.5–18.5) 15.5 (11.5–36.5) 9.0 (3.5–19.0) 12.0 (2.0–37.5)
Min., max. (0, 91.5) (0, 45) (0, 84) (0, 55.5)
52 weeks
Pain subscale Mean (SD) 8.1 (10.4) 14.2 (14.0) 7.5 (9.9) 9.1 (11.4)
Median (IQR) 4.0 (0.0–11.0) 14.0 (2.0–20.0) 4.0 (0.0–10.0) 3.0 (0.0–17.5)
Min., max. (0, 47.5) (0, 48) (0, 42) (0, 37)
Function subscale Mean (SD) 4.0 (7.6) 9.8 (13.4) 3.5 (6.9) 5.3 (8.8)
Median (IQR) 0.5 (0.0–4.0) 4.0 (0.0–14.5) 1.0 (0.0–3.5) 0.5 (0.0–10.3)
Min., max. (0, 44) (0, 48) (0, 43.5) (0, 31)
Total Mean (SD) 12.1 (17.5) 24.0 (27.0) 11.0 (16.1) 14.4 (19.7)
Median (IQR) 4.0 (0.0–15.0) 17.5 (2.0–32.5) 4.0 (0.5–13.5) 4.3 (0.0–27.8)
Min., max. (0, 88) (0, 96) (0, 85.5) (0, 60)
Max., maximum; min., minimum.
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TABLE 66 Participant responses to questions relating to written advice about home exercises to perform to care for
their wrist, asked on 12-week questionnaire
Responses to returned 12-week questionnaire Surgery (N= 182) Plaster cast (N= 167) Total (N= 349)
How useful did you find the written advice about home exercises for your hand and wrist?, n (%)
Very useful 59 (32.4) 38 (22.8) 97 (27.8)
Quite useful 92 (50.6) 85 (50.9) 177 (50.7)
Not very useful at all 15 (8.2) 21 (12.6) 36 (10.3)
Not at all useful 10 (5.5) 11 (6.6) 21 (6.0)
Missing 6 (3.3) 12 (7.2) 18 (5.2)
Have you done any of these home exercises?, n (%)
Yes 151 (83.0) 136 (81.4) 287 (82.2)
No 25 (13.7) 23 (13.8) 48 (13.8)
Missing 6 (3.3) 8 (4.8) 14 (4.0)
If yes, on how many days over the past 12 weeks have you done these exercises?
Mean (SD) 41.8 (28.5) 44.7 (28.6) 43.1 (28.5)
Median (min., max.) 35 (2, 137) 41 (1, 168) 38 (1, 168)
Would you have preferred to have a formal referral to physiotherapy for your wrist injury?, n (%)
Yes 67 (36.8) 56 (33.5) 123 (35.2)
No 102 (56.0) 98 (58.7) 200 (57.3)
Missing 13 (7.1) 13 (7.8) 26 (7.5)
Max., maximum; min., minimum.
TABLE 67 Participant responses to questions relating to the current state of their wrist and treatment preference,
asked on 52-week questionnaire
Responses to returned 52-week questionnaire Surgery (N= 186) Plaster cast (N= 178) Total (N= 364)
Compared with 1 year ago, how is your wrist now?, n (%)
Much better now 149 (80.1) 139 (78.1) 288 (79.1)
Slightly better now 17 (9.1) 17 (9.6) 34 (9.3)
About the same now 9 (4.8) 11 (6.2) 20 (5.5)
Slightly worse now 5 (2.7) 4 (2.3) 9 (2.5)
Much worse now 1 (0.5) 3 (1.7) 4 (1.1)
Missing 5 (2.7) 4 (2.3) 9 (2.5)
Based on your experiences of the treatment that you received as part of this trial, if you injured your wrist
today to the same extent as you did 1 year ago, which treatment would you prefer?, n (%)
No preference 36 (19.4) 68 (38.2) 104 (28.6)
Surgery 137 (73.7) 59 (33.2) 196 (53.9)
Not surgery 8 (4.3) 48 (27.0) 56 (15.4)
Missing 5 (2.7) 3 (1.7) 8 (2.2)
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FIGURE 14 Unadjusted mean PRWE scores (with 95% CIs) over time by randomised group and patient treatment
preference at baseline: (a) no preference; (b) preference for surgery; and (c) preference for no surgery. Modified
from Lancet, vol. 396, Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast
immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre,
open-label, randomised superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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FIGURE 15 Unadjusted mean PRWE scores (with 95% CIs) over time by randomised group and fracture
displacement (as randomised) at baseline: (a) < 1mm; and (b) ≥ 1mm and ≤ 2mm. Modified from Lancet, vol. 396,
Dias JJ, Brealey SD, Fairhurst C, Amirfeyz R, Bhowal B, Blewitt N, et al., Surgery versus cast immobilisation for
adults with a bicortical fracture of the scaphoid waist (SWIFFT): a pragmatic, multicentre, open-label, randomised
superiority trial, pp. 390–401,89 Copyright (2020), with permission from Elsevier.
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FIGURE 16 Unadjusted mean PRWE scores (with 95% CIs) over time by randomised group and fracture
displacement (as recorded on study eligibility form) at baseline: (a) < 1mm; and (b) ≥ 1mm and ≤ 2mm.
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FIGURE 17 Adjusted mean PRWE subscale scores (with 95% CIs) over time by randomised group: (a) pain subscale;
and (b) function subscale.
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FIGURE 18 Adjusted mean SF-12 component subscale scores (with 95% CIs) over time by randomised group:
(a) MCS; and (b) PCS.
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FIGURE 19 Adjusted mean grip strength (with 95% CIs) over time by randomised group.
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Appendix 4 Software output for primary
analysis model
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Appendix 5 Analysis of the agreement between
raters on the imaging
Introduction
This report describes the agreement study that was conducted to validate the radiology assessments that
were fed into the trial analysis. All radiographs and CT scans were assessed independently by three raters
and, when there was disagreement, the three met to discuss the assessment and a consensus was reached.
This study looks at the agreement at the first stage, that is, prior to the consensus meeting.
Methods
The assessments of the three raters were compared in pairs (i.e. A with B, A with C and B with C). When
a categorical assessment was required, the measure of agreement was taken to be the percentage of
radiographs or CT scans on which the two raters gave exactly the same grade. It was decided that 50%
agreement was acceptable and that 80% or greater agreement was good. Percentage agreement is
reported together with a 95% CI.
When a continuous assessment was required, the measure of agreement was taken to be the 95% limits
of agreement and the data were displayed as a Bland–Altman plot. The limits of agreement depend on the
SD of the differences between the two raters and an acceptable agreement was defined as a SD that was
less than 25% of the range of the scale. A SD that was less than 10% of the range was considered good.
The range was taken to be the difference between the largest and smallest measurements made by either
of the two raters.
Fracture
Radiographs at baseline
Rater A versus rater B
Both raters graded 366 radiographs with 62.3% agreement (95% CI 57.3% to 67.3%).
Agreement was classified as acceptable.
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Rater A versus rater C
Both raters graded 433 radiographs with 72.1% agreement (95% CI 67.8% to 76.3%).
Agreement was classified as acceptable.
Rater B versus rater C
Both raters graded 365 radiographs with 59.2% agreement (95% CI 54.1% to 64.2%).
Agreement was classified as acceptable.
Computed tomography scan at baseline
Rater A versus rater B
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Both raters graded 351 CT scans with 62.1% agreement (95% CI 57% to 67.2%).
Agreement was classified as acceptable.
Rater A versus rater C
Both raters graded 430 CT scans with 65.6% agreement (95% CI 61.1% to 70.1%).
Agreement was classified as acceptable.
Rater B versus rater C
Both raters graded 350 CT scans with 61.4% agreement (95% CI 56.3% to 66.5%).
Agreement was classified as acceptable.
Displacement at baseline
The Bland–Altman plots of displacement show the difference in the measurement between two raters
against their average measurement. Horizontal lines show the average difference (solid) and the 95%
limits of agreement (dashed).
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Gap in radiographs
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95% limits of agreement: –0.88 mm, 0.5 mm.
The SD of the differences was 0.35 mm, which is 11% of the range of 3.2 mm.
Agreement was classified as acceptable.
Rater A versus rater C
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Average (mm)
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 C
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m
m
)
95% limits of agreement: –0.82 mm, 0.7 mm.
The SD of the differences was 0.39 mm, which is 12.2% of the range of 3.2 mm.
Agreement was classified as acceptable.
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Rater B versus rater C
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95% limits of agreement: –0.68 mm, 0.95 mm.
The SD of the differences was 0.42 mm, which is 9.7% of the range of 4.3 mm.
Agreement was classified as good.
Step in radiographs
Rater A versus rater B
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95% limits of agreement: –0.8 mm, 0.69 mm.
The SD of the differences was 0.38 mm, which is 6.7% of the range of 5.7 mm.
Agreement was classified as good.
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95% limits of agreement: –0.8 mm, 0.82 mm.
The SD of the differences was 0.41 mm, which is 7.2% of the range of 5.7 mm.
Agreement was classified as good.
Rater B versus rater C
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)
95% limits of agreement: –0.75 mm, 0.89 mm.
The SD of the differences was 0.42 mm, which is 13.5% of the range of 3.1 mm.
Agreement was classified as acceptable.
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Gap in computed tomography scan: coronal plane
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95% limits of agreement: –0.72 mm, 0.7 mm.
The SD of the differences was 0.36 mm, which is 11.3% of the range of 3.2 mm.
Agreement was classified as acceptable.
Rater A versus rater C
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95% limits of agreement: –0.64 mm, 0.69 mm.
The SD of the differences was 0.34 mm, which is 10.6% of the range of 3.2 mm.
Agreement was classified as acceptable.
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Rater B versus rater C
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95% limits of agreement: –0.62 mm, 0.68 mm.
The SD of the differences was 0.33 mm, which is 9.2% of the range of 3.6 mm.
Agreement was classified as good.
Gap in computed tomography scan: sagittal plane
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95% limits of agreement: –0.89 mm, 0.84 mm.
The SD of the differences was 0.44 mm, which is 7.9% of the range of 5.6 mm.
Agreement was classified as good.
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Rater A versus rater C
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95% limits of agreement: –1.04 mm, 1 mm.
The SD of the differences was 0.52 mm, which is 9.3% of the range of 5.6 mm.
Agreement was classified as good.
Rater B versus rater C
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95% limits of agreement: –0.96 mm, 0.98 mm.
The SD of the differences was 0.49 mm, which is 9.9% of the range of 5 mm.
Agreement was classified as good.
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Step in computed tomography scan: coronal plane
Rater A versus rater B
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95% limits of agreement: –0.55 mm, 0.61 mm.
The SD of the differences was 0.29 mm, which is 13.4% of the range of 2.2 mm.
Agreement was classified as acceptable.
Rater A versus rater C
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95% limits of agreement: –0.46 mm, 0.57 mm.
The SD of the differences was 0.26 mm, which is 11.9% of the range of 2.2 mm.
Agreement was classified as acceptable.
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Rater B versus rater C
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95% limits of agreement: –0.55 mm, 0.61 mm.
The SD of the differences was 0.3 mm, which is 19.7% of the range of 1.5 mm.
Agreement was classified as acceptable.
Step in computed tomography scan: sagittal plane
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95% limits of agreement: –0.71 mm, 0.82 mm.
The SD of the differences was 0.39 mm, which is 13% of the range of 3 mm.
Agreement was classified as acceptable.
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95% limits of agreement: –0.67 mm, 0.73 mm.
The SD of the differences was 0.36 mm, which is 11.9% of the range of 3 mm.
Agreement was classified as acceptable.
Rater B versus rater C
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95% limits of agreement: –0.84 mm, 0.79 mm.
The SD of the differences was 0.41 mm, which is 12.6% of the range of 3.3 mm.
Agreement was classified as acceptable.
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Union by radiographs at 52 weeks
Rater A versus rater B
Both raters graded 297 radiographs with 72.4% agreement (95% CI 67.3% to 77.5%).
Agreement was classified as acceptable.
Rater A versus rater C
Both raters graded 295 radiographs with 76.9% agreement (95% CI 72.1% to 81.8%).
Agreement was classified as acceptable.
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Rater B versus rater C
Both raters graded 294 radiographs with 68.4% agreement (95% CI 63.1% to 73.7%).
Agreement was classified as acceptable.
Percentage of union estimated from computed tomography scan at 52 weeks
Rater A versus rater B
0
– 100
– 50
0
50
100
25 50 75 100
Average (%)
A
 –
 B
 (
%
)
95% limits of agreement: –20.21%, 13.01%.
The SD of the differences was 8.47%, which is 8.5% of the range of 100%.
Agreement was classified as good.
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Rater A versus rater C
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95% limits of agreement: –27.15%, 18.7%.
The SD of the differences was 11.7%, which is 11.7% of the range of 100%.
Agreement was classified as acceptable.
Rater B versus rater C
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95% limits of agreement: –18.67%, 17.43%.
The SD of the differences was 9.21%, which is 9.2% of the range of 100%.
Agreement was classified as good.
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Union by radiographs at 52 weeks: summary
Rater A versus rater B
Both raters graded 297 CT scans with 89.6% agreement (95% CI 86.1% to 93%).
Agreement was classified as good.
Rater A versus rater C
Both raters graded 295 CT scans with 84.1% agreement (95% CI 79.9% to 88.2%).
Agreement was classified as good.
Rater B versus rater C
Both raters graded 294 CT scans with 91.5% agreement (95% CI 88.3% to 94.7%).
Agreement was classified as good.
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Union by radiographs at 52 weeks: views
Rater A versus rater B
Both raters graded 297 CT scans with 76.4% agreement (95% CI 71.6% to 81.3%).
Agreement was classified as acceptable.
Rater A versus rater C
Both raters graded 295 CT scans with 71.5% agreement (95% CI 66.4% to 76.7%).
Agreement was classified as acceptable.
Rater B versus rater C
Both raters graded 294 CT scans with 74.5% agreement (95% CI 69.5% to 79.5%).
Agreement was classified as acceptable.
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Union by computed tomography scan at 52 weeks: multiplanar reconstruction
Rater A versus rater B
Both raters graded 292 CT scans with 68.8% agreement (95% CI 63.5% to 74.1%).
Agreement was classified as acceptable.
Rater A versus rater C
Both raters graded 289 CT scans with 76.1% agreement (95% CI 71.2% to 81%).
Agreement was classified as acceptable.
Rater B versus rater C
Both raters graded 289 CT scans with 84.4% agreement (95% CI 80.2% to 88.6%).
Agreement was classified as good.
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Union by computed tomography scan at 52 weeks: estimated
Rater A versus rater B
Both raters graded 292 CT scans with 95.2% agreement (95%CI 92.8 to 97.7%).
Agreement was classified as good.
Rater A versus rater C
Both raters graded 292 CT scans with 92.5% agreement (95% CI 89.4% to 95.5%).
Agreement was classified as good.
Rater B versus rater C
Both raters graded 292 CT scans with 94.5% agreement (95% CI 91.9 to 97.1%).
Agreement was classified as good.
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Union by computed tomography scan at 52 weeks: calculated
Rater A versus rater B
Both raters graded 292 CT scans with 90.1% agreement (95% CI 86.6% to 93.5%).
Agreement was classified as good.
Rater A versus rater C
Both raters graded 292 CT scans with 90.4% agreement (95% CI 87% to 93.8%).
Agreement was classified as good.
Rater B versus rater C
Both raters graded 292 CT scans with 97.3% agreement (95% CI 95.4% to 99.1%).
Agreement was classified as good.
Discussion
Agreement was either acceptable or good on all scales.
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Appendix 6 Health economics
Impact of lost employment and unpaid activities
In addition to considering the costs to the NHS and PSS and the QoL of the patients, this within-trial
analysis reports the impact of treatment allocation on days of lost employment and unpaid activities. As
part of the questionnaires, patients were asked to report if they were in paid employment, how many days
over the period covered by the questionnaire they missed as a result of their wrist injury and how many
days of unpaid activity they lost. While such outcomes are not conventionally incorporated into an
economic evaluation in a UK setting,91 they can be helpful for informing decision-makers who choose to
take a broad definition of benefit (i.e. beyond patient QoL and costs to the NHS) or patients who may
choose to have the surgical procedure done through private health care to reduce the number of days
of work lost. Brief summary statistics are reported for the four relevant time periods, stratified by
treatment allocation.
Results
Impact of lost employment
The summary statistics of the patient-reported days of lost employment are reported in Table 35. Primarily,
the table shows that the majority of patients experienced some days of lost employment in the first 6 weeks
of the analysis period (with only 21.6 % and 31.3% reporting no lost days over that period in the surgery
and plaster cast groups, respectively), but from 12 weeks onwards most were back to full-time work (with
medians of 0 for all other periods). There did, however, remain a number of patients who were forced to
continue missing work as a result of their wrist, characterised by the persistent mean number of days lost,
despite close to 90% reporting no lost days. Only a very small number of patients had to miss work for
most if not all of the period covered by the questionnaire.
Over the entire within-trial period for the complete case analysis, surgical patients reported having lost a
smaller mean number of days than patients in the plaster cast group (16.62 compared with 17.57 days,
respectively) but a larger median number of days (9.5 compared with 5 days, respectively), and surgical
patients also reported fewer no days of work lost (13.7% compared with 28.6%, respectively). Using the
sum of the means for each time period, a larger difference is observed between the two groups, with
mean lost days of employment being 17.30 and 21.69 days, respectively, suggesting a biasing impact of
the inconsistent level of missing data.
This distribution is best explained by the invasive nature of the surgery, necessitating at least some days off
work in more patients, as well as the large impact of a few extreme cases in which patients were absent
from work for the majority of the year. These outliers appear to be more evident in the plaster cast arm,
with 10 patients reporting more than 50 days off work, compared with six patients in the surgical arm.
However, the high rate of missing data may be having a large biasing effect.
These findings appear inconsistent with other studies focusing on the impact of scaphoid fracture on
fixation,44,45 which have found much larger differences in days of work lost, favouring surgery; however,
the source of this difference is not clear.
Using estimates of the average weekly earnings from the Office for National Statistics (£512)165 allows us
to crudely estimate the average societal impact of these lost days of employment, namely £1702 per
person for the surgical arm and £1799 for the cast arm, a difference of £97 per person. However, it is
important to note that, without an estimate of the number of days of work a person would lose if no
treatment was available, it is not possible to interpret these results beyond their comparative value.
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Impact on days of unpaid activity
Similar to the previous section, Table 68 reports the impact of treatment allocation on lost unpaid activity
(e.g. household chores, shopping and helping others) for reasons related to the wrist injury and
subsequent treatment.
The table shows that surgery had a larger impact on lost unpaid activity than plaster cast for the 6 weeks after
randomisation, with larger mean and median values and fewer patients reporting no days lost. However, for
all time points after this, patients allocated to the surgical arm report a smaller impact on unpaid activities
than those in the plaster cast arm. As was seen in the responses to lost days of employment, the results are
highly skewed, with the majority of responders reporting no impact on unpaid activity after 6 weeks but a
very small number continuing to report a large number of lost days throughout the trial period.
Systematic review of previous cost-effectiveness studies
This appendix details the literature review that was conducted to determine whether or not previous
economic evaluations had sufficiently determined the cost-effectiveness of surgical fixation versus plaster
cast immobilisation for treatment of bicortical, minimally displaced fractures of the scaphoid waist in
adults. A secondary aim of the search was to determine if previous mathematical models could be adapted
to estimate the long-term cost-effectiveness of the population and thus remove the need to construct a de
novo mathematical model.
Our strategy (detailed in the following section) did not specify the form of treatment required, if the
evaluation considered the diagnosis or treatment of the fracture or the extent of displacement of the
fracture. The strategy was submitted to Ovid MEDLINE in April 2017, with all published, in process and
other non-indexed citations in any language between 1946 and April 2017 allowed. The review was
conducted by a single reviewer.
TABLE 68 Summary statistics for days of lost unpaid activity reported since last questionnaire
Questionnaire
period
Treatment
allocation
Number of
responses
Mean
days lost
Median days lost
(95% percentile)
Percentage
reporting 0 days
6 weeks Surgery 167 12.41 10 (40) 28.1
Cast 162 10.13 6 (35) 35.8
12 weeks Surgery 163 2.21 0 (18) 83.4
Cast 151 5.03 0 (35) 66.9
26 weeks Surgery 150 1.77 0 (14) 89.3
Cast 140 3.51 0 (25) 85.7
52 weeks Surgery 169 1.08 0 (5) 91.7
Cast 163 2.73 0 (4) 91.4
Total Surgery 118 16.15 11 (54) 21.2
Cast 103 15.90 8 (52) 26.2
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Systematic search strategy
The search was conducted using Ovid MEDLINE through the University of York library on 4 April 2017.
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R), from 1946 to
the present.
1. fracture fixation (17,279)
2. fracturers, bone (59,494)
3. orthopedic fixation devices (4975)
4. 1 or 2 or 3 (75,839)
5. scaphoid bone (1850)
6. wrist joint (8976)
7. wrist injuries (5824)
8. 5 or 6 or 7 (14,701)
9. cost–benefit analysis (70,573)
10. 4 or 8 or 9 (24)
In addition to the strategy submitted to MEDLINE (detailed above), a search of the grey literature was
conducted. The search consisted of iterative investigations of the literature identified using an internet
search engine (Google Scholar; Google Inc., Mountain View, CA, USA), coupled with a targeted search
of NICE’s website to explore any economic evaluations behind current best practice guidance.
The MEDLINE search yielded 24 hits, 16 of which were deemed relevant on review of their titles and only
three of these were relevant after consideration of their abstracts.43,166,167 The search of the grey literature
identified only one fully relevant article from the NICE website and none from the internet search engine
exploration. Consistent with the search strategy, the relevance of the studies was defined by the existence
of some form of economic evaluation at any point of the diagnostic or treatment pathway of a fracture
of the wrist region. No further limits on the type of injury or point of care were placed to ensure that
all studies considering cast immobilisation versus surgical fixation were included. As a result, some of
the studies deemed to be relevant considered the pre-treatment decision of how different diagnostic
strategies compared, but, as these implicitly included the consequences of the treatment used, they were
deemed relevant.
The four studies identified43,88,166,167 were reviewed using the Drummond Checklist for assessing the quality
of economic evaluations,101 the results of which are available later in this appendix.
Of the four studies, two considered the cost-effectiveness of different diagnosis strategies for suspected
scaphoid fractures.88,167 Karl et al.167 explored the relative cost-effectiveness of three strategies – empiric
cast immobilisation for all patients followed by follow-up radiographs, immediate CT scan and immediate
magnetic resonance imaging (MRI) – in a population of patients deemed to have a possible scaphoid
fracture after physical examination, but with a negative initial radiograph. The authors concluded that
initial advanced imaging dominated empiric casting.
Similarly, the economic evaluation that accompanied the NICE guideline (NG38)88 primarily focused on the
cost-effectiveness of suspected scaphoid fractures based on imaging rather than the appropriate treatment
pathway, but contains valuable insights into the pathway. This analysis considered a slightly earlier problem
than Karl et al., being prior to initial investigation. As a result, the decision problem considered whether
MRI or CT scans should be used as the first-line diagnostic tool, and thus considered a broader population
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than Karl et al., by considering all those with suspected scaphoid fractures rather those with indeterminate
initial radiology findings. The analysis included the possibility of patients having cast immobilisation and/or
surgical fixation, but these were considered to be accepted best practice depending on displacement and
union, and as such no analysis of their cost-effectiveness was conducted. The evaluation concluded that
the use of immediate MRI was the most cost-effective approach, dominating all other strategies except
immediate CT scans.
As both Karl et al.167 and NICE NG3888 focused on the cost-effectiveness of the diagnostic strategies prior
to confirmed diagnosis and considered the treatment options to be fixed decisions, they are not directly
applicable to the SWIFFT evaluation.
The study by Hannemann et al.166 considered the cost-effectiveness of pulsed electromagnetic fields in the
treatment of acute undisplaced scaphoid fractures, compared with standard cast immobilisation. While
relevant to the SWIFFT evaluation as an evaluation of treatment options in scaphoid fractures, Hannemann
et al. consider a less severely affected population than SWIFFT, including patients with tuberosity fractures.
In addition, the study does not conduct a long-term mathematical model, instead being limited to a
within-trial analysis over 52 weeks of follow-up.
Finally, Davis et al.43 conducted an evaluation of the cost-effectiveness of open reduction and internal
fixation surgery versus cast immobilisation for acute non-displaced scaphoid fractures. As a result, the
study is relevant to this evaluation. The study is structured based on a decision tree model that estimates
the probability of a patient experiencing one of six possible outcomes after treatment with cast
immobilisation (no complications, non-union and delayed union, each with a normal and arthritis variant)
and seven possible outcomes after surgical fixation (the same as the cast arm but with the addition of a
risk of infection). The model estimates the cost per QALY gained of each treatment by combining the
short-term cost and HRQoL of the different treatment outcomes with long-term estimates of the HRQoL
implications of each outcome; no long-term costs appear to be considered despite the existence of a
long-term arthritis outcome.
As reflected in the review of the Davis study presented in Table 69, there are a number of areas of the model
that were difficult to fully assess. The decision tree and related characterisation of the different possible
post-treatment outcomes are good, considering the potential for non-union and delayed union, infection,
misplaced screws and arthritis. However, our review of the article raised a number of factors that limit the
transferability of the model to the SWIFFT analysis. These factors included the lack of long-term cost
associated with arthritis, a lack of clarity regarding which patients were associated with which resource use,
the use of an unvalidated time trade-off questionnaire completed by 50 medical students who had not
experienced the fracture, a lack of clarity with regard to how the durations and probabilities that informed
the model were derived from the literature and the lack of correlation between non-union and the
probability of arthritis. Furthermore, the lack of definition of non-displacement by Davis et al. makes the
transferability of the model to the SWIFFT population difficult to determine.
Therefore, we determined that, in addition to the planned within-trial economic evaluation of SWIFFT, a de
novo mathematical model was required to investigate the long-term cost-effectiveness of surgical fixation
compared with cast immobilisation. The de novo model is expected to draw from the Davis study, but this
will be determined by the results of a series of targeted parameter-specific literature reviews.
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Drummond Checklist review
TABLE 69 Drummond Checklist101 review of previous economic evaluations identified in the literature review (systematic and grey literature searches)
Study
Was a
well-defined
question
posed in an
answerable
form?
Was a
comprehensive
description of
the competing
alternatives
given?
Was the
effectiveness
of the
programmes
or services
established?
Were all
important
and relevant
costs and
consequences
for each
alternative
identified?
Were costs and
consequences
measured
accurately in
appropriate
physical units?
Were costs and
consequences
valued credibly?
Were costs and
consequences
adjusted for
differential
timing?
Was an
incremental
analysis of
costs and
consequences
of alternatives
performed?
Was allowance
made for
uncertainty in
the estimates
of costs and
consequences?
Did the
presentation
and discussion
of results
include all
issues of
concern to
users?
Davis et al.
(2006)43
Yes. There is a
clear focus from
both a direct and
an indirect
perspective
Yes. All options
are considered;
there is no
explicit ‘do
nothing’, but
perhaps this is
not appropriate.
There is limited
detail on the
surgical option
Yes. Had to rely
on limited RCT
data. Based on
a systematic
review, but
simple averages
are taken
Partially. Short-
term direct and
indirect costs
were well
handled, but it is
not clear how/if
long-term costs
of arthritis are
modelled
Partially. Not very
clear, as it is
based on tariff
payments, so
there is no clear
breakdown.
Outcomes are in
appropriate units
Partially. Costs
are valued
credibly but hard
to test without
trial and tariff
details. Outcomes
are questionable,
as they are based
on 50 medical
students rather
than patients
Unclear. There is
no statement on
discounting but
the results would
suggest it was
applied
Yes Yes, through
one- and two-
way scenario
analyses with
some
conceptualisation
for values chosen
There is no clear
definition of
non-displaced.
There is good
consideration
of the role of
non-arthritis AEs
Karl et al.
(2015)167
Yes. There is a
clear outline of
three different
options and of
the aim and
hypothesis of
the study and
patients
Yes. Alternatives
are well defined.
It is not clear if
all options are
considered, as
possible repeat
rests are not
included or
discussed
Yes, through
limited meta-
analysis, but it
focuses only
on diagnostic
effectiveness
and a little
on treatment
post test
Yes. These
appear to be
sufficiently
identified (given
limitations of
treatment
modelling)
Yes. They appear
to be appropriate
Partially, based
on limited
evidence in the
literature, which
is averaged. The
approach to the
cost of surgery is
questionable. The
utility is based on
Davis, so the
limitations are
the same
Partially. Literature
estimates are
adjusted to 2014
USD. It is not clear
if discounting is
applied; the scale
of the results
would suggest not
Yes Yes, through
one- and two-
way scenario
analyses
Yes, with the
exception of
those raised
elsewhere
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TABLE 69 Drummond Checklist101 review of previous economic evaluations identified in the literature review (systematic and grey literature searches) (continued )
Study
Was a
well-defined
question
posed in an
answerable
form?
Was a
comprehensive
description of
the competing
alternatives
given?
Was the
effectiveness
of the
programmes
or services
established?
Were all
important
and relevant
costs and
consequences
for each
alternative
identified?
Were costs and
consequences
measured
accurately in
appropriate
physical units?
Were costs and
consequences
valued credibly?
Were costs and
consequences
adjusted for
differential
timing?
Was an
incremental
analysis of
costs and
consequences
of alternatives
performed?
Was allowance
made for
uncertainty in
the estimates
of costs and
consequences?
Did the
presentation
and discussion
of results
include all
issues of
concern to
users?
Hannemann
et al. (2015)166
Yes. There is a
clear outline of
the aims of the
analysis, although
a description of
the evaluation in
the abstract is a
little misleading,
as the study is
just a within-trial
report
Yes. There is a
good description,
although it is not
clear if surgery
would have been
an option
Yes, using
linked trial
evidence only
Yes. They were
identified as part
of the trial
Yes. The costs
and health
outcomes are
well reported
Yes, including
the costs from
hospital and
Dutch guidelines
and QoL from
trial EQ-5D, as
well as some
credible societal
costs
N/A. It is only a
1-year timeline,
but it could be
argued that this
should have been
included
Yes Yes. PSA is
presented, but
no scenario
analysis
The study has
limited scope,
as it is only a
within 1 year
trial report
with limited
evaluation
NICE (2016)88 Yes. They are
clearly defined
but it is a little
unclear as to
how the overall
analysis links
to the NICE
guidance, so it is
hard to comment
on its ability to
answer the
primary aim
Yes. They are
very well
described and
motivated; there
is no ‘do nothing’
option, but, as it
is emergency
medicine,
perhaps this is
not a reasonable
option
Partially. The
effectiveness of
the diagnosis is
well established,
but the
effectiveness of
the subsequent
treatments
(cast or surgical
interventions)
is not
Partially. Short-
term costs are
well considered
but long-term
costs and the
consequences
of different
treatment
options are not;
however, it is
hard to
determine if this
had an impact on
the results
Yes. Costs and
consequences are
measured
appropriately
Yes, based on a
good literature
search and,
where no
literature was
available,
reasonable
assumptions
Yes. All costs
occurred in the
first year, but
future QALYs
were discounted
appropriately
Yes Yes, through
scenario analyses
This was overall
a good piece,
given the
limitations of
the evidence,
but there are
concerns around
the failure to
justify the
simplistic
approach to
modelling the
treatment
options
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Table 70 Summary of the key features of the relevant trials
Study
Age of
population at
injury, years
Male to
female
ratio
Characteristics of
original injury OA definition Definition of union
Surgical
intervention type
Definition of
symptoms
This analysis,
as defined by
SWIFFT
(n = 439)
Mean 33
(range 16–80)
84% Unequivocal, bicortical,
minimally displaced
fracture (< 2 mm) of the
scaphoid, presenting
within 2 weeks of injury
Defined within-trial
period by radiography
and CT scan
Disappearance of the
fracture line on
radiographs and
complete bridging on
CT scans compared with
those taken at baseline
As per surgical
preference (open or
percutaneous fixation
with standard
CE-marked headless
compression screw)
Reported in terms of
EQ-5D-3L
Lindström
and Nyström
(1990)102
(n = 229)
Range 15–76 83.8% Scaphoid fractures.
Fractures of the scaphoid
tuberosity were excluded
One or more observations
of reduced joint space,
osteophytes or sclerosis
of joint margins
N/A. Considers only
‘healed fractures’
(not defined)
N/A, as only cast
patients
Patient-reported
weakness of grip, pain
related to wrist motion
and at rest, and impaired
range of motion
Saedén et al.
(2001)27
(n = 61)
29± 13
(surgical group)
37± 20
(cast group)
84%
(surgical)
73%
(cast)
Acute fractures of the
scaphoid visible at first
radiological examination.
Fractures of the scaphoid
tuberosity were excluded
Narrowing of the joint or
reactive changes around
it compared with the
uninjured side
Radiological identified
but not defined
Open fixation using
Herbert screws
Symptoms reported as
score out of 10 across
nine questions including
pain at different times,
wrist movement and
manual work
Lindstrom
and Nystrom
(1992)100
(n = 33)
Mean 27.9
(range 15–52)
72.7% Scaphoid fractures.
Fractures of the scaphoid
tuberosity were excluded
One or more observations
of reduced joint space,
osteophytes or sclerosis
of joint margins
Not defined N/A, as all untreated
patients
Patient-reported pain,
stiffness and weakness
Ruby et al.
(1985)99
(n = 56)
Mean 32
(range 18–85)
89.2% Scaphoid fractures At least the presence of
joint narrowing, severity
determined by
osteophytes and
intraosseous cysts
Not defined N/A, as all untreated
patients
Patient-reported pain in
the wrist
Moritomo et al.
(1999)105
(n = 33)
Mean 26.3 (range
at review of all
patients 13–70)
84.5% Limited details given
other than fracture of
the scaphoid
N/A Not defined N/A. No treatment
details reported
Symptomatic population
defined as seeking help
for injury
Vender et al.
(1987)15
(n = 64)
Median 22 86% Scaphoid fractures Radial styloid pointing,
radioscaphoid narrowing
and midcarpal joint
narrowing
Displacement of the
fragment cortices
> 1mm
N/A. Any patients
who had previous
operations were
excluded
Patients who presented
with clinical concerns
related to the injured
wrist
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Probability of developing osteoarthritis
In the extrapolated model, the probability of OA was modelled for all treatment arms as being an
exponential decay towards a limiting value with the limiting value characterised as a beta distribution for
the PSA. The functional form of the exponential function is:
y = y∞ + a × e
−t
τ
where y∞ is the limiting value, a is a constant and τ is the time constant.
This formula is fitted to the evidence from Lindström and Nyström that, at year 1, 2.6% of patients had
radiological OA and, at year 7, 5.6% had radiological OA.102 Figure 20 shows the goodness of fit of
the fitted function to the observed data, with the bounds showing the 95% CI taking account of the
uncertainty of the time-limiting value.
Probability of developing scaphoid non-union advanced collapse
To estimate the probability of patients with non-union developing SNAC, we conducted a survival analysis
to the patient-level data reported by Moritomo et al.105 The results of the survival analysis are reported in
Table 70, which reports the AIC and Bayesian information criterion (BIC) of the seven regressions explored
alongside the graphical goodness of fit of the Weibull (Figure 21), which was selected owing to having the
lowest AIC and BIC.
Extrapolated model scenario analyses
To develop the mathematical model into the form presented in the previous section, a number of
simplifying assumptions and interpretations of the available evidence were necessary, as is true of all
mathematical models.97 While the assumptions made in the base-case analysis are considered to be the
most reasonable given the evidence available, it is important to test the impact of different approaches on
the results of the analysis. The following scenarios have been constructed to conduct these tests; as far as
possible, other sources of evidence are used to inform the scenarios. However, often the uncertainty is
driven not by contradictory sources but by a complete lack of evidence.
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FIGURE 20 Goodness of fit of the exponential decay to the observed data.
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Scenario 1: definition of non-union at 1 year
In the base-case analysis, we assume that the definition of non-union informative to the extrapolated
model from the previous chapter includes only those patients who are classified as having a non-union
at 52 weeks; therefore, all other diagnoses (union, almost full union, partial union and slight union) are
categorised as union for the sake of the model. If only this ‘pure’ non-union definition is used, there is one
non-union in the surgical arm and four in the plaster cast arm (three of which we define as having surgical
intervention at a later time). If a broader definition is used to include the slight unions, then this increases
to four in the surgical arm and nine in the plaster cast arm. The base-case assumption was made based on
clinical guidance that there is no evidence to suggest that slight unions behave as non-unions; however,
there is uncertainty around this. Therefore, this scenario explores the sensitivity of the model to this
assumption by considering only the ‘pure’ non-unions as informative to the extrapolated model.
Scenario 2: no surgical treatment for those who fail to achieve union with cast
Our base-case analysis assumes that the three patients who failed to achieve union with cast fixation alone
by 52 weeks in the cast plus surgery arm of the trial (i.e. those who did have an identified or suspected
non-union after cast immobilisation but were not treated surgically) can be assumed to receive surgical
intervention at a later time point. This scenario explores this assumption by assuming that these patients
did not receive surgical intervention at a later date and therefore are long-term non-unions.
Scenario 3: probability of non-union after secondary surgery
The base-case analysis uses evidence from SWIFFT to estimate the probability of non-union for patients
who underwent surgery after cast immobilisation (1 of 17 patients who received surgery). This scenario
explores the impact of this assumption by using an estimate from Filan and Herbert168 to estimate the
probability of non-union after secondary surgery (0.195, 95% CI 0.145 to 0.249).
TABLE 71 The AIC and BIC estimates for the survival regressions fitted to the Moritomo et al.105 patient-level data
Regression function AIC BIC
exp 25.12107 26.11681
weibull 22.51636 24.50783
gomp 22.79423 24.7857
loglogistic 24.14154 26.133
lognormal 23.19027 25.18174
gamma 24.33022 27.31742
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FIGURE 21 Weibull and Kaplan–Meier of the SNAC survival analysis.
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Scenario 4: treatment-specific adverse events
The base-case analysis assumed that the choice of treatment affects only the probability of achieving union
and not the subsequent risks of AE development. The base case uses the large study by Lindström and
Nyström102 to inform the three parameters: the probability of having long-term non-OA AEs, the probability
of developing OA and the probability that this OA is symptomatic. The major limitations of this approach
are that the Lindström and Nyström102 study considered only patients treated with cast immobilisation.
As observed by Saedén et al.,27 the act of conducting surgery may result in the development of OA that
may not have occurred with conservative treatment alone and may be associated with a greater level of
non-OA AEs owing to the invasive nature of surgery.
This scenario explores this assumption by using less robust, treatment-specific estimates of AE rates from the
literature. The primary source of evidence is the Saedén et al.27 study, namely a small (n = 62) randomised study
of cast versus Herbert screw fixation for acute scaphoid fracture. The small nature of this study and the age of
the surgical procedure (patients were randomised between 1984 and 1986) were the primary reasons for it being
discounted as the primary source of the base-case analysis. Furthermore, there were concerns that the results of
the Saedén et al.27 study were inconsistent with clinical expectations, as it suggests a higher overall rate of AEs in
the cast immobilisation group. The use of this study changes the estimates reported in Table 29 in Chapter 4 to
those reported in the condensed Table 72, with the base-case estimates reported in the second line of each row.
Estimates of the probability of developing SNAC post non-union remain unchanged from the base case.
TABLE 72 Scenario 4 parameter values (shaded values report the base-case parameter estimates)
Parameter Base-case value (95% CI) Distribution Source
Long-term element of the model – union Markov model
Probability of having long-term adverse symptoms that are not OA related
Cast immobilisation 0.188 (0.043 to 0.405)
0.048 (0.024 to 0.079)
Beta (alpha 3, beta 13)
(alpha 11, beta 218)
Saedén et al. (2001)27
Lindström and Nyström (1990)102
Surgery as last
treatment provided
0.087 (0.011 to 0.228)
Assumed to be the same as cast
Beta (alpha 2, beta 21) Saedén et al. (2001)27
Probability of developing OA
Cast immobilisation Limiting value: 0.308
Time constant: 1.5
CI: 0.123 to 0.527
Limiting value: 0.056
Time constant: 1.5
CI: 0.035 to 0.087
Exponential decay towards
a limiting value, with
limiting value characterised
as a beta distribution
Saedén et al. (2001)27 (only
including STJs)
Lindström and Nyström (1990)102
Surgery as initial
treatment
Limiting value: 0.609
Time constant: 1.5
CI: 0.440 to 0.776
Assumed to be the same as cast
Exponential decay towards
a limiting value, with
limiting value characterised
as a beta distribution
Saedén et al. (2001)27
Probability that developed OA is symptomatic
Cast 0.750 (0.292 to 0.992)
0.992 (0.918 to 1.00)
Beta (alpha 3, beta 1)
(alpha 11.9, beta 0.1)
Saedén et al. (2001)27
Lindström and Nyström (1990)102
Surgery 0.214 (0.050 to 0.454)
Assumed same as cast
Beta (alpha 3, beta 11) Saedén et al. (2001)27
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Scenario 5: additional risk of osteoarthritis development post non-union surgery
The base-case analysis assumes that there is no additional risk of developing OA as a result of multiple lines of
treatment. This assumption implies that, in the case of surgery for non-union after cast immobilisation, there is
no increase in the future risk of developing OA. However, Saedén et al.27 argue that surgery that opens the STJ
may result in the development of OA, but members of the TMG argue that surgery may in fact have a delaying
effect on the progression of OA. This scenario will explore the sensitivity of the result to this assumption by
assuming that patients undergoing surgery as a secondary treatment are, first, twice as likely to develop
OA at any point than if surgery had been conducted as the primary treatment and, second, half as likely.
Scenario 6: quality of life for non-osteoarthritis permanent adverse events
The base-case model assumes that the HRQoL for non-OA permanent AEs is the same as for OA, owing to
a lack of evidence. This scenario tests the impact of this assumption by testing two extreme cases:
1. the HRQoL decrement for non-OA permanent AEs is 50% less than for OA (mean decrement 0.065,
95% CI 0.045 to 0.085) such that they have a greater QoL than OA sufferers
2. the HRQoL decrement for non-OA permanent AEs is 50% greater than for OA (mean decrement 0.195,
95% CI 0.175 to 0.215) such that they have a lower QoL than OA sufferers.
A third subscenario is also considered, which attempts to separately model the role of rare but extremely
impactful surgery-related AEs, such as fusion, chondrolysis and infection. While previous analyses include
non-OA related AEs that are the same for both treatments (the base case) and different (scenario 1), and
the quality of decrement applied is lifelong (–0.130 each year), it is possible that this underestimates the
impact of a small number of high-impact and lifelong AEs that can occur after surgery. In SWIFFT, one
patient was identified as having wrist fusion and reported a QoL for the within-trial period of 0.31 less
than the surgical arm average. This scenario explicitly incorporates this QoL decrement occurring in 0.5%
(roughly 1 in 219) of surgical patients for the rest of their lives.
Scenario 7: proportion of untreated patients who have union
The base-case analysis assumes that all patients in the untreated arm experience non-union, an assumption
necessitated by the reality that it is impossible to estimate the rate in this treatment group. While, in
reality, we know little about the prognosis and natural history of such a patient population, including
whether any patients who did choose to not receive treatment would seek treatment later if symptoms
persisted, we believe that the base case modelled provides a very important role in demonstrating the
value of some form of active treatment. This scenario explores the sensitivity of the result to the assumption
that all no-treatment options result in non-union by using a threshold analysis to estimate the probability
that the injury fails to unite without intervention, at which point the no-treatment arm becomes the most
cost-effective treatment approach. This scenario can be used if future evidence emerges to reflect the validity
of the base-case assumption and therefore the merits of active treatment.
Scenario 8: probability of scaphoid non-union advanced collapse post non-union
To explore the sensitivity of the model to changes in the probability of SNAC occurring at any time point
after a non-union, this scenario doubles and halves the base-case annual probabilities.
Scenario 9: proportion of patients who reject surgery post cast immobilisation
In the base-case analysis, the estimated probability of patients having surgery after a confirmed non-union
after initial cast immobilisation is taken directly from SWIFFT, with 4 of 18 patients not having surgery. This
scenario explores the sensitivity of the model to this parameter through a threshold analysis, identifying the
rate at which patients would have to accept surgery after confirmed non-union after cast immobilisation
for cast plus surgery to be the most cost-effective treatment.
Scenario 10: cost of first-line surgical fixation
The base-case analysis estimates a cost per first-line surgical fixation of £1632, as informed by the relevant
reference cost.92 However, the TMG highlighted that this reference cost was widely considered to be a
large underestimate of the true cost to the hospital of providing this procedure. Attempts were made to
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use data collected during the trial to conduct a bottom-up costing of the procedure, but insufficient unit
costs of the components and large variation in the level of reporting made it impossible to derive a
meaningful estimate. This scenario therefore estimates the impact on the estimated result if the cost of
surgical fixation were doubled to £3264.
Scenario 11: no difference in quality of life in first year
The base-case analysis assumes a QoL difference of 0.02 in favour of the surgical treatment arm in the first
year of the model. This scenario explores the impact of incorporating the difference in baseline QoL
between the two arms by setting the QoL of the two arms as the same (set to the cast value of 0.812).
Scenario 12: no quality of life decrement of non-union without scaphoid non-union
advanced collapse
The base-case analysis assumes the QoL decrement for patients with long-term non-union but no SNAC is the
same as that used for OA (a decrement of 0.130). This scenario tests this assumption by assuming that non-
union patients without SNAC have no QoL decrement, experiencing the same QoL as the general population.
Scenario analyses results
A number of scenarios were conducted to explore some of the elements of uncertainty not well captured
by the PSA, as discussed in the main report and earlier in this appendix. In this section, the results presented
of the different scenario analyses are reduced to reporting the NHB at a cost-effectiveness threshold
of £20,000/QALY, which gives a precise overview of which treatment option is the most cost-effective.
The full list of NHBs across the scenarios are reported in Table 73.
TABLE 73 Results of the scenario analyses, NHB at threshold of £20,000/QALY
Scenario
QALY
Surgery
Cast plus
surgery
Cast
only
No
treatment
Base case: deterministic 19.00 19.02 18.69 14.70
Scenario 1: definition of non-union at 1 year 18.99 19.02 18.58 14.69
Scenario 2: no surgical treatment for those who fail to achieve union with cast 19.00 18.98 18.70 14.69
Scenario 3: probability of non-union after secondary surgery 18.98 18.99 18.69 14.69
Scenario 4: treatment-specific AEs from Saedén et al.27 18.71 18.40 18.06 14.69
Scenario 5a: double risk of OA development post non-union surgery 19.00 19.03 18.70 14.69
Scenario 5b: half risk of OA development post non-union surgery 19.01 19.04 18.68 14.69
Scenario 6a: 50% lower QoL decrement for non-OA permanent AEs 19.07 19.11 18.75 14.69
Scenario 6b: 50% greater QoL decrement for non-OA permanent AEs 18.87 18.90 18.56 14.69
Scenario 6c: explicit inclusion of additional fusion rate 18.97 19.04 18.68 14.69
Scenario 7: proportion of untreated patients who have union Would require 95.5% of untreated patients
to achieve union for it to be the most
cost-effective strategy
Scenario 8a: double annual probability of SNAC post non-union 19.00 19.03 18.65 14.27
Scenario 8b: half annual probability of SNAC post non-union 19.01 19.04 18.75 15.17
Scenario 9: proportion of patients who reject surgery post cast confirmed
non-union
If the proportion of patients having surgery
after confirmed non-union after cast
immobilisation reduces from 0.948 to 0.852,
primary surgery becomes cost-effective
Scenario 10: doubling of cost of first-line surgical fixation 18.92 19.04 18.68 14.72
Scenario 11: no difference in QoL in first year 18.98 19.03 18.68 14.69
Scenario 12: no QoL decrement of non-union without SNAC 19.00 19.03 18.81 16.01
Numbers in bold denote the largest NHB for each scenario.
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Table 73 shows that the cost-effectiveness results are sensitive to a number of key assumptions; while the
headline result does not change in many of them, the incremental difference in NHB reduces in many. While
scenario 4 is striking in that it results in a large change in the NHB and the resultant decision, the small scale
of the Saedén et al.27 study that informs this scenario results in very large levels of uncertainty. Furthermore,
it could be argued that the population used to inform this scenario from the Saedén et al.27 study is not
indicative of those patients considered here, with the cast population indicative of a more severe subset.
Scenarios 1 and 2 highlight the sensitivity of the model to the assumptions regarding the definition of slight
union patients as union or non-union, and whether the three patients who are non-union at 52 weeks
in the cast arm but have not received surgery can be assumed to be offered surgery at some point (as in
the base case) or will remain non-unions (as in the scenario). These scenarios show the key finding of the
analysis that, if initial cast immobilisation is unsuccessful but surgical intervention is offered soon after, it is
highly likely to be cost-effective, as the high upfront cost implications of conducting surgery on all patients
have been avoided, but a high rate of long-term non-union and the AE risks of conducting a lot of surgical
interventions are still avoided.
Scenario 4 shows that the use of the Saedén et al.27 study to inform an estimate of treatment-specific AEs
has a dramatic impact on the cost-effectiveness result. This result was flagged by the clinical advisors of
this section as being contrary to clinical expectations, as surgical intervention would be expected to be
associated with a greater level of AEs than cast immobilisation. However, as Saedén et al.27 found a higher
proportion of symptomatic AEs in the cast arm, the model results respond accordingly. It is likely that the
Saedén et al.27 estimate suffers from small numbers and that the QoL of those reporting symptoms in the
surgical group is less than that in the cast group. However, given the evidence available, it has not been
possible to incorporate such factors without resorting to speculation. The results of this scenario justify
the assumption of treatment-independent AEs made in the base case and highlight the need for further
research into the nature of long-term AEs in this clinical area.
Within-trial analysis results
Summary statistics: costs
This section briefly considers the values observed in terms of costs to the NHS and PSS prior to imputation
for missing values. These results provide a helpful overview of the results reported by patients and prior
to any assumptions being made about the nature of the missing data. The crude summary statistics and
frequency histograms are reported in Table 74 and Figure 22 respectively.
TABLE 74 Within-trial cost summary statistics, complete case
Variable Surgery mean (n, SE) Plaster cast mean (n, SE)
6 weeks £311 (168, £21.38) £233 (169, £19.09)
12 weeks £125 (165, £13.60) £118 (162, £13.29)
26 weeks £78 (153, £13.27) £86 (140, £14.36)
52 weeks £51 (174, £11.15) £90 (163, £28.03)
Imaging £42 (169, £4.72) £43 (170, £4.92)
Surgery (no missing data) £1516 (219, £59.27) £319 (220, £65.10)
Casting (no missing data) £17 (219, £0.73) £13 (220, £0.45)
Total costs, complete case £2350 (83, £94.72) £727 (65, £117.81)
Sum of average costs £2140 £901
SE, standard error.
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As would be expected, these compete case results show high levels of costs at the earlier stage of the trial,
while patients are receiving treatment (p < 0.001). With the exception of the first 6 weeks, when surgical
patients will be having surgical-related reviews, the time-related costs are similar, as are imaging costs.
While some surgical interventions did take place in the plaster cast arm (24 surgeries), resulting in a mean
cost of £319, surgery costs are much greater in the surgery arm of the trials, as would be expected.
0 500 1000 1500
Plaster cast
Patient interaction cost (£) Patient interaction cost (£)
(a)
Fr
eq
u
en
cy
0
20
40
60
0 500 1000 1500
Surgical fixation
Fr
eq
u
en
cy
0
20
40
60
Plaster cast(b)
Fr
eq
u
en
cy
0 500 1000 1500
0
20
40
80
60
Surgical fixation
Fr
eq
u
en
cy
0 500 1000 1500
0
20
40
80
60
Patient interaction cost (£) Patient interaction cost (£)
(c)
Fr
eq
u
en
cy
0 500 1000
Plaster cast
0
50
100
Fr
eq
u
en
cy
0 500 1000
Surgical fixation
0
50
100
Patient interaction cost (£) Patient interaction cost (£)
(d)
Fr
eq
u
en
cy
0 1000 2000 3000
Plaster cast
0
50
100
150
Fr
eq
u
en
cy
0 1000 2000 3000
Surgical fixation
0
50
100
150
Patient interaction cost (£) Patient interaction cost (£)
FIGURE 22 Histograms of patient interaction costs, complete case: (a) 6 weeks; (b) 12 weeks; (c) 26 weeks; and
(d) 52 weeks.
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In contrast, the average cost resulting from cast immobilisation is actually larger in the surgical arm. We
believe this to be because many patients had casts fitted and re-fitted routinely after surgery to inspect
healing, whereas the majority of patients randomised to cast immobilisation required fewer re-fittings.
Overall, the average costs in the surgical arm were found to be statistically significantly greater than in the
plaster cast arm, in terms of both the total costs for patients with complete data across all of the cost
variables and the sum of the average costs, both reported in Table 74.
Summary statistics: quality of life
This section briefly reports the within-trial analysis results for the QoL and cost estimates as complete case,
that is, prior to any imputation for missing data. The results are reported in Table 75 and Figure 23.
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FIGURE 23 Complete case QoL scores by time and treatment: (a) baseline; (b) 6 weeks; (c) 12 weeks; (d) 26 weeks;
and (e) 52 weeks. (continued )
TABLE 75 The QoL summary statistics, unadjusted mean complete case
Variable Surgery mean (n, SE) Plaster cast mean (n, SE)
Baseline 0.6260 (214, 0.0194) 0.5973 (219, 0.0201)
6 weeks 0.7522 (174, 0.0174) 0.7005 (179, 0.0181)
12 weeks 0.8290 (180, 0.0138) 0.7898 (164, 0.0173)
26 weeks 0.8361 (161, 0.0177) 0.8505 (146, 0.0183)
52 weeks 0.8820 (182, 0.0123) 0.8551 (176, 0.0176)
Average QoL, complete case 0.8317 (134, 0.0131) 0.8140 (119, 0.0159)
SE, standard error.
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These crude analyses show that patients in both treatment strategies reported bimodal, highly skewed QoL
scores, with a high proportion reporting a perfect QoL score of 1, which increased with time since injury.
However, there were also a small number of patients reporting very low QoL scores, including a proportion
of negative scores throughout the follow-up period, indicative of some patients experiencing very poor
outcomes. This distribution is typical of such injuries, with initial injury and treatment-related impacts on
QoL reducing over time but some patients continuing to experience AE-related impacts. In addition, the
average scores in the high 0.8 range are indicative of a ‘normal’ population of the age of the patients.107
While Figure 23 shows a similar spread of scores throughout the within-trial period, the mean results
presented in Table 74 do appear to show that the plaster cast arm has lower QoL at all time points. The
complete-case average QoL over the year (i.e. adjusted for the length represented by each questionnaire as
given in Chapter 2) shows a slightly greater score for the surgical patients, alongside a smaller standard
error. However, this difference may be the result of differences in the baseline score, which was 0.0287
higher in the surgical than in the plaster cast arm.
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FIGURE 23 Complete case QoL scores by time and treatment: (a) baseline; (b) 6 weeks; (c) 12 weeks; (d) 26 weeks;
and (e) 52 weeks.
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Missing data results
Missing data were found to occur across the patient-reported questionnaires related to QoL and resource
use at levels reported in Table 76. Overall, the level of missing data was low, but was higher in the plaster
cast arm, most likely because of a lower frequency of interaction and patient buy-in with the treatment,
potentially owing to the perceived importance of the injury if cast immobilisation is deemed to be sufficient
rather than the injury requiring surgical fixation.
Missing data were found to be non-monotonic and patients who were missing in one period were not
necessarily missing in the next. Logistic regression in the QoL and cost variables found many of the
variables to be correlated with previously observed values, which, using the Faria94 framework, led to the
assumption that the data were missing at random. As a result, in the multiple imputation framework,
missingness is assumed to depend on all other missing variables and baseline covariates, specifically
gender, whether or not the injured arm was the patient’s dominant arm, treatment allocation and age.
The variables selected are consistent with those used in the previous chapter and the regression analyses
presented in the next section. The imputation is run 36 times, consistent with the largest proportion of
missing data observed (36.0% in costs at 26 weeks in the plaster cast arm).94
Extended model results
Figure 24 gives scatterplots of the cost-effectiveness results first including all four treatment options and
then including only the two SWIFFT options.
Table 77 provides some of the clinical estimates of the model at three time points. The estimates allow this
model to be validated as additional evidence emerges, specifically the 5-year SWIFFT update.
TABLE 76 Missing data observed in patient-reported questionnaires
Variable, n (%) Surgical fixation (N= 219) Plaster cast (N= 220)
QoL score baseline 5 (2.3) 1 (0.5)
QoL score at 6 weeks 45 (20.5) 41 (18.6)
QoL score at 12 weeks 39 (17.8) 56 (25.5)
QoL score at 26 weeks 58 (26.5) 74 (33.6)
QoL score at 52 weeks 37 (16.9) 44 (20.0)
Cost at 6 weeks 51 (23.3) 51 (23.2)
Cost at 12 weeks 54 (24.7) 58 (26.4)
Cost at 26 weeks 66 (30.1) 80 (36.4)
Cost at 52 weeks 45 (20.5) 57 (25.9)
Imaging 50 (22.8) 50 (22.7)
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TABLE 77 Clinical estimates of the model at three time points
Time point,
years
Percentage of the initial population with
union and OA who are alive
Percentage of the initial population with
SNAC who are alive
No
treatment
Cast
only
Cast +
surgery Surgery
No
treatment
Cast
only
Cast +
surgery Surgery
1 N/A 2.36 2.58 2.59 0.69 0.06 0.00 0.00
5 N/A 4.66 5.08 5.11 11.34 1.02 0.10 0.04
10 N/A 4.79 5.23 5.25 33.53 3.01 0.31 0.13
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FIGURE 24 Scatterplots of the cost-effectiveness results for (a) the four treatment options; and (b) only the two
SWIFFT options.
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Consolidated Health Economic Evaluation Reporting Standards checklist
TABLE 78 Consolidated Health Economic Evaluation Reporting Standards checklist
Section/item
Item
number Recommendation
Page number on
which it is reported
Title and abstract
Title 1 Identify the study as an economic evaluation or use
more specific terms such as ‘cost-effectiveness
analysis’ and describe the interventions compared
113
Abstract 2 Provide a structured summary of objectives,
perspective, setting, methods (including study design
and inputs), results (including base case and
uncertainty analyses) and conclusions
3 to 4
Introduction
Background and objectives 3 Provide an explicit statement of the broader context
for the study
28
Present the study question and its relevance for
health policy or practice decisions
28 to 32
Methods
Target population and
subgroups
4 Describe characteristics of the base-case population
and subgroups analysed, including why they
were chosen
113 and 124
Setting and location 5 State relevant aspects of the system(s) in which the
decision(s) need(s) to be made
113
Study perspective 6 Describe the perspective of the study and relate this
to the costs being evaluated
113 and 121
Comparators 7 Describe the interventions or strategies being
compared and state why they were chosen
125
Time horizon 8 State the time horizon(s) over which costs and
consequences are being evaluated and say
why appropriate
124
Discount rate 9 Report the choice of discount rate(s) used for costs
and outcomes and say why appropriate
124
Choice of health outcomes 10 Describe what outcomes were used as the measure(s)
of benefit in the evaluation and their relevance for
the type of analysis performed
113
Measurement of
effectiveness
11a Single study-based estimates: describe fully the
design features of the single effectiveness study and
why the single study was a sufficient source of clinical
effectiveness data
4 and elsewhere in
report
11b Synthesis-based estimates: describe fully the methods
used for identification of included studies and
synthesis of clinical effectiveness data
113
Measurement and valuation
of preference-based
outcomes
12 If applicable, describe the population and methods
used to elicit preferences for outcomes
N/A
continued
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TABLE 78 Consolidated Health Economic Evaluation Reporting Standards checklist (continued )
Section/item
Item
number Recommendation
Page number on
which it is reported
Estimating resources and
costs
13a Single study-based economic evaluation: describe
approaches used to estimate resource use associated
with the alternative interventions. Describe primary
or secondary research methods for valuing each
resource item in terms of its unit cost. Describe any
adjustments made to approximate to opportunity costs
Page 113 to 121
13b Model-based economic evaluation: describe
approaches and data sources used to estimate
resource use associated with model health states.
Describe primary or secondary research methods for
valuing each resource item in terms of its unit cost.
Describe any adjustments made to approximate to
opportunity costs
131 to 145
Currency, price date and
conversion
14 Report the dates of the estimated resource quantities
and unit costs. Describe methods for adjusting
estimated unit costs to the year of reported costs if
necessary. Describe methods for converting costs into
a common currency base and the exchange rate
124
Choice of model 15 Describe and give reasons for the specific type of
decision-analytical model used, providing a figure to
show that the model structure is strongly recommended
127 to 131
Assumptions 16 Describe all structural or other assumptions
underpinning the decision-analytical model
127 to 131
Analytical methods 17 Describe all analytical methods supporting the
evaluation. This could include methods for dealing
with skewed, missing or censored data; extrapolation
methods; methods for pooling data; approaches to
validate or make adjustments (such as half cycle
corrections) to a model; and methods for handling
population heterogeneity and uncertainty
120 and 128 to 131
Results
Study parameters 18 Report the values, ranges, references and, if used,
probability distributions for all parameters. Report
reasons or sources for distributions used to represent
uncertainty where appropriate, providing a table to
show that the input values are strongly recommended
118 to 119, 135 to
137, 140 to 141 and
142 to 143
Incremental costs and
outcomes
19 For each intervention, report mean values for the
main categories of estimated costs and outcomes of
interest, as well as mean differences between the
comparator groups. If applicable, report incremental
cost-effectiveness ratios
151 to 153 and 157
Characterising uncertainty 20a Single study-based economic evaluation: describe the
effects of sampling uncertainty for the estimated
incremental cost and incremental effectiveness
parameters, together with the impact of
methodological assumptions (such as discount rate,
study perspective)
153
20b Model-based economic evaluation: describe the
effects on the results of uncertainty for all input
parameters and uncertainty related to the structure of
the model and assumptions
157 to 165
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TABLE 78 Consolidated Health Economic Evaluation Reporting Standards checklist (continued )
Section/item
Item
number Recommendation
Page number on
which it is reported
Characterising heterogeneity 21 If applicable, report differences in costs, outcomes or
cost-effectiveness that can be explained by variations
between subgroups of patients with different
baseline characteristics or other observed variability in
effects that are not reducible by more information
N/A
Discussion
Study findings, limitations,
generalisability and current
knowledge
22 Summarise key study findings and describe how they
support the conclusions reached. Discuss limitations
and the generalisability of the findings and how the
findings fit with current knowledge
165 to 167
Other
Source of funding 23 Describe how the study was funded and the role of
the funder in the identification, design, conduct and
reporting of the analysis. Describe other non-monetary
sources of support
4
Conflicts of interest 24 Describe any potential for conflicts of interest among
study contributors in accordance with journal policy.
In the absence of a journal policy, we recommend
authors comply with International Committee of
Medical Journal Editors recommendations
2
DOI: 10.3310/hta24520 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 52
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dias et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
233


EME
HS&DR
HTA
PGfAR
PHR
Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk
This report presents independent research funded by the National Institute for Health Research (NIHR).  
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the  
Department of Health and Social Care
Published by the NIHR Journals Library
